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Abstract 
 
Cutaneous leishmaniasis (CL) is a neglected tropical disease. It presents as 
disfiguring and deforming skin lesions. There is an urgent need for a simple, low-cost 
and non-toxic treatment for use in resource poor countries. As amphotericin B (AmB) 
has transformed visceral leishmaniasis treatment, I have developed and optimised a 
poly (methacrylic acid)-AmB drug (AmB-PMA). This involved the use of a 
commercially available, non-toxic, well-defined narrow molecular weight distribution 
polymer, poly (methacrylic acid sodium salt) (PMA) associated with AmB to create 
AmB-PMA. After chemical synthesis optimisation, AmB-PMA was shown to be less 
toxic than clinical grade AmB, and it was effective against Leishmania spp. 
promastigotes and amastigotes in vitro. To determine in vivo efficacy, studies were 
performed using BALB/c mice. They develop progressive non-healing skin lesions 
and are unable to control parasite growth. Mice were infected subcutaneously with L. 
major (LV39) promastigotes and treated locally with AmB-PMA. Studies were then 
conducted to evaluate the optimum route of administration, treatment frequency and 
dosing schedules. The results showed a reduction in both parasite burden and lesion 
size of the infected treated footpad with no adverse toxicity. Cytokine production was 
determined by quantitative real-time PCR for mRNA at the lesion site and the 
draining lymph node. I found that the AmB-PMA could effectively heal an established 
lesion and cure a CL infection. This was associated with: - (i) increased IFN-γ and 
TNF-α production, (ii) reduced IL-10 and MIP-1β production, when compared to 
infected, untreated lesions. The success of this treatment approach was also 
evaluated by histological studies. In addition, treated mice with resolved primary 
cutaneous lesions mounted a delayed type hypersensitivity response 24 h after 
challenge of the contra-lateral footpad with L. major. My thesis demonstrates the new 
opportunity for a cost-effective AmB based polymer drug that can be used locally to 
cure CL. 
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CHAPTER 1 
1.1 Introduction 
Neglected Tropical Diseases (NTD‟s) are a group of bacterial and parasitic diseases 
that account for an estimated 534,000 deaths worldwide every year (Savioli, L. 
2009). Furthermore the scale of the problem is increasing due to political instability 
and economic variability across the globe. Moreover many of these deaths are 
preventable and are a result of poor living conditions, insufficient access to medical 
care and lack of basic hygiene such as clean running water. This creates a 
debilitating ripple effect that ultimately would not cease if there were not agencies 
such as the World Health Organisation (WHO) attempting to reduce the impact of 
these diseases. Infectious diseases such as leishmaniasis, African trypanosomiasis 
and schistosomaisis, are overlooked because those affected are located in some of 
the most impoverished regions in the world. As a result they do not attract the 
financial and political support necessary to fund the research needed to develop 
preventative therapeutics or cures for these conditions. The WHO characterise these 
diseases as neglected in an attempt to increase awareness into their devastating 
effects on communities and their high incidence in the developing world 
(www.who.int/Leishmaniasis/en/). Tropical diseases, as the term suggests, are 
indigenous in the tropical and subtropical areas of the world however, can occur in 
sporadic or endemic forms in areas that are not tropical such as in the Middle East 
and the Mediterranean. This is the case for parasitic species such as Leishmania 
spp. that can thrive in both tropical and arid environments, and can cause a 
debilitating range of diseases that are species dependent. Its estimated disease 
burden is second in mortality and fourth in morbidity among the tropical infectious 
diseases (Bern et al. 2008). It has been calculated that every 20 seconds a person 
becomes infected with the cutaneous form of leishmaniasis. It is endemic in 88 
countries with an incidence of 12 million infected persons (Zimmermann et al. 2009). 
Cutaneous leishmaniasis (CL) has the potential to self-heal over several months to 
years but it leaves scaring, disfigurement and impairment of the extremities. As it is 
not a life-threatening disease, it is not seen as a priority for world health and hence is 
termed as a neglected disease. Social stigmatism and isolation within communities 
occurs due to the overt visibility of the pathological lesions. This leads to a 
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substantial number of cases left unrecorded and hence the impact of leishmanaisis 
on world public health is severely underestimated. Treatment is lengthy, costly and 
unattainable in most countries where the disease is endemic (Amato et al. 2007). 
The current standard treatment requires intralesional or intramuscular injections of 
anti-leishmanial drugs. The leishmaniases inflicts an immense toll especially on the 
developing world, but increase in travel and mobility and the rapid emergence of 
AIDs-related leishmaniasis has generated a risk for many more people (Blum et al. 
2004). There is currently no licensed vaccine for use in humans available therefore, 
efficient and cost-effective treatments are urgently needed, ideally administrable by 
patients (Scott et al. 2004).  
Polymers have been found to be effective drug delivery systems and have been 
exploited for a wide range of biomedical applications. Professor Shaunak‟s laboratory 
have established that an anti-leishmanial poly(methacrylic acid)(PMA)-AmB drug can 
be created, which I have optimised and tested for the treatment of experimental 
cutaneous leishmaniasis.  
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1.1.1 Leishmania 
 
Figure 1: Prevalence of leishmaniasis worldwide  
Areas of the world where cutaneous (shown in red) and visceral (shown in green) 
leishmaniasis are located. (extracted from 
http://www.wehi.edu.au/media/images/handman/world_map.jpg). 
Leishmania parasites are intracellular flagellate protozoa that infect mammalian hosts 
via the bite of infected female sand flies. There are over 20 species of Leishmania 
that are pathogenic to humans and they are geographically distributed in different 
regions of the globe (Figure 1). 90% of all CL cases occur in Afghanistan, Brazil, Iran, 
Peru, Saudi Arabia and Syria (www.who.int/Leishmaniasis/en/). The manifestation of 
disease in the host is dependent on the strain that infects and the immune response 
of the host (Piscopo and Mallia 2007). Post- treatment deformities and impairment 
are common. Leishmaniases can present themselves in different forms depending on 
the strain that infects (Table 1). These strains can be sub-divided into Old World and 
New World depending on the sand fly that transmits them and their geographical 
location. The Old World strains are spread by Phlebotomus sand fly whereas the 
New World strains are predominately spread by the Lutzoymia sand fly. 
Leishmaniasis can be generally categorised into 3 main forms, cutaneous 
leishmaniasis infecting the skin, which can then manifest into mucocutaneous 
leishmaniasis infecting the skin and mucosal regions of the body, and visceral 
leishmaniasis infecting the internal organs. 
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Main clinical 
pathology 
Main 
geographical 
location 
Old World Leishmania spp.     
Leishmania aethiopica LCL, DCL Ethiopia, Kenya 
Leishmania killicki LCL North Africa 
Leishmania major LCL 
Central Asia, 
North Africa, 
middle east, 
east Africa 
Leishmania tropica LCL 
Central Asia, 
middle east, 
parts of north 
Africa, southeast 
Asia 
Leishmania donovani Visceral, LCL 
Africa, central 
Asia, southeast 
Asia 
Old and New World Leishmania spp.     
Leishmania infantum Visceral, LCL 
Europe, north 
Africa, Central 
America, South 
America 
New World Leishmania spp.     
Leishmania (Viannia) brazilinesis LCL, mucosal 
South America, 
parts of Central 
America, Mexico 
Leishmania (Viannia) panamensis LCL, mucosal 
Northern South 
America and 
southern Central 
America 
Leishmania (Viannia) peruviana LCL Peru 
Leishmania (Viannia) guyanensis LCL South America 
Leishmania (Viannia) lainsoni LCL South America 
Leishmania (Viannia) colombiensis LCL 
Northern South 
America 
Leishmania amazonensis LCL, DCL South America 
Leishmania Mexicana LCL, DCL 
Central America, 
Mexico, USA 
Leishmania pifanoi LCL South America 
Leishmania venezuelensis LCL 
Northern South 
America 
Leishmania garnhami LCL South America 
 
Table 1: Old and New World species of Leishmania and their geographical 
location. 
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The different species that cause leishmaniasis sub-divided into the Old and New 
World depending on the genus of the sand fly. Cutaneous leishmaniasis can be 
described as localised CL (LCL) or can manifest into diffuse CL (DCL) or mucosal 
leishmaniasis. Table extracted and annotated from (Reithinger et al. 2007) 
 
1.1.1.1 Life cycle of Leishmania 
Leishmania major parasites replicate within the digestive tract of a Phlebotomine 
sand fly vector in the form of promastigotes which are flagellate and extracellular, 
and further differentiate into non-dividing metacyclic promastigotes (Stierhof et al. 
1999) (Figure 2 (8)). These are then injected in low numbers (average 100-1000) 
(Rogers et al. 2004), but can be as high as up to 105 (Kimblin et al. 2008) into the 
mammalian host in the saliva of female sand flies during blood feeding (Figure 2 (1)). 
The metacyclic flagellated promastigotes are then engulfed by phagocytic cells 
present in the dermis such as neutrophils, macrophages and dendritic cells 
(Tacchini-Cottier et al. 2000) (Figure 2 (2). Once the promastigotes have been 
internalised into the phagosome, it fuses with the lysosome to form the 
phagolysosome in which the parasite transforms into amastigotes. It is within this 
acidic environment that the amastigotes reabsorb the flagellum to become spherical 
and intracellular (Burchmore and Barrett 2001)(Figure 2 (3)). This allows them to 
multiply by binary fission causing the macrophage to burst and release the protozoa 
which are then engulfed further by macrophages (Figure 2 (4)). The establishment of 
the disease in the host is dependent upon the immuno-competence of the host 
(Gumy et al. 2004;Verma et al. 2010). Sand-flies breed in caves and burrows and are 
infected with Leishmania spp. by biting an infected animal, such as rats, dogs, 
armadillo, hyraxes or humans (Figure 2 (5)). The ingested, infected cells release 
amastigotes into the midgut of the digestive tract where they transform into 
promastigotes (Figure 2 (7)) to complete their life cycle.  
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Figure 2: Life cycle of leishmaniasis 
The life cycle of leishmaniasis can be divided into 2 main stages; The human stage 
whereby infection manifests within the host (1-5) and the sand fly stage where the 
parasite resides and multiplies as promastigotes (5-8). Extracted from http://www.uni-
tuebingen.de/modeling/images/Leishmania_LifeCycle.gif.   
1.1.1.2 Clinical symptoms  
Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis and 
presents as simple raised red papule at the site of the bite of the sand fly. This 
develops into a nodule that can ulcerate over 1-3 months and are predominately 
found on the face and extremities. As mentioned, these lesions have the potential to 
spontaneously heal over several months or years without treatment but almost 
always with scaring. However, once the lesions do evolve, they can develop into 
several clinical forms of the disease, particularly Old World, such as flat plaque, 
hyperkeratotic and wart-like lesions (Murray et al. 2005). Appearance of the lesions 
can vary from between weeks to several months after the bite and this is species-
dependent, for example, L. major and L. aethiopica have a shorter incubation period 
within the host than L. tropica before clinical manifestation (Dowlati 1996a). 
Presentation of the type of lesions can indicate whether the infection is from species 
of the Old World or New World disease. The latter has a greater incidence of 
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developing ulcerative lesions in the host that can disseminate (DCL and mucosal, 
Table 1). L. tropica infection has the ability to develop new nodules around an 
already healed lesion resulting in a form of CL disease called leishmaniasis 
recidivans. Both dissemination of a Leishmania infection and ulcerating lesions 
increases the probability of secondary infection from opportunistic bacteria such as 
Staphylococcus aureus (Palumbo 2009). Specific Leishmania species have been 
shown to spread and infect other organs before presentation of lesions to the skin. L. 
braziliensis has been shown to cause lymphadenopathy with skin lesions in 77 % of 
a 595 person cohort. Two-thirds had enlarged lymph nodes for several weeks before 
the appearance of skin lesions, indicating early spread of L. braziliensis that gives 
rise to additional challenges on treatment (Sousa et al. 1995).   
Mucocutaneous leishmaniasis (MCL) manifests after presentation of a CL lesion. 
Contributing factors to MCL development is if the patient becomes 
immunocompromised after healing of a CL lesion or did not complete a treatment 
regime. MCL initially presents in the nasal mucosa and can lead to septal perforation 
and neighbouring tissue destruction in the form of ulcerations on the skin. Infection 
may also involve the oropharynx and larynx and does not heal spontaneously. 1-10 
% of CL infections caused by L. (Viannia) braziliensis, L. (Viannia) pananmensis and 
L. (Viannia) guyanensis result in disseminated mucosal lesions that can occur during 
active infection or up to 5 years after the host has healed from CL (Murray et al. 
2005). MCL only develops from infections with Leishmania Viannia complex and are 
typically very hard to treat. 
Visceral leishmaniasis (VL) is fatal and the infected person presents with fever, 
weight loss and more characteristically with hepatosplenomegaly due to the 
preferential targeting of L. donovani to the spleen, liver and bone marrow. It also 
causes anaemia and leukopenia and contributes to a significant morbidity and 
mortality in the developing world. Visceral leishmaniasis (VL) has a 100% fatality rate 
within 2 years (Mayor 2008). Several months or years after successful treatment of 
VL or simultaneously at the time of a visceral infection, a cutaneous form of the 
disease can manifest called post-kalazar dermal leishmaniasis (PKDL). Leishmania 
parasites that have been expelled from the internal organs accumulate within 
„maculo-nodular‟ lesions and can lead to mucosal dissemination. It is typically found 
in the Sudan (50 % of cases) and India and can be as a result of incomplete cure of 
VL on treatment (Das et al. 2009).   
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1.1.1.3 Diagnosis of Disease 
Typically diagnosis of cutaneous leishmaniasis is carried out using microbiological 
methods. Slit smears of the CL lesion using a scalpel to extract tissue juice and cells 
are collected and spread onto a glass slide. After fixation with methanol and staining 
with Giemsa the slide is examined by light microscopy. In a recent study this 
diagnostic method detected Leishmania parasites in only 37 % of 110 cases and 
further verification using histological techniques was required (Giemsa and 
haemotoxylin and eosin staining) which highlighted the presence of amastigotes in 
66.6 % (Al-Mutairi et al. 2009). Material from the infected tissue can also be collected 
and cultured in vitro or inoculated into animals such as hamsters. However, the latter 
method can take time before a result is obtained (average of 34.5 days) and both 
culture techniques have a high associated risk of contamination (Reed 1996;Weigle 
et al. 1987). These direct diagnostic techniques can be quick but require skilled 
professionals to clearly identify the presence of amastigotes in infected tissue. More 
recently, a standardised and sensitive PCR method has been employed which has a 
higher sensitivity and specificity due to the ability to synthesise appropriate primers. 
This also leads to the identification of particular species and has shown to be more 
sensitive than direct microscopy in this context (Andresen et al. 1996)(Murray et al. 
2005). Although PCR has greater sensitivity, it is has not been generally applied in 
the field and in endemic regions.  
 
1.1.2 Current therapies 
To date there is no known human vaccine to protect against leishmaniases and 
treatment varies in degrees of efficacy, expense, associated toxicity and by 
geographical location (Mahajan and Sharma 2007).The standard therapy has been 
employed for over half a century and is, as one would expect, severely dated in 
terms of efficacy. Incidence of both resistance and toxicity is high in patients and 
more crucially the treatment is long, requiring frequent hospital visits. Due to the 
increasing prevalence of leishmaniaises, it is becoming more pertinent to replace 
standard therapy i.e. repeated injections of toxic antimonials, with shorter courses 
that are non-parenteral, less toxic and more effective agents.  
Cutaneous lesions that are on the extremities can be self-healing; however this can 
take months or even years to occur and results in significant life-long scarring. 
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Depending on the species, infections can lead to complications such as spreading to 
mucosal regions and severe disfigurement. Patients with multiple lesions in sensitive 
areas such as the face, hands, feet and joints should crucially seek medical 
treatment as well as those who are immunocompromised. The standard therapy is 
daily injections either intralesionally or intramuscularly of pentavalent antimony for 20 
days.  
The following is an evaluation of some of the current and prospective treatments for 
leishmaniases. It must be noted that as there are many species that present varying 
symptoms based on their geographical location (as detailed Table 1), and also 
dependent on the immunological capacity of the host, there are many published 
studies, that show conflicting evidence. Many studies that have taken place are 
uncontrolled clinical trials whereby assumptions are performed to produce a standard 
with which to compare. Another factor is that some species, such as L. major can 
eventually self-heal and this can further skew results generated by a human clinical 
trial.  
1.1.2.1 Drug Therapy 
1.1.2.1.1 Systemic  
1.1.2.1.1.1 Pentavalent antimonials  
Pentavalent antimonial compounds (Sb (V)) such as sodium stibogluconate 
(Pentostam, GlaxoSmithKline, SSG) and its generic form meglumine antimoniate 
(Glucantime, Aventis Pasteur, MA) were introduced in 1945 and are currently the 
gold standard treatment for cutaneous leishmaniasis, particularly for Old World 
species such as L. major. Both are very similar drugs containing 100 mg/ml and 85 
mg/ml of pentavalent antimony (Sb) respectively. MA is more readily available 
worldwide and is less expensive than Pentostam. Surprisingly, the mode of action of 
these compounds still remains poorly understood although it is generally accepted 
that Sb(V) is reduced to the more toxic and potent anti-leishmanial agent, Sb(III) 
(Shaked-Mishan et al. 2001). Whether this occurs within the macrophage or the 
amastigote, and the mechanism of the reduction of Sb(V), still requires clarification 
(Croft et al. 2006). Frezard et al, indicated that thiols such as cysteine and 
glutathione actively promote the reduction of Sb(V) to Sb(III) within infected 
mammalian cells (Frezard et al. 2009). However, other theories on the mechanism of 
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antimonials suggest that they cause an inhibition in the generation of ATP and GTP 
within Leishmania amastigotes (Singh and Sivakumar 2004). Regardless of the mode 
of action, it is generally believed that when the pentavalent form is reduced, the 
presence of Sb(III) has a mutagenic effect and has been shown in vivo to give rise to 
DNA damage (Lima et al. 2009). 
WHO recommends intralesional systemic antimonials for CL and intramuscular or 
intravenous administration for VL, though this is dependent on the species and 
clinical manifestation of disease (WHO 2009). Patients with mild forms of L. major 
disease with early non-inflamed lesions can be treated locally by intralesional 
injections over a period of 20 days weekly or with alternating day treatment of either 
SSG or MA. Presentation with multiple lesions to cosmetically sensitive areas such 
as the face and joints, are treated systemically either via slow intravenous or 
intramuscular injections with the recommended dosage of 20 mg per kg per day for 
at least 20-30 days of SSG or 60 mg per kg per day of MA. Antimonial compounds 
cannot be administered orally and route of treatment can vary according to their 
availability within the specific country. In South America parenteral administration of 
MA for 20 days is the standard regimen for treating CL (Herwaldt 1999), however, the 
United States only recommended treatment is 20 mg/kg/day intravenously for 20 
days of SSG  (Cruz et al. 2009). Systemic antimonial treatment is associated with a 
variety of side effects (Firdous et al. 2009). Hence, close monitoring and frequent 
hospital visits are essential, that in-turn can be costly. Local treatment limits these 
toxic side effects; however these are broad, ranging from nausea and mylagia in at 
least 50 % of patients to skin rashes, hepatoxicity and cardiotoxicity (at least 10 %) 
(Frezard et al. 2009)(Berman 1996). Investigations have shown that antimonials are 
embryotoxic and teratogenic in rats (Paumgartten and Chahoud 2001). Alternative 
treatment is recommended in pregnant women.  A study comparing treatment in 
pregnant infected women reported 57 % of the patient cohort had spontaneous 
abortions in the first 2 trimesters. The group that were treated with liposomal AmB 
had no miscarriages (Mueller et al. 2006). Intramuscular and intralesional injections 
are often very painful and efficacy is usually operator dependent which can lead to 
inadequate infiltration into the lesions during administration (Faghihi and Tavakoli-kia 
2003). This further complicates treatment and can result in low patient compliance, 
which in turn increases the prevalence of resistance to treatment. If administration is 
successful, there appears to be no significant difference in efficacy between alternate 
intralesional injections for 30 days compared with intramuscular treatment over 2 
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weeks for 6 days (15 mg/kg/day) (Alkhawajah et al. 1997). Efficacy is also varied as 
shown in a recent clinical study that found low cure rates in adults and a complete 
inability to cure children less than 5 years of age (Palacios et al. 2001). This may be 
due to increased clinical resistance as shown by recent studies in Bihar in India that 
have shown cure rates of only 35% on treating VL systemically (Sundar 2001). The 
therapeutic efficiency of Glucantime for the treatment of CL however, has been found 
to be completely dependent on the geographical location, treatment regime and 
country where it is used (Santos et al. 2008). Resistance has also become 
increasingly apparent to antimonial treatment due to contributing factors such as 
attempting to discover optimum therapeutic dosage and progressively increasing 
total dose to suppress unresponsiveness (Panagiotis et al. 2010).  
1.1.2.1.1.2 Pentamidine isethionate  
Pentamidine isethionate (Pentacarinat, Sanofi-Aventis) is an aromatic diamidine and 
is primarily used for treating Pneumocystis jiroveci pneumonia (formerly known as 
Pneumocystis carinii) at a dosage of 4 mg/kg/dose for at least 2 weeks. This drug is 
also toxic to some protozoa and fungi including Leishmania and African 
trypanosome. It is a second line treatment that is used if patients are unresponsive to 
treatment of antimonials. However, it is used as the mainstay treatment of CL in parts 
of South America such as French Guyana where more than 90 % of cases are due to 
L. guyanensis which is less sensitive to antimonials and has a high risk of causing 
dissemination. Increasing numbers of CL patients have not been responding to the 
dosing regimens in use which may be due to emerging resistance or low patient 
compliance (Bray et al. 2003). As treatment is for 3 weeks there have been reports 
that only 50% of patients finish the course of treatment. This is a typical occurrence 
for many drug treatments in this part of the world leading to resistance as a common 
complication (van der Meide et al. 2009). However, efficacy has been described, 
Soto et al reported that a total of seven injections of 2 mg/kg of pentamidine 
administered on alternating days resulted in cure of 95 % of patients infected with 
Columbian CL, and more recently that this efficacy was comparable (86 %) on 
administration of only 4 injections on alternating days (Soto et al. 1994). Although, 
the majority of the cohort studied (64 %) presented side effects mostly including 
myalgias, injection-associated pain and nausea, these were reversible on completion 
of treatment. Moreover, an increased dose of 3 mg/kg of 4 injections on alternating 
days demonstrated a 96% healing. A low dose treatment (4 mg/kg) consisting of 2 
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injections administered 48 h apart resulted in cure in over 80% without any toxic side 
effects in French Guyana (Nacher et al. 2001).  
However, pentamidine has been shown to be less tolerated in patients with renal 
disease as hyperglycemia has been reported after only 1 dose of 200 mg (Soto-
Mancipe et al. 1993). In one study, pentamidine was shown to less effective than 
glucantime as indicated by the presence of parasites after 2 weeks of pentamidine 
therapy and overall efficacy of 35 % healed compared with 78 % cured of those 
treated with Glucantime (Andersen et al. 2005).   
Overall, due to the short treatment regimen and high efficacy for treating CL, 
Pentamidine is an attractive alternative therapeutic for patients that are unresponsive 
to antimonial treatment (Berman 1997).  
1.1.2.1.1.3 Miltefosine (Impavido) 
This is a phospholipid derived drug (hexadecylphosphocholine, HePC) that was 
principally synthesised as an anti-cancer agent. It has also been found to be a potent 
anti-Leishmanial drug. Miltefosine treatment has been approved for treatment of VL 
with a dose between 50-100 mg daily for 28 days (Sundar and Olliaro, 2007). 
Miltefosine has also been investigated in treating CL and has been shown to 
demonstrate efficacy with the use of 2.5 mg/kg/day (~150 mg/day) for 28 days. It has 
the exceptional benefit of oral administration and also excellent bioavailability. Due to 
these benefits there is high tolerability by patients, and with a minimal hospital 
requirement, makes it a practicable therapeutic option. It also has a long half-life in 
the body of up to 5-6 months before complete elimination from the body. A study 
reported that 100 mg per day for 28 days led to long-term cure rates in excess of 95 
% of patients with VL (Sundar et al. 1998). Further to this, an open-label phase I/II 
trial whereby both patients and researchers know the details of the drug that is being 
administered in 32 patients infected with CL that were treated with 133-150 mg/day 
for 30 days, demonstrated a 94 % cure rate (Soto et al. 2001). In 2004, Soto and 
colleagues also showed in a large, placebo-controlled study whereby patients with 
CL were administered the active drug miltefosine or a placebo, that the cure rate of 
CL in Columbia and Guatemala was 91 % for treatment of L. panamensis. However, 
efficacy rate was reduced on treatment of L. mexicana (60 %) and L. braziliensis (33 
%) lesions (Soto et al. 2004). Although, a more recent clinical trial of Miltefosine 
treatment for patients infected with L. (Viannia) guyanensis gave rise to a 74.5 % 
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cure rate; greater than antimonial treatment (53.6 %). However 48.3 % of patients 
had adverse side effects of vomiting (Talhari A et al. 2011). Adverse reactions to the 
drug have also been shown on treating patients with VL (approximately 40%) for the 
first two weeks with miltefosine. These included motion sickness, vomiting and 20% 
had diarrhoea as side effects (Sundar and Rai 2002). Another disadvantage is that it 
is teratogenic and it is mandatory that women of child-bearing age use reproductive 
contraception during, and at least 2-3 months after, treatment period (Sindermann 
and Engel 2006). However a recent study recommended that this should be 
extended to at least 5 months based on miltefosine‟s long half-life in the body (Dorlo 
et al. 2008). Despite this, miltefosine has been recently registered for treatment of CL 
in Columbia (2005), MCL in Bolivia and the first oral drug to be registered for treating 
VL in India (2002).  
1.1.2.1.1.4 Azoles 
Azoles are sub-divided into two classes, imadizoles such as ketaconazole (Nizoral) 
and triazoles such as fluconazole and itraconazole (Sporanox). They are broad 
spectrum fungistatic compounds that act by selectively inhibiting the biosynthesis of 
ergosterol in cell membranes and thereby causing cell death. Although their 
mechanism and antifungal activity is the same, triazoles are metabolised slower in 
the body and therefore appear to interfere less with human sterol synthesis resulting 
in a reduced related toxicity compared with imadizoles. Due to this, ketaconazole has 
been shown in reports to be associated with poor tolerability in humans due to 
adverse side effects on the gastrointestinal tract such as vomiting, nausea and 
hepatotoxicity. Itraconazole is significantly better tolerated. Despite this, both classes 
demonstrate considerably less toxic side effects to humans compared with other 
therapies such as antimonials. They are antifungal synthetic agents that can be taken 
orally and can be used to treat leishmaniasis. However, they do demonstrate slower 
anti-leishmanial activity on some Leishmania strains compared to antimonial 
treatment (Palumbo 2009). Ketaconazole has been found to have mixed therapeutic 
efficacy in the treatment of CL, and this has been shown to be species dependent. A 
study investigating ketaconazole treatment (600 mg/day for 28 days) on patients 
infected with L. panamensis demonstrated a 76 % clinical cure, although the patient 
cohort was small (21 patients) (Saenz et al. 1990). This was comparable to 
Pentostam (20 mg active agent antimonial/kg for 20 days) that gave rise to a 68 % 
cure rate in the same study. In contrast a recent report found that there was only a 30 
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% cure rate of treatment of L. brazilienesis compared to 96 % efficacy of Pentostam 
which also generated a more rapid response (Navin et al. 1992).  Oral treatment of 
200 mg per day for 6 weeks of fluconazole was found to accelerate the healing rate 
in CL in a study in Saudi Arabia (Alrajhi et al. 2002). However the length of treatment 
and resulting cost made it an unrealistic first choice. It has to be noted that the 
conflicting data reports seem to be due to, in part, uncontrolled studies without 
placebo controls. 
1.1.2.1.1.5 Paromomycin (Aminosidine) 
Paromomycin is an aminoglycoside antibiotic that is licensed in Europe for the 
treatment of bacterial diseases. It is administered parenterally with the recommended 
dose of 15 mg/kg/day for 10 days. Aminosidine is also recommended for the 
treatment of protozoan infections such as tapeworm and also leishmaniasis.  It has 
been shown to be effective in treating VL systemically, with 79 % of patients healed 
after 14-16 mg/kg/day of injections over 19 days (Chunge et al. 1990). However, it 
has shown less potential as an anti-leishmanial agent in treatment of CL. Ninety 
military patients in Columbia were administered intraperitoneally with either 12 mg or 
18 mg/kg/day of aminosidine sulphate over either 7 or 14 days. Twelve months post 
treatment, cure rates ranged from 10-50 % (Soto et al. 1994). As described 
previously, it can be used alone; however parasitic resistance appears to be readily 
induced and therefore combination therapy with antimonials has been investigated 
(Croft et al. 2006). Due to this, investigations into combination therapy with 
antimonials such as Pentostam have shown promise. Systemic administration over 
20 days cured 82 % of patients in an India based pilot study. Significantly, treatment 
with Pentostam alone, gave rise to comparable efficiency but with double the 
treatment time (40 days) (Thakur et al. 1992). It should be noted that due to this drug 
being an aminoglycoside it can give rise to renal toxicity if absorbed systemically and 
eighth cranial nerve palsy due to its ototoxic properties, particularly when used in 
combination therapy or for a long period of time (Berman 1997). Therefore 
investigations into a topical application for treating CL have been conducted and are 
discussed in Section 1.1.2.1.2.1.1.  
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1.1.2.1.2 Topical treatment 
Topical therapy for CL would be an ideal route to treat a localised skin disease. As 
the standard first line treatment is invasive using pentavalent antimonials, it can often 
require hospitalisation. Topical treatment would greatly reduce the cost of treatment 
per person and therefore would be more suitable for those in poverty stricken 
endemic regions. As local treatment could be self-administered, there would be no 
need for hospitalisation and the labour-intensive monitoring of potential systemic side 
effects such as hypoglycaemia and cardiotoxicity. However, it is important to note 
that this type of therapy is dependent on the morphology of the lesions. If the majority 
of the lesions are ulcerating, then there is a high success rate using topical 
applications. However, if the lesion present as hyperkeratotic or are due to being 
infected with L. tropica, L. aethiopica and L. donovani, then topical therapy would be 
limited due to the lesions having poor permeability and the nature of these strains to 
disseminate and cause a variety of other complications including lymphadenopathy 
(Amato et al. 2004; Bailey and Lockwood 2007; Kim et al. 2009). Topical therapy for 
CL infections could therefore evolve to be species specific.  
1.1.2.1.2.1 Incorporation of active drugs into topical applications 
1.1.2.1.2.1.1 Paromomycin 
Incorporation into a topical ointment using paromomycin as an alternative approach 
to treating CL has been extensively investigated. However, the results remain varied 
on its potential at healing CL lesions (Sundar & Rai 2002). Methylbenzethonium 
chloride was first utilised in a topical application with paromomycin because of its 
ability to suppress the growth of L. major in in vitro and has also been shown to 
increase the cutaneous permeability of paromomycin (el-on et al. 1983; El-on and 
Messer 1986). A controlled clinical study of 39 patients using a combination of 15% 
paromomycin sulphate solubilised in soft paraffin and either 5% or 12% 
methylbenzethonium chloride gave rise to a cure rate of 74 % after 2 applications per 
day for 10-20 days (el-On et al. 1992). There was no significant difference between 
the differing percentage of methylbenzethonium chloride and it was found that the 
total parasite burden was alleviated after the first 10 days of treatment. This efficacy 
was also found by Neal and colleagues in vivo using a 15 % aminosidine sulphate 
ointment containing 10 % urea and soft white paraffin (Neal et al. 1994). The 
combination with methylbenzethonium stimulates more local side-effects than that of 
urea, which is non-irritant in mice. This cured L. major lesions in non-healing BALB/c 
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mice after 10 days of treatment. Efficacy was maintained without urea, although 
some relapses did present 10 weeks post treatment. This treatment was not effective 
in treating L. mexicana and L. panamensis lesions in these genetically susceptible 
mice (Neal et al. 1994). A more recent clinical study in Guatemala confirmed the 
former findings of high healing rate of 91.4 % on completion of treatment using a 15 
% paromomycin and 12 % methylbenzethonium chloride ointment, twice daily, for 20 
days (Arana et al. 2001) This ointment is licenced and commercially known as 
Leshcutan (Teva Pharmaceuticals). Side-effects of treatment in patients consisted of 
local inflammatory reactions although this was coupled with an increased efficacy of 
the paromomycin/ methylbenzethonium ointment (Palumbo 2009). A randomised 
controlled study also described efficacy (79.3 %) of topical 15 % paromomycin and 
12 % methylbenzethonium chloride ointment which was comparable to intramuscular 
treatment of antimonials (MA). However, clinical healing took longer in patients that 
were administering the topical application (Armijos et al. 2004). This was also shown 
by Faghihi and colleagues in a double blind ranodmised trial that a four week 
treatment schedule or paromomycin ointment was shown to provide significantly 
higher cure rates than a shorter two week course or two weeks placebo (Faghihi et 
al. 2003). However, a double-blind randomised trial in Iran demonstrated that 15 % 
paromomycin ointment showed inefficient healing of CL lesions after 30 days of 
treatment compared to the placebo control (Iraji and Sadeghinia 2005). A recent 
meta-analysis of 14 randomised controlled trials of topical paromomycin was 
performed to ascertain the overall potential of this drug as a treatment for CL. Kim 
and colleagues found that there was similar efficacy to intralesional antimonials for 
Old World infections (L. major) but there was less efficacy than parenteral 
antimonials for New World infections (L. braziliensis) (Kim et al. 2009). This is not 
surprising, considering the higher prevalence of dissemination of localised infections 
and development of MCL in the latter.  
As an alternative to the toxic and irritant effects of methylbenzethonium chloride, 
Gentamicin has been shown to be beneficial with paromomycin as an anti-
leishmanial ontiment against several Leishmania species in vivo (Grogl et al. 1999). 
As a result a formulation of paromomycin and gentamicin in a hydrophilic base called 
WR279, 396 completed a Phase II trial and a Phase III trial is ongoing due to it 
demonstrating 94 % efficacy in treating L. major infections after 20 days of treatment 
(Ben Salah et al. 2009). A hydrophilic base such as a cream or gel is of particular 
importance in investigating a topical application as it has been shown to increase the 
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cutaneous permeation of parmomycin by 20 times on hairless mouse skin in the 
absence of the stratum corneum (Castro et al. 2003). This is the outermost barrier of 
the skin and limits the permeability of many drugs. A study conducted by Gonçalves 
and colleagues demonstrated that a 10 % parmomoycin gel alone was efficacious 
against experimental L. amazonensis and L. braziliensis infections (Gonçalves et al. 
2004). Another avenue that has been explored more recently is the utilisation of 
liposomes. These are lipid vesicles that can encapsulate target molecules and are 
utilised as drug carriers. Topical liposomal paromomycin has been described to be 
effective in reducing both lesion size and parasite burden in an L. major experimental 
mouse model (Jaafari et al. 2009). Further investigations by Carneiro and colleagues 
support these findings lending promise to its potential as a topical application in 
clinical trials (Carneiro et al. 2010).  
1.1.2.1.2.1.2 Azoles 
Ketaconazole is an oral treatment for CL and was recently incorporated into a cream 
for topical application. In a study of 73 patients only 15.7 % of those treated with 
ketoconazole cream had healed lesions in comparison to 14.3 % of those who were 
treated with the placebo. After one month of this treatment this rose marginally to 
28.9 %, highlighting the difficulty of incorporating a drug into a topical application 
(Momeni et al. 2003). Further studies on variants of imidazoles did not yield any 
promising results. Either 2 % miconazole or 1 % clotrimazole were applied topically 
for 30 days to patients twice daily. However, after completion of the treatment 
regimen only 16 % of the latter showed signs of healing and no healing was 
observed in the miconazole treated group (Larbi et al. 1995).  
1.1.2.1.3 Physical local therapy 
In rural poverty stricken areas where there are limited resources, typical treatment 
would involve physical local therapy. Further to this, investigations into creating local 
therapy that are not invasive and that do not require buying pharmaceuticals have 
been explored. Described below are a few examples; 
1.1.2.1.3.1 Removal of lesion 
Lesions can be removed via curettage with applied heat or freezing or surgical 
removal. This can be effective but is limited to very early nodular lesions and is not 
appropriate for Leishmania species that disseminate. This type of method has been 
associated with a high relapse rate and also potential infection (Dowlati 1996b).  
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1.1.2.1.3.2 Thermotherapy 
Leishmania species are heat-sensitive. Temperatures of 50°C for 30 seconds per 
lesion 1-3 times per week have been found to heal lesions. This has led to the 
production of a radio-frequency heat generator, FDA-approved portable thermal 
device that can be utilised in impoverished areas. Heat can be discomforting to 
patients and therefore local anaesthetic (1% lidocaine HCL) may be administered by 
injection, requiring a trained professional. Velasco-Castrejon and colleagues 
conducted a study in Mexico of a cohort of 201 patients that demonstrated 95 % cure 
of L. mexicana CL lesions after one single application (Velasco-Castrejon et al. 
1997). No follow up was recorded. Although the results are promising, thermotherapy 
generally results in the formation of skin bullas due to the heat administered  
(Piscopo & Mallia 2007).  
1.1.2.1.3.3 Cryotherapy 
Is a common treatment for Old World CL lesions and consists of repeated 
applications of liquid nitrogen to the lesion and up to 2 mm surrounding it. The 
mechanism of effective parasite removal involves the rapid freezing of cells to cause 
destruction and ischemic necrosis (Asilian et al. 2004). Freezing time varies between 
10-30 seconds per application and is repeated 2-3 times in a 30-120 second time 
period. Lesions and immediate surrounding tissue appear whitened after application. 
Successful elimination of the lesion occurs typically with some oedema and blistering 
which is followed by crusting over 2-3 days. Side-effects include local pain and 
reversible hypo-pigmentation in 68 % of patients (Minodier and Parola 2007). A 
randomised clinical trial conducted in Iran demonstrated that cryotherapy in 200 
patients treated fortnightly with a total of 3 session‟s demonstrated 57.15 % cure of 
CL lesions. An investigation of combining this therapy with Glucantime, showed a 
cure rate of 90.9 % (Asilian et al. 2004). A more recent study also illustrated a greater 
benefit of cryotherapy in combination with systemic administration of itraconazole 
(80.95 % cure rate after 6-8 weeks of treatment)(Al-Mutairi et al. 2009). A 
comparison study between intralesional MA and cryotherapy treatment with L. tropica 
infected children in Iran revealed that there were no significant differences between 
the 6 week treatments. This was recommended as an alternative therapy for children 
who have a lower response rate to MA than adults (Layegh et al. 2009). Follow up of 
only 6 months revealed no relapse.  
 
Chapter 1 
Introduction 
Karina D. Corware 
 
44 
 
1.1.2.1.3.4 Photodynamic therapy (PDT) 
PDT is an established method of therapy in dermatology for treating pre-malignant 
and malignant skin conditions. It involves the topical application of photosensitizers, 
in this case, porphyrin precursors to the lesions so that they can become activated on 
irradiation of applied visible red light. This stimulates the production of free radicals 
and induces a cytotoxic effect to unwanted cells so that they become necrotic 
(Fritsch et al. 1998). As it is applied to the site of infection it is well-tolerated with few 
adverse effects such as burning sensations and alteration of pigmentation which is 
reversible after completion of therapy. The former may result in the need for a local 
anaesthetic. The success rate of PDT therapy is dependent upon the accumulation of 
the photosensitiser in diseased cells for long periods of time (Choudhary et al. 2009). 
This therapy requires professionals with technical expertise in a hospital setting. It is 
also time consuming and, although there is indications that there are benefits, further 
long-term follow-up on the incidence of relapse is essential to consider this as a 
realistic therapy.  
 1.1.2.2 Amphotericin B 
Since registration of antimonials, there has been much investigation into alternative 
therapies and the anti-leishmanial potential of amphotericin B (AmB) was a 
significant step forward in medical therapy of the disease. However, this molecule on 
its own is extremely toxic to both Leishmania and its plagued host, and it became 
necessary to develop a modified version of AmB that would maintain efficacy with 
limited toxicity.  
AmB is a polyene antibiotic drug extracted from gram-positive Streptomyces nodosus 
by E R Squibb and Sons in 1955. AmB is a potent antifungal and after over 40 years 
of clinical use. Hence, it is the most effective drug on the market for treating systemic 
fungal infections. It is active against a broad spectrum of fungi including yeasts but 
has no activity against bacteria (Dupont 2002). The name AmB originates because of 
its amphoteric properties as it contains both an amine and carboxylic acid group. It is 
zwitterionic at neutral pH. As shown (Figure 3), the molecule also possesses a 
hydrophobic region consisting of a long conjugated carbon-carbon chain and a 
hydrophilic region made up of many hydroxyl groups. It is a “molecular 
schizophrenic” and is classed as an amphipathic molecule due to the asymmetric 
distribution of the polar and non-polar groups (Adediran et al. 2009). The orientation 
and quantity of the carbon double bonds in the hydrophobic region gives rise to a 
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molecule with a low energy state that is responsible for absorption of light in the UV 
visible region enabling identification of characteristic properties. AmB is a yellow 
powder that is also odourless.   
 
 
Figure 3: Structure of Amphotericin B 
Amphotericin B has zwitterionic properties as it has a long hydrophobic C=C back 
bone (shown in red) with a hydrophilic region of hydroxyl groups (shown in blue). 
 
1.1.2.2.1 Mode of Action 
1.1.2.2.1.1 Channel formation 
Most antifungals act by interfering with the integrity of fungal membranes and AmB is 
no exception. It interacts with sterols within the cellular membranes to create pores 
that disrupt the cellular structure resulting in cell death (Kasai et al. 2008). Research 
indicates that the primary mode of action of AmB is to interact with the sterol 
components of cell membranes resulting in formation of ion-permeable channels. It 
has been suggested that AmB carries this out in 2 stages. The first stage is forming a 
non-aqueous channel that is permeable to monovalent cations such as potassium 
ions but not to protons (H+) and glucose (Cohen 1992;Ramos et al. 1996). This is 
followed by the second stage of interacting with sterols to form an aqueous pore that 
is permeable to monovalent cations and anions including Ca2+. This results in 
irregular ionic distribution and ultimately cell death (Baginski et al. 1997b;Brajtburg et 
al. 1990;Fujii et al. 1997) (Ellis 2002).  Only when there is a sufficient quantity of AmB 
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present does it interact with sterols. Pore formation in lipid membranes will occur 
when the AmB concentration exceeds a critical value of 16 AmB molecules per 
liposome (Weakliem et al. 1995). The exact molecular structure of each AmB-sterol 
channel is not known, and several models have been suggested.  Kruijff and Demel 
proposed that there are approximately 8 AmB molecules that interconnect with 8 
sterols to form a circular arrangement (de and Demel 1974). It has also been 
concluded that at least 6-8 AmB molecules are involved in the formation of these 
channels and that they are stabilised by strong hydrogen bonds between the 
hydroxyl groups within the AmB molecule, (Bonilla-Marin et al. 1991;Khutorsky 
1992), and also by Van der Waal‟s forces along the hydrophobic carbon-carbon 
double bonded chain (Herve et al. 1989;Paquet et al. 2002). The hydrophilic hydroxyl 
groups are positioned inwards and make up the inner lining of the channel as the 
lipophilic carbon chain interacts with the cell membrane. Molecular simulations 
propose that with this orientation, AmB molecules interconnect alternatively with 
sterol molecules to form a lipid bilayer that remains stable and open by hydrogen 
bonding between the AmB molecules (Baginski et al. 1997b).  
1.1.2.2.1.2 AmB-Sterol Interactions 
As stated, research suggests that two types of interactions can occur between AmB 
and sterols. To maintain an AmB-sterol channel, strong hydrogen bonding is believed 
to be present between sterol molecules and the mycosaminyl groups in AmB 
molecules (Baginski et al. 2002). Weak Van der Waal‟s forces are also described to 
aid the interaction between the hydrophobic tail of AmB and the steroid rings in 
sterols (Paquet et al. 2002). AmB interacts with ergosterol in fungal cells and the 
ergosterol precursors episterol and 5-dehydroepisterol in Leishmania parasites. It 
can also interact with cholesterol in mammalian cells. The use of AmB as an effective 
antifungal drug is governed by it having a higher affinity to interact with ergosterol 
rich rather than cholesterol rich membranes (Archer and Gale 1975) (Baran and 
Mazerski 2002).  
The structures of ergosterol and cholesterol are shown in Figure 4. They show minor 
structural differences only. However, it is suggested that these small differences are 
significant and this results in AmB interacting more favourably with ergosterol 
(Baginski et al. 2002). Unlike cholesterol, ergosterol contains an additional carbon 
double bond and methyl group on its side chain and another carbon double bond 
within the steroid ring. It is the additional double bonds that provide it with the ability 
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to decrease the intermolecular distance to AmB and thereby build stronger 
electrostatic interactions between the molecules (Baginski et al. 1989). This theory is 
reinforced by findings from Readio and Bittman demonstrating that the binding affinity 
constant for AmB to ergosterol is Ka = 6.9 x 105 M-1 compared to that of AmB to 
cholesterol of Ka = 5.2 x 104 M-1 (Readio and Bittman 1982). This suggests that a 
greater concentration of AmB is necessary to interact with cholesterol than with 
ergosterol. Modelling experiments have shown that cholesterol orientates in a freer 
and non-specific manner, which may, in part, be due to it containing fewer carbon 
double bonds (Baginski et al. 1997a).  
 
 
 
Figure 4: Structural differences of Cholesterol and Ergosterol 
(A) Cholesterol and (B) Ergosterol. Ergosterol contains 2 additional C=C bonds and a 
methyl group on its side chain compared to cholesterol (highlighted in red on Figure 
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4B). It appears that this slight difference in structure of ergosterol gives rise to a 
higher binding affinity to AmB. Extracted and annotated from www.doctorfungus.org  
 
1.1.2.2.1.3 Cell Death 
 AmB kills Leishmania parasites by forming aqueous pores with ergosterol precursors 
that lie within the cellular membrane. This results in the depolarization of the 
membrane and an increase in membrane permeability, leading to osmotic cell lysis. 
Fungal cells contain a cellular wall so are killed indirectly by the increase in 
intracellular pH and the disorganization of the outer membrane, causing loss of 
potassium. As mentioned, there is a minimum concentration threshold that is 
required for AmB to create these aqueous pores resulting in a steep alteration of 
ionic gradients. Below this threshold, AmB forms non-aqueous pores and 
demonstrates cell membrane damage that is toxic but potentially reversible. 
1.1.2.2.1.4 Toxic effects of AmB in mammals 
Fungal and mammalian cells are both eukaryotic and therefore antibiotics that kill or 
inhibit fungal membranes can also be toxic to host mammalian cells. As AmB 
interacts with sterols, it does have an affinity to construct transmembrane channels 
with cholesterol in mammalian cell membranes. This interaction is believed to 
contribute to its toxic properties. It is due to these toxic properties that there is a 
dose-limiting factor among patients and a maximum dose of only 0.6 mg/kg of body 
weight per day that can be administered under careful medical monitoring. More 
recent developments have shown that it is possible to increase this to 10 mg/kg/day. 
However, it should be noted that this is possible due to modifications of the target 
drug (Sundar et al. 2009). Due to its toxicity, AmB is typically administered as an 
infusion over a period of time. Toxic side-effects can present in patients as quickly as 
1-3 hr after infusion and characteristically present as flu-like symptoms such as fever, 
chills, nausea, vomiting, rigors and anaphylaxis in up to 70% of patients to 
hypotension, pulmonary congestion, lethargy and agitation (Cleary et al. 1988;Deray 
2002). Although reactions are patient dependent, this is a frequent response.  Hence 
AmB is initially administered at a very low dose which is incrementally increased 
depending on the side-effects that occur. These can be treated effectively with 
hydrocortisone, diphenhydramine and antihistamines. In severe cases the toxic 
effects lead to hepatotoxicity, thrombocytopenia, leukopenia and nephrotoxicity, and 
ultimately irreversible organ damage. This is partly due to the AmB-induced increase 
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in concentration of free intracellular calcium (Sabra et al. 1990). Over 80% of patients 
will develop reversible renal impairment during their treatment and this increases the 
incidence of death by 2-2.7 fold (Luber et al. 1999). Renal dysfunction is due to a 
reduction in the filtration rate of the glomerulus as a result of capillary 
vasoconstriction from the drug‟s infusion. It is also a direct consequence of AmB‟s 
interaction with cholesterol in the tubular cell membranes resulting in renal tubular 
dysfunction (Sawaya et al. 1995). This can lead to polyuria, polydypsia and a 
decrease in the concentrating ability of the kidney. A study in rats showed that the 
rate and severity at which these appear is dependent on the extent of hydration 
during AmB treatment. An excess of 4 L daily diuresis can prevent renal dysfunction 
(Mayer et al. 2002). It has been established that administration by slow infusion with 
excess fluids is essential in limiting AmB-related toxicities(Rubin et al. 1989). A 
randomized placebo controlled study of 20 patients illustrated that salt loading of 1L 
0.9% NaCl provided a protective effect against AmB-related renal dysfunction 
(Llanos et al. 1991).  
1.1.2.2.2 Aggregation of AmB 
 AmB is amphipathic in nature and has low aqueous solubility. These properties have 
also been shown to contribute to toxicity in humans (Torrado, 2008). AmB in water 
forms a mixture of small monomers and self-associated aggregates. Water soluble 
monomeric AmB has been shown to not exhibit toxic tendencies in the body 
(Legrand et al. 1992). However, when AmB is in its aggregated form, it has been 
found to be the cause of toxicity and therefore its aggregation status has become a 
focal point of new research (Barwicz et al. 1992;Bolard et al. 1991;Gallis et al. 1990). 
There are numerous theories on the interactions that occur between AmB molecules 
that lead them to aggregate. Mazerski and Borowski suggest that AmB monomers 
prefer to reduce the apolar surfaces that are exposed in solution and therefore 
interact between themselves and form aggregates. A general consensus is that it is 
dependent on the concentration of AmB. The following equation illustrates this. 
 
   2[monomer]    [dimer] 
This therefore means that:  Keqm = [dimer] / [monomer]2 . The formation of dimers, 
from this equation, requires the presence of 2 monomers and therefore for the 
formation of larger aggregates a greater concentration of AmB molecules is needed. 
Keqm 
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To determine the state of AmB in a particular solution the use of UV 
spectrophotometer has been employed. Due to the presence of seven conjugated 
double carbon bonds in its structure, AmB can be characterised by its optical 
properties in the region between 300-450 nm. An absorption peak in the region of 
320 and 340 nm, typically at 328 nm Figure 5, peak 1) is characteristic for AmB 
aggregates (Gruszecki et al. 2003). AmB in its monomeric form exhibits an additional 
peak at 409 nm (illustrated in Figure 5, peak 4) (Menez et al. 2006). A ratio between 
the 2 peaks can be calculated to highlight the aggregation state of AmB within a 
solution. A ratio of 1 would imply that both peaks are approximately equal to each 
other, whereas a ratio of 2 would indicate a highly aggregated species. In a 
predominately monomeric state a ratio of 0.25 would be recorded (Barwicz et al. 
1992). When the spectrum of AmB is measured, there are 2 more peaks present; in 
the region of 358 nm (Figure 5, peak 2) and 370 nm (Figure 5, peak 3). These 2 
peaks are believed to be characteristic of super aggregates (Sanchez-Brunete et al. 
2004) and do not appear to alter or influence the state of toxicity of AmB. 
 
 
Figure 5: UV spectrum of AmB 
This spectrum illustrates the characteristic peaks of AmB recorded in the visible light 
region. At 328 nm (peak 4) AmB is arranged in an aggregated state compared to at 
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409 nm (peak 1) when AmB is in a monomeric state. Between 350 and 400 nm there 
are 2 further characteristic peaks which generally remain unchanged.   
 
As mentioned, the major determinant of the formation of aggregates of AmB is 
concentration. At below 10-4 M, AmB is found in a monomeric state with an 
absorption spectrum at 409 nm. As the concentration increases, the peak in the 
region of 320-340 nm emerges indicating the formation of aggregates (Romanini et 
al. 1999). The medium in which AmB is solubilised is an additional factor, as well as 
pH and temperature that can also influence the aggregation state. In polar organic 
solvents such as methanol and DMSO, AmB remains in a monomeric state. In 
aqueous solutions, AmB readily forms aggregates. The critical aggregation 
concentration of AmB in aqueous solutions is 10-6 M. At concentrations below this, 
AmB is in a soluble monomeric state and therefore targets only ergosterol-containing 
membranes (Legrand et al. 1992). This therefore means that no toxicity is observed 
in mammalian cells. On administration, intravenous AmB becomes highly bound to 
lipoproteins (Ridente et al. 1999). Above this concentration, AmB begins to 
aggregate and the interaction with cholesterol occurs. This leads to a higher 
prevalence of toxicity and also RBC lysis (Bolard et al. 1991; Gaboriau et al. 1997). 
Insoluble super-aggregates do not exhibit toxicity in mammalian cells (Sanchez-
Brunete et al. 2004). Heating of AmB has also been shown to alter the aggregation 
state. An AmB-deoxycholate formation heated to 70°C for 20 min results in a mixture 
of monomer and super-aggregated forms of AmB (van Etten et al. 2000). 
1.1.2.2.3 Formulations of AmB 
The potential of AmB as a therapeutic medicine is severely limited by its associated 
toxic side-effects. As described, they primarily lead to severe renal function 
impairment and even nephrotoxicity (Sabra et al. 1990). AmB is a hydrophobic 
molecule and therefore insoluble in aqueous solutions.  However, it is soluble in 
organic solvents such as DMSO, however this is a carcinogen. There are various 
formulations on the market that have tried to increase AmB solubility so that it can be 
administered in humans more efficiently to target pathogens with a lower incidence of 
side effects. The pharmacological activity and toxic side effects are directly 
dependent on the molecular organisation of AmB in a formulation (Gagos et al. 
2008).  
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1.1.2.2.3.1 Fungizone  
This formulation is produced by Bristol Myers, Squibb and contains the detergent 
sodium deoxycholate to enable AmB to form a micelle dispersion on reconstituting 
the lyophilised powder with buffered water. It has been available since 1958 for 
treatment of fungal infections and has a 1:2 ratio of AmB: deoxycholate which is 
administered intravenously (Torrado, 2008). Usually described as the conventional 
formulation, Fungizone is inexpensive to manufacture with a vial containing 50 mg of 
AmB costing £ 3.59 (British National Formulary, 2010). It is essential to administer it 
slowly over a period of several hours as there is high patient to patient variability in its 
tolerance. This means that it requires a high level of hospital care and is not ideal in 
the rural areas where leishmaniasis occurs. The Fungizone formulation does not 
have the ability to control the aggregation state of AmB and has been unable to 
alleviate the toxic side-effects that are characteristic of this potent drug (Adams and 
Kwon 2004). Therefore its administration still poses a threat to patients often 
resulting in kidney failure which leads to early termination of treatment.  However, it is 
still considered in countries as second line treatment for example in Brazil for 
mucocutaneous leishmaniasis due to the extensive literature on its efficacy and low 
cost (Amato et al. 2008). Fifteen alternate 6 h infusions of 1 mg/kg Fungizone 
resulted in cure responses at day 30 and a 96. 3 % cure after a 6 month follow up. 
However, this was associated with 64 % of patients with fever and/or rigors and 19 % 
having anemia (Sundar et al. 2010). Fungizone is ineffective in treating experimental 
L. major infections. This highlights the need for further modifications to the active 
drug AmB to create a more effective treatment that can be used for CL (Yardley and 
Croft 2000) (Barratt and Legrand 2005;Golenser et al. 1999).  
1.1.2.2.3.2 Lipid formulations 
Lipids have been used over the years due to their flexibility in providing a delivery 
system for drugs and vaccines (Alving 1991) (Bhowmick et al. 2009). The most 
important attribute is the ability to eliminate toxicity of potent active drugs such as 
AmB. There are three lipid formulations that are currently marketed drugs for the 
treatment of systemic fungal infections. However, liposomal AmB in the form of 
AmBisome has been the most extensively investigated in the treatment of 
leishmaniases, particularly for visceral. Although lipid formulations are less toxic 
thereby allowing for greater efficacy in man, they all are associated with a high cost 
that is related to manufacturing the liposomal delivery systems. In countries such as 
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Brazil, treatment with a lipid formulation, such as AmBisome, necessitates that all 
other therapeutics have been tried and failed (Table 2) (Amato et al. 2007). Lengthy 
paperwork has to be submitted to government officials before it can be released 
(Conceicao-Silva 2010) 
1.1.2.2.3.2.1 Abelcet  
Abelcet involves the encapsulation of AmB into 2 phospholipids which are combined 
in a 7:3 molar ratio; L-α-dimyristoylphosphatidylcholine (DMPC) and L-α-
dimyristoylphosphatidylglycerol (DMPG). It appears as a flattened ribbon-like 
multilamellar structure with an AmB: lipid molar ratio of 2:1 and has a particle size of 
1600-11,000 nm (Dupont 2002). The main disadvantage is that due to its size and 
colloidal nature; it can be removed from the circulation in the body quickly, leading to 
an increased risk of hepatic disorders. On administration, Abelcet is reconstituted in 
5% dextrose and given as an intravenous infusion.  
1.1.2.2.3.2.2 Amphocil and Amphotec  
An alternative is Amphocil (Europe and USA, Sequus Pharmaceutical) that stabilises 
AmB with cholesteryl sulphate in equimolar concentrations to make a disc-shaped 
colloidal complex that forms a dispersion on reconstitution. It has a similar efficacy to 
Fungizone but has been shown to be less toxic and haemolytic in man (Mullen et al. 
1997). Administration involves intravenous infusion and it is recommended that 
premedication such as hydrocortisone is given to limit adverse reactions. 
1.1.2.2.3.2.3 AmBisome 
This is a very expensive (per vial = £99.98) (BNF 2010) but highly effective medicine 
for treating fungal infections. It is a lipid based delivery system that encapsulates 
AmB within a closed fluid-filled unilamellar liposome. This drug delivery system was 
created to increase the efficacy of AmB whilst reducing its toxicity. Liposomes are 
spherical vesicles made from mixtures of phospholipids and cholesterols. 
Phospholipids are amphiphilic molecules containing a polar hydrophilic head 
attached by glycerol carbons to hydrophobic fatty acid side chains. On introduction 
into water, the phospholipids arrange into bilayer structures. These bilayer structures 
can transform from a gel to a liquid crystalline state on increasing temperature. This 
phase transition temperature (Tc) is specific to each phospholipids synthesised and 
is important in the design of a liposome as it will result in increased permeability and 
the release of contents if it enters an environment that is at or above the transition 
Chapter 1 
Introduction 
Karina D. Corware 
 
54 
 
temperature. To this end, liposomes that are manufactured for drug delivery into man 
should be prepared from phospholipids with a Tc above 37°C. The liposome 
manufactured for AmBisome formulation contains hydrogenated soy 
phosphatidylcholine (Tc = 50-60°C) and distearoyl phosphatidylglycerol (Tc = 55°C). 
The high phase transition temperatures aid the stability of the drug enabling AmB to 
remain within the liposome at physiological conditions (Adler-Moore and Proffitt 
2002). A high molar fraction of cholesterol is included that also helps maintain the 
integrity of the liposome and limits leakage of its contents by binding with AmB. This 
single liposomal bilayer preparation has 80 nm of unilamellar charged liposomes and 
can effectively shield the body from the toxic side-effects of AmB. Small liposomes 
such as this are known to have long circulation times in the bloodstream and 
AmBisome is no exception having a half-life of 5-24 h. This also means that AmB 
remains bioavaliable in tissues for several weeks after the drug has been 
administered. The drug can bind to the cell walls of Leishmania spp. causing the 
liposome to disrupt and releasing AmB to the target ergosterol in the cell membrane.  
AmBisome has been proven to be effective against visceral leishmaniasis when 
given at 5 mg/kg as a 5 day course and more recently as a single dose 1 h infusion 
of 10 mg/kg of body weight (Sundar 2001; Sundar et al. 2010). The latter therapeutic 
dose was associated with infusion-related fevers or rigors in 40 % of patients (304 
patient cohort) with 2% having increased anemia and thrombocytopenia. Less than 1 
% developed nephrotoxicity demonstrating minimal toxic side effects and significantly 
less renal damage than typically seen when administering other AmB formulations 
(Sundar et al. 2010;Walsh et al. 1999). AmBisome is the gold standard for treating 
visceral leishmaniasis, though its expense means that it is only available to the rich 
(WHO and Secretariat 2007). A single dose of AmBisome can cost up to 225 times 
more than Fungizone (£3.59 vs £99.98 per vial (BNF 2010) and is therefore not 
affordable to most poor patients in the developing countries. More recent clinical 
trials have shown that it is possible to treat VL with a large bolus single injection 
(Sundar et al, 2010). This, however, was followed by two weeks of miltefosine. 
Although the price of AmBisome has been reduced to approximately £12/vial ($20), 
this new line of treatment is still not cost-effective to impoverished endemic regions 
(Sundar and Olliaro 2007).  
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1.1.2.2.3.3 Oral formulations 
Amphotericin B has been successfully modified using liposomes to formulate a drug 
that is antileishmanial and has low toxicity. However due to the amphiphilic nature of 
AmB it has low solubility which prevents gastrointestinal absorption. Therefore 
current formulations are administered intravenously which necessitates medical 
supervision. This increases the overall cost of the drug and limits its use in rural 
endemic areas. This has encouraged research into developing an oral AmB 
formulation (Chappuis et al. 2007;Oliveira et al. 2011;Singh & Sivakumar 
2004;Thornton and Wasan 2009). Nanosuspensions of AmB have been developed 
that had been shown to adhere to the gastrointestinal tract, improve oral 
bioavailability and reduce renal toxicities (Italia et al. 2009). On assessment of its 
potential in L. donovani infected BALB/c mice, there was a reduction in parasite load 
but no overall cure (Kayser et al. 2003). Cochleates that are lipid bilayer sheets have 
also been used to incorporate AmB resulting in a formulation called Biooral 
Amphotericin B (BioDelivery Sciences International (BDSI). Santangelo and 
colleagues demonstrated a dose dependent reduction in the kidneys of C. albicans 
infected mice (Santangelo et al. 2000). This antifungal efficacy was also found by 
Zarif and colleagues and also against other mouse models of fungal infections such 
as aspergillosis (Zarif et al. 2000; Delmas et al. 2002). BDSI initiated a Phase I 
clinical trial for Bioral AmB in 2008 (BDSI). More recent investigations have resulted 
in an oral lipid-based formulation of AmB called iCo-009 (iCo Therapeutics Inc). It 
has shown significant antifungal and antileishmanial activity in vivo (Wasan et al. 
2009a; Wasan et al. 2009b). In addition, Wasan and colleagues established that a 
variant iCo-010 is stable for over 60 days at temperature ranging from 30 C to 43 C 
as a lipid formulation. This is of particular relevance for parasitic diseases such as 
leishmaniasis that can be found in tropical regions of the world (Wasan et al. 2010). 
The progress of developing an oral formulation is slow and problematic due to the 
nature of AmB, however researchers have shown that it is feasible and holds future 
promise. 
1.1.2.2.3,4 Amphotericin B formulations for CL infections 
Although pentavalent antimonials are first line therapy for CL infections, AmB has 
been utilised as a second line treatment particularly with New World infections that 
have a high prevelance of developing into MCL. Traditional treatment of pentavalent 
antimonials is 20 mg/kg per day administered intravenously or intramuscularly over 
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20 days (Herwaldt and Berman 1992). Both liposomal and deoxycholate formulations 
have been shown to be efficacious for treating VL but their role in treating various 
forms of CL has yet to be evaluated and a standardised regimen is not fully defined. 
It has been used, on occasion, for CL patients that have demonstrated resistance to 
antimonial drugs, immunocompromised patients or those that have developed MCL 
(Torre-Cisneros et al. 1994; Paradisi et al. 2005; Delvin et al. 2005; Musa et al. 
2005). The efficacy of AmB in treating CL infections is still debated with few research 
groups investigating its potential. An early report by Convit and Kerdel-Vegas treated 
two patients with diffuse CL with AmB, however both relapsed several months after 
treatment was completed (Convit and Kerdel-Vegas 1965). Animal studies have 
shown unresponsiveness to different forms of liposomal and deoxycholate 
formulations of AmB against experimental CL infections (Yardley et al. 2000). 
However, more recently liposomal AmB has been advocated as the drug of choice 
for those presenting MCL (Amato et al. 2007). A reported case of a child with severe 
diffuse CL (L. mexicana) that had had six cycles of pentavalent antimonials and 
immunotherapy was successfully cured on treatment with intravenous deoxycholate 
AmB (Morrison et al. 2010). A further case study of a student infected with L. 
braziliensis was clinically cured with intravenous liposomal AmB administered daily 
for 7 days with a further dose twice weekly for 3 weeks (Brown et al. 2005). A small 
non-randomised trial of seven patients, five of which had failed to heal their CL 
infections with a full course of antimonials achieved complete clinical cure within 1 
month of treatment with liposomal AmB. A total of 6 doses of 3 mg/kg AmBisome 
were administered intravenously to seven patients confirmed to have CL due to L. 
braziliensis and no relapse was observed after 12 months. Interestingly, assessment 
of the cost of treatment in this study revealed that the cost of AmBisome treatment 
was 46.5 % less than the total cost of antimonial therapy when accounting for the 
medical assistance required for the side effects of the treatment (Solomon et al. 
2007). Further to this, Solomon and colleagues conducted a small non-randomised 
clinical study of 13 patients that had CL due to L. tropica. The therapeutic response 
was maintained with a total of 6 doses of 3 mg/ kg AmBisome and resulted in 84 % 
(11/13 participants) clinically cured within 2 months (Solomon et al. 2010).  A larger 
study of 20 patients that was conducted by Wortmann and colleagues demonstrated 
an 84 % (16/19 participants) cure rate on administration of liposomal AmB for CL 
infections. However, infusion-related reactions occurred in 25 % and mild renal 
toxicity in 45 % of patients. This high level of reported side effects could be due to in 
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part to the fact that the dosing regimen is still undefined compared to that of VL 
treatment (Wortmann et al. 2010). Further to this, a recent case study reported that a 
patient treated with liposomal AmB for CL had memory difficulties and confusion after 
completion of the course. Although this central nervous system toxicity resolved over 
a few weeks it is worth noting that neurological toxicities are found in up to 20 % of 
cases (Glasser & Murray, 2011). Investigations by Ramanathan and colleagues 
identified efficacy of liposomal amphotericin B in patients identified with different 
leishmanial species. Overall 6 patients that were treated with liposomal AmB for 5-7 
days healed. Three of the patients were identified to be infected with L. braziliensis, 
two with L. infantum chagasi and one with L. tropica. Although the study is small, it 
does suggest that liposomal AmB is efficacious against several CL species 
(Ramanathan et al. 2011).  
Although the studies described indicate that AmB formulations can be used to give 
favourable results in healing CL infections, the majority of these studies are individual 
cases. It is worth noting that the Cochrane analyses have shown that there are, as 
yet, no randomised controlled trials in the literature that demonstrate greater efficacy 
between lipid-based and deoxycholate formulations nor whether amphotericin is 
superior in treating CL infections than pentavalent antimonials (Gonzalez et al. 2009).  
1.1.2.2.3.5 Incorporation of AmB into a topical formulation 
There has also been research into developing a topical AmB application as this 
would allow for higher dose administration with limiting systemic toxicities. A topical 
formulation of AmB in the form of eye drops was developed by Bristol-Myers Squibb 
and is effective against a broad range of fungal corneal infections (Mahdy et al. 
2010). Further to this, cationic nanoparticles have also been shown to be effective as 
a vehicle for the introduction of AmB into the eye (Das and Suresh 2011). However, 
few investigations have been conducted to explore a topical AmB application for CL 
infections. Different lipid-based formulations were tested in an experimental model of 
CL that found that AmB incorporated into a phospholipid structure or in cholesteryl 
sulphate dispersed into ethanol induced a reduction in lesion size over the treatment 
course (3 weeks) (Frankenburg et al. 1998). AmB-deoxycholate was not effective as 
a topical treatment. Further to this, a clinical study of 19 patients that had L. major 
cutaneous lesions in Israel exhibited accelerated healing compared to the placebo-
treated lesions with a topical preparation of Amphocil that was dispersed into 5 % 
ethanol aqueous solution (Vardy et al. 1999; Vardy et al. 2001). No side effects were 
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reported in this study. More recently an infant with CL that had not responded to 
repeated cycles of paromomycin ointment was administered a colloidal solution of 
AmB and cholesteryl sulphate in the presence of 5 % ethanol topically for 3 weeks. 
All skin lesions resolved with no side effects and no relapse was reported 3 months 
after termination of treatment (Zvulunov et al. 2003). The data described suggests 
potential in this topical formulation of AmB, however further studies are required. 
 
1.1.2.3 Summary of Therapy 
Few studies reported and discussed in this Chapter are large randomised control 
trials that have a long term follow up of treatment efficacy. This is of particular 
importance when assessing the relevance of each trial and hence caution has to be 
taken when comparing studies that do not have the same experimental design. Due 
to the poverty stricken area where CL is prevalent there is difficulty in maintaining 
long term trials. Few patients that undergo treatment are able to financially support 
themselves or their family during clinical trials and hence compliance can vary 
substantially between studies. In endemic areas, it is often unrealistic for patients to 
travel long distances regularly for treatment. This often involves taking absence from 
work which means that no income is being generated per person leading to a knock-
on effect on the economy of an endemic area.  
It is certain that a standardised format is required for clinical trials so that drug 
efficacy can be assessed and compared on an even platform. Since 2008, the 
Cochrane collaboration has attempted to narrow the variability of treatment efficacy 
by critically assessing the trials compiled from a variety of trial databases. The 
assessment of drug efficacy in this analysis was defined by the percentage of 
patients that were „cured‟ at 3 months after treatment had terminated. This was 
defined by the absence of all inflammatory signs on the skin and complete scaring. 
Only a third of studies reporting efficacy of Old World CL infections described this 
primary outcome (Gonzalez et al. 2010). Furthermore in 49 trials compiled involving 
5559 patients, only 2 studies had sufficient data and acceptable experimental design 
that the results could be pooled (Gonzalez et al. 2008). Importantly, the studies that 
were included in the Cochrane analyse did not ascertain the quality of life or 
aesthetic impairment that is commonly associated with specific CL infections. The 
Cochrane Library highlights many issues that compromise the integrity of data 
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collected in clinical studies and emphasises the need for a universal standardised 
method for clinical trials to conform to so that statistical analyses are significantly 
relevant (Gonzalez, U et al. 2009; Gonzalez, U et al. 2010). This is crucially important 
when addressing the issue of resistance to treatment and the use of combination 
therapy. Poorly designed studies waste resources and can compromise potentially 
efficacious treatments in countries where financial constraints provide limited 
alternatives.   
As mentioned the first line therapy for cutaneous leishmaniasis infections that is 
recommended by the WHO is intralesional or systemic pentavalent antimonials 
(Minodier, P and Parola, P. 2007). The need for alternatives is due to, among others, 
the route of administration. Intralesional injections are favoured for local treatment 
and this, as discussed, requires skill by a trained professional and is associated with 
considerable discomfort to the patient (Blum, J et al. 2004). Intramuscular, 
intraperitoneal and intravenous injections cause considerably more pain to the 
patient and are associated with more severe side effects hence requiring close 
medical supervision. The length of treatment and pain decreases patient compliance. 
The Cochrane studies highlighted that 16.08 % (894 of 5559) of the total number of 
participants in the studies analysed were lost on follow up of treatment success 
(Gonzalez et al. 2008). The need for medical assistance is another factor that overall 
increases the cost of treatment per patient as exemplified by Table 2. If one can 
afford the cost, the treatment regime can be reduced substantially whilst providing 
100 % efficacy (Amato et al. 2007). These factors have led to the urgent requirement 
for alternative drug therapy options that are ideally less invasive, have fewer side 
effects so that patient compliance is improved and therefore reduce cost.  
As discussed, caution has to be taken when evaluating efficacy of drug treatment. 
Importantly Gonzalez and colleagues demonstrate that there was no randomised 
control trial evidence in the studies assessed to suggest that either intralesional or 
systemic antimonial treatment is of benefit to treating Old World CL (Gonzalez et al. 
2008). However, as a result of the Cochrane analyses, there is good evidence to 
suggest that alternative effective treatments for Old World leishmanial infections such 
as L. major and L. tropica can be realised. This includes the use of fluconazole (200 
mg) for 6 weeks (Alrajhi et al. 2002) and topical 15 % paromomycin with 12 % 
methylbenzethonium chloride (Ben-Salah et al. 1995; Asilian et al. 2006) for treating 
L. major infections. Alternatives for L. tropica infections include the use of 
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itraconazole (200 mg) for 6 weeks and the use of intralesional rather than 
intramuscular pentavalent antimonials (Gonzalez, U et al. 2008). Gonzalez and 
colleagues have also used the Cochrane library to evaluate treatment of New World 
infections caused by L. brazilienisis and L. panamensis infections and support the 
use of pentavalent antimonials for effective treatment, in particular 10 days of 
intramuscular administration (Gonzalez et al. 2009). Alternatives including the use of 
intravenous or topical amphotericin b, azoles and non-invasive therapies were 
inconclusive in their efficacy in treating New World infections dues to the lack of 
randomised controlled trials.  
Overall it is clear that a standardised experimental design approach is necessary in 
seeking alternative efficacious and cost-effective treatments for CL in resource poor 
regions. However, at present the drug treatment that has the most support in favour 
of its treatment of CL remains pentavalent antimonials (Gonzalez et al. 2008; 
Gonzalez et al. 2009). This treatment has been the mainstay therapeutic for CL for 
many years and alternative therapies are urgently needed. Research in the 
development of alternatives are ongoing however if a standardised approach to 
experimental design is not reached, few drugs will be seen as potentials to further 
develop and for pharmaceutical companies to invest in.  
Another issue to note is whether the ideal therapeutic should be species specific. A 
key problem in treatment of patients with CL is the many different species that can 
cause similar clinical symptoms. Often the technology such as PCR is not available 
to accurately determine the species causing infections and this can cause a knock on 
detrimental effect of increased drug resistance and overall cost of medical care. 
Many studies described in this Chapter fail to specify the Leishmania species that is 
being treated and this could contribute to failure of patients developing clinical cure. 
As highlighted by Solomon and colleagues, reports of Old World CL infections in 
particular have not used speciation to identify between L. major and L. tropica 
(Solomon et al. 2010). This also has an impact on drug development such as topical 
applications. Development of topical applications is ideal for localised CL infections 
primarily caused by L. major. This would eliminate the requirement of medical 
supervision and would also be more accessible to patients in rural endemic regions. 
It is clear that to maximise the potential of research development in this area and 
other drugs, speciation is critical.       
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A further issue that is necessary to address in investigating novel CL drug therapies 
is that most of the drug treatments described, some of which are licensed, lack a full 
understanding of their mechanism of action within the body. It is surprising to find that 
a drug that is licensed for use in man does not necessarily require full exploration of 
its mode of action. One would hope that this is more due to the crucial urgency of 
developing new treatments for this neglected disease, and I find this encouraging in 
terms of the realistic potential of developing a novel drug for the treatment of CL. All 
drugs mentioned above do exhibit, to varying degrees, toxicities in the body, and 
indeed if more thorough investigations into the mechanism of the drugs in the body 
were performed the levels of toxicity may be different. However, this in itself is a 
lengthy task that may not be fruitful and I believe that the increasing prevalence of 
leishmaniasis in the world requires that, limited toxicities should not discourage novel 
treatments to be marketed. After all, a drug is a foreign particle in the body.  
 
Drug 
Cure rate 
(mean in 
%) 
Dose 
Daily 
cost 
(USD) 
Proposed 
therapy 
Total cost 
(USD) 
Antimonial 
pentavalent 
67% 
1 ampole 
= 5 mg 
Sb5+ 
6.32 
20 
mg/kg/d 
28x 
176.96 
Pentamidine 90% 
1 ampole 
= 300 mg 
59.19 2,140 mg 422.22 
Itraconazole 39% 
1 tablet = 
100 mg 
6.73 
400 mg 6 
weeks 
282.86 
Amphotericin B 
deoxycholate 
88% 
1 ampole 
= 50 mg 
11.67 2,500 mg 583.5 
Liposomal 
amphotericin B 
100% 
1 ampole 
= 50 mg 
205 2,500 mg 12,300.00 
Colloidal dispersion 
of amphotericin B 
100% 
1 ampole 
= 50 mg 
139 2,200 mg 6,139.00 
 
Table 2: Example of the cost of treatment of leishmaniasis in South America 
This illustrates the different drugs and their price, length of treatment regime and cure 
rates that could be used to treat infections caused by mucocutaneous Leishmaniaisis 
in South America. Table extracted from (Amato et al. 2007).   
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There is therefore an urgent need for a new cost-effective and safe alternative drug 
to treat cutaneous leishmaniasis. This drug should ideally have a short schedule of 
administration and can be self-administered preferably topically or orally (Gonzalez et 
al. 2008). Amphotericin B is a potent anti-leishmanial drug that is readily available, 
cheap with no emergence of resistance after many years of use. As described, AmB 
has the potential to be incorporated into a variety of different applications despite its 
unfavourable characteristics and was therefore the obvious choice of drug for this 
project. Polymers are ubiquitous in nature and are far more cost effective than 
liposomes. Professor Shaunak‟s laboratory has extensive experience in the 
development of novel polymeric drugs and this project investigated the potential to 
develop a novel polymer-based AmB drug.  
 
1.1.3 Polymers 
Advances in biotechnology and bioengineering have resulted in increasing interest in 
the use of polymers in biomedical research. Polymers can be naturally occurring or 
synthetic and have a wide range of properties that are very attractive to the 
pharmaceutical industry as effective drug delivery systems. They are compounds 
called macromolecules formed by the joining of smaller repeating units of monomers 
covalently bonded together in a linear manner. Naturally occurring polymers such as 
dextran and albumin are easily available but many purification steps are required. In 
addition, their high immunogenicity limits their use for drug delivery systems. 
Advantages of synthetically made polymers such as PEG and poly(N-
hydroxyproplmethacrlamide)(HPMA) is that the molecular weight, structural design 
including functional groups, and charge of the macromolecule can be specifically 
designed to incorporate the required drug of interest (Khandare and Minko 2006). In 
developing a drug for treatment in man, the therapeutic molecule is required to be 
stable under physiological conditions, produce minimal side effects and be 
biocompatible (Liu et al. 2009). Drug delivery systems are used to favourably 
optimise the pharmacokinetics of insoluble and toxic molecules by incorporating them 
into water-soluble polymers allowing them to meet these criteria.  
Polymers have a range of attractive properties that are extremely advantageous for 
drug delivery systems and have been employed in a wide range of applications. The 
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following details these properties with examples of their applications in therapeutic 
treatment. 
1.1.3.1 Advantages of soluble polymer-drug conjugates 
1.1.3.1.1 Increased bioavailability 
Polymers can improve the bioavailability of low molecular weight drugs. By coupling 
with a high molecular weight polymer, the hydrodynamic volume of the molecule is 
increased. This favourably alters the biodistribution of the drug by reducing renal 
excretion, and thereby increases the circulation time of the drug (Kissel et al. 2001). 
Poly(ethylene glycol)(PEG)-based conjugates have  been widely used to resolve this 
issue; for example, photodynamic therapy is a non-invasive procedure to treat 
tumours. A study to enhance MRI guided photodynamic therapy in cancer treatment 
illustrated the benefits of conjugating a PEGylated bifunctional polymer poly-(L-
glutamic acid) to an MRI contrast agent and a photosensitizer. Clinically available 
photosensitizers have low molecular weights and poor tumour specificity. Results 
clearly showed that the PEGylated conjugate had a longer circulating half-life, 
reduced non-specific liver uptake and significantly increased tumour uptake. This 
study clearly exemplifies the benefits of using polymers for biomedical applications. 
Molecules of less than 15 kDa are usually excreted by the renal system and therefore 
there are limits on the size of polymer that can be used if it is not biodegradable. Very 
large polymers (>60 kDa) accumulate in the lysosomes of cells and can potentially 
lead to storage disease syndrome (Schneider et al. 1997).  
1.1.3.1.2 Improved stability 
 A main goal for pharmaceutical industry is to synthesise a drug that can act 
effectively and be stable in the bloodstream. The use of proteins in therapy is often 
limited by their short circulating half-life. They are also at high risk of being 
recognised and degraded by the immune system (Zalipsky 1995).  Therefore, they 
need to be incorporated into a polymeric delivery system. Conjugation to polymers 
can protect these sensitive substances as well as reduce their immunogenicity so 
that they can be safely administered to man. The PEGylation of bovine adenosine 
deaminase (trade name ADAGEN) by an amide bond has been clinically proven for 
treatment of immunodeficiency diseases (Elvira et al. 2005). As a result of 
PEGylation, this protein has a circulating half life 6.4 times greater than without 
PEGylation.  
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1.1.3.1.3 Increased solubility of compounds 
 Many therapeutic compounds have poor solubility in water and have been modified 
by incorporating them into water-soluble polymers. Hydrophobic agents can be 
encapsulated into the hydrophilic polymer and carried to target sites so that they can 
be safely administered to patients. Dextrin sulphate is a long chain polymer 
containing 20% sulphur and on its own has been shown to inhibit the binding of HIV-
1 to CD4+ T lymphocytes (Shaunak et al. 1994). Treatment of Candida spp. 
infections has been improved by the complexation of gamma-cyclodextrin with the 
drug natamycin to create vaginal bioadhesive tablets. The use of dextrin aided the 
drug by increasing its solubility and stability when in aqueous solutions and reduced 
its related side effects without minimising its antimycotic activity (Cevher et al. 2008).  
1.1.3.1.4 Lysosomotropic delivery 
 Lysosomotropic delivery was first identified by De Duve to describe the selective up 
take of substances by lysosomes of the cells irrespective of chemical structure (de et 
al. 1974). Water soluble polymers are taken up mainly by endocytosis where they are 
passed through the endosomal pathway to the lysosome. Lysosomes are membrane 
bound vesicles that engulf and degrade foreign material by lowering pH in their acidic 
environment. This finding increased the desirability of using polymers as drug 
delivery systems as it gave rise to an alternative pathway for the entry of a drug to 
target cells (Khandare & Minko 2006).This was especially important in the treatment 
of intracellular pathogens such as Mycobacterium and Leishmania. By incorporating 
a drug into a water-soluble polymer, both the biodistribution and the efficacy of the 
drug was increased without the presence of non-specific toxicity (Duncan 1999). This 
delivery system has been used in the development of novel anti-cancer drugs by 
using water soluble polymers such as HPMA [N-(2-hydroxpropyl) methacrylamide] 
(Duncan et al. 2005).   
 
1.1.3.2 Synthesis of Polymers 
 A polymer should ideally have a narrow molecular weight distribution if it is to be 
used in a drug delivery system. The polydispersity index determines the degree of 
varied molecular weights within a polymer and is defined as the ratio of the weight 
divided by the number of average molecular weight (Mw/Mn). Uniform synthesis of 
individual polymer chains creates a narrow molecular weight distribution. The use of 
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a narrow MWD active ester polymer is advantageous if creating a polymer-drug 
delivery system as it ensures that individual interactions are alike, therefore 
increasing the ease of reproducibility during chemical synthesis and creating a well 
defined precursor. Furthermore, batch-to-batch variation in size and composition also 
leads to heterogeneity in the biological responses to the polymers.  
Free radical polymerisation is a technique employed to generate batches of 
polymers, within which individual polymer chains are varied in their length. This 
results in a broad molecular weight distribution (MWD). To obtain a narrow MWD 
polymer a technique called atom transfer radical polymerisation (ATRP) is used 
(Monge and Haddleton 2004). 
1.1.3.2.1 Narrow molecular weight active ester polymers 
 
 
Figure 6: Schematic demonstrating the polydispersity obtained by different 
polymerisation methods 
Polymers synthesised by free radical polymerisation typically give rise to a wide 
polydispersity (shown in blue). Polymers generated via ATRP method have a 
narrower range of polydispersity (shown in green).   
 
Succinimide esters such as N-methacrlyoxysuccinimide and N-acryloxysuccinimide 
are the most commonly used reactive ester monomers that can be used to create 
precursor co-polymers. These polymers have usually been synthesised by free 
radical polymerisation which can lead to a broad range of polydispersity (Figure 6) 
Chapter 1 
Introduction 
Karina D. Corware 
 
66 
 
(Nilles and Theato 2007). More recently, ATRP was used to create a narrow MWD 
non-water-soluble homopolymer, poly (N-metharcyloxysuccinimide)(PMAOS, Figure 
7 (A)) (Godwin et al. 2001). This polymer had an active ester functional group which 
is stable in water unlike other active esters but can readily hydrolyse in sodium 
hydroxide to form a water soluble linear anionic poly (N-methaacrylic acid sodium 
salt) as shown in Figure 7 (B).  By using a precursor, it enabled the creation of a 
variety of functionalised polymers which had the same molecular weight 
characteristics but with varied chemical properties. This was advantageous in 
developing a drug delivery system because it allowed a greater degree of optimising 
potential without repeating multiple synthesises. 
 
 
Figure 7:Structure of Poly(N-methacryloxysuccinimide) (PMAOS)  and Poly(N-
methacrylic acid sodium salt)(PMA-Na)  
On addition of NaOH, the precursor active ester monomer Poly(N-
methacryloxysuccinimide) (PMAOS) (A) can be hydrolysed to form a water soluble 
acid derivate SB-GD-19 (Poly(N-methacrylic acid sodium salt)(PMA-Na)). 
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1.1.3.3 Poly (methacrylic acid) polymers  
Polymethacrylic acid includes both polyacrylic acids and polymethacrylic acid. PMA-
Na polymers are sensitive to pH and are within a class of stimuli-responsive or smart 
polymers that contain desirable properties that can be exploited for therapeutic 
purposes (Jeong and Gutowska 2002). When the pH is below 4, the polymer 
arranges into a hypercoiled form to minimise hydrophobic interactions. This leads the 
polymer to become ionised and to swell. This has been exploited for therapeutic use. 
The drug budesonide is used to treat rhinitis and asthma and has a bioavailability of 
only 10.7 % via oral administration. Hydrogels consisting of the polymer poly 
(methaacrylic acid) have been shown to be effective at increasing the absorption of 
budesonide via nasal administration. This is because the mucosa has a pH of 7 and 
therefore causes the hydrogel to swell resulting in controlled release of the drug 
topically (Nakamura et al. 1999). Microparticles of PMAA have also been loaded with 
insulin and on evaluation of release kinetics was shown to provide a sustained 
release of insulin for more than 5 h in vitro (Sajeesh and Sharma 2004). Further to 
this, cyclodextrin complexed insulin that is encapsulated into a PMAA hydrogel was 
found to be beneficial when tested in vivo on diabetic rats (Sajeesh et al. 2010). 
PMAA only decomposes at high temperatures (200ºC) and therefore is relatively 
stable. This property has also been exploited  in chemical industry whereby PMAA 
has been approved for use in adhesives, in lime scale prevention and as a thickener. 
More recently a patent has been published for its use in protecting carbon and black 
steel from corrosion (Witteler et al. 2010) 
 
1.1.4 Project Background and Aims 
The main aim of this project was to develop a cost effective AmB drug that can be 
used to effectively treat cutaneous leishmaniasis with the aim of  providing a topical 
therapeutic of AmB. Currently there is no water-soluble AmB based drug that can be 
administered to treat cutaneous leishmaniasis without side effects. Previous work 
performed by Dr Debbi Harris in Prof Shaunak‟s lab illustrated the ability to use 
polymers, in particular PMAA to create an AmB-PMA drug. As described in this 
chapter, polymers can be tailor-made to enhance the efficacy of therapeutic 
molecules in man. The work of developing AmB-PMA was initially driven towards 
creating an alternative drug for the treatment of visceral leishmaniasis. However, 
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although the AmB-PMA drug synthesised gave rise to low red blood cell lysis and 
cellular toxicity in vitro, its efficacy in vivo was variable. One major source of 
variability was the synthesis of the precursor polymer. Although methods were 
meticulously carried out, the polymerisation reaction required to generate the 
precursor polymer limited controllability and resulted in the synthesis of small batches 
that, ultimately, could not be reliably reproduced. It was therefore necessary to; first 
fully optimise the chemical synthesis employed to create AmB-PMA including the 
source of the polymer; secondly to test its biological activity to identify correlates 
between the physico-chemical and biological properties of AmB-PMA that could 
enhance its efficacy in vivo.  
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1.2 Materials and Methods 
1.2.1 Synthesis of Polymer SB-GD-19 
Copper mediated atom transfer radical polymerisation was performed to create a 
narrow molecular weight distribution precursor polymer poly(N-
methacryloxysuccinimide) SB-GD-19. This process and the chemical characterisation 
of the polymer was performed by Dr Sibu Balan at the London School of Pharmacy  
1.2.1.1 Atom transfer radical polymerisation 
This technique allowed the exploitation of free radicals to create a controlled 
environment to convert a monomer into a polymer. This resulted in a polymer chain 
that slowly and steadily grew to produce a well-defined end group. In this case 
copper bromide (Cu (I) Br) was used and purified for 24 h using a 1:1 ratio of water 
and acetic acid followed by washing with methanol and drying under vacuum. As 
detailed in Figure 8 the active ester monomer N-methacryloxysuccinimide (2) and 
initiator 2-bromo-2-methyl-(2-hydroxyethyl) propanoate (2) were synthesised by Dr 
Anthony Godwin. A typical polymerisation reaction followed involving mixing the 
monomer with Cu (I) Br, to produce a solution before raising the temperature to 80°C 
and adding the initiator solubilised in anhydrous DMSO. This solution was left to stir 
overnight before precipitating the precursor polymer by slow addition to acetone. The 
precursor polymer was collected and solubilised in DMSO before purification via 
precipitation a further three times with acetone. The white product was then isolated 
by filtration and dried under vacuum at room temperature. By altering the monomer 
to initiator ratio, a specific molecular weight of precursor polymer could be created. 
The result was a white powder that was kept under argon at 4°C and was called SB-
GD-19 (Figure 8, (3)). The Mw of SB-GD-19 was determined as 18 kDa using the 
following techniques. 
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Figure 8: Schematic illustrating the syntheses of monomer and precursor 
polymer SB-GD-19  
Schematic illustrating the steps involved in generating SB-GD-19 via ATRP. In brief, 
the monomer (1) was synthesised by the addition of acid chloride and N-
hydroxysuccinamide (NHS) in the presence of dichloromethane (DCM). The active 
ester monomer was then catalysed by Cu(I)Br and 2,2-bipyridine into the precursor 
polymer SB-GD-19 (3) via atom transfer radical polymerisation (ATRP). Extracted 
and annotated from (Godwin et al. 2001). 
 
1.2.2 Chemical characterisation of polymers 
1.2.2.1 Gel permeation chromatography 
This technique was used to determine the molecular weight and polydispersity of the 
precursor polymer between the batches synthesised. Non-aqueous GPC was 
performed using Waters Styragel HR4 and HR3 (7.3 x 300 mm) columns coupled to 
a Gibson 133 refractive index detector. The elution conditions were 50 mM sodium 
phosphate buffer adjusted to pH 7.4 with 150 mM NaCl with a flow rate of 0.7 ml 
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/min. The molecular weight was obtained by using poly (methacrylic acid) sodium salt 
of known molecular weight of 18,500 Da as a standard (Sigma Aldrich). 
1.2.2.2 Nuclear magnetic resonance spectroscopy 
This technique and the analysis were carried out by Dr Mire Zloh at the London 
School of Pharmacy. The resulting spectra were obtained by the use of a Burker 
Avance spectrometer operating at nominal 1H frequency of 400 MHz and equipped 
with a 5 mm BBO probe including Z-axis pulse field gradients. Samples were 
analysed in DMSO or deuterium oxide and acquired at 300 K. These were then 
analysed using TOPSPIN 1.3 software. 
 
1.2.3 Synthesis of AmB-PMA 
1.2.3.1 AmB-PMA drug synthesis using SB-GD-19 
1.2.3.1.1 Method 1 
All glassware and plastic were sterilised to remove endotoxin by autoclaving (121°C 
15 min x 2 cycles) and dried in an oven overnight. AmB (Fungizone, Bristol Myers 
Squibb) was used in all syntheses. In a typical reaction, DMSO (2 ml, Sigma Aldrich) 
was added to the precursor polymer SB-GD-19 (100 mg) for a stock of 50 mg/ml and 
solubilised at room temperature overnight. On the day of synthesis, 4 PD-10 columns 
were equilibrated with MilliQ water, sterilised with 70% ethanol, and flushed with 
polymyxin B (10 µg/ml solution in H20) to remove endotoxin. DMSO (1.632 ml) was 
added to AmB in a round bottom flask and allowed to solubilise for 1 h using a 
magnetic stirrer. SB-GD-19 solution was treated twice with activated charcoal (25 
mg, 25% w/w) to remove endotoxin. At room temperature SB-GD-19 solution (1.2 ml, 
50 mg/ml) was added drop-wise to the AmB solution.1 N NaOH (655 µl, 2 eq) was 
diluted with H20 (119 µl) and slowly added to the yellow mixture after 5 min as shown 
in Figure 10. This enabled the hydrolysis of the precursor polymer to its acid salt 
derivative poly(methacrylic acid sodium salt) polymer, shown in Figure 9, and the 
simultaneous association of the acid salt derivative and AmB (Figure 10). This was 
immediately followed by H20 for injection (10.818 ml, 2 x total vol). This mixture was 
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then allowed to stir for 1 h at room temperature, after which, the reaction solution was 
run down 4 x PD-10 columns in parallel to remove DMSO and un-reacted AmB. The 
elutant was collected, filtered through a 0.2 µm filter into an amber glass vial and 
frozen for at least 18 h at -80°C. This was then lyophilised to yield a yellow/orange 
product. 
 
Figure 9: Hydrolysis of polymer SB-GD-19 
Hydrolysis of SB-GD-19 yields the reactive acid derivative and bi-product N-
hydroxysuccinimide. This acid derivative can then associate with AmB. 
 
1.2.3.1.2 Method 2 
All glassware and plastic were sterilised to remove endotoxin by autoclaving (121°C 
15 min x 2 cycles) and dried in an oven overnight. AmB (Fungizone, Bristol Myers 
Squibb) was used in all synthesises. In a typical reaction, DMSO (2 ml) was added to 
SB-GD-19 (100 mg) for a stock of 50 mg/ml and solubilised at room temperature 
overnight. On the day of synthesis, DMSO (1.632 ml) was added to AmB in a round 
bottom flask and allowed to solubilise for 1 h using a magnetic stirrer. SB-GD-19 
solution was treated twice with activated charcoal (25 mg, 25% w/w) to remove 
endotoxin. At room temperature SB-GD-19 solution (1.2 ml) was added dropwise to 
AmB solution.1 N NaOH (655 µl, 2 eq) was diluted with H20 (119 µl) and slowly 
added to the yellow mixture after 5 min (Figure 10). This was immediately followed by 
H20 for injection (10.818 ml, 2 x total vol). This mixture was then allowed to stir for 60 
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min at room temperature, and then inserted into 2 x 7 kDa Slide-a-Lyzer cassette 
(Pierce, ThermoScience) that had been pre-soaked for 1 min in sterile H20 for 
irrigation (Baxter) via needle and syringe, and submersed into 3 L of sterile H20 for 
irrigation (200 x total dialysate vol) for 24 h. The dialysate solution was then removed 
from the cassette, filtered through a 0.2 µm filter into an amber glass vial and frozen 
for at least 18 h at -80°C. This was then lyophilised to yield a yellow/orange product. 
 
Figure 10: Schematic illustrating the association between PMA and AmB 
during synthesis. 
In the presence of NaOH and water, AmB and PMA interact to yield AmB-PMA via 
electrostatic interactions. 
 
1.2.3.2 AmB-PMA synthesis using Poly (methacrylic acid sodium salt) HP-18  
HP-18 is a GPC standard and purchased from Sigma-Aldrich. All glassware and 
plastic consumables are heat sterilised to ensure endotoxin free as described above. 
H20 for injection (10 ml) was added to HP-18 (50 mg) in a glass vial and solubilised 
on a rotor (35 rpm) at room temperature overnight. On the day of synthesis, DMSO 
(9.709 ml) was added to 1 vial of Fungizone (containing AmB, 50 mg) and allowed to 
stir for 1 h. HP-18 solution was treated with activated charcoal (12.5 mg, 25% w/w) at 
room temperature and passed through a 0.2 µM filter to remove endotoxin and any 
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un-solubilised particulates. AmB solution (2 ml) was added to a round-bottom flask 
followed by dropwise addition of 1N NaOH (100 µl, 15 µl per 3 sec) using a 
multistreamer pippette. After 5 min, HP-18 solution (2 ml of 5 mg/ml solution) was 
added dropwise to the dark yellow viscous solution followed immediately by H20 for 
injection (8 ml, 2 x vol) (Figure 10). This reaction mixture was left to stir at room 
temperature for 1 h before transferring into a Slide-a-Lyzer cassette (Pierce, 
ThermoScience) that had been pre-soaked for 1 min in sterile H20 for irrigation. This 
was then submerged into the sterile H20 for irrigation in 3 L (200 x total dialysate vol) 
and left stirring at ambient temperature for 24 h. The dialysis solution was changed 
after 5 h and 13 h with fresh water for irrigation. 
Optimisation experiments examining the effects of AmB loading and dialysis were 
performed and the method was altered as follows. Only one change of water after 4 h 
was performed. This was more manageable and did not alter the efficiency of the 
dialysis process. Regularly the drug synthesis was carried out by doubling all 
volumes of reagents. Investigations were performed to determine whether syntheses 
of AmB-PMA could be created using double the volumes of the reagents to increase 
yield. The conclusion was that this did not alter the characteristics of AmB-PMA 
produced.  
 
1.2.4 Chemical characterisation of AmB-PMA 
1.2.4.1 UV spectroscopy 
UV spectroscopy was performed using a Cary UV-Visible spectrophotometer. AmB 
absorbs UV light in the region of 300-450 nm.  The absorbance spectra of AmB for all 
batches of AmB-PMA synthesised were measured over this range.   
To establish the weight percentage of AmB within each AmB-PMA drug synthesised, 
the optical density was measured at 409 nm and determined using a standard curve. 
The standard curve of concentration relative to the optical density (OD) was created 
using a serial dilution of AmB in aqueous 50% methanol. The source of AmB 
(Fungizone) was initially solubilised in water for injection at 3 mg/ml. A serial dilution 
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was then performed using 50 % methanol creating a standard curve ranging from 
1.05 to 6 µg/ml of AmB. The AmB-PMA drug was then solubilised at 1 mg/ml total 
weight in water before being diluted to a final concentration of 10 µg/ml in 50 % 
methanol. The absorbance at 409 nm was measured 3 times and the average % 
AmB determined. 
Once the proportion of % AmB loading had been determined, a fresh sample was 
solubilised in water at 1 mg/ml AmB and diluted in water to a final concentration of 10 
µg/ml of AmB. It was then measured across a wavelength range of 300-450 nm and 
a spectra was formed that illustrated the aggregation ratio of the AmB within the 
drug. Hitachi UV solutions software was used to generate a spectrum which was then 
transformed into GraphPad Prism software to optimise quality. 
1.2.4.2 pH  
 The stability of AmB-PMA was assessed using buffer solutions to generate a 
spectrum of pH solutions. A 0.2 M dibasic sodium phosphate solution and a 0.1 M 
citric acid solution were freshly made. These were combined as per the table below 
to create a range of sub-stock solutions. Samples were reconstituted at 1 mg/ml AmB 
and allowed to solubilise. pH buffer solutions were added incrementally to AmB-PMA 
until the solution turned turbid. This was then repeated and aliquots taken. These 
were then centrifuged at 1800 rpm for 5 min to assess the release of AmB at different 
pH values. Aliquots of the supernatants were transferred to a flat-bottom plate and 
the OD measured at 409 nm. The results were expressed as the % of solubility of 
AmB-PMA when 100% solubility is at pH 7.3. 
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0.2 M 
Na2HPO4 (ml) 
0.1 M citrate 
(ml) 
pH 
25.7 24.3 5.0 
26.7 23.3 5.2 
27.8 22.2 5.4 
29.0 21.0 5.6 
30.3 19.7 5.8 
32.1 17.9 6.0 
33.1 16.9 6.2 
34.6 15.4 6.4 
36.4 13.6 6.6 
40.9 9.1 6.8 
43.6 6.5 7.0 
 
Table 3: pH buffer solutions 
Table detailing the exact quantities of 0.2 M Na2HPO4 and 0.1 M citrate buffers 
required in order to obtain the desired pH in the range of pH 5-7.  
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The following 2 techniques were performed in collaboration with Bryn Monnery (PhD 
student) in the Department of Chemistry, Imperial College London.   
1.2.4.2.1 Circular dichroism 
Circular Dichroism (CD) is defined as the differential absorption of left and right-
handed circularly polarised light. It can aid in determining the structure of a molecule 
or, in this case, the AmB-PMA drug. CD spectra were measured over the range of 
250-450 nm with 5 mm pathlength cuvettes. The scan speed was set at 100 nm /min 
and one scan of each sample was performed at room temperature. Both samples 
were diluted to a final concentration of 8.3 µg/ml AmB in water for injection. 
1.2.4.2.2 Dynamic light scattering (DLS) 
DLS is a technique that is used to determine the size distribution profile of molecules 
within a solution. In this case it can be used to measure the size of particles in AmB-
PMA and compare them to Fungizone to establish the type of drug being created. In 
this instance, the Coulter Beckman N4 Plus machine was used. Samples were 
reconstituted at 1.5 mg/ml AmB in water and a total of 10 runs were performed. 
 
1.2.5 Biological characterisation of AmB-PMA 
1.2.5.1 Media, culture conditions and washing buffers 
Culture medium for primary human cells was RPMI 1640, 330 μg/ml L-glutamine, 200 
IU/ml penicillin, 200 μg/ml streptomycin (Invitrogen) supplemented with either 10% 
heat inactivated human serum (North London Blood Transfusion Centre, UK) or 10 % 
heat-inactivated Foetal Calf Serum (FCS, Invitrogen).  Serum free media was RPMI 
1640, 330 μg/ml L-glutamine, 200 IU/ml penicillin, 200 μg/ml streptomycin 
(Invitrogen) without serum. All primary cells were maintained at 37°C, 5% CO2 in a 
humidified atmosphere. The washing buffer was phosphate buffered saline (PBS, 
Sigma). Storage medium was RPMI 1640, 330 μg/ml L-glutamine, 200 IU/ml 
penicillin and 200 μg/ml streptomycin buffered with 25 mM HEPES and 
supplemented with 5% heat-inactivated human serum. 
 Chapter 1 
 Material and Methods  
 Karina D. Corware 
 
 
78 
 
 
L. major (LV39) and L. mexicana (M379) promastigotes were maintained in 
Schneiders Drosophila Medium (SD) (Invitrogen) supplemented with 10% heat-
inactivated foetal calf serum and 10 µg/ml gentamicin, in a humidified chamber at 
26ºC, 5% CO2. L. donovani (HU3) promastigotes were maintained in M-199 Medium 
(Invitrogen) supplemented with 40 mM Hepes, 100 uM adenosine, 0.5 mg/L hemin, 
50 µg/ml gentamicin and 10% heat-inactivated FCS.  
1.2.5.2 Endotoxin Assay 
Limulus amebocyte lysate is an aqueous extract of blood cells from the horseshoe 
crab.  This reacts with bacterial endotoxin or lipopolysaccharide (LPS) resulting in the 
formation of a gel and is used to determine the levels of endotoxin in samples.  
Pyrotell gel clot tests (Cape Cod Associates) were used to detect the presence of 
endotoxin in samples at a sensitivity of 0.06 EU/ml.  Equal volumes (100 μl) of 
sample and lysate were incubated for 37°C for 1 h and examined for the presence of 
a gel clot.  Only batches of polymer and AmB-PMA that were confirmed endotoxin-
free by this method were used in in vitro and in vivo studies. 
1.2.5.3 Toxicology of polymers (SB-GD-19, HP-18) and AmB-PMA 
1.2.5.3.1 Haemolysis assay 
This assay indicated the potential of the polymer and AmB-PMA to lyse red blood 
cells (RBCs). The assay was performed by taking a 2% v/v solution of washed RBCs, 
and a stock solution of synthesised AmB-PMA containing 1 mg/ml of AmB prepared 
in serum free culture media. A 1 % (v/v) solution of the detergent Triton X-100 was 
used as a positive reference for complete cell lysis. Fungizone was used as a 
positive comparison. The assay contained equal volumes of AmB-PMA and RBC 
solution in a 96 well microtitre plate and was incubated for 1 h. After incubation the 
plate was centrifuged and the supernatant transferred to a non-sterile flat-bottom 
plate to measure the optical density at 409 nm. The degree of RBC membrane 
disruption was quantified using the OD respective to the amount of released 
haemoglobin in the supernatant. The percentage of heamolysis was calculated using 
the Triton X-100 treated wells as a 100% haemolysis reference.  
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1.2.5.3.2 MTT viability assay 
This assay was performed to demonstrate the extent of leishmanial killing by the 
synthesised AmB-PMA drug. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) was used as the readout for this assay.  
To determine the ability of AmB-PMA and the polymer to kill Leishmania spp. 
approximately 100,000 Leishmania promastigotes per well were seeded in a 96 well 
microtitre plate in supplemented SD media. An equal volume of AmB-PMA or 
polymer was added to wells in triplicate and incubated for 24 h in a humidified 
chamber at 26°C, 5 % CO2. Triplicates of 2 % v/v of Triton were added for positive 
cytotoxicity. After a 24 h incubation, MTT reagent (Sigma Aldrich) was added, and 
the plate was incubated for a further 24 h. The plates were then centrifuged (1600 
rpm for 5 min) and the supernatant removed. DMSO (75 µl /well) was added to 
dissolve the formazan crystals with mixing, and the viability of the cells determined by 
their optical density (OD) measured at 570 nm. 100 % viability was determined using 
the OD of the untreated wells (cells with SD media only) after incubation with MTT. 
Each assay was performed in triplicate (n=3) and the values obtained were then 
pooled and plotted (mean ± SEM).   
1.2.5.4 UV Spectrophotometry  
1.2.5.4.1 Blood plasma 
This assay identified the state of AmB within the AmB-PMA drug in the presence of 
human blood components. Fresh blood was collected into an EDTA vial and spun at 
15,000 rpm for 15 min to separate the plasma and red blood cells. The plasma was 
removed and diluted 1:5. Fungizone and AmBisome were solubilised as per 
manufacturers’ instructions and diluted to a final concentration of 1 mg/ml AmB in 
water for injection. The AmB-PMA drug was also made up to a 1 mg/ml AmB 
concentration in water for injection. All samples tested were serially diluted to a final 
concentration 15 µg/ml AmB in 20% plasma and spectra measured at 0 h and 3 h. 
This experiment was also conducted in serum free media. 
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1.2.5.4.2 Blood Serum 
Further investigations involved the use of serum. Whole blood was directly taken into 
a syringe and immediately added to serum separating tubes to prevent clotting. 
AmBisome and Fungizone were reconstituted at 4 mg/ml AmB and the AmB-PMA at 
5 mg/ml AmB in water for injection.  These were then added to the blood at a final 
concentration of 1 mg/ml and 10 µg/ml AmB. The samples were then kept rotating in 
an incubator at 37°C for 1 h.  Whole blood in serum separating tubes was used as a 
negative control. Samples were then spun at 13,000 rpm for 8 min.  An interphase 
appeared, separating blood (bottom) and serum (top). Serum was then extracted 
from the top layer and was serially diluted in RPMI media. The spectra were 
measured as described.  
1.2.5.5 Culture of primary human cells 
1.2.5.5.1 Isolation of peripheral blood mononuclear cells 
Blood was obtained from the North London Blood Transfusion Clinic in the form of a 
screened buffy coat residue of four healthy blood donors. Peripheral blood 
mononuclear cells (PBMCs) were separated by centrifugation over a Ficoll-Plaque 
gradient (GE Healthcare). After washing, the cells were resuspended in culture 
medium. When monocytes or PBMC’s were required for immunomodulatory studies, 
the cells were seeded in culture media and allowed to rest for at least 24 h before 
use. This was a precautionary measure to avoid false positive results that may have 
occurred due to the activation of these cells during bleeding.  
1.2.5.5.2 Generation of monocyte-derived macrophages 
Monocytes were obtained as described above and isolated by a minimum of 2 h 
adhesion to plastic. Non-adherent cells were removed and monocytes were washed 
in PBS before being allowed to grow for at least 4 days in culture medium to 
differentiate into macrophages. 
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1.2.5.5.3 Source of peritoneal cells 
Peritoneal dialysis fluid was obtained by informed consenting patients that were 
training to become independent in continuous ambulatory peritoneal dialysis. This 
was due to developing chronic renal failure as a result of hypertension, insulin-
independent diabetes or chronic childhood pyelonephritis. Patients who suffered from 
peritonitis were excluded.  
This study and collection of peritoneal fluids was approved by the Hammersmith 
Hospital Trust Ethics Committee (registration no. 2000/5767). The process was 
supervised by Prof. Shaunak. 
1.2.5.5.4 Isolation of peritoneal macrophages 
Cells were obtained from the peritoneal fluid by centrifugation and re-suspension in 
culture medium. Macrophages were isolated by adherence to plastic for a period of 2 
h. Non-adherent cells were removed by washing with PBS (Sigma) supplemented 
with 2 % heat inactivated serum to optimise their removal. 
1.2.5.5.5 Isolation of Bone-Marrow derived mouse cells 
BALB/c mice were sacrificed by cervical dislocation and the femurs and tibias 
removed under sterile conditions. These were then placed in PBS (Sigma) and Bone 
marrow mouse precursor cells were obtained by flushing the femurs and tibias of 
mice with ice cold DMEM (Invitrogen) using a 30-gauge needle with a 0.3 ml syringe 
(BD healthcare, UK). The cells were then further washed with DMEM before being 
counted using the trypan blue exclusion method (Altman et al. 1993). They were then 
seeded at 5 x 106/ 50 ml DMEM in hydrophobic Teflon bags (FEP film 100°C, 
DuPont). After eight days differentiation in culture containing L929 supernatant (M-
CSF) at a final concentration of 10 % (v/v) at 37°C with 10 % CO2, BM macrophages 
were harvested for experimentation. 
1.2.5.5.5.1 L929 supernatant 
L929 fibroblasts were cultured in vented cell culture flasks (Corning, USA) at 37°C 
with 10 % CO2 for 10 days. Cell-free supernatant was then collected and filter 
sterilised before the efficacy of M-CSF was tested. Bone-marrow derived mouse 
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macrophages were cultured in DMEM for macrophage differentiation and L9292 
supernatant was used as a source of macrophage-colony stimulation factor (M-CSF) 
at a final concentration of 10 % (v/v).  
1.2.5.5.6 U937 cell line 
Cells were maintained in culture medium and split 1:5 at least once a week to 
maintain healthy growth. When required, the non-adherent cells were centrifuged and 
washed in PBS before use.   
1.2.5.6 MTT cytotoxicity assay on primary human cells 
To determine the cytotoxicity of AmB-PMA, the polymer and Fungizone the following 
technique was used; Triplicate 1:2 dilutions of HP-18 or SB-GD-19, AmB-PMA and 
Fungizone in RPMI 1640 glu, pen/strep 10% foetal calf serum (FCS) were added to 
adherent cells (final volume 50 µl up to a concentration of 500 µg/ml AmB). A 96-well 
flat bottom plate was used for adherent cells i.e. monocytes, MDMs and peritoneal 
macrophages, and a V-bottom 96 well plate was used for non-adherent cell line 
U937. Approximately 100,000 cells per well were seeded to a microtitre plate before 
the addition of an equal volume of samples (50 µl, SB-GD-19, HP-18, AmB-PMA and 
Fungizone). Triplicates of 2 % Triton in RPMI was added for positive cytotoxicity. The 
plates were incubated at 37°C, 5% CO2 for 3 h.  25 µl of MTT reconstituted in H2O for 
injection at 5 mg/ml was then added to each well and incubated for a further 3 h. The 
plates were then centrifuged at 1600 rpm for 5 min, the supernatant was removed 
and DMSO (75 µl /well) was added. The viability of the cells was then determined by 
their optical density (OD) at 570 nm and it was expressed as the percentage of viable 
cells in comparison to the untreated wells (cells with RPMI 1640, glutamine, 
pen/strep 10% foetal calf serum (FCS) only). Each assay was performed in triplicate 
(n=3) and the values obtained were then pooled and plotted (mean ± SEM).   
1.2.5.7 Measurement of cytokine and chemokine release from stimulated 
human cells 
These experiments were conducted to evaluate the immunomodulatory effects of the 
PMA polymer and AmB-PMA drug on U937 cell line and human primary cells. 
Fungizone was also tested as a comparison. After 3 h incubation, the cells were 
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collected and processed to evaluate the release of MIP-1β, TNF-α, IFN-γ and IL-6 
using real-time quantitative PCR.  
Human primary cells (MDMS, monocytes and peritoneal macrophages) or cell line 
U937 were plated at 1 x 106 cell/ml (400µl/well) on a 48 well flat bottom plate and left 
to adhere overnight at 37ºC, 5%, CO2 . AmB-PMA, HP-18 and Fungizone were 
added to the cells in either duplicates or triplicates at a range of concentrations. The 
plate was then incubated for 3 h at 37ºC, 5%, CO2, after which the plate was 
centrifuged (1800 rpm, 5 min) and the supernatant removed. Trisol was added to the 
wells and the pellet of cells and Trisol were harvested for RNA extraction. Each 
assay was performed with a negative control; i.e. cells with no additional stimulant, 
and also a positive control; i.e. the addition of LPS (25 ng /ml) as this would induce a 
large chemokine and cytokine response. 
1.2.5.8 RNA isolation and analysis 
Harvested materials were homogenised in Trisol (Tri Reagent, Sigma Aldrich) so that 
total RNA could be extracted and stored at -20°C until processed. RNA was isolated 
using Max Tract tubes (Qiagen) and the phenol/chloroform method of precipitating 
RNA. After isolation, total RNA was solubilised in RNase-free water (50 µl).  
1.2.5.9 Reverse transcription of RNA 
The optical density of the isolated RNA was measured using a nanodrop (ND-1000, 
Thermo Scientific) which determined the quantity of RNA in ng /µl. This was 
determined by calculating the RNA/DNA ratio at a wavelength of 260 nm and 280 nm 
respectively. Equal amounts of each RNA sample were then prepared for reverse 
transcription (200-800 ng). Qiagen QuantiTect Reverse Transcription (RT) kits were 
used to undertake the reverse transcription of mRNA to cDNA. This was performed in 
2 steps. Firstly 7 x QuantiTect gDNA wipe-out buffer was added to the purified RNA 
samples and incubated at 42°C for 2 min to remove any contaminating genomic 
DNA. Secondly, the RNA samples were then reverse transcribed by adding a master 
mix consisting of Quantiscript Reverse Transcriptase, 5 x Quantiscript RT Buffer and 
RT primer mix. This reaction mixture was incubated (42°C, 15 min) and then 
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inactivated (95°C, 3 min). The resulting cDNA was diluted to a final reaction volume 
of 80 µl with nuclease-free H20 and stored at -20°C. 
1.2.5.10 Quantitative real-time PCR 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using a 
RotorGene 3000 (Corbett Research) to quantify the chemokine and cytokine mRNA 
levels within the individual samples collected. This method was used on both human 
and mouse samples collected. The PCR product was determined by measuring the 
binding of the fluorescent dyes sybr green and sybr gold (Sigma Aldrich and 
Invitrogen respectively). These dyes bind to double stranded DNA and emit 
fluorescence that is proportional to the copy number of the PCR product generated.  
A typical reaction mix contains 2 x Sybr Green Jumpstart Taq Readymix (10 µl, 
Sigma Aldrich), cDNA or plasmid standards (2 µl), forward and reverse (0.25 µM) 
gene-specific primers diluted to a final reaction volume of 20 µl in RNase-free water. 
Once the samples are loaded into the PCR machine the reaction begins by 
denaturation of the double stranded DNA and the Taq-antibody present in the Sybr 
Green mix. On average 40 cycles then follow as described in Table 4.    
The temperature, at which the fluorescent data used for quantification was collected, 
was based on the melting temperature of the PCR product. Acquisition was set up 2-
4°C below the melting temperature of the product which was where half of the 
double-stranded product was completely denatured. This limited the detection of 
primer dimers and non-specific products with a lower melting temperature and hence 
limited incorrect quantification. Before the primers were used, they were amplified 
and their products run on an agarose gel to confirm that the correct amplification 
product was generated.  
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  Temp °C Time 
Activation of polymerase 95 3 min 
Amplification of PCR product (x40)     
Denaturation 95 5 sec 
Primer annealing Gene dependent 2 sec 
Extension 72 8 sec 
Fluorescence acquisition Gene dependent 8 sec 
Melting Curve (Tm)     
Temp Ramping+ fluorescence 
Acquisition 
0.1°C/ sec 72°C to 95°C 
Table 4: Cycle of a polymerase chain reaction 
This table describes the step-wise details of a PCR run after insertion of a sample 
into a PCR machine. 
 
1.2.5.10.1 Melting curve 
At the end of a PCR reaction a melting curve was produced by heating the PCR 
products to 95°C from 72°C in 1°C increment. This caused complete denaturation of 
the product depending on the length and GC content. This simultaneously gave rise 
to the progressive loss of Sybr Green and Sybr gold fluorescence due to the fact that 
the dyes bind to the minor grooves of double stranded DNA. A graph of loss of 
fluorescence and temperature was generated for all double stranded DNA molecules 
in the PCR reaction. This revealed the accuracy of the triplicate of each sample and 
also detected the presence of primer dimers that may have been amplified. 
Quantification to generate real copies was based on the samples that peaked at their 
specific melting temperature.  
1.2.5.11 Plasmid standards  
Target nucleic acids can be quantified either by relative quantification or absolute 
quantification. The former is most common to use and gives rise to a ratio between 
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the quantities of target relative to the house keeping gene HPRT. The result is 
normalised values which can be used to determine gene expression in different 
samples. Absolute quantification involves determining a real number of target 
molecules that are expressed as a concentration of copy number. This requires the 
development of a plasmid whereby the target sequences are incorporated. The 
sequences within the plasmid need to be identical to the primer binding sites of the 
desired target so that the standard and the target will amplify at equal efficiencies.   
1.2.5.11.1 Generation real mRNA copy numbers relative to HPRT for human 
and cell line samples 
The PCR RotorGene software calculated the fluorescence threshold cycle (Ct) for 
each sample that was then interpolated against the standard curve. A standard curve 
was run for each PCR reaction by performing a serial dilution of a plasmid containing 
the sequence of interest. In this case, the human multigene plasmid pTTScy14 
pGEMTA created by Dr Ian Teo was used as the standard to generate real copies of 
the human genes in Table 5. The copies of mRNA were then expressed as the 
absolute copy number/ 105 absolute copies of HPRT.  
 
Gene Forward primer sequence Reverse primer sequence 
HPRT GCTCGAGATGTGATGAAGGAG TCCCCTGTTGACTGGTCATTA 
MIP-1β ACCCTCCCACCGCCTGCTGC GTTCCAGGTCATACACGTACTC 
IFN-γ AAACGAGATGACTTCGAAAAGCTGA CTTCGACCTCGAAACAGCATCTGACT 
TNF-α AGGCGGTGCTTGTTCCTCA GTTCGAGAAGATGATCTGACTGCC 
IL-6 CACACAGACAGCCACTCACCT CTGCCAGTGCCTCTTTGCTG 
Table 5: Primer sequences of human chemokine and cytokine genes 
For each chemokine and cytokine studied to determine the immunomodulatory 
effects of cells upon stimulation with AmB-PMA, both a forward and a reverse 
sequence had to be generated.  
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1.2.5.12 Leishmania spp. 
1.2.5.12.1 Strains 
Leishmania major (LV39, MRHO/SU/59/P-strain) was a gift from the laboratory of Dr 
Ingrid Mϋller at St Mary’s Hospital (Imperial College). L. donovani (HU3) and L. 
mexicana (M379) were a gift from Dr. Vanessa Yardley (London School of Hygiene & 
Tropical Medicine). L. donovani amastigotes were obtained by harvesting a spleen of 
an infected golden hamster (Mesocritetus auratus) and were used within 24 h to 
minimise their transformation into un-infective promastigotes.  
Both strains were either obtained fresh or grown up from frozen (-150°C) on blood 
agar slopes for 1 week before transferring them on to liquid media. Horse blood was 
added to nutrient agar with gentamicin and plated out in 25 ml culture bottles 
(Fisher). 
1.2.5.12.2 Macrophage Infection Experiments 
These experiments were performed to assess the pharmacological activity of AmB-
PMA against amastigotes that had been phagocytosed by macrophages. 
1.2.5.12.2.1 Human monocyte-derived macrophages 
Healthy dividing amastigote cultures were used to infect macrophages and 
Fungizone (Squibb) was used as a positive control. Human peritoneal or monocyte 
derived macrophages were isolated as described and approximately 750,000 cells 
were plated onto chamber slides (Lab-Tek) and allowed to adhere for 24 h. 
Amastigotes were pelleted and washed with PBS before resuspending in serum free 
media as Leishmania spp. are sensitive to complement-mediated lysis. Amastigotes 
were added to the aspirated macrophages at an MOI of 5:1. Infection took place at 
37°C with 10 % CO2 and was established by processing one well by removing and 
fixing the cells and staining with Giemsa-May Grunwald to count microscopically the 
number of intracellular amastigotes. The media was then aspirated and the 
macrophages washed with PBS. The samples of AmB-PMA were added to the cells 
in culture medium and incubated for a further 3 days. Macrophages were then 
washed to remove extracellular amastigotes before allowing the slides to dry. These 
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were then fixed with methanol and stained with Giemsa-May Grunwald. Microscopy 
was used to determine the number of amastigotes present and infected and non-
infected macrophages. This was then expressed as the infection index by calculating 
Infection index = Average number of parasites per infected cells 
   Percentage of infected cells  
1.2.5.12.2.2 Mouse Bone-Marrow derived macrophages 
Macrophages derived from mouse bone-marrow precursor cells were isolated as 
described and approximately 5x105/ml were plated onto chamber slides (Lab-Tek) 
and allowed to adhere for 24 h. Healthy dividing L. major promastigotes were added 
to unactivated macrophages or, macrophages activated with a combination of 
recombinant mouse IL-4 (20 Units/ml, PeproTech,EC, UK) and IL-10 (10 U/ml, 
PeproTech) cytokines, at an MOI of 5:1 in the presence or absence of different 
concentrations of AmB-PMA (1 mg/ml, 0.3 mg/ml and 0.1 mg/ml AmB) and incubated 
at 37°C with 10 % CO2 in air. To determine the end-point of the experiment, at 
different times after the infection and treatment the chambers were removed and the 
cells fixed and stained with Giemsa to count the intracellular amastigotes 
microscopically.       
1.2.5.13 Statistical Analysis 
All data was analysed using GraphPad Prism vs5 software and are shown as mean ± SEM 
(standard error of mean). The statistical difference between data was analysed using 
Mann-Whitney U T-tests.  
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1.3 Results 
1.3.1 Part A: Chemical Synthesis and Characterisation 
1.3.1.1 SB-GD-19 
The precursor poly (methacrylate sodium) salt was synthesised via atom transfer 
radical polymerisation as described in Materials and Methods. In the presence of 
copper (I) acting as a catalyst, and 2, 2-bipyridine that is a ligand that was used to 
solubilise the copper (I) and to control the redox reaction, ATRP of the monomer 
occurs (Figure 11). During the reaction the mixture changed colour from brown to 
green which signified the oxidation of copper as it was dissociating from the ligand. 
This polymerisation process was complete in 10 min. Dr Sibu Balan had optimised 
this method so that the resulting polymer had a narrow molecular weight defined by 
uniform linear chains, which was determined using gel permeation chromatography 
and nuclear magnetic resonance. Syntheses were performed in small batches and 
therefore the following methods were essential in maintaining reproducibility.   
 
 
Figure 11: Preparation of polymer SB-GD-19 
Schematic illustrating the steps involved in generating SB-GD-19 via ATRP. The 
monomer is catalysed by Cu(I)Br and 2,2-bipyridine into SB-GD-19 via controlled 
radical polymerisation called atom transfer radical polymerisation (ATRP).  
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1.3.1.1.1 Gel permeation chromatography 
GPC, also known as size exclusion chromatography, is a form of liquid 
chromatography whereby molecules within a mixture are separated depending on 
their size and molecular weight. A mixture is passed through a column packed with 
non-porous beads and eluted in fractions. Large molecules within a mixture cannot 
enter the pores between the beads and elute first. Smaller molecules can pass into 
the pores and therefore elute at a slower rate. The time it takes for the fractions of 
the mixture to elute is the retention time. Using this information a correlation between 
the size and molecular weight can be obtained by calibrating with a known 
substance. A graph illustrating the retention time against molecular weight can be 
drawn as seen in Figure 12. This technique is very useful in determining the 
molecular weight of large biomolecules such as polymers.  
In this instance the molecular weight and the polydispersity of the precursor polymer 
was determined by GPC. Polydispersity (PD) is the molecular weight distribution 
(MWD) within each batch of polymer and it can be calculated by the division of the 
weight average molecular weight (Mw) by the number average molecular weight 
(Mn). 
PD = Mw/Mn.  
The PD value is always greater than 1. The higher the quantity of individual polymer 
chains that are uniform in length, the closer the PD value is to 1. This is the most 
desirable outcome as the variability in the polymer during its synthesis is decreased. 
An issue with polymer synthesis is reproducibility and maintenance of tight PD values 
between batches. Figure 12 illustrates 3 individually synthesised batches of 
precursor polymer that are not significantly different. To determine the molecular 
weight and hence the PD, the molecular weight of a known substance is used.  In 
this case poly(methacrylic acid) sodium salt from a commercial source was used 
(HP-18). Figure 12 confirmed that individual batches are ‘identical’ by this analytical 
technique and that the synthesis protocol of SB-GD-19 was reproducible. It also 
suggested the possibility of using HP-18 as the starting material for the creation of 
AmB-PMA as described in Materials and Methods, Method 2. 
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Figure 12: GPC of individually synthesised batches of precursor polymer. 
With the use of a commercially sourced standard (HP-18), the molecular weight and 
polydispersity of the synthesised batches of SB-GD-19 polymer were determined 
using Gel permeation chromatography (GPC). In this case three individually 
synthesised batches of precursor polymer SB-GD-19 were indistinguishable on GPC 
analysis verifying tight reproducibility. 
 
1.3.1.1.2 1H-NMR 
Electromagnetic radiation is used to identify structures and functions of 
macromolecules by exploiting the use of isotopes; in this case, 1H isotope. Isotopes 
are used because they have charged atomic nuclei that display spin. This is due to 
the nucleus having an odd number of protons or neutrons. Hydrogen is an isotope 
and displays spin due to only having one proton. Other elements that display spin are 
isotopes such as 13Carbon and 15Nitrogen. If an element has an atom that displays 
spin then it is given a spin quantum number and can generate a magnetic field like a 
magnet. In this case hydrogen has a ½ spin quantum number.  In the presence of an 
external magnetic field two spin states exist. The spin can be aligned (+1/2 state) 
with the external field creating a low energy level, or it can be opposed (-1/2) in a 
higher energy level (Figure 13). 
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Figure 13: Energy levels within a Hydrogen atom 
Hydrogen has ½ spin quantum number and therefore can generate a magnetic field 
between the 2 energy states created by +1/2 and -1/2 spin. A schematic extracted 
from http://teaching.shu.ac.uk/hwb/chemistry/tutorials/molspec/nmr1.htm  
 
The aligned spin state with lower energy is more populated than the higher state. If a 
sample is irradiated with a radio frequency energy that corresponds to the spin state 
difference between the set of nuclei (i.e. the lower and higher levels), then this will 
cause excitation of the nuclei into the higher -1/2 spin state. As the energy levels are 
resonating, the nuclei will fall back to a lower energy spin state (+1/2). The 
fluctuations in the excitation of nuclei are known as resonance frequencies and are 
dependent on the strength of the external magnetic field and the radio frequency that 
is applied, which results in the generation of an NMR spectrum. Due to the fact that 
the signals produced are dependent on two variables, the NMR was performed using 
deuterium oxide or DMSO. This enhances the NMR signal produced without 
interfering with the resonances demonstrated by individual organic compounds. This 
is particularly useful when using hydrogen as the isotope as it limits the interference 
of water solvent within the signals of interest. Deutrium atoms in particular have 
sufficiently different magnetic properties from ordinary hydrogen and do not peak in 
the area of spectrum that is analysed. It therefore does not contribute to the NMR 
signal that is obtained.  
Figure 14 illustrates the 1H-NMR spectrum of the precursor polymer and 
demonstrates clean, well defined single peaks. There are four defined peaks which 
equates to the four different environments that hydrogen is found within this polymer. 
The peaks reside in different places within the spectrum due to the need for slightly 
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different strengths of applied external magnetic fields to bring them into resonance at 
a particular radio frequency. The width of the peaks indicates the amount of 
hydrogen in each differing environment. This spectrum was performed to confirm that 
the precursor polymer had been synthesised. Figure 15 illustrates the fully 
hydrolysed form of SB-GD-19 that is required for a reaction synthesis to occur, and 
HP-18 (a commercially bought standard poly (methacrylic acid) sodium salt) to 
compare. It is evident that both spectra are identical and have a strong absorbance 
peak indicative of CH3 with a large amount of hydrogen present due to the width of 
the peaks. These NMR spectra confirmed the structural components of SB-GD-19 
and verified that synthesis of the precursor polymer had been successful. After full 
hydrolysis SB-GD-19 was indistinguishable from HP-18 by this chemical analytical 
technique.   
 
 
Figure 14: 1H-NMR spectrum of precursor polymer SB-GD-19  
Samples of SB-GD-19 were analysed in DMSO or deuterium oxide. An 1H-NMR 
spectrum was generated by the electromagnetic frequency applied against 
absorbance of the precursor polymer SB-GD-19.There are four peaks which illustrate 
four different environments that hydrogen exists in within this polymer. The breadth of 
the peak is the quantity of hydrogen within the specific environment.  
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Figure 15 1H-NMR spectra of SB-GD-19 and HP-18 
(A) Fully hydrolysed SB-GD-19 demonstrates two defined peaks and with the use of 
the commercial standard HP-18 (B), the molecular structure of the synthesised SB-
GD-19 polymer can be deduced as shown. Both have a defined large peak (a) that 
equates to the number of CH3 groups both polymers possess. 
 
1.3.1.2  HP-18 
The main advantage of a commercially bought polymer such as poly (methacrylic 
acid) sodium salt HP-18 is that it is synthesised to be a standard for GPC. This 
dictates that it has been characterised using very stringent guidelines whereby the 
molecular weight of unknown compounds may be determined. A data sheet was 
provided with every batch purchased detailing the molecular weight and the GPC 
(Figure 16). As described the NMR spectra (Figure 15 (b)) illustrated no chemical 
differences in characteristics between the two polymers. This was recognised as a 
point of exploration into the use of HP-18 for synthesis. 
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Figure 16: GPC spectrum of HP-18 
This spectrum was provided in the data sheet with each batch of HP-18 (Sigma 
Aldrich).  
 
1.3.1.3  Biological Activity of Polymers 
Polymers that are tailor-made to promote properties of a drug invariably require 
thorough characterisation of their biological activity. In vitro methods can initially be 
employed to determine this activity on a range of human cell types. Moreover, 
assessing the toxicity of both SB-GD-19 and HP-18 was paramount before use in the 
synthesis of AmB-PMA.   
1.3.1.3.1 Haemolysis Assay 
A haemolysis assay indicates the toxic properties of a compound by allowing 
quantification of the amount of red blood cells it can lyse in a set time. This aids in 
the assessment of this compound to be used in vivo especially if considering 
intravenous administration. Fresh purified red blood cells (RBC) were incubated for 1 
h with each polymer and the resulting quantity of lysed RBC’s was determined by 
their optical density (OD). Each experiment was performed at least on three separate 
occasions in duplicate. From the experiments conducted, one could calculate that if a 
compound had a high haemolytic potential, it would follow that it would present high 
cytotoxicity when exposed to human primary cells. 
  Chapter 1  
 Results Part A   
 Karina D. Corware 
 
 
 
96 
Both SB-GD-19 and HP-18 were found to have a negligible ability to lyse RBCs after 
1 h and 4 h at concentrations of up to 2 mg/ml. (Figure 17 and Figure 18 
respectively).  
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Figure 17: Haemolytic potential of SB-GD-19  
SB-GD-19 at a concentration range of up to 2 mg/ml was incubated with a 2 % v/v 
RBC solution for a 1 h (a) and 4 h (b) incubation and found to have negligible 
haemolytic potential. Representative data from an experiment with each 
concentration tested in duplicate. 
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Figure 18: Haemolytic potential of HP-18 
HP-18 at a concentration range of up to 2.5 mg/ml was incubated with a 2 % v/v RBC 
solution for a 1 h (a) and 4 h (b) incubation and found to have negligible haemolytic 
potential. Representative data from an experiment with each concentration tested in 
duplicate. 
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1.3.1.3.2 Toxicity of polymers to primary human cells 
It was essential to evaluate whether either polymer had a toxic influence when added 
to human primary cells. These assays were conducted on at least three separate 
occasions in triplicate by MSc student Gabrielle Mroziewicz under my supervision. 
The representative results from one experiment are shown.  
MTT was used to determine the viability of these cells in the presence of the 
polymers. MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) is a 
tetrazolium salt that is oxidized in the presence of living cells by mitochondrial 
dehydrogenase resulting in a dark blue product. Cells that are damaged or dead do 
not have mitochondrial dehydrogenase activity and therefore would not cause 
oxidation of tetrazolium and produce a dark blue product.  
1.3.1.3.2.1 Fungizone 
In the following cytotoxicity experiments, Fungizone was used as a positive control. 
This drug is well known for its toxic properties (Adams and Kwon 2004) and was also 
the source of AmB for the synthesis of the AmB-PMA. It was found that when human 
primary cells and U937 cells were exposed to Fungizone, there was a dose-
dependent effect on cell viability i.e. increasing concentrations led to decreasing 
cellular viability. 
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Figure 19: Cytotoxic effects of Fungizone  
A dose-dependent cytotoxic effect was found on monocytes (open square points with 
dashed black line) and U937 (black triangle with solid black line) in the presence of 
Fungizone with an LD50 = 217 µg/ml and 350 µg/ml respectively. In brief, 1x10
5 cells 
/well were seeded to a microtitre plate before the addition of equal samples of 
Fungizone in triplicate at a range of concentrations up to 500 µg/ml for 3 h. The cells 
were incubated for a further 3 h with MTT before the addition of DMSO. The optical 
density of the supernatant was measured at 507 nm to calculate the percentage cell 
viability. Representative data is shown from an experiment performed in triplicate.  
 
1.3.1.3.2.2 Monocytes 
Peripheral blood mononuclear cells (PBMCs) were isolated from a fresh buffy coat 
(National Blood Service). After extracting cells via centrifugation and incubating at 
37°C, the adherent monocyte population was washed and isolated. Both polymers 
maintained 100 % viability when incubated for 3 h at concentrations of up to 2 mg/ml 
AmB (Figure 20).  
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Figure 20: Viability of monocytes stimulated with either SB-GD-19 or HP-18 
The viability of monocytes remained at 100 % after a 3 h stimulation with up to 500 
µg /ml of both SB-GD-19 (purple triangle) and HP-18 (blue filled square). In brief, 
1x105 cells /well were seeded to a microtitre plate before the addition of equal 
volumes of polymer in triplicate at a range of concentrations up to 500 µg/ml for 3 h. 
The cells were incubated for a further 3 h with MTT before the addition of DMSO. 
The optical density of the supernatant was measured at 507 nm to calculate the 
percentage cell viability. Representative data is shown from an experiment performed 
in triplicate.  
 
1.3.1.3.2.3 Peritoneal Macrophages 
Peritoneal macrophages were isolated from dialysis waste bags. The availability of 
these bags was sporadic, depending on the quantity of the patients undergoing 
treatment. Once collected the tissue macrophages were harvested via centrifugation. 
Yield was not high which limited the experiments that were performed using this cell 
type. Macrophages were stimulated for 3 h with SB-GD-19, after which no cellular 
toxicity was observed. This is shown as 100 % cell viability which was maintained up 
to a concentration of 0.5 mg /ml.  
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Figure 21: Cytotoxic effects of SB-GD-19 on peritoneal macrophages 
Peritoneal macrophages were isolated via centrifugation of peritoneal fluid and 
adhered to plastic for 2 h. The cells were then washed and 1x105 cells /well were 
seeded to a microtitre plate before the addition of equal volumes of SB-GD-19 in 
triplicate at a range of concentrations up to 500 µg/ml for 3 h. The cells were 
incubated for a further 3 h with MTT before the addition of DMSO. The optical density 
of the supernatant was measured at 507 nm to calculate the percentage cell viability. 
100 % viability of peritoneal macrophages stimulated with SB-GD-19 for 3 h was 
found. Representative data is shown from an experiment performed in triplicate.  
 
1.3.1.3.2.4 U937 cell line 
Due to the low yield of peritoneal macrophages generated and the sporadic 
accessibility, it was necessary to find an alternative cell type to evaluate the polymers 
and AmB-PMA. A U937 cell line was used to assess the toxicity of HP-18 due to the 
lack of peritoneal tissue macrophages. This cell line was exposed to HP-18 for 3 h 
and maintained 100 % viability as shown in Figure 22. 
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Figure 22: Viability of U937 cells on stimulation with HP18 
Non-adherent U937 cells were added to a V bottom plate (1x105 cells /well) before 
the addition of HP-18 in triplicate at a range of concentrations up to 500 µg/ml for 3 h. 
The cells were incubated for a further 3 h with MTT before the addition of DMSO. 
The optical density was measured at 507 nm and the viability of U937 cells was 
maintained after 3 h at 100 %. Representative data is shown from an experiment 
performed in triplicate. 
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1.3.1.3.3 The proinflammatory effect of polymers on blood-derived cells 
It was important to establish if the polymers had any capacity to activate 
proinflammatory immune responses from human primary cell types. Excessive 
activation could directly conflict with the benefits to incorporate a polymer into a 
biomedical application. In the following assays, cells were stimulated with both 
endotoxin-free SB-GD-19 and HP-18 at a range of concentrations after 3 h co-
culture. The cells were then harvested so to measure chemokine and cytokine mRNA 
levels using quantitative real-time PCR. Lipopolysaccharide (LPS) was a positive 
control as it is a potent activator of a proinflammatory innate immune response with 
production of chemokines and cytokines such as MIP-1β and TNF-α respectively. 
Results are illustrated either as fold increases with respect to the unstimulated cells 
or as mRNA expression levels with respect to HPRT (housekeeping gene). Each 
experiment was performed on three separate occasions and each real-time PCR was 
performed in triplicate to limit variability.   
1.3.1.3.3.1 Monocytes 
No statistical difference in the proinflammatory activity of monocytes was found on 
stimulation with SB-GD-19 (data shown at 500 µg /ml, Figure 23). On evaluation of 
HP-18, a wider range of concentrations were used. Between 50 µg /ml and 200 µg 
/ml no statistical difference in the production of MIP-1β, TNF-α or IL-10 was seen to 
occur in monocytes stimulated with HP-18 (Figure 24).  
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Figure 23: Proinflammatory effect of monocytes stimulated with SB-GD-19 
Adhered monocytes were incubated for 3 h with a range of concentrations of SB-GD-
19. The cells were then pelleted and added to Trisol for RNA extraction and the 
generation of cDNA for real-time RT-PCR. No significant difference was observed in 
the expression of the proinflammatory chemokine MIP-1β (a) and cytokine TNF-α (b) 
between the unstimulated monocytes and those stimulated with SB-GD-19 at 500 µg 
/ml. (***= P < 0.005, **= P <0.01, *= P < 0.05, ns = not significant.) Representative 
data of an experiment performed in triplicate. 
  Chapter 1  
 Results Part A   
 Karina D. Corware 
 
 
 
105 
MIP-1
un
st
im
ul
at
ed
LP
S
g/
m
L

50
g/
m
L

10
0
g/
m
L

15
0
g/
m
L

20
0
0
1.0×106
2.0×106
3.0×106
4.0×106
1.0×108
ns
ns ns
ns
(a)
C
o
p
ie
s 
o
f 
m
R
N
A
 /
1
0
5
H
P
R
T
TNF-
un
st
im
ul
at
ed
LP
S
g/
m
L

50
g/
m
L

10
0
g/
m
L

15
0
g/
m
L

20
0
0
1.0×10 5
2.0×10 5
3.0×10 5
4.0×10 5
ns
ns
nsns
(b)
C
o
p
ie
s 
o
f 
m
R
N
A
 /
1
0
5
H
P
R
T
IL-10
un
st
im
ul
at
ed
LP
S
g/
m
L

50
g/
m
L

10
0
g/
m
L

15
0
g/
m
L

20
0
0
5.0×105
1.0×106
7.5×106
1.0×107
ns ns ns ns
(c)
C
o
p
ie
s 
o
f 
m
R
N
A
 /
1
0
5
H
P
R
T
 
Figure 24: Proinflammatory effects of monocytes stimulated with HP-18 
Adhered monocytes were incubated for 3 h with a range of concentrations of HP-18. 
The cells were then pelleted and added to Trisol for RNA extraction and the 
generation of cDNA for real-time RT-PCR. No significant differences was observed in 
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mRNA expression of MIP-1β (a), TNF-α (b), or IL-10 (c) on stimulation of monocytes 
with HP-18 between 50 µg /ml to 200 µg /ml compared to the unstimulated 
monocytes. (***= P < 0.005, **= P <0.01, *= P < 0.05, ns = not significant.) 
Representative data generated from an experiment performed in triplicate. 
 
1.3.1.3.4 Polymer HP-18 
It became apparent through the techniques employed that SB-GD-19 and HP-18 
were indistinguishable chemically and also biologically, therefore focus of my thesis 
shifted to synthesising AmB-PMA with HP-18. Through this optimisation process and 
the commencement of in vivo studies, further work was carried out to ensure that HP-
18 did not stimulate a proinflammatory response. This further work involved 
experimenting with a wider range of concentrations (31.25 to 250 µg /ml) and 
experimenting on 3 more different cell types including tissue macrophages. 
Experiments were performed on at least three separate occasions and were 
conducted by MSc student Gabrielle Mroziewicz under my supervision.  
1.3.1.3.4.1 U937 cell line 
U937 cells that were stimulated with a range of concentrations of HP-18 for 3 h 
showed no significant up-regulation of expression of MIP-1β (Figure 25(a), average 
p=0.06). TNF-α was also not found to be elevated compared to the unstimulated cells 
(average p=0.1) and IFN-γ levels were at the limit of detection (Figure 25(b)). 
 
 
 
 
 
 
 
 
 
  Chapter 1  
 Results Part A   
 Karina D. Corware 
 
 
 
107 
 
 
MIP-1
U
ns
tim
ul
at
ed
LP
S
 
25
0
12
5
62
.5
31
.2
5
0
5.0×102
1.0×103
1.0×104
2.0×104
(a)
ns
ns
ns
ns
g/ml
c
o
p
ie
s
 o
f 
m
R
N
A
 /
1
0
5
 c
o
p
ie
s
 o
f 
H
P
R
T
TNF-
U
ns
tim
ul
at
ed
LP
S
25
0
12
5
62
.5
31
.2
5
0
2.0×103
4.0×103
6.0×103
8.0×103
ns ns
ns
ns
(b)
g/ml
c
o
p
ie
s
 o
f 
m
R
N
A
 /
1
0
5
 c
o
p
ie
s
 o
f 
H
P
R
T
 
 
Figure 25: Proinflammatory effects of U937 cells stimulated with HP-18 
U937 cells were incubated for 3 h with a range of concentrations of HP-18. The cells 
were the pelleted and added to Trisol for RNA extraction and the generation of cDNA 
for real-time RT-PCR. No significant differences was observed in mRNA expression 
of MIP-1β (a) and TNF-α (b) on stimulation of U937 cells with HP-18 between 31.25 
µg /ml to 250 µg /ml compared to the unstimulated U937 cells. (***= P < 0.005, **= P 
<0.01, *= P < 0.05, ns = not significant.) Representative data generated from an 
experiment performed in triplicate. 
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1.3.1.3.4.2 Monocyte-derived macrophages (MDM) 
Monocyte-derived macrophages (MDM) were obtained from fresh buffy coat. 
Adherent monocytes were washed and allowed to differentiate into MDMs for 5 days 
before stimulating with HP-18 for 3 h. No upregulation of mRNA expression of MIP-
1β and TNF- α production was found (Figure 26 a, b respectively). 
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Figure 26: Proinflammatory effects of MDMs stimulated with HP-18 
Adhered MDMs were incubated for 3 h with a range of concentrations of HP-18. The 
cells were then pelleted and added to Trisol for RNA extraction and the generation of 
cDNA for real-time RT-PCR. No significant differences was observed in mRNA 
expression of MIP-1β and TNF-α in MDM when stimulated with the polymer (HP-18) 
at a concentration range 31.25-250 µg/ml compared to the unstimulated MDMs. (***= 
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P < 0.005, **= P <0.01, *= P < 0.05, ns = not significant.) Representative data 
generated from an experiment performed in triplicate. 
 
1.3.1.3.4.3 Peritoneal Macrophages 
A low yield of peritoneal tissue macrophages was isolated which limited the 
assessment of HP-18 to 2 concentrations. At 125 µg/ml and 62.5 µg/ml, there was no 
upregulation of mRNA expression observed with respect to the unstimulated cells in 
either MIP-1β or TNF-α (Figure 27 a, b respectively). 
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Figure 27: Proinflammatory effects of peritoneal macrophages stimulated with 
HP-18 
Peritoneal macrophages were isolated via centrifugation of peritoneal fluid and 
adhered to plastic for 2 h. The cells were washed and seeded to a microtitre plate 
and incubated for 3 h with a range of concentrations of HP-18. The cells were then 
pelleted and added to Trisol for RNA extraction and the generation of cDNA for real-
time RT-PCR. No elevation of mRNA levels of MIP-1β and TNF-α was observed 
compared to unstimulated macrophages in the presence of HP-18. ***= P < 0.005, 
**= P < 0.01, *= P < 0.05, ns = not significant, P > 0.05. Data shown is from an 
experiment performed in triplicate and representative of results collected over three 
separate occasions.    
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1.3.1.3.5 Activity against Leishmania spp. 
It was also necessary to assess the anti-leishmanial activity of the polymers before 
their use in the reaction synthesis. This was performed on all three species; L. major, 
L. mexicana and L. donovani. Figure 28 demonstrates 100 % viability of 
promastigotes from L. major when exposed to either SB-GD-19 or HP-18. This is 
representative of data collected from all three species.   
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Figure 28: Anti-leishmanial activity of HP-18 and of SB-GD-19 
In brief, L. major (1x105 promastigotes /well) were seeded to a 96 well microtitre 
plate. Polymer was added in triplicate up to a concentration of 250 µg/ml and 
incubated for 24 h. MTT reagent was then added before a further 24 h incubation. 
The cells were pelleted and DMSO added to determine the cell viability via 
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spectrophotometry. The viability of the promastigotes was calculated compared to 
100 % viability of the untreated cells. No anti-leishmanial activity was observed when 
promastigotes where exposed to either SB-GD-19 (a) or HP-18 (b). Representative 
data from two experiments performed in duplicate. 
 
1.3.1.4 Polymer summary 
As shown in the experiments detailed in this section, SB-GD-19 and HP-18 have 
indistinguishable chemical characteristics using the analytical techniques used. 
There was also in vitro biological consistency between the two polymers. No toxicity 
was observed on either RBCs or human monocytes and U937 cells. Neither polymer 
demonstrated any killing activity against leishmania spp. promastigotes. Monocytes 
were not stimulated in the presence of either polymer and further analysis of HP-18 
on peritoneal macrophages did not alter these findings. In summary, SB-GD-19 and 
HP-18 are biologically inactive and are chemically similar. One could postulate that if 
a drug can be synthesised using SB-GD-19, then it could also be synthesised with 
HP-18. This would be most advantageous as it would remove the requirement for 
synthesising the polymer and hence eliminate the variability between batches of 
polymers synthesised.  
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1.3.2 Part B: Characterisation of AmB within the AmB-PMA  
Once an AmB-PMA batch was synthesised thorough characterisation of its properties 
were required. This involved firstly the use of UV spectrophotometry to determine the 
chemical characteristics before focusing on in vitro assays to evaluate its efficacy as 
an anti-leishmanial drug. 
1.3.2.1 Quantitation of AmB loading 
1.3.2.1.1 UV Spectrophotometry 
AmB can absorb light at a wavelength of 300-450 nm. On construction of a standard 
curve with a known concentration of AmB material, such as Fungizone, the loading of 
AmB within a synthesised batch of AmB-PMA was determined. Investigations into 
this were previously conducted (Harris 2006). As discussed (Chapter 2 introduction), 
the extent of aggregation of AmB is dependent on both concentration and the 
solubilising media. Irrespective of solution, at high concentrations, AmB is in an 
aggregated state which strongly absorbs light at 328 nm. As the concentration 
decreases, the spectra shift from a predominately aggregated peak to a ratio of both 
aggregated and monomeric states. Further decrease in concentration allows for AmB 
to be completely in its monomeric form absorbing light in the region of 405-409 nm. 
AmB is also more prone to aggregate at a lower concentration in aqueous solutions 
(10-6 M) than in organic solvents such as DMSO (10-3 M) (Balakrishnan and 
Easwaran 1993).  
The experiments performed found that a non-linear association between absorbance 
and AmB concentration at both 328 nm and 409 nm occurred in water at high 
concentrations. AmB was found to be completely monomeric at the low concentration 
of 10-6 (924 ng /ml). However, this low concentration absorbed light at the limit of 
detection of the spectrophotometer (0.02 abs). It was therefore necessary to find an 
alternative medium that maintains AmB at a higher concentration in a monomeric 
state. DMSO was an obvious alternative as it gave rise to AmB in a monomeric state 
at 10-4 M (92.4 µg /ml); however, this was not a favourable solvent to solubilise AmB-
PMA. AmB is soluble in alcohol, and it was previously found that 50 % methanol in 
water gave rise to AmB in a completely monomeric form with a peak at 409 nm. This 
1:1 ratio was consistent allowing for a reproducible standard curve using Fungizone 
to which extrapolation could be carried out to determine the percentage weight of 
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AmB within each synthesis. On every assessment of a newly synthesised batch of 
AmB-PMA the standard Fungizone would also be tested to limit variability between 
differing days. A representative standard curve is shown in Figure 29 illustrating a 
direct linear correlation between concentration and absorbance (r2 = 0.997).  
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Figure 29: Linear regression of Fungizone (AmB-deoxycholate)  
Fungizone was solubilised in a final solution of 50 % methanol to give rise to a linear 
regression. This was used as an internal reference when performing readings on the 
UV spectrophotometer. Data pooled from 5 different readings with an r2= 0.997.  
 
Both AmB-PMA and Fungizone are not fully solubilised directly in methanol or in 
methanol: water (1:1). Therefore, all samples were solubilised in water for injection at 
a concentration of 1 mg/ml before performing a serial dilution in 50 % methanol. The 
UV measurements at 409 nm were recorded within 60 min from solubilisation to limit 
AmB degradation.  
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1.3.2.1.1.1 UV-visible spectra of AmB-PMA 
AmB can be present in one solution in varying different states. Once the loading of 
AmB was established, the absorbance of the AmB-PMA over a range of 300-450 nm 
could be visualised and directly compared at the same concentration with Fungizone, 
AmBisome and other synthesised batches. This proved essential during the 
optimisation process of the reaction synthesis, as it highlighted trends and 
anomalies. It was also a more visual identification into the reproducibility between the 
synthesised batches; not only the loading but also the state of AmB. Figure 30 
demonstrates the spectra of both AmBisome, Fungizone and an example of the 
spectra of AmB-PMA. Fungizone and AmBisome typically contain AmB in a defined 
aggregated state depicted by a prominent peak at 328 nm. In comparison, AmB-PMA 
typically has a reduced peak at 328 nm and a prominent peak at 409nm, 
demonstrating the presence of AmB in its monomeric state. This shift in spectra is 
indicative to the interaction of the polymer and AmB. However, it is not due to the 
polymer alone, as this does not absorb light within the range of 300-450 nm.  
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Figure 30: Spectra of AmB in different AmB-based drugs  
Samples were reconstituted in water for injection and serially diluted to 10 µg/ml 
AmB. The spectra across 300-450 nm was measured to determine the state of AmB 
within each samples. AmB is in a predominately aggregated state in AmBisome 
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(328nm, black dashed line) compared with Fungizone (grey). Detection of AmB in its 
monomeric state at 409nm is most prominent in AmB-PMA (blue).   
1.3.2.2 Screening 
On determination of the percentage loading and the state in which AmB is present, 
analysis of its biological properties in vitro were performed. This involved conducting 
haemolysis assays which indicated the level of toxicity of AmB-PMA, and anti-
leishmanial assays using MTT. Figure 31 and Figure 32 illustrate the ‘ideal’ 
properties of AmB-PMA with potent anti-leishmanial activity and low haemolytic 
potential.  
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Figure 31: Assay illustrating AmB-PMA with low haemolytic potential 
A 2% v/v solution of RBCs was added to AmB-PMA and Fungizone for a final 
concentration of up to a 100 µg/ml for 1 h. The optical density of the supernatant was 
measured to calculate the red cell lysis induced by the drug. AmB-PMA has a 26.8 % 
haemolytic potential at a concentration of 100 µg/ml AmB (blue square). This is a 
reduction of 66.4 % compared to Fungizone (93.2 %, black triangle) after a 4h 
incubation. Representative data of three pooled batches of AmB-PMA tested in 
duplicate on two separate occasions. 
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Figure 32: Assay illustrating the anti-leishmanial properties of AmB-PMA 
L. major promastigotes (1x105 /well) were seeded in a 96 well titre plate with an equal 
volume of AmB-PMA at a range of concentrations up to 3 µg/ml AmB for 24 h. MTT 
reagent was used to measure an optical density read-out at 570 nm. Representative 
data of 2 synthesised AmB-PMA batches (blue squares) tested in duplicate with an 
LD50 = 0.05. 
 
1.3.2.3 Optimisation of AmB-PMA synthesis of SB-GD-19 
Previous synthesis of AmB-PMA using SB-GD-19 created batches of AmB-PMA with 
tight reproducibility and low haemolytic potential. However, results from several 
visceral leishmaniasis studies showed that the batches synthesised were poor at 
reducing parasite burden in vivo even though they showed excellent anti-leishmanial 
killing activity in vitro. It was therefore necessary to optimise this synthesis protocol 
before investigating its effects on cutaneous lesions in vivo. On commencement of 
the optimisation process, there were several initial stages within the synthesis 
protocol that were highlighted as possibilities in causing the variability between in 
vivo and in vitro data. These variables are discussed in the following section.    
During optimisation of the synthesis protocol, UV spectrophotometry was used 
extensively to gauge the effects when components and their quantities were 
changed. The haemolytic potential of the individual batches of AmB-PMA was also 
readily used as an output in the indication of toxicity.  
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1.3.2.3.1 Method 1- SB-GD-19 
SB-GD-19 and AmB are both insoluble in water. Hence, DMSO was used as the 
solvent for making the AmB-PMA drug. The precursor polymer was solubilised in 
DMSO overnight at 50 mg/ml. Activated charcoal was then added to remove 
endotoxin as described in Materials and Methods and was easily removed by 
centrifugation. AmB was solubilised in DMSO for 1 h prior to synthesis at 34.5 mg/ml. 
On addition, a viscous yellow solution was formed.  
1.3.2.3.1.1 Sodium hydroxide (NaOH) 
NaOH was essential for the synthesis because it forced the hydrolysis of the 
precursor polymer into an acid derivative and allowed it to interact with AmB. In a 
standard reaction NaOH was added at 2 equivalents to the non-aqueous volume in 
the reaction mixture. This was then allowed to stir for 1 h before the reaction mixture 
was passed down a PD 10 column for purification. Due to the necessary presence of 
NaOH, further experiments were carried out to ensure that hydrolysis was occurring. 
This was performed using NMR over an 8 h period where it was found that the 
precursor polymer SB-GD-19 had not hydrolysed fully. Interaction between PMA and 
AmB was believed to only occur with the precursor polymer in its hydrolysed state. 
Therefore, if full hydrolysis was not occurring then this could result in insoluble 
syntheses forming that aggregated on the PD-10 column. It was found that 10 
equivalents of 1N NaOH were required for the full hydrolysis of the polymer. 
However, this approach was detrimental to the stability of AmB in the synthesis 
protocol used. On creation of two batches of AmB-PMA using 4 and 6 equivalents of 
1 N NaOH, both syntheses led to solutions whose colour was much darker and could 
be easily filtered. On characterisation, both exhibited a high degree of RBC lysis after 
a 1 h incubation. There was a 50 % increase in haemolytic potential of the AmB-PMA 
synthesised with greater equivalents of 1 N NaOH than that of a typical reaction 
containing only 2 equivalents (Figure 33). From this, it was clear that two equivalents 
of NaOH were the maximum that could be used in a single reaction mixture. It also 
highlighted the issue that within one synthesis, there may be insoluble aggregates 
forming due to the incomplete hydrolysis of SB-GD-19.  
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Figure 33: Haemolytic potential of AmB-PMA was dependent on NaOH during 
synthesis  
A 2% v/v solution of RBCs was added to AmB-PMA samples and Fungizone for a 
final concentration of up to a 100 µg/ml for 1 h. The optical density of the supernatant 
was measured to calculate the red cell lysis induced by the drug. A typical synthesis 
with 2 equivalents of NaOH (pink line) lysed 26.8 % RBC. AmB-PMA batches 
synthesised with 4 (blue line) and 6 (purple line) equivalents of NaOH lysed RBCs by 
70.2 % and 76.2 % respectively. Fungizone (black solid line) had a haemolytic 
potential of 98.6 %. Values assessed at 100 µg/ml of AmB. Representative data of a 
single experiment performed in duplicate.   
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1.3.2.3.2 Purification of AmB-PMA 
Purification of a compound can be carried out by size exclusion chromatography 
(SEC), whereby the desired sample can be collected depending on its size. Two 
types of SEC were assessed for the purification of AmB-PMA.  
1.3.2.3.2.1 PD-10 columns 
At the end of a synthesis reaction, PD-10 columns were used to remove DMSO and 
any small molecular weight contaminants including free AmB that had not interacted 
with the polymer. This was carried out by SEC whereby particles are separated 
based upon their size and molecular weight. The end product was the purified AmB-
PMA. These columns were initially used because it was more time-efficient and it 
seemed to provide a good method of purification. This method also separated 
aggregates of AmB that could have formed, resulting in a AmB-PMA synthesis that 
contained predominately monomeric AmB.   
1.3.2.3.2.2 Dialysis 
Dialysis is an alternative gentle but effective method to remove impurities and purify 
a substance. The semi-permeable dialysis membrane selectively allows small solutes 
to diffuse out of the dialysate into the surrounding dialysis solution while allowing the 
larger molecules to be retained. In this instance, dialysis over a determined period of 
time can be sufficient to remove low affinity interactions between AmB and the 
polymer and also free AmB resulting in the remainder solution containing high affinity 
interactions. Time and pH needed careful consideration as it is well established that 
increasing the amount of time that AmB is in solution increases its tendency to 
aggregate. This contributes to the AmB toxicity in mice. Altering the pH also affects 
the aggregation status of AmB and thereby its toxicity in vivo. 
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1.3.2.3.3 Establishing optimum pH for dialysis 
1.3.2.3.3.1 Preliminary dialysis experiments 
To investigate the initial potential of purification via dialysis, a series of batches of 
AmB-PMA that had already been synthesised using PD-10 columns were 
reconstituted and dialysed using slide-a-lyzer cassettes with a molecular cut-off 
(MWCO) of 3,500 Da. AmB has a molecular weight of 920 Da and therefore this cut-
off should allow removal of free AmB but not the AmB that was associated via 
electrostatic interactions with HP-18 where the molecular weight was 18 kDa.  
A batch of AmB-PMA was first dialysed simply against MilliQ water at room 
temperature with 2 h changes. After 5 changes of the dialysis solution, the dialysate 
appeared unaltered in colour intensity. This indicated that no loss of AmB was 
occurring and that it may be necessary to cause a shift in the environment to promote 
loss of additional low affinity bound and toxic free AmB. One could suggest that if 
there was a high concentration of free AmB within the dialysate, then it would quickly 
form high molecular weight aggregates which would not be able to pass through the 
dialysis membrane. As discussed in the Introduction, the state of AmB is pH-
dependent and that on addition of NaOH, a highly alkaline environment of pH 12, 
AmB shifts to a completely monomeric state. By altering the pH, the free AmB within 
the dialysate would be in a monomeric state and it would pass easily into the dialysis 
solution. Addition of 0.25 M NaOH to both dialysate and dialysis solution ensured that 
an additional osmotic gradient was not being created. After 1 h, the dialysis solution 
turned yellow. This was dialysed for a further hour before an aliquot of both the 
dialysis solution and dialysate were harvested. The remaining dialysate was left to 
dialyse for a further 22 h in fresh dialysis solution. The spectra are shown in Figure 
34. These indicate a large loss of AmB had occurred from the cassette. No 
subsequent loss of AmB was observed after a further 22 h of dialysis against NaOH. 
This suggested that even the batches synthesised with a higher binding affinity could 
be disrupted by an excessive alkali solution causing AmB to leave the dialysis 
solution. A further 5 syntheses were reconstituted and dialysed in several molar 
concentrations of NaOH as summarised in Table 6. Initially, aliquots of the dialysates 
were taken and the spectra measured to determine the percentage of AmB being 
dialysed out. However, the percentages of AmB measured in this way were very 
high, with OD readings of over 1.5 absorbance units.  
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Through my research, I have found that absorbencies above 1.0 OD units produce 
unreliable, inconsistent results. Therefore it became clear that these syntheses would 
have to be lyophilised to a powder in order to accurately determine the loading of 
AmB. There was also concern that reconstitution for dialysis at 10 mg/ml of AmB for 
dialysis was too high considering that Fungizone, when it is administered to patients, 
is reconstituted at a maximum of 5 mg/ml AmB. As discussed previously, a high 
concentration of AmB within a solution creates a higher presence of aggregation 
(Romanini et al. 1999). Therefore the latter 2 batches (e and f) synthesised described 
in Table 6 were reconstituted at this lower concentration of AmB as this may have 
caused additional stress on the AmB within the AmB-PMA. 
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Figure 34: Effects of dialysis with NaOH on AmB-PMA synthesis 
The UV spectra demonstrates the effects of dialysis in NaOH showing AmB-PMA at 
10 µg/ml AmB pre-dialysis (purple dashed line) and post-24 h dialysis (purple solid 
line). The loss of AmB was measured from the dialysis water after 2 h (blue line). No 
further loss of AmB was recorded in the dialysis solution from 3 h to 24 h.
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Table 6: The effects of dialysis with NaOH 
AmB-PMA syntheses were reconstituted in water for injection and dialysed in varying strengths (Molar solutions) of NaOH and length of time. 
The products were then lyophilised a further time before the AmB loading was determined via UV spectrophotometry at 409 nm. Dialysis in the 
presence of NaOH significantly altered the final percentage of AmB within the AmB-PMA compared to initial loadings. All 6 syntheses 
lyophilised to a black powder. This is not a characteristic of AmB.  
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All 6 of these syntheses lyophilised to a black flaky powder that appeared like burnt 
charcoal instead of the yellow powder expected. All were solubilised to form a rich 
orange-brown solution. However, it was evident that the various methods of dialysis 
with NaOH on reconstituted lyophilised material altered the physico-chemical 
characteristics of the AmB-PMA. It was necessary to synthesise fresh batches and 
purify via dialysis only without first purifying via PD-10 columns and lyophilisation. 
The following sections detail the findings on dialysis with varying pH solution and 
dialysis time on freshly synthesised AmB-PMA using Method 1. 
1.3.2.3.3.2 NaOH 
The preliminary experiments demonstrated the necessity to optimise the approach of 
using NaOH as a dialysis solution. However, the experiments did not clearly identify 
trends using NaOH, as the AmB-PMA that was being used at the start of the 
experiment had already been passed through a purification process. Although they 
did indicate that a decreasing concentration of dialysis solution may prove to be a 
more gentle approach. AmB-PMA was synthesised and purified in a strong (1 and 2 
from Table 8 & 4 and 5 from Table 7) or weak alkaline environment (6, 7 and 8, Table 
7). Overall, there was a noticeable retention of AmB when dialysed in the varying 
concentrations of NaOH rather than with a buffered water protocol. This is reflected 
in the spectra shown of syntheses 5 and 7 in Figure 35 which illustrate a 
predominately monomeric AmB as a result of the presence of an alkaline solution.  
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Table 7: AmB-PMA batches purified in different dialysis solutions over 24 h 
After each synthesis, the AmB-PMA solution was dialysed for a maximum of 24 h in different dialysis solutions to determine the effect of time and 
dialysis solution on the final concentration and the state of AmB within the AmB-PMA. After dialysis the AmB-PMA was lyophilised to a yellow 
powder before determining its AmB loading via UV spectrophotometry at 409 nm
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Figure 35: Spectra of AmB-PMA dialysed in either water or NaOH  
Reconstituted in water at a final concentration of 10 µg /ml AmB, AmB-PMA 
synthesis 5 was dialysed in NaOH and is shown in purple. It demonstrates a high 
peak at 409 nm indicating AmB is in its monomeric state. AmB-PMA synthesis 7 was 
dialysed in water and demonstrates a ratio of 1:1 between monomeric and 
aggregated state of AmB (shown in blue).  
1.3.2.3.3.3 Na2HPO4  
The manufacturers of Fungizone supply a 2 ml vial of phosphate buffer with every 
bottle. Included are specific instructions detailing the need to add this vial of buffer to 
dextrose before intravenous administration to human. This raises the pH of dextrose 
from an acidic pH 4.8. A buffer solution has a greater capacity to maintain pH stability 
than the addition of NaOH. Na2HPO4 has a buffering capacity within the pH range of 
5.8-8.0. pH 8 would be the most appropriate pH for AmB-PMA syntheses as it is 
close to physiological pH (7.3). An AmB-PMA synthesis reaction was generated to 
have a 40 % AmB loading and purified in Na2HPO4 (Table 8 (3a-e)). At specific time 
points, an aliquot was harvested and all were lyophilised to a yellow powder. 
Noticeably, the final concentration of AmB after lyophilisation was reduced by 
approximately 20%. This was surprising as no change in the colour of the dialysis 
solution was noted during purification. The substantial loss in AmB during dialysis did 
not justify further investigation into dialysis using Na2HPO4.        
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Table 8: AmB-PMA synthesised with SB-GD-19 and purified via dialysis with varied dialysis solutions 
Three syntheses of AmB-PMA were generated and then used to determine the effects of different dialysis solutions containing either Na2HPO4 
or NaOH on the final concentration of AmB. The final loading of AmB-PMA was determined via UV spectrophotometry after lyophilisation
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1.3.2.3.3.4 Time 
Time is an important factor to consider when dialysing considering the ease of AmB to form 
aggregates in solution over time. It was crucial to assess the loss of AmB over an extended 
period of time and also the state that AmB is predominately present in within the AmB-PMA 
drug. An AmB-PMA reaction was synthesised with a 38 % AmB loading and it was dialysed 
in a 3,500 MWCO Slide-a-Lyzer cassette (Synthesis 1, Table 8). It was dialysed against a 
solution of 0.25 M NaOH for 2 h and then 0.125 M NaOH for 2 h followed by 0.0625 M 
NaOH for 2 h, all with hourly changes of the dialysis solution, before finally dialysing 
overnight in sterile water buffered at pH 8. The dialysis solution was changed hourly in the 2 
h periods and by incrementally lowering the concentration of NaOH. Half of the dialysate 
was then removed and lyophilised. The remainder (Synthesis 2, Table 8) was dialysed for a 
further 24 h with 4 hourly changes of the buffered water. After lyophilisation, synthesis 1 had 
an AmB loading of 26.5 % and synthesis 2 of 27.2 %. This indicated that after 24 h dialysis 
in alkaline conditions, the low affinity associated AmB-PMA molecules had been removed. A 
further 24 h of dialysis did not alter the AmB loading further. This suggested that 24 h was a 
sufficient period of dialysis. The spectra of synthesis 2 illustrated a higher proportion of AmB 
in its aggregated state than that of synthesis 1. Dialysis extended further than 24 hours 
seemed to implicate a detrimental effect on the association of AmB and PMA and therefore 
the focus of additional studies was on what was happening during the 24 h dialysis. 
Synthesis 3 was created and dialysed for a total of 24 h. Aliquots of the dialysate were 
removed at 2 h, 4 h, 6 h, 18 h and the remainder at 24 h. These were all frozen, lyophilised 
and the percentage weight of AmB determined. As shown in Table 8, there was no 
significant difference in loading within this 24 h period. The spectrum shifts slightly between 
synthesis 3a and 3c over the first 6 h. Between 18 h and 24 h, the spectra remains 
unchanged (Figure 36). This indicates that dialysis of the AmB-PMA reaction mixture is 
necessary for a total period of between 18 and 24 h. 
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 Figure 36: The effects of the duration of dialysis on the spectra of AmB 
One AmB-PMA synthesis was generated and during dialysis aliquots were extracted and 
lyophilised. These were then reconstituted to determine their AmB content and the state in 
which AmB was in the synthesis. Syntheses 3a (orange, 2 h dialysis), 3b (green, 4 h 
dialysis), 3c (light green, 6 h dialysis), 3d (pink, 18 h dialysis), 3e (blue, 24 h dialysis).The 
latter two were similar in spectra indicating that AmB became stable and maintained this 
stability from 8-24h. 
 
During dialysis with NaOH and buffered water, the dialysis solution was changed hourly in 2 
h periods. This was time-consuming and a vast amount of solutions that required sterilisation 
and endotoxin-free were being utilised. Syntheses 8a, 8b and 8c were made to assess the 
difference, if any, of changing the solutions 2 hourly instead of hourly. As detailed in Table 7, 
all had AmB loadings +/- 5% indicating that there was no difference in the dialysis method 
used. All subsequent synthesises were performed using dialysis in buffered water at room 
temperature with 2 hourly dialysis changes. 
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1.3.2.3.3.5 Stability 
All batches of AmB-PMA were stored as a lyophilised powder at 4°C in amber glass vials 
under argon. By changing the synthesis purification method from PD-10 columns to dialysis 
and the introduction of various pH solutions, it was possible that the compound stability was 
compromised with time. To investigate this, 4 batches were synthesised, two of which were 
dialysed with buffered water (Syntheses 6, 7) and two with the NaOH protocol (Syntheses 4, 
5) as illustrated in Table 9. Over a period of 10 days, there was no significant difference in 
AmB loadings of the batches dialysed using buffered water. Syntheses 4 and 5 that were 
dialysed against NaOH were found to have a significantly lower AmB loading after 10 days 
of storage. This indicated that syntheses 4 and 6 were likely to have less stable interactions 
between AmB and SB-GD-19. The spectra of these samples confirmed the finding that 
dialysis in buffered water resulted in more stable batches with a ratio of 1:1 aggregated to 
monomeric forms of AmB (Figure 37(a)). The spectra of the NaOH-dialysed batches had 
shifted significantly with a more predominant monomeric peak (Figure 37(b)). This was not 
characteristic of the AmB-PMA drug. The concern was that the state of AmB was varying 
over time in the lyophilised powder after dialysis against NaOH.  
 
 
 
Table 9: Change in AmB loading after 10 days as a lyophilised powder at 4°C 
Syntheses 4 and 6 were dialysed against NaOH before lyophilisation as a yellow powder 
and storage under argon at 4°C. Syntheses 5 and 7 were dialysed against buffered water 
(H20 pH 8) before lyophilisation. 
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Figure 37: Change in spectra of batches stored over 10 days 
AmB-PMA batches were reconstituted in water for injection at 1 mg/ml AmB before their 
absorbance spectra was measured across 300-450 nm at a final concentration of 10 µg/ml. 
Synthesis batch 7 (a) purified in water with 1st reading (blue) and 2nd(black) 10 days apart 
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illustrating little change. Synthesis 6 (b), purified in NaOH with 1st reading (blue) and 2nd 
reading (black) 10 days apart showing shift in spectra. 
 
1.3.2.3.3.6 Molecular Weight Cut Off of Dialysis Cassettes  
As stated the dialysis membrane is made up of a cross-linked matrix of polymers which can 
be made to a variety of pore sizes depending on the size of molecule that needs to be 
retained. This is called the molecular weight cut off (MWCO) of the dialysis membrane and it 
is typically recommended that it should be at least half the size of the molecular weight of the 
molecules that need to be retained. This takes into account other factors that could influence 
the permeability of the molecules through the membrane such as molecular shape, ionic 
charge and polarity. In this case SB-GD-19 has a molecular weight of 18 kDa so a dialysis 
cassette of 7 kDa was appropriate. A series of experiments were carried out to investigate 
the influence of dialysis of the AmB-PMA syntheses in cassettes of MWCO’s of 3.5 kDa, 7 
KDa, 10 kDa and 12-14 kDa. One synthesis was introduced into all 3 cassette chambers and 
after dialysis for 24 h and lyophilisation, was found to have a different percentage loading of 
AmB. The loading of AmB seemed to increase when dialysed in a chamber with an 
increased MWCO. This suggested that at a MWCO of 12-14 kDa a proportion of the SB-GD-
19 polymer was filtering out of the dialysate leaving a more concentrated AmB-PMA after 
freeze drying. This is understandable considering the polydispersity of the polymer. Figure 
38 demonstrates what was found. When dialysing with a 3.5 kDa MWCO, a minimal amount 
of polymer was lost compared to the significant proportion lost when dialysed in a membrane 
with a 12-14 MWCO. To ensure the loss of poorly associated AmB-PMA and free AmB only, 
and to minimise the loss of well associated AmB-PMA batches, a MWCO of 7 kDa was 
finally used for all subsequent experiments. Therefore, all subsequent syntheses were 
purified by dialysis using a slide-a-lyzer chamber of 7 kDa for 24 h at room temperature 
against water for irrigation. 
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Figure 38: A schematic of the polydispersity of SB-GD-19 
This schematic illustrates the polydispersity of SB-GD-19 and the theoretical amount of 
AmB-PMA lost when dialysed in a 3 kDa, 7kDa, 10 kDa and 12-14 kDa dialysis chamber. 
The optimum dialysis chamber for the retrieval of AmB-PMA was found to be using a 7 kDa 
dialysis chamber. 
 
1.3.2.4 Formulation of AmB-PMA protocol using HP-18 
From the experiments using SB-GD-19, a substantial amount had been learnt which could 
be applied to formulating and optimising a protocol using HP-18 to synthesise batches of 
AmB-PMA. It was evident that factors such as pH could influence the type of AmB-PMA drug 
created and therefore investigations into this and other factors such as the addition of NaOH 
and the ratio of solvent and solution present in the mixture were required using HP-18. As 
parameters in the reaction synthesises were altered, haemolytic data became an important 
output measure. Individually synthesised batches were subjected to solubility and toxicity 
testing in an attempt to define the factors that were crucial in enabling the association of HP-
18 and AmB. 
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1.3.2.4.1 Ratio of solvent and solution 
SB-GD-19 and free AmB have restricted solubility but are both soluble in DMSO. HP-18 is a 
salt and therefore readily enters into a liquid phase in water, but is less soluble in organic 
solvents such as DMSO. The initial synthesis protocol of AmB-PMA, involved the use of 
AmB and SB-GD-19 separately solubilised in DMSO and then added together. This, on 
addition with NaOH and water, led to synthesis of the AmB-PMA reaction mixture. The 
mixture had a 2:1 ratio of water to DMSO due to the addition of water. This ratio was 
believed to be important. Both precursor polymer and AmB are readily solubilised and more 
importantly stable in DMSO. Therefore there is no requirement for either to form interactions 
with each other. Indeed the simple addition of SB-GD-19 and AmB did not yield a soluble 
product. Once NaOH was added to the mixture, SB-GD-19 was hydrolysed and shifted into a 
less stable form as it became the acid derivative. This reaction appeared to be sufficient for 
association of the polymer and AmB to occur. The reaction mixture had double the reaction 
volume of endotoxin free water added. This addition of water was believed to promote the 
solubility of the final product after freeze drying. 
As stated previously, HP-18 is only soluble in water and therefore the ratio that was applied 
to the synthesis involving SB-GD-19 needed to be changed. Fungizone readily solubilised in 
water and was administered in this medium to patients. Therefore it theoretically appeared a 
possibility that AmB-PMA could be made in water only. This would be of great benefit as the 
use of DMSO is associated with toxic properties in man. However, addition of AmB and HP-
18 in water together did not yield a soluble formulation, which indicated that the ratio which 
was present using SB-GD-19 was a more important parameter than first defined. The 
interactions between the polymer and AmB may have been jeopardised by eliminating the 
solvent: solution gradient. As Fungizone can be solubilised in both mediums, a mixture of 
HP-18 in water was added to AmB in DMSO. This yielded a soluble batch of AmB-PMA on 
lyophilisation and reconstitution. It is believed that the gradient allowed synthesis to occur. 
However, it was noticeable that other steps in the synthesis required exploration as these 
batches also exhibited high toxicity and varied loadings of AmB despite keeping all other 
synthetic conditions constant. 
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1.3.2.4.2 Addition Mechanism  
Preliminary experiments allowed the elimination of some variables in the reaction process. 
The SB-GD-19 synthesis protocol was carried out using a ‘forward addition’ mechanism of 
slowly adding the precursor polymer to AmB, as the reverse yielded an insoluble product. It 
was found that no differing characteristics in the batches made with HP-18 were found when 
using a forward addition reaction compared to a reverse addition; i.e., AmB added slowly to 
HP-18. As AmB is light-sensitive, more control could be attained by adding HP-18 slowly to 
AmB.  Therefore a forward addition reaction was maintained.  
1.3.2.4.2.1 N-hydroxysuccinamide (NHS) 
As stated and shown in Figure 9 (Materials and Methods), SB-GD-19 was hydrolysed by the 
slow addition of NaOH to form the acid derivative and a leaving group NHS. In the presence 
of AmB this allowed for the association of the two molecules to take place (Figure 10, 
Materials and Methods). Ability to create AmB-PMA was consistently possible using this 
synthesis protocol. This indicated that NHS may have some beneficial attributes within the 
reaction mixture to allow this association to occur. Investigations followed involving the 
addition of NHS when attempting to form AmB-PMA using HP-18. As HP-18 is a fully 
hydrolysed salt, it does not contain NHS within its structure and therefore would not be 
accountable within its molecular mass. After establishing the difference in moles of both 
polymers, the mass of NHS that was needed was calculated as 85.6 mg. NHS was added at 
different stages within the synthesis reaction and appeared to hinder the synthesis in all 
instances. These findings indicated that NHS was not as crucial in the reaction and was 
merely a leaving group which had to be produced when using SB-GD-19.  
1.3.2.4.2.2 NaOH 
This was essential in a synthesis with SB-GD-19 and was required to be present in excess 
to ensure hydrolysis of the precursor polymer to its acid derivative. Using HP-18 eliminated 
this requirement. However, I have stated that small amounts of NaOH added to AmB shifts it 
into its monomeric state which could be beneficial in synthesis. It seemed appropriate to 
investigate the addition of NaOH in the reaction mixture. Sodium hydroxide was added in 
excess as per the reaction protocol of Method 2 (Materials and Methods). When applying 
this in an HP-18 reaction, the reaction mixtures were difficult to filter and the resulting 
batches had a very low percentage loading of AmB, confirming that AmB had come out of 
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solution. In this instance, the use of NaOH was not for hydrolysis of the polymer, but actually 
to maintain AmB in a monomeric state. This difference had to be taken into account when 
deciding the quantity and the timing at which NaOH was added to the reaction process. By 
adding a small amount of NaOH to AmB, with thorough mixing at the start of the reaction, 
one could postulate that when HP-18 was added to AmB, the probability of AmB associating 
with HP-18 (instead of forming aggregates) was increased. Addition of NaOH to AmB 
produced a colour change from bright yellow to a deep orange solution. This could be an 
indication of AmB shifting into a monomeric state and preliminary experiments suggested 
that 50 µl /ml of 1 N NaOH for a standard single reaction was sufficient to promote this 
change in colour. This was therefore kept constant while determining the AmB 
concentration.   
1.3.2.4.3 Dialysis 
Investigations into dialysis for optimisation of synthesis of AmB-PMA with SB-GD-19 
concluded that all synthesises should be purified using dialysis 7 kDa cassettes for 24 h at 
room temperature and sterile endotoxin-free water. This was maintained so that parameters 
such as optimum concentration of HP-18 could be evaluated. All batches were lyophilised 
and reconstituted at 1 mg/ml AmB to assess the loading of AmB. These were then incubated 
for 1 h with red blood cells to test their haemolytic potential.  
1.3.2.4.4 Concentration of HP-18  
The starting concentration in a reaction with SB-GD-19 was 50 mg/ml and therefore initial 
reactions with HP-18 were also at 50 mg/ml. Two syntheses were made with 50 mg/ml of 
HP-18; they were insoluble (syntheses 1a and 1b, Table 10). This high concentration, which 
saturates the reaction, was necessary when using the precursor polymer as only a 
proportion would be effectively hydrolysed. There was no reason that the same 
concentration would be required when using HP-18. It may be possible for the polymer to 
associate with AmB at lower concentrations, and therefore synthesises were carried out 
using a lower concentration of HP-18 (Table 10). HP-18 at 5 mg/ml appeared to consistently 
yield soluble AmB-PMA batches and possessed indistinguishable characteristics in both 
appearance and texture to that of those made with SB-GD-19. This was an important 
development in the project. There was concern that using a commercially sourced polymer 
instead of one that was synthesised in the lab would increase the price of the individual 
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reactions especially using a high concentration of 50 mg/ml. In developing AmB-PMA using 
HP-18 at 5 mg/ml, 90% less polymer was actually being used.  Investigations into a lower 
concentration of AmB were also conducted. A concentration between 2 mg/ml and 4 mg/ml 
was used but yielded low AmB loadings (Syntheses 6, Table 10). One could propose that 
this low concentration would limit the availability for AmB to associate with HP-18 and that a 
threshold of 5 mg/ml was necessary for the solubility of AmB-PMA. The focus of 
investigations was on reactions performed using an initial concentration of 5 mg/ml in a 1:1 
volume ratio with AmB so as to establish finding the appropriate concentration of AmB in the 
reaction, which could be more influential in allowing electrostatic bonds to form between 
AmB and HP-18.  
 
 
Table 10: Identifying trends between the starting concentrations of AmB and HP-18  
Synthesised batches of AmB-PMA with a fixed concentration of HP-18 illustrates the effects 
of AmB concentration determined by haemolytic potential. All batches synthesised were 
soluble in water upon reconstitution.  *insufficient amount to test haemolysis.   
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1.3.2.4.5 Concentration of AmB 
1.3.2.4.5.1 Solubilising media 
As HP-18 is a salt and therefore readily soluble in water, an experiment was performed to 
determine whether the simple addition of HP-18 to AmB, both solubilised in water, would 
yield a soluble product. Two reaction syntheses were made, but both reaction products were 
insoluble with a bright yellow precipitate clogging the filter. This indicated that insoluble 
aggregates of AmB were present. AmB in water quickly re-organises into aggregates that 
are stable. Therefore, there was no requirement for AmB to associate with HP-18 which is 
also stable in water. In this instance, AmB was solubilised at a concentration of 16.1 mg/ml 
not the 34.5 mg/ml used in the synthesis protocol for SB-GD-19 (syntheses 1a and 1b, Table 
10). This was due to the fact that at a higher concentration, the AmB solution turned into a 
viscous and cloudy suspension. This solubility problem was resolved by solubilising AmB in 
DMSO which then enabled the association with HP-18 when added slowly to the reaction 
mixture. This indicated that both DMSO and water were necessary to aid the association of 
the starting materials. 
1.3.2.4.5.2 Optimisation of the concentration of AmB 
Noticeably, the batches of AmB-PMA synthesised had varying haemolytic potential which 
must have related to the high concentration of AmB that manifested within the AmB-PMA. 
Syntheses were made with an initial AmB concentration of 2 mg/ml through to 24 mg/ml 
(Table 10 and Table 11). At this stage, all other variables such as NaOH, HP-18 
concentration and reaction process remained unchanged. All these synthesises, except one 
(synthesis 5, Table 10) gave rise to similar physical characteristics and were all soluble after 
lyophilisation. 
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Table 11: AmB-PMA syntheses to determine the optimum starting concentration of 
AmB 
AmB-PMA batches synthesised with HP-18 polymer to determine the optimum concentration 
of AmB for the synthesis reaction. All batches were soluble in water on reconstitution. * 
Insufficient to test haemolysis. 
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Figure 39: Graph evaluating the relationship of the starting concentration of AmB and 
the haemolytic potential of AmB-PMA 
Batches of lyophilised AmB-PMA were reconstituted at 1 mg/ml AmB to determine their AmB 
loading via UV spectrophotometry at a final concentration of 10 µg/ml AmB (shown in blue). 
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The haemolytic potentials of the batches were then determined on incubation for 1 h with 2 
% v/v RBCs. The percentage haemolysis is shown at 50 µg/ml AmB in red (triangles). 
Overall an increase in the starting concentration of AmB, increased the haemolytic potential 
of the lyophilised AmB-PMA. 
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Figure 40: Effect of concentration of AmB on the characteristics of the AmB-PMA 
drug 
A starting AmB concentration of 7 mg/ml was used to create synthesis 3a and upon 
lyophilisation and reconstitution in water for injection to determine its AmB loading via UV 
spectrophotometry, a prominent aggregated peak was visualised (black line). Synthesis 4 
(blue line) with a starting concentration of 5 mg/ml illustrates a 1:1 ratio between monomeric: 
aggregated state of AmB. Details of syntheses are shown in Table 10. 
 
Subsequent investigations of the individual batches of AmB-PMA were based upon their 
spectra in water and evaluated on the aggregation state of AmB and the degree of red cell 
lysis to identify trends. It was found that an increase in AmB concentration correlated with an 
increase in the percentage of haemolysed red blood cells (Table 10). Noticeably, between 7 
mg/ml and 12 mg/ml initial AmB concentration, the percentage haemolysis increased rapidly 
to 92%. All AmB-PMA batches synthesised are illustrated in Figure 39 clearly showing this 
relationship. There was also an increase (11 to 25 %) in the final loading of AmB between 
batches synthesised with an initial concentration of 2-5 mg/ml (Table 10). Between a starting 
 Chapter 1 
Results Part B   
 Karina D. Corware 
 
 
141 
 
 
concentration of 5 mg/ml and 7 mg/ml of AmB, there was an indication of a shift occurring in 
the way that AmB-PMA was being formed. This was reflected in the spectra analysis and 
degree of haemolysis as illustrated by Figure 40. Taking this into account, synthesising 
reaction mixtures with an AmB concentration between 5 and 6 mg/ml of AmB was focused 
on (Table 11). In these experiments, the starting AmB concentration was increased in 100 
µg increments. The resulting batches had an AmB loading of approximately 30% and they 
showed a progressive increase of red cell haemolysis with even small increases in the 
concentration of AmB. Their spectra in water were remarkably consistent for all 8 of these 
batches; the AmB within each being in a predominately aggregated form. Therefore it was 
concluded that the initial concentration of AmB should be between 5.1 mg/ml and 5.2 mg/ml. 
This was due to the fact that both of these syntheses gave the lowest ratio of aggregated to 
monomeric AmB, and the smallest percentage haemolysis (Figure 41). 
 
0 10 20 30 40 50
0
20
40
60
80
100
7a
7c
7d
7f
7h
7g
Fz
7e7b
g/ml AmB
%
 h
a
e
m
o
ly
s
is
 
Figure 41: Haemolytic potential of batches synthesised with an initial AmB 
concentration between 5 and 6 mg/ml 
 Chapter 1 
Results Part B   
 Karina D. Corware 
 
 
142 
 
 
Haemolysis assay of 8 AmB-PMA batches synthesised with an AmB concentration between 
5 and 6 mg/ml, increasing in 100 µg increments with synthesis 7a shown in blue, 7b shown 
in red, 7c shown in pink, 7d shown in dark green, 7e shown in orange, 7f shown in purple, 7g 
shown in cyan and 7h shown in light green. Fungizone was used as a positive control and is 
shown in black and illustrated 100 % haemolysed RBCs at 50 µg/ml AmB. All batches were 
lyophilised to a yellow powder and reconstituted in water for injection. Their AmB loading 
was determined via UV spectrophotometry at 409 nm. Details of synthesis reactions are 
shown in Table 11. A 2% v/v solution of RBCs was added to AmB-PMA batches and 
Fungizone up to a concentration of 50 µg/ml AmB for 1 h. The optical density of the 
supernatant was measured to calculate the red cell lysis induced by the drug. 
 
1.3.2.4.6 Yield of AmB-PMA using optimised HP-18 protocol 
After optimisation, the yield of AmB-PMA powder was recorded. Table 12 demonstrates 8 
independently synthesised batches illustrating that the average yield was 75.6 mg ± 4.58. 
 
 
Table 12: Yield of AmB-PMA  
Amber bottles were weighed before collection of the syntheses from the dialysis chambers. 
The AmB-PMA was then frozen to -80°C within these amber bottles before lyophilisation. 
The final product was then weighed again (after) and the yield (mg) calculated. A total of 8 
syntheses are shown which is representative data of 54 AmB-PMA syntheses evaluated. 
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1.3.3 Part C: AmB-PMA synthesis and optimisation  
Modifications to the synthesis protocol would translate to little in terms of drug 
development if characterisation of the AmB-PMA were not determined. The following 
illustrates the characteristics of batches using the optimised protocol in comparison 
to Fungizone.  
1.3.3.1 Chemical characterisation of the AmB-PMA batches 
Collaborating with Bryn Monnery enabled me to determine the chemical 
characteristics of AmB-PMA using DLS and CD. As established from the 
investigations into AmB-PMA formation with HP-18, the requirement for AmB in its 
monomeric form was not as important as the requirement for making the individual 
batches non-haemolytic and chemically stable. The following two techniques were 
performed on the optimised syntheses.  
1.3.3.1.1 Dynamic light scattering (DLS) 
DLS is an experimental method that can be used to determine the size, shape and 
interactions of particles in a solution. It measures the intensity and the polarization of 
the light that is scattered when the molecule passes through the solution. Figure 42 
displays the diameters and the polydispersities for Fungizone and Batch 7f (synthesis 
detailed in Materials and Methods, section 1.2.3.2). Both are similar in size with 
AmB-PMA 7f having an average diameter of 61.3 nm and Fungizone an average 
diameter of 53.4 nm. This is notable because it means that although Fungizone is 
being modified to be less toxic and haemolytic, its particle size is not changing. 
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Figure 42: Dynamic light scattering (DLS) of AmB-PMA and Fungizone 
AmB-PMA batch 7f (a) and Fungizone (b) were reconstituted at 1.5 mg/ml AmB in water for injection and a total of 10 runs were performed to 
determine their average diameter. There was no significant difference between the structural size of AmB-PMA 7f and Fungizone. 
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1.3.3.1.2 Circular dichroism (CD) 
This was performed to assess the structural integrity of the AmB-PMA compared to 
that of Fungizone. As shown in Figure 43, both molecules demonstrate strong 
dichroic doublets that indicate the presence of small aggregates. This reflects the 
spectra as measured using the UV spectrophotometer. CD did not provide any 
further information than that provided via UV spectrophotometry and therefore the 
latter was an acceptable method to use alone in the chemical characterisation of 
AmB-PMA. Both these techniques to evaluate the structure and size of the AmB-
PMA showed that it had very similar characteristics to Fungizone.  
 
 
Figure 43: Circular dichroism of Fungizone and AmB-PMA  
Samples of AmB-PMA and Fungizone were reconstituted in water for injection at a 
final concentration of 8 µg/ml AmB at room temperature. The CD spectra show 
defined dichroic doublets. The spectra were measured over a range of 250-450 nm 
with 5 mm pathlength cuvettes.  
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1.3.3.2 Biological Characterisation of AmB-PMA 
1.3.3.2.1 Relationship between spectra of AmB and haemolysis influencing 
the reproducibility of AmB-PMA  
Two batches were synthesised identically with an initial AmB concentration of 5.2 
mg/ml to establish the reproducibility of the optimised reaction process. The % AmB 
loadings were within 2 % of each other. The spectra for these 2 batches (Figure 44 a) 
showed that they have different amounts of aggregated AmB. Synthesis 8a had an 
aggregated peak with an absorbance of 1.04 OD units and synthesis 8b had an 
absorbance peak of 0.7 OD units Figure 44. This difference in aggregation fits with 
the difference in the percentage haemolysis observed of 55 % and 26 % RBC lysis 
respectively. This result identified a relationship between the degree of aggregation 
and percentage haemolysis. A spectrum containing a peak at 328 nm demonstrates 
AmB in an aggregated state. The results showed that a peak at this wavelength 
which has an absorbance of greater than 0.80 OD units represented by AmB-PMA 
8a, (orange line, Figure 44(a)) also had significantly increased haemolytic activity in 
vitro demonstrated in Figure 44(b). An absorbance reading of less than 0.80 OD units 
such as AmB-PMA 8b shown in blue gave rise to a lower degree of haemolysis 
(Figure 44(b)). This relationship was used to predict the haemolytic potential of the 
subsequent reaction mixtures based solely upon their spectra in water. Importantly, it 
also indicated that the presence of some aggregated AmB did not cause RBC lysis. 
Batches of AmB-PMA that did have spectra below 0.8 absorbance (abs), also had 
consistently similar spectra. On further analysis, it was found that the area under the 
spectra calculated remained constant with a difference of 0.294 ± 0.034 (analysis of 
35 synthesised batches). 
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Figure 44: A trend between the UV absorbance of AmB-PMA and its haemolytic 
potential 
(a) Spectra of AmB-PMA 8a with an absorbance of more than 0.8 OD units (orange 
line) and 8b with an absorbance of less than 0.8 OD units (blue line). AmB-PMA was 
reconstituted at a final concentration of 10 µg/ml AmB in water for injection, before 
conducting a UV measurement between 300-450 nm. 
(b) Haemolysis assay was performed by incubation of AmB-PMA with 2 % v/v 
solution of red blood cells for 1 h. Fungizone was used as a positive comparison and 
Triton was used as a positive control for 100 % lysis. Synthesis 8b has a reduced 
haemolytic potential of 26.3 % AmB (blue line) compared to 8a with 55 %. (orange 
line). Fungizone had a 100 % haemolysis (black line) and is shown as a positive 
reference. 
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1.3.3.2.2 Toxicity of AmB-PMA 
After establishing the synthesis protocol it was necessary to determine whether there 
had been any alterations to the toxicity of the improved AmB-PMA synthesised with 
HP-18. The following toxicity experiments were performed on the U937 cell line and 
also human monocytes. Each experiment was carried out on at least three separate 
occasions and the representative results from one experiment are shown here. 
1.3.3.2.2.1 U937 
Figure 45 shows that AmB-PMA overall did not exhibit toxicity on U937 cells after 3 
h. There is a slight decrease in viability that was not significant at a concentration of 
200 µg/ml AmB. At this concentration, Fungizone dramatically caused a 74.7 % loss 
in cell viability.  
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Figure 45: Viability of U937 cells stimulated with AmB-PMA or Fungizone 
Non-adherent U937 cells were added to a V bottom plate (1x105 cells /well) before 
the addition of AmB-PMA and Fungizone in triplicate at a range of concentrations up 
to 200 µg/ml for 3 h. The cells were incubated for a further 3 h with MTT before the 
addition of DMSO. The optical density was measured at 507 nm and illustrated no 
significant toxicity of the cells when stimulated with AmB-PMA.  Fungizone was 
measured as a positive reference. Representative data from an experiment 
performed in duplicate. 
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1.3.3.2.2.2 Monocytes 
On experimentation with monocytes it was found that there was an average of 92 % 
viability of monocytes when stimulated with up to 400 µg/ml of AmB of AmB-PMA 
(blue line, Figure 46). Fungizone stimulated a slow decrease in viability which gave 
rise to only 50% cell viability at a concentration of 250 µg/ml of AmB (black dashed 
line, Figure 46). There was a sharp decrease to a low 8.5 % viability on stimulation 
with 500 µg AmB in contrast to 60 % when stimulated with AmB-PMA.  
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Figure 46: Viability of monocytes stimulated with AmB-PMA or Fungizone 
Monocytes were seeded to a flat bottom plate (1x105 cells /well) and stimulated for 3 
h with AmB-PMA or Fungizone up to a concentration of 500 µg/ml AmB. MTT was 
used to determine cell viability on measuring the OD at 507 nm. Representative data 
from an experiment performed in triplicate revealing significantly less viability of 
monocytes with Fungizone than with AmB-PMA. 
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1.3.3.2.3 The proinflammatory effect of AmB-PMA on blood-derived cells 
As described previously (Chapter 2, Results Part A), both SB-GD-19 and HP-18 
polymers did not stimulate a proinflammatory effect in terms of upregulation of 
chemokine MIP-1β and cytokine TNF-α when exposed to both U937 cell line and 
primary human cells. After the optimisation of the synthesis protocol, it was 
necessary to evaluate whether, by forming an AmB-based drug, a proinflammatory 
effect could be produced. Cytokines such as TNF-α, IFN-γ and IL-10 and chemokine 
MIP-1β were among those that were evaluated using quantitative real-time PCR. The 
following data represents work performed by both myself and MSc student Gabrielle 
Mzoriewicz under my supervision on at least three separate occasions. Quantitative 
real-time RT-PCR was performed in triplicate and the following data is expressed as 
absolute copies of mRNA levels normalised by the house keeping gene HPRT (as 
described in Materials and Methods). 
1.3.3.2.3.1 U937 
U937 cells were stimulated in the presence of AmB-PMA and studied over a range 
from 12.5- 200 µg/ml to assess levels of mRNA expression. Figure 47 illustrates that 
there was no upregulation of MIP-1β and TNF-α levels at these concentrations after 
3 h stimulation with AmB-PMA when compared to unstimulated cells. LPS was used 
as a positive control. Real-time PCR was run with IFN-γ primers but the product in 
this instance was below the limit of detection. 
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Figure 47: Proinflammatory effects of AmB-PMA on U937 cells 
U937 cells were seeded on a V-bottom plate and stimulated for 3 h with AmB-PMA. 
Cells were harvested and RNA extracted before performing PCR. Data shown is of 
the expression of MIP-1β and TNF-α in U937 cells when stimulated with AmB-PMA in 
the range of 12.5-200 µg/ml AmB. No significant differences in mRNA expression 
were observed relative to mRNA expression of unstimulated cells. 
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1.3.3.2.3.2 Monocytes 
Monocytes were stimulated with AmB-PMA and it was found that there was a 
variable response to upregulation of chemokine and cytokine mRNA. MIP-1β 
expression was stimulated in the presence of 50-100 µg/ml AmB within AmB-PMA 
(Figure 48 (a)). TNF-α was shown to be significantly upregulated also at 50 µg/ml 
AmB as did IFN-γ (Figure 48, (b and c respectively)).  
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Figure 48: Proinflammatory response of AmB-PMA stimulated monocytes. 
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Monocytes were seeded on a flat bottom plate and stimulated for 3 h with AmB-PMA. 
Cells were harvested and RNA extracted before performing PCR. Data shown is of 
the expression of MIP-1β, TNF-α and IFN-γ in human monocytes in the presence of 
AmB-PMA between 50-200 μg/ml AmB.  ***= P < 0.002, **= P <0.01, *= P < 0.05, P > 
0.05 and ns = not significant. Pooled data from 2 experiments performed in triplicate. 
 
1.3.3.2.3.3 Monocyte-derived Macrophages (MDM’s) 
Experimentation on MDMs was also carried out and it was thought that these would 
illustrate a proinflammatory response in the presence of AmB-PMA similar to that of 
monocytes. However, this was not the case and no upregulation in the range of 12.5-
200 µg/ml AmB was observed in either MIP-1β or TNF-α (Figure 49). Real-time PCR 
runs performed with IFN-γ primers on cDNA of the stimulated MDMs generated 
mRNA copies below the limit of detection and hence could not be evaluated. 
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Figure 49: Proinflammatory response of AmB-PMA stimulated monocyte-
derived macrophages 
MDMs were seeded on a flat bottom plate and stimulated for 3 h with AmB-PMA. 
Cells were harvested and RNA extracted before performing real-time PCR runs. Data 
shown is mRNA expression of MIP-1β and TNF-α in the presence of AmB-PMA in 
the range of 12.5-200 µg/ml AmB. No differences between unstimulated and 
stimulated cells with AmB-PMA were observed. Representative data of an 
experiment performed in triplicate.  
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1.3.3.2.3.4 Peritoneal Cells 
The induction of MIP-1β and TNF-α in the presence of AmB-PMA was studied over 
the range of 25-200 µg/ml AmB. Figure 50 shows that there is evidence of 
upregulation of mRNA expression of TNF-α at 100 µg/ml AmB. There was no 
significant change in MIP-1β expression.  
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Figure 50: Proinflammatory response of AmB-PMA stimulated peritoneal 
macrophages  
Peritoneal macrophages were isolated from peritoneal fluid by adherence to plastic 
for 2 h. They were then seeded to a 48 well flat bottom plate before the addition of 
AmB-PMA at a concentration range of 25-200 µg/ml AmB and incubated for 3 h 
before harvest and RNA extraction. TNF-α expression was significantly upregulated 
compared to unstimulated peritoneal macrophages at a concentration of 100 µg/ml 
      Chapter 2                                   Results Part C   
  Chapter 1  
  Results Part C   
  Karina D Corware 
 
 
 
157 
AmB. Representative data from an experiment performed in triplicate. ***= P < 0.002, 
**= P <0.01, *= P < 0.05, and ns = not significant. 
 
1.3.3.2.4 The proinflammatory effect of Fungizone on blood-derived cells 
It has been well established that Fungizone stimulates an upregulation of chemokine 
and cytokine levels. However, it was necessary to verify this and the most effective 
way was to stimulate with monocytes. This was not only to ensure the effects of 
Fungizone (Pai et al. 2005;Rogers et al. 1998) but also to verify that the AmB-PMA 
acts in a different way to Fungizone, as shown by the cytotoxicity assay. On 
stimulation of monocytes at a concentration range of 50-150 µg/ml AmB, Fungizone 
induced a significant upregulation of mRNA production of MIP-1β and TNF-α (Figure 
51). IFN-γ mRNA production was only stimulated with Fungizone at a concentration 
of 50 µg/ml AmB.  
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Figure 51: Proinflammatory response of Fungizone stimulated monocytes 
Monocytes were seeded on a flat bottom plate and stimulated for 3 h with AmB-PMA. 
Cells were harvested and RNA extracted before performing PCR. Data shown is of 
monocytes stimulated with Fungizone in the range of 50-150 µg/ml AmB. MIP-1β and 
TNF-α were significantly upregulated at these concentrations. IFN-γ mRNA 
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production was upregulated at only 50 µg/ml AmB.  ***= P < 0.002, **= P <0.01, *= P 
< 0.05, P > 0.05 and ns = not significant. Representative data from two experiments 
performed in triplicate. 
  
1.3.3.2.5 Overview of proinflammatory responses 
On investigation of the proinflammatory effects of HP-18, AmB-PMA and Fungizone, 
many cell types illustrated no upregulation of mRNA expression of the cytokines and 
chemokines measured. Noticeably, experimentation using monocytes did yield 
interesting data which is summarised in Figure 52. Fungizone (deoxycholate-AmB) 
stimulated high levels of TNF-α in monocytes as well as IFN-γ. AmB-PMA also 
stimulated production of IFN-γ but significantly less production of TNF-α compared 
with Fungizone (p=0.004).   
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Figure 52: Overview of proinflammatory responses in monocytes 
Data illustrates proinflammatory responses of monocytes stimulated with HP-18 
(PMA-Na), AmB-PMA and Fungizone, the latter two at 50 µg/ml AmB. Data illustrates 
the production of TNF-α and IFN-γ in the presence of polymer and drug formulations 
in comparison to the maximal production of both cytokines as shown by stimulation of 
monocytes with LPS.  
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1.3.3.2.6 Anti-leishmanial Activity of AmB-PMA  
It was essential to evaluate the anti-leishmanial properties of AmB-PMA. This was 
performed with several different strains of Leishmania spp. and on different cell 
types. Firstly experiments were performed by simple addition to stationary phase L. 
donovani and L. major. This was then incubated for 24 h and evaluated using MTT 
readout. Fungizone was also tested and used as a positive comparison. Figure 53 
illustrates indistinguishable differences in terms of the efficacy of AmB-PMA and 
Fungizone to kill Leishmania species.  
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Figure 53: Anti-leishmanial activity of AmB-PMA and Fungizone 
Leishmania spp. were seeded to plastic and either AmB-PMA or Fungizone added at 
up to 3 µg/ml AmB. Data shown illustrates the efficacy of AmB-PMA on L. major 
promastigotes LD50 =0.3 ± 0.1 μg/ml AmB and for L. donovani promastigotes was 
0.12 ± 0.1 μg/ml AmB compared to Fungizone (LD50= 0.09 µg/ml AmB). Pooled data 
from 3 experiments performed in duplicates. 
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1.3.3.2.6.1 Human Monocyte-derived macrophages (MDM’s) 
A more relevant model for determining the anti-leishmanial activity of AmB-PMA in 
vitro was to infect differentiated MDMs. Leishmania spp.  are obligate intracellular 
parasites that survive and multiply within the phagolysosome of predominantly 
macrophages in their mammalian hosts. Therefore efficacy of AmB-PMA would 
require that it can access the amastigotes residing inside the phagolysosome.  
Human monocytes were allowed to differentiate for 8 days before being infected with 
Leishmania spp. Once infection was determined via Giemsa-staining, the AmB-PMA 
was added at various concentrations and Fungizone was used as a positive control. 
Data illustrated in Figure 54 is from 6 separate experiments and are presented as a 
percentage of the infection index calculated from the untreated infected 
macrophages (control). The infection index is the division of the average number of 
parasites per infected cell by the percentage of infected cells.  The average LD50 of 
AmB-PMA was 0.14 µg/ml AmB and Fungizone was 0.11 µg/ml against L. mexicana. 
Experiments of L. donovani showed that the LD50 of the AmB-PMA and Fungizone 
were 0.31 µg/ml AmB and 0.24 µg/ml AmB respectively.  
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Figure 54: Anti-leishmanial activity of AmB-PMA and Fungizone on MDMs 
Harvested amastigote isolates (from a donor animal) were used to infect MDMs 
adhered to chamber slides at a MOI of 5:1. After infection (+21 h) macrophages were 
washed and AmB-PMA was added to the cells for 3 days. Macrophages were then 
washed and methanol fixed before being stained with Giemsa-May Grunwald. The 
number of amastigotes, infected and non-infected macrophages present were 
calculated via microscopy. Data shown illustrate the inhibition of L. mexicana 
amastigote growth within MDMs (a) of AmB-PMA (LD50= 0.14 µg/ml AmB) compared 
to Fungizone (LD50= 0.11 µg/ml AmB). (b) This graph shows the inhibition of L. 
donovani amastigote growth within MDMs of (LD50= 0.31 µg/ml AmB) compared to 
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Fungizone (LD50= 0.24 µg/ml AmB). These assays are representative of pooled data 
from 6 experiments performed by Debbi Harris and myself. 
 
1.3.3.2.6.2 Mouse macrophages 
The effect of AmB-PMA on the survival of intracellular L. major was also tested using 
a homogenous population of unactivated macrophages derived from bone-marrow 
murine precursor cells that were allowed to differentiate for 8 days in vitro. The 
mature macrophages were then infected with L. major promastigotes at a ratio of 5:1 
in the presence or absence of 3 different concentrations of AmB-PMA (1.0 mg/ml, 0.3 
mg/ml, 0.1 mg/ml AmB) and incubated at 37°C for 3 days. At different times after 
infection and treatment, cells were fixed and Giemsa stained to microscopically count 
the presence of intracellular amastigotes. This highlighted that 4 days post infection, 
macrophages were lysed and free parasites were visualised, therefore the effect of 
AmB-PMA on intracellular parasite survival was determined 3 days post infection and 
treatment. Figure 55(a) represents the findings as amount of viable amastigotes per 
100 infected macrophages. Addition of the AmB-PMA significantly reduced the 
intracellular parasite load in the infected macrophages. It was also found that the 
reduction in parasite load was dose-dependent. 
Subsequent experiments were performed using activated macrophages. In vivo, 
macrophages become activated during immune responses by cytokines secreted by 
cells of both the innate and adaptive immune system. Therefore, to mimic the 
activation that would be occurring in an active non-healing leishmanial disease, the 
infected macrophages were activated with a combination of IL-4 and IL-10 cytokines. 
Figure 55(b) illustrates that the parasite growth was strongly enhanced in these 
activated macrophages; however, on addition of AmB-PMA the dose-dependent 
reduction of the intracellular parasite load is maintained.  
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Figure 55: L. major infected murine macrophages stimulated with AmB-PMA 
Bone-Marrow derived murine precursor cells were extracted and purified before 
allowing to differentiate for 8 days in culture. (a) Unactivated macrophages were 
infected with L. major promastigotes and stimulated in the absence or presence of 
AmB-PMA at 3 different concentrations 1 µg/ml, 0.3 µg/ml and 0.1 µg/ml AmB. (b) 
macrophages were infected with L. major promastigotes and activated with IL-4 or IL-
10 cytokine before being stimulated in the absence or presence of AmB-PMA at 3 
different concentrations 1 µg/ml, 0.3 µg/ml and 0.1 µg/ml. Representative data of an 
experiment performed in duplicate. 
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 1.3.3.3 Physico-chemical Characteristics 
1.3.3.3.1 Stability of AmB-PMA in solution 
Investigations into treatment of AmB-PMA in a visceral leishmaniasis model showed 
discrepancies of the properties between its pharmacological data in vitro and in vivo. 
It was necessary to explore the reasoning behind these discrepancies and in doing 
so obtain more information that would benefit the studies in cutaneous leishmaniasis. 
The AmB-PMA drug maintains itself via electrostatic interactions. It is therefore more 
sensitive to external environments than a liposomal construct like AmBisome. The 
discrepancies identified between the in vitro and in vivo data were thought to be due 
to the AmB-PMA entering the blood stream. It was credible to assume that on 
entering the blood stream, AmB would be forced to alter to the environment leading 
to the strong interactions ‘falling’ apart. This could result in the loss of activity in killing 
Leishmania and a loss of AmB to the environment. AmB can therefore either 
aggregate or be taken up by serum and removed from the bloodstream.   
A series of experiments were conducted in vitro to attempt to visualise what 
happened when AmB-PMA entered the blood stream. AmBisome and Fungizone 
were also investigated and used as a comparison. Experiments were performed on 
two batches that had been administered intravenously into a mouse model of visceral 
leishmaniasis. Syntheses 175A had a loading of 36.8 % and 175B had a loading of 
32%. The former gave an adverse reaction to one mouse and both had a low 
therapeutic efficacy in reducing parasite load in vivo.  
A haemolysis assay of 175A showed a high haemolytic potential. However, when this 
was carried out supplemented with 10% human serum, negligible RBC lysis was 
observed. This was unsurprising as a haemolysis assay identified the effects of AmB-
PMA on RBCs alone, but did not take into account the potential influence of plasma 
and serum. 45 % of blood is composed of red blood cells, white blood cells and 
platelets. The remainder is serum (55 %) which is predominately water (92 %), 
minerals and serum albumin (plasma protein). It was concluded that UV 
spectrophotometry should be used to attempt to visualise the various states of AmB 
in different blood components.   
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1.3.3.3.1.1AmB-PMA in Plasma 
Spectra were obtained with these AmB-PMA batches solubilised at a final 
concentration of 15 µg/ml AmB in 20% plasma at 0 hrs and 3 hrs. This experiment 
was also carried out in RPMI only as this is the medium used in haemolysis assay. 
Both batches in water had an approximate 1:1 ratio between monomeric and 
aggregated states of AmB. This was echoed when measured in 20% plasma and did 
not alter over the time period of 3 h (Figure 56). This indicated that the AmB-PMA 
that were synthesised remained stable in plasma.  
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Figure 56: UV spectra of AmB-PMA in various solutions 
AmB-PMA samples were reconstituted at 1mg/ml AmB in water for injection. A fresh 
vial of blood was collected into an EDTA vial and the plasma extracted via 
centrifugation. Samples were measured at a final concentration of 15 µg/ml AmB in 
either, water, RPMI or 20 % plasma at 0 h and 3 h time-points. Spectrum of 
syntheses 175A (a) in water (black line) plasma (blue line) and RPMI (red) and 175B 
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(b) in water (black line), plasma (blue line) and RPMI (red line). Data is shown at 3 h 
with no change after 24 h.  
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Figure 57: UV spectra of Fungizone in various solutions 
Fungizone was reconstituted at 1mg/ml AmB in water for injection. A fresh vial of 
blood was collected and the plasma extracted. Samples were measured at a final 
concentration of 15 µg/ml AmB in either, water, RPMI or 20 % plasma at 0 h and 3 h 
time-points. The spectra of Fungizone is shown in water (black line), plasma (blue 
line) and in RPMI (red) after 3 h. 
 
AmBisome shown below (Figure 58) maintains identical spectra in all 3 mediums, 
unsurprisingly due to its formulation within a liposome. Surprisingly, Fungizone has 
noticeably different spectra in the varying media (Figure 57). In water it is as 
expected and the spectrum shows AmB in a predominately aggregated state. There 
is only a slight shift in the spectra of AmB in RPMI and water and neither is 
influenced by time.  However the AmB then shifted almost completely into a 
monomeric state when measured in plasma. Fungizone is known for its toxic side 
effects when administered into the bloodstream. Indeed, it is necessary to administer 
to patients very slowly via transfusion.  
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Figure 58: UV spectra of AmBisome in various solutions 
AmBisome was reconstituted at 1 mg/ml AmB in water for injection. A fresh vial of 
blood was collected into an EDTA vial and the plasma extracted via centrifugation. 
Samples were measured at a final concentration of 15 µg/ml AmB in either, water, 
RPMI or 20 % plasma at 0 h and 3 h time-points.  
The serum was harvested via centrifugation of whole blood collected into a serum 
separating tube. Samples in serum were at a final concentration of 1 mg/ml and 10 
µg/ml of AmB and were measured at 1 h. The spectra shown illustrate no significant 
change in AmBisome in water (black), plasma (blue), RPMI (red) or serum (purple) 
within a 24 h period. 
 
1.3.3.3.1.2 AmB-PMA in human Serum 
Collection of blood is usually carried out into tubes containing EDTA so as to prevent 
clotting of the blood. To study the effects of whole serum in the presence of AmB-
PMA, blood had to be collected directly into a syringe and used immediately. Whole 
blood was decanted into serum separating tubes with the samples at varied 
concentrations and incubated on a rotor at 37°C for 1 h and 24 h. After this, the tubes 
were spun and the serum fraction removed, diluted with RPMI and the UV 
absorbance measured. All samples were at a final concentration of 1 mg/ml and 10 
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µg/ml AmB. As these were initial investigations, two concentrations, at opposite ends 
of the spectrum were used. To measure the spectra and remove background 
associated with the serum, the spectrophotometer was calibrated against serum and 
RPMI without supplementation of drug. AmBisome illustrated no evidence of 
haemolysed red blood cells in the serum at both these concentrations. The spectra 
remained unchanged over time demonstrating one large peak at 328 nm. After a 1 h 
incubation, it was evident that both Fungizone and the AmB-PMA analysed were 
haemolysing the blood at a concentration of 1 mg/ml. This was shown by the red 
serum collected. This hindered the ability to measure AmB and therefore the samples 
had to be diluted in RPMI so that a spectrum of the various states of AmB could be 
identified. A serial dilution was performed to determine at what point a spectra could 
be visualised. It was found that a 1:100 dilution provided clear spectra with defined 
peaks that could be accurately compared (Figure 59). 
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Figure 59: UV spectra of AmB-PMA, Fungizone and AmBisome in human 
serum 
Serum was harvested via centrifugation of whole blood collected into serum 
separating tubes. Samples in serum were at a final concentration of 1 mg/ml and 10 
µg/ml AmB and were measured at 1 h. Spectra shown is AmB-PMA 175A (blue line), 
Fungizone (black line) and AmBisome (red) in human serum. 
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The AmB-PMA illustrated a complete shift in the state of AmB from a 1:1 ratio in 
water to a more dominant monomeric state. These measurements were made at a 
final concentration of 10 µg/ml AmB. After a 24 h incubation both concentrations 
illustrated red blood cell haemolysis. As expected, a higher concentration of AmB-
PMA displayed a more intense colour of red within the serum than that of the lower 
concentration of 10 µg/ml AmB. Due to this intensity, the 10 µg/ml diluted 1:100 with 
RPMI was the only read out obtained. There was no additional shift observed over 
the 23 h incubation period. Not surprisingly, once AmB had established its stability 
within its environment it did not fluctuate.   
Fungizone echoed the exact same traits within serum as AmB-PMA. The only 
difference being that the shift in the spectra was more pronounced; moving from 
AmB in a completely aggregated state to a completely monomeric state.   
1.3.3.3.1.3 AmB-PMA in water 
As it has been shown extensively in the literature, AmB in solution over time will 
spontaneously form aggregates unless in strongly alkali solutions. The AmB-PMA is 
easily solubilised in water and has a pH of 7.3. It was necessary to establish the 
extent of variability of AmB within the AmB-PMA over time. Fungizone was used as a 
comparison. Figure 60 shows that within the first 4 hours of reconstitution in water for 
injection, AmB is highly motile between states of aggregation. After this time, AmB 
appears to be stable and this is conserved up to 72 h post reconstitution. Noticeably 
the most fluctuations occur in the extent AmB aggregates. AmB within Fungizone is 
in a highly aggregated state and appears stable on immediate reconstitution and 
therefore UV spectrum was monitored for a period of 2 h only. This data highlights 
that AmB-PMA should not be stored in solution. 
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Figure 60: Variability of AmB-PMA and Fungizone in solution over time  
Both AmB-PMA (a) and Fungizone (b) were reconstituted in water for injection at an 
initial concentration of 1 mg/ml AmB before measuring UV absorbance between 300-
450 nm at a final concentration of 10 µg/ml AmB over a time period of 1-72 h. 
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1.3.3.3.1.4 AmB-PMA in solutions with varying pH 
It is well established that pH can greatly influence the state of AmB when in solution 
(Sanchez-Brunete et al. 2004). Indeed, it has already been shown that the state of 
AmB within AmB-PMA can alter over the first few hours when reconstituted in water 
for injection (section 1.3.3.3.1.3). Therefore, it was necessary to conduct a series of 
experiments into the effects that pH has on the state of AmB within the AmB-PMA 
drug when reconstituted in water for injection. These experiments were conducted on 
6 individual AmB-PMA batches using a phosphate-citrate buffer solution to vary the 
pH. Each pH experiment involved reconstitution of an AmB-PMA batch at 1 mg/ml 
AmB in water for injection. In water for injection the pH of the AmB-PMA syntheses 
was an average of 7.3. Stocks of buffer solutions were made up over a range of pH 
from 5.0 to 6.8.  This allowed for a slow and closely monitored reduction in pH of the 
AmB-PMA samples with the ability to remove aliquots at regular intervals.  
Throughout the experiments the pH was recorded and the buffer solution was 
incrementally added to determine the point at which the aqueous clear AmB-PMA 
solution turned turbid. The turbidity of the solution was an indication that the AmB 
within the AmB-PMA was undergoing changes, causing it to aggregate and come out 
of solution. The aliquots that were removed during the experiments were then 
centrifuged (18,000 rpm for 3 min) and photographed as shown in Figure 61. This 
highlighted that the AmB within the AmB-PMA remained stable in weak acidic 
solutions (pH 6.8 to 7.3), as the solution remained clear after centrifugation. 
However, when the acidity was increased, the solution became turbid and upon 
centrifugation a yellow precipitate was formed indicating that AmB had dissociated 
from the HP-18 polymer. This provided a strong indication that the stability of AmB-
PMA was pH-dependent and that this occurred rapidly within a narrow pH region. To 
further assess this, the supernatants of the centrifuged AmB-PMA samples were then 
measured using UV spectrophotometry and the percentage solubility of the samples 
at different pH was determined by using the OD reading generated at pH 7.3 as a 
positive reference. Figure 62 highlights a region between pH 6.3 and pH 6.6 which 
appears to be where the solubility of AmB-PMA decreases sharply. This is also 
shown by the photographs of the final solutions. Centrifugation of AmB-PMA at a pH 
greater than pH 6.6 resulted in a completely aqueous solution. In contrast, 
centrifugation of AmB-PMA for the same length of time at a pH lower than 6.3, 
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caused a yellow precipitate to be readily formed. This is indicative of AmB 
aggregates forming out of solution. 
 
Figure 61: AmB-PMA in varying pH solutions after centrifugation 
Batches of AmB-PMA were reconstituted at 1 mg/ml AmB in water for injection 
before the incremental addition of phosphate-citrate buffer solution to determine the 
point at which the aqueous AmB-PMA solution turned turbid due to the influence of 
the acidic pH on AmB. At regular intervals aliquots were removed and centrifuged 
(18,000 rpm for 3 min) to verify visual findings of turbidity. Those solutions that 
appeared cloudy on addition of acidic pH formed a precipitate upon centrifugation. 
The turbidity of the AmB-PMA solution correlated with its acidity. The photograph is 
representative of 6 individual experiments highlighting a narrow point at which AmB 
is forced to precipitate out of solution.  
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Figure 62: Solubility (%) of AmB-PMA on reduction of pH in solution 
Syntheses of AmB-PMA were reconstituted in water for injection at a concentration of 
1 mg/ml AmB. Various stocks of phosphate-citrate buffer with known pH were slowly 
added to an aliquot of AmB-PMA until aggregates began to form and the solution 
became turbid. Gentle centrifugation (18,000 rpm, 3 min) was performed to 
determine whether AmB had been disrupted by the pH. The OD of the supernatants 
was then recorded at 409 nm and the results expressed as the percentage of 
solubility of AmB-PMA when 100 % solubility was determined at pH 7.3 (i.e. in water 
for injection). Pooled data from 6 syntheses is shown. 
 
1.3.3.3.2 Stability of AmB-PMA as a lyophilised powder 
As shown, AmB within the AmB-PMA appears to fluctuate in solution and therefore 
studies were conducted to determine whether this was also evident when stored as a 
lyophilised powder. Synthesis 7g (Figure 63) was synthesised and lyophilised to a 
yellow powder exhibiting characteristics typical of the AmB-PMA drug. It was 
reconstituted at 1 mg/ml AmB and was found to have a loading of 31.5 % AmB. The 
spectrum, detailing the state of AmB within synthesis 7g, showed a predominately 
aggregated peak of 0.8 abs (blue line, 328 nm). Synthesis 7g was re-characterised 
17 days later after being sealed under argon and stored at 4°C. It was found to have 
a loading of 30% AmB with a spectrum that was similar to that of the first reading 
(Figure 63, black line). Synthesis 8c was also evaluated and the spectra shown in 
Figure 64.  It was first characterised with a loading of 24.1 % AmB (spectrum shown 
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in blue) and upon reconstitution 15 days later, was found to have a loading of 22.2 % 
AmB. The spectra show no significant changes in the state of the AmB over the 15 
day period when stored as a lyophilised powder (Figure 64). 
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Figure 63: UV spectra of AmB-PMA synthesis 7g stored as a lyophilised 
powder over 17 days 
Synthesis 7g was reconstituted to a final concentration of 10 µg/ml AmB and its 
spectrum measured over 300-450 nm, shown in blue. 17 days later the AmB loading 
was re-determined by reconstitution at 1 mg/ml total weight. On establishing the 
loading, synthesis 7g was reconstituted again at 10 µg/ml AmB in water for injection. 
The spectrum is shown in black illustrating little change in the state of AmB when 
stored as a lyophilised powder. 
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Figure 64: UV spectra of AmB-PMA syntheses 8c stored as a lyophilised 
powder over 15 days 
Synthesis 8c was reconstituted to a final concentration of 10 µg/ml AmB and its 
spectrum measured over 300-450 nm, shown in blue. 14 days later the AmB loading 
was re-determined by reconstitution at 1 mg/ml total weight. On establishing the 
loading, synthesis 8c was reconstituted again at 10 µg/ml AmB in water for injection. 
The spectrum is shown in black confirming no significant change in the state of AmB 
over time. 
 
Both syntheses 7g and 8c showed minimal change in AmB loading and spectra over 
approximately 2 weeks. This was encouraging and led to further investigations 
involving analysis of a total of 8 syntheses stored over a prolonged period of time. 
Figure 65 illustrates syntheses 10 and 11 that had been synthesised and lyophilised 
to a yellow powder on two separate occasions. Their AmB loadings were determined 
and their spectra recorded via UV spectrophotometry before being sealed under 
argon and stored at 4°C for 9 months. Synthesis 11 was first characterised with an 
AmB loading of 31 % and a spectrum with a dominant peak at 328 nm of 0.6 abs 
(Figure 65(a) shown in blue). After 9 months, synthesis 11 was re-characterised and 
found to have an AmB loading of 28 %. Synthesis 10 was first characterised with an 
AmB loading of 21 % and a spectrum with a dominant peak of 0.8 abs at 328 nm 
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(Figure 65(b), shown in blue). After 9 months synthesis 10 was found to have an 
AmB loading of 23.8 %.  
The AmB loading of the AmB-PMA syntheses stored as lyophilised powder did not 
change significantly over the 9 month storage period. However, on evaluation of the 
UV spectra to determine the state of AmB within the syntheses, it was notable that a 
slight shift between the individual spectra sets had occurred. This was also evident, 
to a lesser extent, in the spectra of syntheses 7g and 8c measured over the period of 
approximately 2 weeks (Figure 63 and Figure 64 respectively). Due to this 
discrepancy, the spectra were re-analysed and the area under each spectrum was 
calculated. As detailed in Table 13, the syntheses have an average difference in the 
area under the spectrum of before and after storage of 0.03 abs*nm between 
readings. This difference was minimal and was consistent with the expectation of 
variability between measurements on different days. Furthermore, the patterns of the 
spectra had remained unchanged, indicating no significant shift between the states of 
AmB within the syntheses over the storage periods. Overall, the data illustrated that 
AmB-PMA remained stable in the form of a lyophilised powder stored at 4°C under 
argon over 9 months. 
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Figure 65: UV spectra of AmB-PMA stored as lyophilised powders over 9 
months  
All syntheses were reconstituted to a final concentration of 10 µg/ml AmB before their 
spectra was measured between 300-450 nm. Approximately 9 months later, the AmB 
loading was re-determined by reconstitution at 1 mg/ml total weight. On establishing 
the loading, the samples were reconstituted again at a final concentration of 10 µg/ml 
AmB in water for injection. The spectrum of Synthesis 11 1st reading is shown in blue 
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(a) and the 2nd reading is shown in black (b). The spectrum of Synthesis 10 1st 
reading is shown in blue (a) and the 2nd reading is shown in black (b). 
 
Syntheses 
1st reading  
area under spectrum 
(abs*nm) 
2nd reading  
area under spectrum 
(abs*nm) 
Difference between 
readings (abs*nm) 
7g 0.286 0.33 0.044 
8c 0.375 0.397 0.022 
10 0.321 0.279 0.054 
11 0.273 0.256 0.017 
 
Table 13: Area under the spectra of AmB-PMA syntheses 
Due to the discrepancies found between the spectra of the syntheses when re-
analysed 9 months later after storage at 4°C under argon, the area under the spectra 
was calculated using Hitachi UV solutions software. This shows a minimal difference 
of an average 0.03 abs*nm between the 1st and 2nd reading of the four syntheses 
shown.  
 
1.3.3.3.3 Appearance 
On completion of the reaction synthesis, the product was a deep orange solution that 
was easily taken up by a syringe and inserted into a dialysis chamber. During dialysis 
the product (dialysate) did not change significantly in colour. However it is the 
lyophilisation process that limited the ability to pre-determine the exact characteristics 
of a synthesis reaction mixture. During synthesis optimisation, batches of AmB-PMA 
that were synthesised in synergy could, upon lyophilisation, appear very differently. 
Figure 66 illustrates the differing appearance of two AmB-PMA batches prepared and 
synthesised on the same day following an exact protocol. It is notable that the two 
have differing textures; one appears as a light and fly-away powder and the other as 
a flaky powder with a noticeably deeper orange colour. 
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Figure 66: The effect of lyophilisation on the characteristics of AmB-PMA 
Two batches of AmB-PMA were synthesised using the optimised protocol and 
polymer HP-18. The resulting solution was dialysed for 24 h, frozen at -80°C and 
lyophilised. These two batches illustrate the effects that lyophilisation had on the 
formation of the AmB-PMA powder. On the left-hand side, an AmB-PMA batch that 
appears burnt and has a rich orange colour. On the right-hand side, an AmB-PMA 
batch that is lighter in appearance and texture.  
 
1.3.3.3.4 Incorporation into a topical application 
As shown, AmB-PMA remains stable as a lyophilised powder and therefore 
experiments involving the incorporation of AmB-PMA onto gauze for topical 
application were conducted. This involved the addition of sterile gauge that is 
typically applied to wounds into the freshly synthesised AmB-PMA solution collected 
from the dialysis chamber. This was then frozen at -80°C before lyophilisation (Figure 
67(a)). Photographs were taken throughout the experiments to record the findings. 
To assess whether AmB-PMA had been retained on the gauze, water for injection 
was added to the solution. This resulted in a yellow solution as shown in Figure 
67(b). No precipitate was visualised. 
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Figure 67: Incorporation of AmB-PMA into a topical application 
(a) Photograph demonstrating the sterile white gauze before (on the left) and after 
lyophilisation with AmB-PMA (on the right). (b) Photograph of AmB-PMA gauze (on 
the left) that was then reconstituted in water for injection (on the right). A yellow 
opaque solution was formed with no AmB precipitate deposited at the bottom of the 
bottle. These photographs are representative of 2 individual syntheses. 
 
1.3.3.3.5 Disruption of AmB-PMA 
Throughout these investigations the aim was to optimise methods in which AmB 
would form stable interactions with PMA. This also included assessing the ease in 
which AmB-PMA could disassociate. AmBisome and Fungizone are currently 
marketed drugs and therefore it was appropriate to use both as a comparison. 
AmBisome and Fungizone were reconstituted as per the manufacturer’s instructions. 
All 3 samples were then centrifuged at 30,000 rpm at a final concentration of 1 mg/ml 
AmB in water for injection. The photographs in Figure 68 illustrate my findings. 
Before centrifugation all 3 readily formed an aqueous solution, as shown in Figure 
      Chapter 2                                   Results Part C   
  Chapter 1  
  Results Part C   
  Karina D Corware 
 
 
 
183 
68(a). After 30 min centrifugation, both AmBisome and Fungizone exhibited a yellow 
precipitate at the bottom of the centrifuge tube. As AmB has a distinctive yellow 
colour as one of its characteristics, one could deduce that this was AmB coming out 
of solution. After 2 h centrifugation this deposit increased in the Fungizone solution. 
AmBisome appeared unchanged. After 2 h of centrifugation, AmB appeared to be 
depositing in the AmB-PMA solution. However, on visual comparison, the AmB 
precipitate that had accumulated in AmB-PMA was proportionally smaller than that of 
either Fungizone or AmBisome. 
 
 
Figure 68: Stability of AmB in drug formulations after ultracentrifugation 
(a) Photograph of AmBisome, Fungizone and AmB-PMA reconstituted in water for 
injection at 1 mg/ml AmB. (b)Photograph of the samples of AmBisome, Fungizone 
and AmB-PMA after 30 min centrifugation (30,000 rpm). (c) Photograph of the 
samples of AmBisome, Fungizone and AmB-PMA after 2 h centrifugation (30,000 
rpm). These photographs are representative of 2 experiments performed on separate 
occasions.   
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1.4 Discussion 
Cutaneous leishmaniasis (CL) is a vector borne neglected tropical disease that is 
endemic in over 70 countries across the world. The disease presents as single or 
multiple skin lesions on exposed body parts that can develop into large ulcers or 
disfiguring and deforming skin lesions. CL plagues particularly poverty-stricken areas 
where there is economical instability resulting in lack of medical care. As detailed by 
WHO, the public health impact worldwide of leishmaniasis has been grossly 
underestimated for many years (WHO 2009). New foci of leishmaniasis are also 
emerging due to changes in climate and environment caused by; deforestation (Patz 
et al. 2000), urbanization and travel (Desjeux 2004;Lawn et al. 2004). This has led to 
the spread of leishmaniasis in previously non-endemic regions such as in the state of 
Texas in the USA (Wright et al. 2008). Factors such as civil conflict has also resulted 
in an increasing number of soldiers returning from countries, such as Iraq, to receive 
treatment for CL (Jumaian et al. 1998)(Bailey et al. 2005). To date there is no 
effective human vaccine and current therapy is limited by toxicity, cost and long 
treatment regimes (Mahajan and Sharma 2007). Pentavalent antimonials have been 
the first line recommended treatment for over 70 years which has resulted in 
increasing resistance in many endemic regions (Kedzierski et al. 2009). Due to the 
progressive development of the disease, the optimum treatment should kill the 
parasite rapidly and ideally cause acceleration of tissue repair to minimise scaring. 
To date, there is no cost-effective, water soluble CL treatment that is short in therapy 
and free from side-effects (Reithinger et al. 2007).  
Leishmania spp. are obligate intracellular protozoan parasites that preferentially 
infect, multiply and persist within the phagolysosome of the host macrophages 
(Ribeiro-Gomes et al. 2004;van et al. 2004). Therefore it is essential for an effective 
CL therapeutic to be able to be delivered to this phagolysosome to kill the parasites. 
Amphotericin B is a polyene anti-fungal antibiotic that has also anti-leishmanial 
properties. It is the only anti-leishmanial drug which has been clinically used for over 
50 years without the emergence of parasite resistance. It binds selectively to 
parasitic membranes that are ergosterol-rich (Baran and Mazerski 2002;Kasai et al. 
2008). However it can also bind to human cholesterol and it is this property that gives 
rise to its adverse toxicities when administered to man (Kawabata et al. 2001). In 
vitro, water soluble formulations of AmB such as Fungizone have been demonstrated 
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to disrupt the integrity of the amastigote membrane and cause death (Fujii et al. 
1997). However, due to the amphipathic nature of AmB, it readily forms aggregates 
in water that can cause toxicity in the host (Brajtburg and Bolard 1996) (Deray 2002) 
(Baginski and Czub 2009). AmBisome, a liposomal preparation, has been shown to 
be efficacious in treating VL caused by members of L. donovani complex (Olson et 
al. 2008) (Syriopoulou et al. 2003). Recent developments have shown that a single 
dose can eliminate L. donovani infections (Sundar et al. 2010). It is due to the 
encapsulation of AmB into a liposome that enables it to be taken up into the infected 
macrophages without clinical toxicity (Adler-Moore and Proffitt 2002). However, due 
to its expense and mode of delivery (intravenous infusion) it is not an appropriate 
therapy for cutaneous lesions. Fungizone is a more cost-effective alternative that has 
also shown efficacy in treating VL, however, both Fungizone and AmBisome have 
mixed limited efficacy against CL induced by L. major  (Barratt and Legrand 
2005;Yardley and Croft 2000).  
The use of polymers is an alternative and more cost-effective avenue that has been 
increasing used over the years to develop effective therapeutics (Liu et al. 2009). The 
ability to elect characteristics that can improve or are lacking in, otherwise effective 
drug molecules, is very desirable. As described, AmB is potentially a very useful 
molecule and is cheap to manufacture. If ‘correctly packaged’ such as within a 
liposome (AmBisome) it has life-changing properties, particularly in the context of 
treatment for visceral leishmaniasis (Sundar et al. 2010). To this end, work involving 
‘packaging’ AmB into a drug that alleviated its disadvantageous properties, such as 
solubility in water and toxicity, commenced.  
Previous work had shown that a drug construct of AmB and polymethacrylic acid 
(PMA) could be synthesised (Harris 2006). This AmB-PMA drug had low cytotoxicity 
and low red cell lysis properties in vitro. It was as effective as commercially available 
Fungizone in killing L. donovani parasites in vitro. This work included the 
identification of an AmB loading of between 26 - 30% for an AmB-PMA synthesis that 
gave rise to optimal stability, anti-leishmanial activity and minimal toxicity (Harris 
2006). However it proved difficult to maintain consistent efficacy when administered 
intravenously in vivo in an experimental model of VL induced by infection with L. 
donovani. My aim was to apply the methods used in developing an alternative AmB 
therapy for VL to treating cutaneous leishmaniasis. In so doing, thorough optimisation 
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of the existing protocols of AmB-PMA synthesis was required, including modification 
of the polymer before assessing its biological properties. 
1.4.1 Polymer-drug constructs 
The precursor polymer SB-GD-19 was synthesised as a 20 g batch and carefully 
chemically characterised before being used. It was reproducible and demonstrated 
consistent peaks on GPC and NMR (Figure 12 and 14 respectively). It also showed 
no red cell toxicity and no toxicity on stimulation with human primary cells (Figure 17, 
20 and 21). However, the problem that arose was that the AmB-PMA synthesised 
using SB-GD-19 had variable and inadequate in vivo activity when administered 
intravenously in the VL (i.e., L. donovani) animal model. The exact reasons for this 
still remain to be fully defined and were not the objective of this thesis. The most 
likely reason is the instability of the AmB-PMA in the micro-environment of the blood 
stream. This may have been due, in part, to the partial rather than the complete 
hydrolysis of the precursor polymer by sodium hydroxide. As described, the 
generation of AmB-PMA with SB-GD-19 required the presence of NaOH to drive the 
hydrolysis reaction. Both AmB and SB-GD-19 are soluble and stable in DMSO. This 
stability may have resulted in an incomplete reaction mixture or low affinity 
interactions. In vivo, these low affinity interactions between the polymer and AmB 
could have resulted in dissociation due to the preference of AmB to associate with 
lipoproteins in the bloodstream. This would have changed the distribution of the AmB 
away from the target organs; the liver and spleen. An alternative approach was 
therefore considered for the synthesis of AmB-PMA for the treatment of cutaneous 
leishmaniasis.  
After full hydrolysis, the precursor polymer SG-GD-19 had an NMR similar to that of 
the commercially purchased standard HP-18 (Figure 15). Both polymers have a Mw 
of 18 kDa. The difference in chemical characteristics was that HP-18 is an 18 kDa 
polymethacrylic acid sodium salt and is soluble in water rather than DMSO.  Before 
establishing whether synthesis of AmB-PMA could be obtained using HP-18 it was 
necessary to evaluate its biological characteristics.  
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1.4.1.1 Biological properties 
Although chemically, SB-GD-19 and HP-18 were similar, their effects biologically 
could have been different. PBMC’s and a U937 human cell line were used to 
evaluate these properties. The latter were used as this is a cell line that is commonly 
utilised to study monocyte properties in vitro and can be easily cultured to high 
concentrations (Minafra et al. 2010). No toxicity was observed to red blood cells on 
incubation with HP-18 for up to 4 h (Figure 18). Stimulation of monocytes and U937 
cells with HP-18 did not cause cell death (Figure 20 and Figure 22). A thorough 
assessment of the proinflammatory properties of HP-18 was also conducted. The 
maximal proinflammatory response occurred with 25 ng /ml of ultrapure Salmonella 
minnesota lipopolysaccharide (LPS). On incubation with HP-18, there was no 
upregulation of mRNA expression of proinflammatory cytokines compared to 
unstimulated cells. As described, monocytes circulate in the periphery and upon 
stimulation by foreign material become activated and mature into macrophages 
(Mosser and Edwards 2008). Therefore, it seemed appropriate that investigations 
into the effects of the polymer on human primary cells would include monocytes and 
MDMs where Leishmania spp. parasites reside and replicate (Ribeiro-Gomes et al. 
2004). On stimulation of both these cell types with HP-18 over an overall 
concentration range between 31.25-250 µg /ml, HP-18 did not induce the production 
of MIP-1β, TNF-α or IL-10 (Figure 24 and Figure 26 respectively). Preliminary in vivo 
studies did include administration of AmB-PMA via the peritoneum, and therefore 
human peritoneal macrophages were utilised. However the accessibility was 
unpredictable and the yield became increasingly low and frequently too few cells 
were harvested (1x105/ml) to enable proinflammatory experiments to be conducted. 
Due to this only a narrow range of concentrations of HP-18 were tested (125 µg/ml 
and 62.5 µg/ml) and no upregulation of MIP-1β or TNF-α was found upon 3 h 
incubation with HP-18 (Figure 27a and b respectively).      
The original aim of testing the proinflammatory effects in vitro was to prevent the use 
of a substance in vivo that would give rise to an excessive immune response. Indeed 
it is commonly known that excess release of TNF-α can cause fever and ultimately 
death, although there are great benefits in this cytokine in an appropriate immune 
response (Kollias et al. 1999). Similarly, excess IFN-γ can also lead to 
proinflammatory diseases such as inflammatory bowel disease (Ito et al. 2006). 
Therefore it was reassuring that the results obtained from these studies did not 
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illustrate upregulation of these cytokines in human primary cells. In addition, PMA 
has been shown to be blood compatible when used to create scaffolds in tissue 
engineering (Zhu et al. 2003) and has already been approved for use in therapeutics 
for asthma (Nakamura et al. 1999). Further to this, more recent work with PMA has 
included encapsulation of therapeutic peptides for oral administration that has been 
tested in rats (Sajeesh et al. 2010). This research indicates the multiple usages of 
HP-18 in terms of a platform for the safe introduction of therapeutic medicine into 
humans. Hence it appeared reasonable to test the hypothesis on whether an AmB-
PMA drug could be synthesised using HP-18. On this basis and the additional 
similarities of HP-18 to the SB-GD-19 polymer, in terms of chemical characteristics 
and no cellular toxicity, creation of AmB-PMA with HP-18 was investigated. The use 
of HP-18 gave rise to potentially many benefits including the elimination of batch to 
batch variability as it is commercially available at a large synthesis scale. Also, its 
solubility in water minimised the use of DMSO in the AmB-PMA reaction mixture.   
1.4.2 Synthesis of AmB-PMA  
All reaction syntheses were conducted in endotoxin free conditions. The previous 
synthesis method with SB-GD-19 required that the polymer was solubilised in DMSO. 
However, as HP-18 was only soluble in water, modifications to the synthesis protocol 
were required. These included evaluating the use of sodium hydroxide. When using 
the precursor polymer SB-GD-19 for synthesis, NaOH had to be added in the 
presence of both AmB and the polymer. NaOH drove the reaction because it was 
necessary to hydrolyse the precursor polymer before its interactions with AmB could 
take place. If NaOH was introduced into the reaction mixture at any other point in the 
synthesis, the association of AmB and PMA would not be formed and insoluble 
aggregates of AmB were seen. This was not an issue when undertaking synthesis 
with HP-18 because the polymer was already in a hydrolysed form.  However, simply 
mixing HP-18 and AmB together did not yield a soluble product. Both HP-18 
solubilised in water and AmB solubilised in DMSO were stable. In a reaction, 
molecules re-arrange themselves into their most stable state, but in this case both 
the polymer and the AmB were in a stable state. For AmB-PMA to be formed, the 
reaction needed to be driven physico-chemically. Addition of a strong alkali such as 
NaOH to AmB forced it into a monomeric state as exemplified in Figure 114. When 
aqueous HP-18 was added to this monomeric AmB, it allowed the AmB to re-arrange 
into a more preferable state with HP-18. This method gave rise to a product whose 
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physico-chemical and biological characteristics were similar to AmB-PMA batches 
that were originally synthesised with the precursor polymer (SB-GD-19). This 
association is believed to involve the negatively charged backbone of the anionic 
polymer and the zwitterionic nature of AmB. Polycarboxylic acids such as PMA have 
a self-assembling ability to form strong hydrogen bonds and oligomeric structures 
with an outer polyanionic coat in water in the presence of oppositely charged 
polyelectrolytes (Zeghal 1999). As AmB and PMA are charged molecules, 
electrostatic interactions will form non-covalent interactions. Investigators have 
shown that variability in the pH can cause AmB to be instable and contribute to its 
toxicity. Sanchez-Brunete and colleagues synthesised a water soluble formulation of 
AmB that was characteristically similar to Fungizone. Two methods were used, one 
of which involved the increase followed by decrease of pH. The other method did not 
involve fluctuations in pH, and it is this method that had lower toxicity (Sanchez-
Brunete et al. 2004). However, as described in the following pages, the method 
detailed and shown in Figure 114 was actually beneficial in creating stable, non-toxic 
associations between AmB and HP-18.  
 
 
Figure 69: Schematic of method of synthesis between AmB and PMA-Na 
Shifting AmB into its monomeric and less stable state, allowed for its association with 
PMA when added in water. This method is attainable on the addition of NaOH. 
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Purification of AmB-PMA still required a considerable amount of chemical 
optimisation. The use of PD-10 columns was simple and time-efficient. They allowed 
for quick identification of drug formation and effective removal of any free AmB. 
However the use of these columns limited the ability to control other parameters in 
the purification of AmB-PMA that might hinder its resulting composition. As already 
noted, there were inconsistencies found in using AmB-PMA to treat VL in vivo and its 
efficacy in vitro even though batches that were compared had similar chemical 
characteristics (i.e. their percentage loading of AmB and their spectra in water). 
Further investigations into identifying specific parameters were necessary so that 
reliability in vivo was obtainable and the use of PD-10 columns limited this 
extensively.  
Dialysis was a technique that resolved all these issues. This was achieved by 
determining the optimum characteristics of each batch of AmB-PMA by studying the 
influence of time, pH and membrane pore size on its biological characteristics.  
Experiments showed that the membrane pore size of the cassettes was important in 
obtaining high affinity between AmB and PMA. The use of a 7 kDa dialysis 
membrane in the cassette was found to be the optimum molecular weight cut off for 
the reaction mixture. This is schematically represented in Figure 6. It enabled the 
removal of free AmB from the reaction mixture without the loss of AmB-PMA.  
These dialysis cassettes were used to determine the appropriate dialysis solution for 
purification. Synthesis reaction mixtures were purified in sterile water, alkali solution 
(NaOH) and buffered sterile water (Na2HPO4) to determine the optimum conditions 
for the isolation of AmB-PMA. Dialysis against Na2HPO4 solution at pH 8 to 9 
produced batches with a very low percentage loading of AmB (Table 8). Dialysis 
against a NaOH solution at a pH in excess of pH 11 gave rise to batches that 
lyophilised to a flaky powder which was black in colour (Table 6). Both of these 
solutions substantially altered the physico-chemical characteristics of AmB-PMA and 
had a detrimental effect. Neutral pH sterile water was set as the optimum dialysis 
solution to isolate AmB-PMA. Once this was identified and controlled, the focus 
moved on to the time for which dialysis was undertaken. This was a key parameter 
because prolonged dialysis (i.e. >2 h) led to an increase in the aggregated forms of 
AmB within the synthesised batches (Figure 36). Those synthesised using HP-18 are 
shown in Table 8 (syntheses 3a-e) and demonstrated that dialysis for 24 h led to a 
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high affinity and chemically stable batch of AmB-PMA with a 1:1 ratio of aggregated 
AmB: monomeric AmB.  
Temperature was strictly controlled throughout both synthesis reactions and also 
dialysis at room temperature of 23°C. This was to prevent any temperature-induced 
aggregation of AmB that would be caused by fluctuating temperature (Lambing et al. 
1993). Dialysis at room temperature, using sterile water at the neutral pH 7 for 24 h 
using a dialysis cassette with 7 kDa MWCO produced AmB-PMA batches that were 
stable and had very similar characteristics in vitro. The definition of these relatively 
simple chemical synthesis conditions for the optimum isolation of high affinity 
syntheses was an important new set of observations.  
1.4.2.1 Monomeric and aggregated AmB  
The aim to generate a monomeric preparation of AmB was based upon the 
observation that aggregated AmB is responsible for its in vivo toxicity. (Bolard et al. 
1991;Deray 2002;Legrand et al. 1992). However, to make AmB-PMA in which the 
AmB is predominately in the monomeric form, meant that several unfavourable 
physico-chemical conditions had to be created. This is highlighted in Table 8 and 
Figure 37(b). Both these experiments show AmB-PMA with a UV spectrum that is 
predominantly monomeric but is not stable in solution or as a lyophilised powder. My 
results suggest that it is very difficult to reproducibly synthesize stable and safe 
formulations of AmB. In this context, it is important to remember that the AmB in 
Fungizone and in liposomal AmB is predominately in an aggregated form, as shown 
by their UV spectra (Figure 30). My results suggest that a 1:1 ratio of AmB in the 
AmB-PMA that I synthesised formed strong electrostatic interactions and had stable 
physico-chemical properties. In vitro toxicity was also low as reflected by the 
haemolysis data showing that these syntheses had, on average, 20 % red blood cell 
toxicity at 50 µg/ml of AmB compared to 100% of Fungizone (Figure 44). These 
studies suggest that the current consensus, that all new AmB preparations should 
ensure that the AmB is kept as monomeric as possible to avoid toxicity issues, does 
not apply when AmB is being associated with polymethacrylic acid (Ramos et al. 
1995;Sanchez-Brunete et al. 2004)(Selvam and Mishra 2008).   
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1.4.2.2 Starting concentration of polymer and AmB for the chemical synthesis 
To make AmB-PMA with the precursor polymer SB-GD-19, a concentration of 50 
mg/ml of the precursor polymer and 34.5 mg/ml of AmB were used. In contrast, only 
5 mg/ml of the hydrolysed polymer HP-18 and 5.15 mg/ml of AmB were used in the 
modified chemical synthesis protocol (Materials and Methods). This meant that 90 % 
less polymer was used to synthesis AmB-PMA. Final yields of the purified, lyophilised 
AmB-PMA were similar with an average 75.6 mg ± 4.58. This therefore meant that 
although the hydrolysed polymer was more costly due to being purchased from a 
commercial source, the 90 % reduction in the quantity required for AmB-PMA 
synthesis resulted in the overall process being more cost-effective and efficient and 
that this approach was a better way to progress my studies. 
1.4.2.3 Chemical properties of AmB-PMA 
Optimisation of the chemical characterisation was introduced to identify the 
properties of the AmB-PMA batches that were being synthesised using the optimised 
controls discussed above. Fungizone was used as the source of AmB for syntheses 
and therefore it was also used as a comparison for chemical characterisation. The 
percentage loading of AmB and the ratio of aggregates to monomeric AmB could be 
accurately measured using a UV spectrophotometer as described in the Materials 
and Methods. Its UV spectroscopic distribution could be measured accurately and 
these results were confirmed by CD studies of AmB-PMA (Figure 43). DLS was used 
to determine the size of the drug compared to Fungizone. The median diameter of 
AmB-PMA was 61 nm compared to 53 nm for Fungizone (Figure 42(a) and (b) 
respectively). AmBisome has been shown to have a mean diameter of 78 nm (Olson 
et al. 2008). If the mean diameter of a formulated drug exceeded 100 nm, then it 
would have been too large to be endocytosed by macrophages. This would have 
made it an ineffective therapeutic product for leishmaniasis. Both CD and DLS 
identified the similarities of the physico-chemical characteristics of Fungizone and 
AmB-PMA. 
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1.4.2.4 Stability studies 
As described, AmB readily forms aggregates in solution, therefore optimisation of the 
AmB-PMA synthesis protocol, including altering variables to increase reproducibility 
and decrease toxicity would be fruitless if, after synthesis, the AmB-PMA solution 
was kept in solution. As shown, the first 5 h in solution is the most crucial, therefore 
immediate use of AmB-PMA when in solution would be beneficial (Figure 59).  
Disassociation studies involving the disruption of AmB-PMA were conducted via 
centrifugation.  Visual comparisons of AmB-PMA were made with Fungizone and 
AmBisome (Figure 66). AmB-PMA reconstituted in water for injection remained 
stable and in solution after 30 min and only started to precipitate after 2 h of 
centrifugation (Figure 66 (a) and (b) respectively). One could deduce that this is the 
time limit in which solubilised AmB-PMA should be administered in vivo. Both 
Fungizone and AmBisome contained precipitates after 30 min of centrifugation. 
Future work would entail the quantitation of these experiments to determine the 
proportion of AmB that was precipitating and whether this would affect the biological 
activity of the drug.  
The UV spectra of AmB within AmB-PMA in water is similar when inserted into 
human plasma (Figure 56(a) and (b)). This stability is not consistent with Fungizone 
that substantially shifts in the presence of human plasma (Figure 56(c)). The state of 
AmB becomes predominately aggregated when placed into RPMI in both AmB-PMA 
and Fungizone. RPMI is commonly used for in vitro cell culture techniques and has a 
pH 7.15 ± 0.1 (Invitrogen). It contains buffering salts which could interfere with AmB. 
On insertion into human serum at high concentrations both AmB-PMA and 
Fungizone caused cell lysis, indicating that this may have contributed to the 
variability found when administered in vivo as treatment of visceral leishmaniasis. At 
low concentrations, there appears to be no shift in the state of AmB in human serum 
in comparison to water (Figure 58 and Figure 56 respectively). Liposomal AmB does 
not shift in any of the conditions described and remains completely aggregated in 
solution (Figure 57).  
To eliminate the aggregation of AmB over time in solution, the method of 
lyophilisation of AmB-PMA into a powder was used. Importantly, when stored as a 
powder the UV spectra were similar on analysis over a total period of 9 months and 
the AmB-PMA remained stable and bioactive. As shown, the lyophilisation process 
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itself could give rise to unfavourable characteristics in terms of the texture of the 
AmB-PMA powder and its properties (Figure 66). Although the ability to control the 
lyophilisation method would require substantially more time, ¾ of the AmB-PMA 
batches synthesised gave rise to visual characteristics that were seen as ‘ideal’ in 
terms of appearance, toxicity and anti-leishmanial potential (Figure 31 and Figure 
32). Further studies involved the incorporation of the optimised AmB-PMA drug into a 
matrix to determine whether AmB-PMA would be retained in the structure. After 
lyophilisation of the pre-soaked AmB-PMA gauze, it was removed from the amber 
vial and reconstituted in water which resulted in a yellow opaque solution. One could 
postulate that the solution consisted of soluble AmB-PMA, as dissociation of the 
interactions between these two molecules would result in the precipitation of AmB as 
it aggregates. This solidified the possibility of incorporating AmB-PMA into a topical 
application. This could be applied to lesions on the addition of sterile water to release 
the AmB-PMA. This would offer several advantages such as enable patients to 
collect the medication and administer at home, ultimately avoiding the expense of 
hospitalisation (Garnier and Croft 2002) (Aguiar et al. 2009).   
 1.4.2.5 Biological activity of AmB-PMA 
Evaluation of the proinflammatory responses of AmB-PMA was conducted on both 
human primary cells and U937 cell line, as shown for the polymer. The cytotoxicity of 
AmB-PMA was also assessed and compared to that of Fungizone, known for its 
toxicity to human cells (Adams and Kwon 2004). Concentrations of up to 200 µg/ml 
AmB of AmB-PMA were added to U937 cells with 100 % cell viability maintained. 
This was in stark contrast to Fungizone that decreased the viability by 74.7 % at 200 
µg/ml AmB (Figure 45). At a higher concentration of 400 µg/ml AmB, monocytes 
maintained an average of 92 % viability as appose to a dose dependent effect in cell 
death when stimulated with Fungizone (Figure 46). The source of AmB used to 
synthesis AmB-PMA was Fungizone, and therefore it was interesting to find that 
using the optimised synthesis protocol of AmB-PMA described, one can dramatically 
reduce cellular and haemolytic toxicity of AmB. This attenuation of toxicity that was 
found compared to Fungizone could allow for the total AmB administered to be 
increased to patients. At present, a key limitation of currently available drugs is their 
long treatment regimes, particularly Fungizone which is in excess of 20 days due to 
its limited dose administrated to man (Kleinberg 2006). This is in addition to toxic 
side-effects, which can prolong total treatment time further and necessitate the 
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requirement of hospital monitoring (Baginski & Czub 2009;Sundar et al. 2004). 
Overall this results in an increase in the total cost per patient. Indeed the success of 
a high dose of liposomal AmB is an indication that a higher dose and shorter regime 
is feasible if cost is not a limiting factor (Amato et al. 2007). 
The assessment of proinflammatory properties showed that AmB-PMA did not 
stimulate inflammatory responses in U937 cells, MDMs or peritoneal macrophages 
(Figure 47, 49 and 50 respectively). However, the most interesting result was on 
stimulation with monocytes. Over a concentration range of 50-200 µg/ml AmB, MIP-
1β, TNF-α and IFN-γ were upregulated after 3 h incubation with AmB-PMA. Most 
noticeably, at 50 µg/ml AmB demonstrated significant upregulation of the tested 
chemokine and cytokines. This data was then compared with Fungizone. AmB has 
been shown to stimulate the production of cytokines and the studies conducted also 
showed that Fungizone stimulated the production of MIP-1β, TNF-α and also IFN-γ 
(Figure 51,a-c) (Pai et al. 2005;Rogers et al. 1998). However, importantly the 
maximal TNF-α response that could be induced with AmB-PMA was 29 ± 6 % of the 
maximal response seen with LPS. This contrasted significantly with 108 ± 22 % for 
Fungizone (Figure 52, p=0.004). The maximal IFN-γ response with AmB-PMA and 
deoxycholate-AmB was similar to the maximal response seen with LPS. Both 
Fungizone and AmB-PMA did not stimulate the release of IL-10.  
This proinflammatory data was invaluable in hypothesising the mode of action of 
AmB-PMA and its efficacy in vivo. Both Fungizone and AmB-PMA were shown to 
both stimulate IFN-γ production in human monocytes, indicating that both 
formulations have an immunomodulatory effect. However, Fungizone also stimulates 
high levels of TNF-α, an excess of which can give rise to an inappropriate immune 
response resulting in fevers and chills (Janeway et al. 2008; Kollias et al. 1999). One 
might assume that this may be a contributing factor to the toxic properties of 
Fungizone. Indeed at the concentrations assessed (up to a 150 µg/ml AmB) only 65 
% cellular viability was observed (Figure 46). This was taken into account, but was a 
necessary limitation of the experiments to gain further information on the modification 
of the biological characteristics that had occurred due to our synthesis methods with 
HP-18. 
The 50% lethal dose (LD50) of AmB-PMA for L. major promastigotes was 0.3 ± 0.1 μg 
/ml AmB and for L. donovani promastigotes was 0.12 ± 0.1 μg/ml AmB (Figure 53). 
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This efficacy was found to be indistinguishable to that of Fungizone and was also 
found on treating infected macrophages in vitro. This is an appropriate but lengthy 
experiment, providing the closest indication of the potential of an anti-leishmanial 
drug in vivo. AmB-PMA was able to inhibit L. donovani amastigotes in macrophages 
with an LD50 = 0.31 μg/ml AmB which was not dissimilar to Fungizone (LD50 =0.24 
μg/ml AmB, Figure 54).  Infection of L. major promastigotes in murine tissue 
macrophages also proved effective on treatment with AmB-PMA (Figure 55). In 
addition this was a dose-dependent response. In summary the activity of AmB-PMA 
against Leishmania spp. in vitro was as effective as Fungizone. 
 1.4.3 Summary 
Development of AmB-PMA involved non-covalently associating the non-toxic, well-
defined narrow molecular weight distribution polymer, polymethacrylic acid sodium 
salt (PMA-Na) with AmB to create water soluble AmB-PMA. In evaluation of the data 
shown in this thesis, one can confidently describe AmB-PMA as efficacious in killing 
Leishmania spp. in macrophages and is non-toxic to human cells. It has limited 
immuno-modulatory properties that consist of the stimulation of IFN-γ production in 
monocytes which could lead to a more favourable immune response in vivo. 
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CHAPTER 2 
2.1 Introduction 
2.1.1 The immune system 
The human body is protected against pathogenic microorganisms and harmful 
environmental substances by a highly specialised defence system consisting of cells 
and molecules that comprise the immune system. This protective mechanism can be 
divided into two main components, the innate and adaptive immune response. On a 
daily basis, a healthy individual will encounter many foreign microorganisms that will 
be rapidly detected and destroyed within minutes or hours by the innate immune 
response. If this early response is evaded, the adaptive immune response is 
activated to control and attempt to eliminate infection. 
2.1.1.1 Innate Immunity 
The innate immune system principal role is to detect the presence of a foreign 
microorganism, allergen or danger signals within its environment, and if possible, 
control and eliminate them. For a microorganism to invade the body, it must first 
infiltrate the epithelial surfaces that serve as a mechanical, chemical or 
microbiological barrier against infection (Table 14). Epithelial cells that are held 
together by tight junctions seal the internal milieu from the external environment. 
Penetration of microorganisms can occur through the external epithelium of the skin 
via insect bites, abrasions or wounds, or via internal epithelial surfaces such as the 
respiratory or gastrointestinal tract mucosa and the eyes, nose and mouth. In this 
instance, infections usually remain localised and are eliminated rapidly by the innate 
immune response.  
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 Skin Gut Lungs Eyes/nose 
Mechanical 
Epithelial cells joined by tight junctions 
Longitudinal flow of air and fluid Movement of 
mucous by cilia 
 
Chemical 
                         
Fatty acids 
Low pH                  
Enzymes 
(pepsin) 
 Salivary 
enzymes 
(lysozyme) 
Antibacterial peptides  
Microbiological Normal flora   
 
Table 14: Epithelial barriers to infection 
 This table illustrates the different forms of epithelial barriers that compile the first line 
of defence from foreign particles (extracted and annotated from (Janeway et al. 
2008)  
 
2.1.1.1.1 Phagocytosis 
At the site at which a pathogen breaches the epithelial cell defences of the host, it is 
recognised and engulfed by tissue-resident populations of phagocytes such as 
macrophages and dendritic cells. Macrophages have the ability to phagocytose both 
intracellular and extracellular pathogens as well as particular antigen (Janeway et al. 
2008). During phagocytosis, a pathogen is internalised into a membrane-bound 
phagosome. As the phagosome matures, its pH becomes increasingly acidic. As this 
occurs it fuses with one or more lysosomes to form a phagolysosome. Lysosomes 
are membrane bound granules containing enzymes, proteins and peptides to 
degrade internalised pathogens. On generation of the phagolysosome, the lysosomal 
contents are released, due to the acidic environment, to attack the pathogen. 
During phagocytosis, the macrophage becomes activated to synthesise and release 
biologically active proteins cytokines and chemokines. This provides a signal to other 
innate immune cells and subsequently a large infiltrate of leukocytes; predominately 
neutrophils are recruited to the site of infection. Neutrophils have a wide range of 
functions including destroying pathogens, tissue remodelling and production of 
Chapter 2 
Introduction 
Karina D. Corware 
 
199 
 
chemokines. The influx of neutrophils to a site of infection or injury is the first in a 
series of reactions that comprise the inflammatory response (Kennedy and DeLeo 
2009;Voyich and DeLeo 2002). Neutrophils are typically short-lived cells that die by 
spontaneous apoptosis, however this lifespan is increased in an inflammatory site of 
infection (Nathan 2006). 
2.1.1.1.2 Macrophage  
Macrophages have a dual role, they are the primary host and effector cells for 
Leishmania spp. Tissue residing macrophages act as sentinels in the periphery whilst 
monocytes remain circulating in the blood stream and mature into macrophages 
upon stimulation. They are crucial in detecting invading pathogens and activating the 
innate immune response (Mosser and Edwards 2008). Macrophages are also able to 
present antigen to naive CD4+T cells, although they do not exhibit the same potency 
in antigen presentation as dendritic cells (Morrissette et al. 1999). They also aid in 
the remodelling of tissues and wound healing (Khanna et al. 2010;Porcheray et al. 
2005). 
2.1.1.1.2.1 Reactive oxygen and nitrogen intermediates 
These intermediates are produced by a variety of cellular mechanisms; the most 
important of which is the process of respiratory burst triggered by phagocytosis. Both 
neutrophils and macrophages can produce toxic substances such as superoxide 
anions, hydrogen peroxide and nitric oxide. Activation of this process within these 
phagocytes depends upon the assembly of the cytosolic components of NADPH 
oxidase enzyme including p47-phox and p67-phox to the membrane-associated 
flavocytochrome cytochrome b (Figure 70) (Bedard and Krause 2007;Dang et al. 
2001;Uhlinger et al. 1993). This multi-protein enzyme complex NADPH oxidase can 
then catalyse a set of sequential reactions to reduce oxygen molecules to superoxide 
anions. These are short-lived and dismutate to secondary products such as hydrogen 
peroxide, hypochlorous acid, hydroxyl radicals and singlet oxygen (Quinn and Gauss 
2004). These all accumulate within the phagosome or extracellular space so to exert 
toxic effects on extracellular pathogens (Condliffe et al. 1998). 
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Figure 70: The multi-protein enzyme complex NADPH oxidase  
The assembly of NADPH-oxidase occurs by the translocation of the cytosolic 
components such as p47-phox and p67-phox to the plasma or phagosome 
membrane (outside of the cell) to associate with flavocytochrome b. This activated 
oxidase mediates the transfer of electrons from cytosolic NADPH to intraphagosomal 
molecular oxygen to form superoxide anions. Diagram extracted and annotated from 
http://www6.ufrgs.br/favet/imunovet/molecular_immunology/pathohomotissueblood_
WBCqualitative.html  
 
Nitric oxide (NO) is another key cytotoxic agent that can be generated by many cells 
of the immune system such as macrophages, neutrophils and dendritic cells (Tripathi 
et al. 2007). NO is produced by the high output form of nitric oxide synthase 
(iNOS/NOS2) and can be constitutively expressed by endothelial and neuronal 
isoforms of nitric oxide synthase NOS1 and NOS3. iNOS is an inducible enzyme that 
is activated by cytokines such as TNF-α and IFN-γ and other microbial stimuli such 
as lipopolysaccharide (van der Veen 2001). Its function is dependent on the 
availability of its substrate L-arginine (Bogdan et al. 2000;El-Gayar et al. 
2003;Rodriguez et al. 2003)to drive the following reaction: 
L-arginine +02 + NADPH +iNOS/NOS2 = L-citrulline and NO 
This NO is a potent inducer of apoptosis by inhibiting both cellular respiration and 
DNA synthesis in tumour cells. It also has the ability to inhibit iron dependent 
pathways that are crucial for microbial growth and replication such as Leishmania 
species (Chakravortty and Hensel 2003;Green et al.1990;Tripathi et al. 2007). 
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2.1.1.1.3 Pattern Recognition Receptors (PRRs) 
A crucial aspect of the innate immune response is the ability to respond fast to 
invading microorganisms and to danger signals and to distinguish between host and 
non-host molecules. There are patterns of molecular structures present on many 
pathogens that are not present on the host’s cells. These are known as pathogen-
associated molecular patterns (PAMPs). Phagocytic cells can identify these patterns 
using a variety of cell-surface receptors known as pattern recognition receptors 
(PRRs)(Akira et al. 2006;Janeway et al. 2008). The macrophage mannose receptor 
is a multipronged molecule that binds to sugar molecules present on the surfaces of 
many bacteria and viruses (Xu et al. 2010b). Anionic polymers and acetylated low-
density lipoproteins can also be recognised with scavenger receptors found on the 
macrophage surface membrane. 
2.1.1.1.3.1 Toll-like Receptors 
Toll-like receptors are a family of PRRs that have been shown to play a crucial role in 
recognition of microbial molecular patterns in innate immune responses (Janssens 
and Beyaert 2003). This receptor family was originally discovered in Drosophila and 
named Toll, hence the homologous proteins in mammals and other animals are 
known as Toll-like receptors (TLRs) (Belvin and Anderson 1996). There are 11 
known TLR receptors that each recognises a unique set of PAMPs or ligands that are 
characteristic of pathogenic organisms (Table 15)(Cai et al. 2009;Kawai and Akira 
2010). TLRs are a family of type 1 transmembrane signalling receptors that consist of 
an extracellular leucine-rich repeating domain (LRR) and an intracellular Toll/IL-1 
(TIR) receptor domain (Anderson 2000). Stimulation of TLRs initiates a signalling 
cascade whereby the transcription factor NF-κB is triggered to promote the 
transcription and release of proinflammatory cytokines and chemokines (Barton and 
Medzhitov 2003;Brightbill et al. 1999;Janssens & Beyaert 2003). This cascade is 
dependent on the adaptor protein MyD88 which functions downstream of all TLRs 
(Figure 71)(Kawai & Akira 2010;Medzhitov et al. 1998). This leads to the expression 
of co-stimulatory molecules CD80/CD86 on macrophages and tissue dendritic cells 
highlighting the presence of foreign molecules, and also results in the ability to 
induce maturation of dendritic cells (Banchereau and Steinman 1998;Kaisho and 
Akira 2001). This allows the migration of dendritic cells to lymphoid tissue to activate 
T cell priming and the adaptive immune response (Lore et al. 2003;Schnare et al. 
2001). 
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Toll-like 
Receptors 
Ligands 
TLR2+TLR1 bacterial lipoproteins 
TLR2+TLR6 
bacterial lipoproteins, lipoteichoic acid, yeast cell 
wall mannans 
TLR2+? GPI anchors (parasites), bacterial porins, HMGB1 
TLR3 dsRNA 
TLR4 LPS, HSPs, HMGB1, some viral proteins 
TLR5 bacterial flagellin 
TLR7 ssRNA (viral) 
TLR8 ssRNA (viral) 
TLR9 CpG-containing DNA (viral and bacterial) 
TLR10 Unknown 
TLR11 Toxoplasma profiling 
 
Table 15: List of mammalian toll-like receptors and their ligands 
 There are 11 mammalian Toll-like receptors which are activated upon identification 
of their specific ligands. Table adapted from (Bauer and Hartman 2008) 
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Figure 71: PAMP recognition via TLRs 
Upon PAMP recognition, the corresponding Toll-like receptor (TLR) becomes 
activated resulting in a cascade of events involving the release of NF-κB. This then 
activates the transcription and synthesis of proinflammatory cytokines that are 
required during the innate immune response. This cascade pathway is dependent on 
the adaptor protein MyD88. Diagram extracted from (Kawai & Akira 2010). 
 
2.1.1.2 The adaptive immune response 
The adaptive immune response becomes activated only after both physical barriers 
and innate immune response have failed to destroy the invading pathogen allowing it 
to continue to replicate, or in the case of allergens, allowing persistent exposure. The 
accumulation of antigen with the raised cellular environment generated by the innate 
immune response activates the adaptive immune response. Antigen presenting 
dendritic cells (DC) and also macrophages are at the interface between the innate 
and adaptive immune systems (Janeway et al. 2008). However it is dendritic cells 
that possess the ability to transport antigenic peptides from the infected tissue to the 
draining lymphoid tissue and activate specific immune responses (Sillq et al. 2005). 
This initiation process is dependent on a complex series of events that result in the 
activation and maturation of DCs, the processing and presentation of antigenic 
peptide and the interaction of a fully activated dendritic cell displaying an appropriate 
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antigenic peptide: MHC complex to mature naïve CD4 or CD8 T cell (Joffre et al. 
2009;Lanzavecchia et al. 1999;Mempel et al. 2004).  
2.1.1.2.1 Maturation of an antigen presenting cell  
As previously mentioned, dendritic cells reside in peripheral tissues where they are 
most likely to detect and interact with microbial pathogens. They contain the majority 
of TLRs giving them high sensitivity to the presence of pathogens or danger signals 
(Reis e Sousa 2004a). Exposure to PAMPs on pathogens results in the activations of 
TLR signalling causing a shift in gene expression within the cell which allows for the 
commencement of maturation (Diebold 2009).  
During the process of maturation, there is an increase in the proteolytic processing of 
the antigens to produce antigenic peptides. These can then be presented on the cell 
surface by peptide: MHC complexes for recognition by naïve T cells. MHC class I 
molecules display antigenic peptides from intracellular pathogens such as viruses 
that have replicated within the cytosol of the dendritic cells. This antigen bound MHC 
class I molecule is recognised by CD8 T cells. This causes activation and 
differentiation of naïve CD8 precursor cells into CD8+effector T cells that are able to 
destroy infected cells displaying this MHC class I: peptide complex on their surface 
(Svensson and Wick 1999). MHC class II molecules present antigenic peptides of 
pathogens that have been processed via phagocytosis, to naïve CD4 T helper cells 
(Boes et al. 2002). Immature dendritic cells generally express low levels of MHC-
peptide complexes and co-stimulatory molecules. However upon maturation, there is 
an increased expression of MHC molecules on their surface so to maximise T cell 
priming in the lymphoid tissue (Reis e Sousa 2004b). Co-stimulatory molecules such 
as CD80, CD86, and CD40 are also upregulated to increase the efficacy of T cell 
stimulation. CD83 is also expressed once a dendritic cell is fully matured within the 
lymphoid tissue (Lechmann et al. 2002). 
Expression of cell surface receptor CCR7 is a key step in the maturation process. 
CCR7 is a chemokine receptor for chemokine ligand CCL-21 (Debes et al. 2005). 
Chemokines are a sub-family of chemoattractant cytokines that are released during 
the early phase of infection by a wide range of cells in different organs (Bachmann et 
al. 2006). Upon stimulation by chemokines, the dendritic cell alters its morphology 
and becomes elongated in response to the chemotactic gradient created to aid 
migration into the lymphoid tissue. Immature dendritic cells express chemokine 
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receptors such as CCR1 with its ligand expressed in peripheral tissues(Sallusto et al. 
2000). This allows the localisation of the dendritic cells to the peripheral tissue where 
they can function at detecting non-self molecules. Upon maturation however, CCR7 
receptor is upregulated on the cell surface whilst all other chemokine receptors are 
downregulated. The ligands for CCR7 are CCL-21, CCL-19 and SLC which are all 
expressed within the lymphoid tissues thereby instructing the migration of the 
partially matured dendritic cell (Debes et al. 2005). Naïve T cells also express CCR7 
receptor which allows for the homing of re-circulating naïve T cells from the blood or 
neighbouring lymphoid tissues into the lymph node draining the site of infection 
(Luchtefeld et al. 2010). CCR7 and its ligands CCL-21 and SLC are critical factors in 
the cell migration to the lymphoid T cell zones (Kellermann et al. 1999;Willimann et 
al. 1998). Mice deficient in both these chemokines demonstrated impairment in the 
migration of both dendritic and T cells to the lymphoid tissues. However, these 
observations also revealed that CCL-19 was not essential in this process (Britschgi et 
al. 2010).   
2.1.1.2.1.1 T cell priming steps; recognition, activation and differentiation  
Activated dendritic cells populate the T cell-rich areas within the secondary lymphoid 
tissue to maximise the interactions with the re-circulating T cells. Complete activation 
of the T cell involves several signals and the T cell receptors (TCR) expressed on its 
cell surface that are composed of variable αβ glycoprotein chains non-covalently 
associated with a non-polymorphic protein CD3 (Wucherpfennig et al. 2010). This 
accessory molecule is important in the recognition of antigen and in signal 
transduction via CD3 complex after interaction with antigen. Once both cells have 
associated, a low affinity interaction takes place between cell adhesion molecules 
DC-SIGN, ICAM1, ICAM2 and CD58 displayed on dendritic cells and ICAM-3, LFA-1 
and CD2 on the resting T cells (Dustin and Springer 1991;Sasada et al. 2002;Varga 
et al. 2010). This provides time for the T cell to ensure that the appropriate peptide is 
being displayed. On recognition of the peptide: MHC ligand, the TCR/CD3 complex 
undergoes a conformational change resulting in a higher affinity binding between the 
peptide: MHC and T cell complex (Gil et al. 2005). This binding is detected by the T 
cell and initiates the activation of various signal transduction pathways. One of which 
involves the co-stimulatory molecules that determine the survival of the T cell. 
Interactions between co-stimulatory molecule CD40 on dendritic cells and its ligand 
(CD40L) expressed on T cells contribute to the changes in the MHC complex (Cella 
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et al. 1996;Elgueta et al. 2009). This results in the co-stimulatory molecules CD80 
and CD86 binding to the receptor CD28 on the T cell (Fujii et al. 2004). Ligation of 
CD28 is critical in activating clonal expansion (Bjorgo and Taskon 2010). Another is 
the production of IL-2 that is essential for proliferation and differentiation of the 
activated T cell. Both the binding of the MHC:peptide and TCR/CD3 complexes and 
ligation of CD28 triggers the synthesis of IL-2 through NFκB production (Banchereau 
& Steinman 1998). Proliferation of naïve T cells occurs for 4-5 days after activation 
and results in the differentiation of armed effector T cells. Activated T cells undergo 
changes to their expression of co-stimulatory and adhesion molecules. Down 
regulation of CCR7 occurs whilst there is an increase in the expression of chemokine 
receptors such as MIP-1β. A naïve CD8 T cell differentiates into a cytotoxic T cell 
that can kill any infected cell presenting the antigenic peptide on its surface. CD4 T 
cells can differentiate into functionally polarized Th cell subsets. There are at least 
four subsets; Th1, Th2, Th17 and regulatory T cell (Treg). These can be 
distinguished by the differential expression of transcription factors and cytokine 
genes. Differentiation into Th2 T cell occurs in the presence of both IL-4 and IL-2 
upon stimulation with antigen. Th1 subsets generate in an environment that is IL-2, 
IFN-γ and IL-12 rich (Glimcher and Murphy 2000;Korn et al. 2009;Lee et al. 
2009;Mosmann et al. 1986).  
2.1.1.2.1.2 Th1 and Th2 CD 4 T cell subsets     
After antigen recognition, naïve CD4 T cells become activated and produce cytokine 
IL-2 for clonal expansion. T cell proliferation is triggered by the high affinity 
interaction of IL-2 with its receptor resulting in the emergence of effector CD4+T cells 
(Letourneau et al. 2010;Minami et al. 1993). After this they have the potential to 
differentiate into different phenotypes by expressing different patterns of genes that 
ultimately determine their function in the adaptive immune response. The direction of 
Th cell differentiation is principally determined by the cytokines that are expressed 
within the priming environment, although other factors do appear to play a role 
(Figure 72). In particular, the transcriptional factor GATA-3 plays a central role in Th2 
differentiation and can actively inhibit the expansion of Th1 cells (Ouyang et al. 
1998;Zhu et al. 2006) . Whereas, the T-box transcription factor T-bet plays a key role 
in Th1 cell development and actively produces IFN-γ for continued differentiation of 
TH1 cells (Mullen et al. 2001;Szabo et al. 2002). The type of antigen that is displayed 
as well as the dose detected can influence the Th1/Th2 balance as well as the 
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strength of interaction between the TCR and MHC: peptide complex (Constant et al. 
1995;Hosken et al. 1995;Tao et al. 1997). The polarisation of CD4 T cells determines 
the type of adaptive immune responses that are generated. The cytokines expressed 
by both Th1 and Th2 T cells promote growth of their own Th subsets, which can 
inhibit the development of the opposing subset .i.e. IL-12 secreted by Th1 cells 
down-regulated the development of IL-4 producing Th2 cells (Manetti et al. 
1993;Seder et al. 1992). Although one subset will not be mutually exclusive, there is 
often one subset that is predominating in each specific immune response raised. 
Regulation of the Th1/Th2 paradigm occurs by both negative and positive feedback 
mechanisms within the two subsets of cells. Generation of T reg cells are also 
essential in modulating both Th T cell responses and limiting the immune pathologies 
as a result of continued proliferation of either subset (Chaudhry et al. 2009). These 
cells release transforming growth factor beta (TGF-β) and other cytokines that are 
both able to inhibit T cell proliferation via the proliferation of T reg cells (Mangan et al. 
2006).  
 
 
Figure 72: Activation and differentiation of CD4+ T cells into Th1 and Th2 cells 
Naïve T helper cell precursors require the production of IL-2 and the IL-2 receptor 
CD25 for the continued clonal expansion. In the presence of specific cytokines and 
transcriptional factors such as T-bet and GATA-3, the naïve T helper cell can 
differentiate into either Th1 or Th2 cells respectively. These can activate their own 
expansion by the further release of cytokines such as IL-4 for Th2 and IFN-γ for Th1 
expansion. Extracted from (Murphy and Reiner 2002) 
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2.1.1.2.1.3 Th2 CD4+T cells  
Th2 T cells secrete IL-4, IL-5, IL-6, IL-10 and IL-13 and are involved in developing a 
humoral immune response, alternative activation of macrophages and resolution of 
inflammation (Figure 72). GATA-3 is essential for the proliferation and in turn 
induction of Th2 cytokines in CD4+ T cells, even in the absence of IL-4 (Ouyang et al. 
1998). Retroviral infection of GATA-3 in committed Th1 cells can induce the 
expression of Th2 cytokines whilst inhibiting the production of IFN-γ (O'Garra and 
Arai 2000). Cytokine secretion from Th2 cells activates mast cells and eosinophils to 
destroy extracellular pathogens such as helminth worms through activation of naïve 
B cells to produce the antibody IgE and IgG1 class (Figueiredo et al. 2010). However 
stimulation of eosinophils can also induce allergic proinflammatory responses shown 
to contribute toward the cause of asthma through airway hyper-reactivity (Xue et al. 
2009).   
2.1.1.2.1.3.1 IL-10  
IL-10 is an anti-inflammatory cytokine that actively inhibits monocytes, macrophages, 
NK and Th1 cells during infection. It is produced by a variety of cells such as 
macrophages, dendritic cells, B cells, mast cells and distinct populations of Tregs. It 
acts by downregulating MHC class II and CD80/CD86 expression on APCs to inhibit 
the production of an array of proinflammatory cytokines TNF-α, IL-12, IL-18, IL-6 and 
also NO (de Waal Malefyt et al. 1991;Fiorentino et al. 1991). It also inhibits the 
production of both CC and CXC chemokines that are essential in the recruitment of 
cells during inflammation. Through the active inhibition of IL-2, IL-10 can directly 
affect the production of T cells and influence Th1/Th2 differentiation (Moore et al. 
2001). As part of a Th2 response, IL-10 stimulates and enhances B-cell proliferation, 
differentiation and antibody production (Rousset et al. 1992). It can also play a 
regulatory role in co-operation with IL-12, to prevent excessive secretion of Th2 
cytokines IL-4, IL-5 and IL-13. This prevents the development of infections such as 
hepatitis C. Indeed it has been shown to reduce liver fibrosis when given as a 
treatment in patients with chronic hepatitis C (Nelson et al. 2000). Sub-cutaneous 
injections of recombinant IL-10 downregulated Th1 cytokine IFN-γ and TNF-α, and in 
doing so reduced the clinical signs of  inflammatory psoriasis in patients (Reich et al. 
2001).   
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2.1.1.2.1.3.2 IL-4 
IL-4 is an essential cytokine for the differentiation of Th2 CD4+T cells. Its production 
is induced by IL-2 and triggers it to act through signal transducer STAT6 to stimulate 
Th2 proliferation (Hebenstreit et al. 2006;Liao et al. 2008). Th2 response before and 
after nematode infection failed to mount in IL-4 knock-out mice. IL-10 and IL-5 
secretions were also reduced in these mice (Kopf et al. 1993). IL-4 also stimulates 
IgE production in B cells and the production of IgE receptors on their cell surface 
(Kabesch et al. 2003). It also activates other immune cells such as macrophages, 
eosinophils, basophils and mast cells (Pawankar et al. 1997). This can result in an 
allergic response and has been associated with contributing to the pathogenesis of 
asthma. Treatment with an IL-4 blockade that binds and sequesters IL-4 secretion 
gave rise to an anti-inflammatory mechanism, thereby reducing the production of IgE 
and has been shown to reduce asthmatic symptoms in mice (Steinke and Borish 
2001) (Zavorotinskaya et al. 2003). 
2.1.1.2.1.4 Th1 CD4+T cells   
Th1 immune response is effective at eliminating intracellular pathogens such as 
bacteria, viruses and parasites such as Leishmania. This is a cell-mediated form of 
immunity that involves the release of the cytokines IL-2, IL-12, IFN-γ and TNF-β to 
stimulate antimicrobial activity in phagocytes (Figure 72). The continued expansion of 
Th1 cells by the downregulation of GATA-3 and expression of IFN-γ is induced by the 
transcription factor T-bet (Lighvani et al. 2001;Usui et al. 2006).  Mice deficient in T-
bet are unable to develop Th1 cells and demonstrate a dramatic reduction of IFN-γ 
(Szabo et al. 2002). Th1 cells can also induce the activation of B cells to produce 
antibodies of the IgG sub-classes and natural killer cells to further generate IFN-γ 
(Abbas et al. 1996;Mohr et al. 2010). Autoimmune diseases, such as type-1 diabetes 
and inflammatory bowel disease have been shown to be linked to prolonged 
proliferation of Th1 T cells (Pakala et al. 1999;Parronchi et al. 1997). Whereas 
reduced expression of T-bet has been detected in airways of patients with the Th2 
cell mediated disease allergic asthma (Finotto et al. 2002).  
2.1.1.2.1.4.1 IL-12 
IL-12 is a 75 kda heterodimer formed by two glycosylated subunits p35 and p40 
covalently linked. IL-12p35 chain is a mature protein that is ubiquitously expressed in 
cells at low levels (Xu et al. 2010a). However, IL-12p40 chain is only expressed in 
cells able to generate the bioactive IL-12(p70) such as phagocytes and B cells 
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(Toichi et al. 2006). Secretion of IL-12 is dependent on both subunits and stimulates 
the production of cytokines from both Th1 and NK cells that include, IFN-γ, TNF-α 
and IL-2 (Goriely and Goldman 2008). IL-12 signalling involves the activation of 
transcription factor STAT4 through the IL-12 receptor (IL-12R) and is crucial in the 
differentiation and proliferation of Th1 cells from antigen-stimulated naïve CD4+T 
cells (Kaplan et al. 1996;Murphy & Reiner 2002). CD4+T cells upregulate IL-12 
receptors during TCR stimulation, which are only maintained on the surfaces of Th1 
cells. The IL-12 receptor is a complex of 2 chains, IL-12Rβ1 and IL-12Rβ2. Naïve 
CD4+T cells do not express IL-12Rβ2 chain until antigen activation after which it is 
inhibited by the presence of IL-4 for the generation of Th2 cells (Szabo et al. 1997) 
(Hamza et al. 2010). IL-12 deficient mice are unable to generate an IFN-γ Th1 
response (Magram et al. 1996).  
2.1.1.2.1.4.2 TNF-α 
TNF-α is a potent proinflammatory cytokine with immunoregulatory properties 
released by a range of cell types such as Th1 T cells, macrophages, neutrophils, 
eosinophils and mast cells. It acts as a chemoattractant for granulocytes such as 
eosinophils, mast cells, neutrophils and circulating monocytes so to increase 
microvascular permeability and activate T cells to the site of infection (Janeway et al. 
2008). This occurs by its ability to upregulate adhesion molecules and 
chemoattractants such as IL-8 to aid the migration of cells to sites of infection. TNF-α 
can also induce the production of proinflammatory mediators prostaglandins and 
other cytokines such as IL-1, IL-6 and granulocyte-macrophage colony stimulating 
factor (GM-CSF). GM-CSF can promote differentiation of dendritic cells and also 
Tregs. Tight regulation of TNF-α production is essential to the host as high levels can 
lead to exacerbation of the immune response (Kollias et al. 1999). This can lead to 
chronic activation of innate immune cells resulting in chronic inflammatory arthritis, 
Chrohn’s or bowel disease (Jones et al. 2004;Tammali et al. 2007). TNF-blocking 
agents have been shown to be effective in treating rheumatoid arthritis in both mice 
and humans (Elliott et al. 1994;Maini et al. 1995). In an open-labelled trial, which 
provides both researchers and the participants full information into the treatment that 
is being administered, of anti-TNF therapy for Chrohn’s disease, 8 out of 9 patients 
entered clinical remission after only one infusion (Targan et al. 1997). More recently it 
has been demonstrated that TNF can exhibit immunosuppressive properties 
indicating it may act as a regulator of the Th1 immune response (Ma et al. 2000). 
Murine macrophages treated with TNF-α downregulated IL-12 after stimulation with 
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both LPS and IFN-γ. This also occurred in dendritic cells (Zakharova and Ziegler 
2005). This immunosuppressive pathway has been shown to involve CD4+CD25+ T 
regulatory cells (Chen et al. 2007).  
2.1.1.2.1.4.3 IFN-γ 
The 3 member Interferon family can be separated into different groups depending on 
their function. Type 1 interferons (IFN-α and IFN-β) are antiviral proteins that are 
secreted by virus-infected cells. However, more recently they have been shown to 
play a protective role in the innate immune system in response to parasitic infections 
(Diefenbach et al. 1998;Mattner et al. 2004;Une et al. 2003). Type II interferon IFN-γ 
plays a central role in the generation of potent immunomodulatory effects. It is 
structurally unique, binds to a separate receptor and is encoded by a separate 
chromosome than Type 1 interferons. IFN-γ was originally considered to be 
expressed only by T and NK cells, but has since been shown to be produced by 
other cells such as antigen presenting macrophages (Munder et al. 1998). As 
previously mentioned, IFN-γ stimulates the development of effector CD 4 Th1 cells. 
Th1 cells then activate antimicrobial activity of infected macrophages (Ribeiro-Gomes 
et al. 2004). IFN-γ also triggers the transcription of a range of genes involved in MHC 
protein expression, antigen processing and apoptosis (Hisamatsu et al. 1996). It can 
also effectively suppress Th2 immune responses. Production of IFN-γ is controlled by 
IL-12 and IL-18 secreted by phagocytes and requires the presence of T-bet for 
upregulation in dendritic cells (Otani et al. 1999) (Lugo-Villarino et al. 2003). 
Recognition of a pathogenic antigen by a macrophage in the innate immune 
response stimulates the secretion of IL-12 and chemokines such as macrophage 
inflammatory protein MIP-1α which attract NK cells to migrate to the site of infection 
(Salazar-Mather et al. 2000). The secretion of IL-12 promotes IFN-γ synthesis within 
these activated cells. Activated CD4+ Th1 T cells in the adaptive immune response 
are stimulated to augment IFN-γ production via the secretion of both IL-12 and IL-18 
(Schindler et al. 2001). IL-18 is produced by antigen presenting cells and contributes 
to IL-12 induced Th1 development (Yang et al. 2001). IFN-γ production is 
downregulated by the presence of IL-4 and IL-10, both key cytokines in the 
generation of Th2 response (Himmelrich et al. 2000;Reich et al. 2001).  
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2.1.1.2.1.5 Classical and alternative activation of macrophages 
Macrophages can be activated by at least 2 different pathways that both involve nitric 
oxide synthase (iNOS/NOS2) and arginase. Both enzymes use the substrate L-
arginine and can be influenced by cytokines secreted from both Th1 and Th2 T cells 
and ultimately relates to the killing or survival of the parasite (Kropf et al. 
2004a;Peluffo et al. 2004). IFN-γ mediated Th1 responses and proinflammatory 
microbial stimuli such as lipopolysaccharides (LPS) augment classical activation of 
macrophages whereby NOS2 oxidises L-arginine in a two-step pathway to produce 
nitric oxide (Rodriguez et al. 2007). Mice with a defective NOS2 gene have increased 
susceptibility to Leishmania (Wei et al. 1995). Th2 related cytokines such as IL-10 
and IL-4 suppress IFN-γ mediated induction of NOS2 (Hesse et al. 2001). Instead 
they promote alternative activation of macrophages that induces the enzyme 
arginase 1 to reduce L-arginine into ornithine and urea (Iniesta et al. 2002;Modolell et 
al. 1995;Munder et al. 1999). This product has been shown to be required for 
polyamine synthesis which maintains the survival and growth of Leishmania 
parasites in macrophages (Kropf et al. 2005). One of the consequences of arginase 
activity is a high substrate turnover and a decrease in L-arginine. Sub-physiological 
levels of L-arginine induce T cell hypo-responsiveness and have been linked to the 
cause of a variety of conditions such as chronic inflammation, pregnancy and 
infectious diseases such as leishmaniasis (Kropf et al. 2007;Modolell et al. 
2009;Munder et al. 2006).  
 
2.1.1.3 Immune response to Leishmania spp.  
It is well established that the resolution of a leishmanial infection is dependent on an 
appropriate immune response governed by the generation of CD4+ Th1 T cells 
(Alexander and Bryson 2005). The immune response of humans to infection is not as 
well characterised as the responses found in mice. Experimental cutaneous 
Leishmania infection of inbred strains of mice has given essential insight into the cell-
mediated response to this intracellular parasite (Gumy et al. 2004;Rosas et al. 2005) 
(Choi and Kropf 2009). Typically, a large number of parasites (104-107) are 
inoculated subcutaneously to the footpad or ear to initiate infection (Kropf et al. 
2004b). Subsequent lesion formation correlates with increasing parasite numbers, 
and healing is associated with appropriate immune activation. Most inbred strains of 
mice (C57BL/6, CBA, C3H/He and 129Sv/Ev, etc) develop small local cutaneous 
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lesion at the site of injection which spontaneously resolve within several weeks. 
These mice self-heal and have a genetically resistant phenotype that correlates with 
an IFN-γ driven Th1 response (Sacks and Noben-Trauth 2002). However, BALB/c 
mice are highly susceptible to infection, and develop progressive uncontrolled 
parasite growth and lesion pathology (von and Udey 2004) (Ronet et al. 2008). The 
parasites will eventually disseminate to the internal viscera and may cause systemic 
disease (Nicolas et al. 2000). BALB/c mice are unable to heal this infection; they are 
the prototype of genetically susceptible mice and develop a dominant Th2 response 
(Campos-Neto 2005;Louis et al. 2003). The division between the different Th cell 
types found in mice is not as distinct in humans, although there is evidence of a good 
correlation between Th1 cell responses and parasite burden in patient lesions (Louzir 
et al. 1998). Researchers have also shown that detected levels of IL-10 in patients 
correlates with the severity of infection (Verma et al. 2010). The following is a 
summary of events on Leishmania infections in both human and mouse with an 
overview schematically represented in Figure 73.  
 
Figure 73: A schematic demonstrating the pathways that can occur on 
activation by Leishmania spp. 
Antigen presenting cells (APC) uptake Leishmania spp. via endocytosis before 
migrating to the nearest secondary lymphoid tissue for presentation to naïve T cells. 
Depending on the environment and cytokines released, naïve T cells become 
activated and differentiate into either Th1 or Th2 cells. This allows for the secretion of 
cytokines generating an immune response in response to the infection. Extracted and 
annotated from (Akira et al. 2001). 
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2.1.1.3.1 Establishment of Leishmania infection within the host 
Leishmania have developed numerous strategies whereby they can evade the 
immune response. The saliva of the sand fly has recently been shown to play a role 
in facilitating natural transmission of Leishmania spp. into the host (Belkaid et al. 
1998b) (Courret et al. 2003). Within the midgut of the sand fly, the parasite produces 
a promastigote secretory gel (PSG) containing a unique mucin-like protein 
filamentous proteophosphoglycan (fPPG) (Ilg et al. 1996). This PSG forms a plug in 
the anterior part of the midgut where the highly infective metacyclic promastigotes 
accumulate (Rogers et al. 2004;Stierhof et al. 1999). This alters the midgut of the 
sand fly damaging the stomodeal valve, forcing it to remove the PSG and parasites 
from its gut via regurgitation before it can effectively intake a blood feed. Hence, 
augmenting the probability of promastigote transmission two fold; increasing the 
number of times a sand fly has to penetrate the epithelial layers of a host in order to 
have a complete feed, and in doing so increasing the number of infective parasites 
that are transmitted into the host (Rogers et al. 2002;Volf et al. 2004).  
Upon injection into the host, both sand fly saliva and PSG with Leishmania spp. have 
been shown to further enhance infection into the host (Rogers et al. 2004). Natural 
transmission of saliva by infected or non-infected sand flies induced the recruitment 
of both neutrophils and macrophages in vivo. However, the latter was increased 5-
fold on injection of both PSG and sand fly saliva (Rogers et al. 2009;Teixeira et al. 
2005). The migration of neutrophils to the site of sand fly bite and parasite inoculation 
is an innate immune response that occurs within minutes. It has been shown in 
susceptible BALB/c mice that depletion of neutrophils at this early stage increases 
parasite survival (Tacchini-Cottier et al. 2000). In vivo imaging has revealed that 
neutrophils actively capture L. major parasites rapidly after inoculation (Peters et al. 
2008). The parasitized dying neutrophils are subsequently taken up by macrophages.  
Since uptake of apoptotic cells does not induce an inflammatory response, this 
represents a mechanism of ‘silent entry’ whereby the parasite can be rapidly 
internalised by neutrophils without inducing an anti-parasiticidal response (van et al. 
2007) (Gueirard et al. 2008). Although unable to replicate, Leishmania species can 
survive within neutrophils which appear to be a temporary host cell during the first 
few hours to days of infection (Laskay et al. 2003) (Charmoy et al. 2010). It has been 
shown that the presence of internalised parasites also enhance the longevity of the 
neutrophil to ensure engulfment by macrophages (Aga et al. 2002;van et al. 2004). 
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This silent entry has been shown to last from a few days to 4-5 weeks before the 
generation of a lesion and the recruitment of macrophages to activate the host’s 
defence mechanisms (von 2007) (Thalhofer et al. 2010). Typically, in vivo infection is 
carried out with a high concentration of promastigotes (105-107); however more 
recently low inoculation (<1000 of metacyclic promastigotes) has been shown to 
more closely mimic disease progression present in natural infections (Belkaid et al. 
2000;Belkaid et al. 2002b). 
2.1.1.3.2 Recognition of Leishmania in the host 
The Toll-like receptor signalling pathway plays a key role in the recognition of 
Leishmania and the activation of an innate immune response through signalling 
pathways to eliminate the parasite (Tuon et al. 2008). On recognition of specific 
antigens, the TLR pathway triggers the nuclear translocation of NFκB and expression 
of proinflammatory cytokines such as TNF-α (Barton and Medzhitov 2003; Janssens 
and Beyaert 2003). As previously described this signalling cascade is dependent on 
the adaptor protein MyD88 (Muraille et al. 2003; Kawai & Akira 2010). C57BL/6 
resistant mice lacking MyD88 are unable to control L. major infections indicating the 
involvement of TLR in recognition (de Veer et al. 2003; Debus et al. 2003). However 
the contribution of TLRs to the leishmanicidal responses remains unknown. 
Leishmania synthesise a family of glycoconjugates such as lipopohsphoglycan (LPG) 
and glycoinositolphospholipids (GIPL) that coat its surface membrane. LPG is a 
complex glycophospholipid that is GPI anchored and a major surface molecule of 
Leishmania metacyclic promastigotes (McConville et al. 1995). LPG has been 
identified as a TLR2 agonist and that in an in vitro study LPG directly binds to TLR2 
in infected human NK cells (Becker et al. 2003). Guerra and colleagues identified that 
on infection with L. amazonensis, C57BL/6 mice deficient of TLR2 were susceptible 
to infection (Guerra et al. 2010). This data is supported by earlier findings that levels 
of TLR2 mRNA were significantly higher in infected resistant rather than susceptible 
mice (Charmoy et al. 2007). L. major infected mice deficient in TLR4 were also less 
able to control parasite growth and unable to resolve cutaneous lesions in contrast to 
TLR-4 competent mice that healed (Kropf et al. 2004). TLR4 signalling appears to 
contribute to the activation of efficient killing of L. major parasites within 
macrophages and healing of CL infections. Signalling through TLR4 has been shown 
to control IL-10 expression and increase IFN-γ production during L. major infections 
(Antoniazi et al. 2004). A further in vitro study implicates TLR3 in the recognition 
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process and the participation of both TLR2 and TLR3 in the phagocytosis of L. 
dononvani promastigotes (Flandin et al. 2006). More recent investigations have 
indicated the involvement of TLR9. Liese and colleagues have shown that TLR9 
deficient mice develop increased parasite burdens and a more severe CL infection in 
response to L. major. However, it should be noted that TLR9 deficiency did not inhibit 
the generation of Th1 cells in these mice and ultimately the CL infection was 
resolved. The study suggests that although TLR9 signalling is required for the innate 
immune response to Leishmania, in particular for NK activation, protective T cell 
responses and resolution of infection are not TLR9 dependent (Schleicher et al. 
2007; Liese et al. 2007). The evidence described lends support to the concept that 
the activation of an appropriate immune response, in this case, killing of Leishmania 
parasites and resolution of CL infections, involves the cooperation between multiple 
receptors and is not due to one TLR acting alone (Underhill 2003).   
2.1.1.3.3 Persistence of infection 
As shown in the susceptible BALB/c mouse model, clonal expansion of Th2 cells in 
the very early phase of infection is induced by the presentation of the Leishmania 
antigen LACK (homologue of the receptor for activated C kinase protein)(Aseffa et al. 
2002;Launois et al. 1997;Launois et al. 2007). This upregulates IL-4 production, 
which in turn inhibits the expression of IL-12Rβ2 subunits on activated 
undifferentiated CD4+T cells (Himmelrich et al. 2000;Tacchini-Cottier et al. 2000).  A 
T cell effector immune response is then generated that is unable to efficiently 
respond to IL-12 and downregulates IFN-γ (Kalinski et al. 2000). This in turn inhibits 
NO production within infected macrophages enabling parasite growth (Hesse et al. 
2001;Modolell et al. 2009;Radwanska et al. 2007). However further work into the role 
of IL-4 in leishmanial infections has revealed that it can activate opposing functions. 
Early release during initial activation of dendritic cells in the presence of L. major 
induces the differentiation of Th1 CD4+T cells (Louis et al. 2003). However, during 
the priming of T cells, this cytokine then induces Th2 differentiation and the 
development of a persistent infection (Biedermann et al. 2001;Mohrs et al. 
2000;Noben-Trauth et al. 2003). Although researchers have identified that IL-4 is not 
solely responsible in generating a persistent progressive Th2-driven leishmanial 
infection, as it has been shown that BALB/c mice defective in IL-4 expression 
generated a pronounced unresolved infection (Noben-Trauth et al. 1996) (Lehmann 
et al. 2000) (Kropf et al. 2003). This appeared to be the result of the induction of 
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other cytokines such as IL-10 and IL-13 known to promote a Th2 response. IL-13 has 
similar biological functions to IL-4 in generating Th2 T cells. BALB/c mice deficient in 
IL-4 and treated with IL-13Rα fusion protein that blocks IL-13 activity were resistant 
to L. major infection (Kropf et al. 1999).  However, even in the absence of IL-4 
expression, C57BL/6 mice become susceptible to L. major on the sole expression of 
the IL-13 transgene which suppresses IL-12 and IFN-γ production (Matthews et al. 
2000).  
IL-10 has also been shown to be a crucial mediator in the persistence of infection 
(Padigel et al. 2003). It is effective in downregulating the classical activation of 
infected macrophages that generate NO (Iniesta et al. 2002;Vouldoukis et al. 1997). 
This inhibition by IL-10 greatly increases susceptibility to infection with Leishmania 
spp. in resistant strains and pathogenesis of disease in humans and therefore IL-10 
deficient mice have been shown to resolve leishmanial infections (Buxbaum and 
Scott 2005;Karp et al. 1993) (Murray et al. 2002). In a chronic infection with 
Leishmania parasites, mice administered with anti-IL-10 gave rise to complete 
healing of lesions and sterile cure as did IL-10 deficient mice, illustrating the potent 
effects of IL-10 on the outcome of disease (Belkaid et al. 2001). Further to this, in 
vitro data reported by Kane and Mosser indicated that amastigotes residing within the 
macrophages stimulate the production of IL-10, resulting in down-regulation of IL-12 
and TNF-α secretion and in turn inhibition of the activation of neighbouring infected 
macrophages (Kane and Mosser 2001). Furthermore, a positive correlation between 
the severity of a leishmanial disease and IL-10 levels have been identified in patients 
(Ghalib et al. 1993) (Verma et al. 2010).   
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Figure 74: Images of Leishmania spp. infecting macrophages within its host 
(a) Electron microscope image of Leishmania promastigote invading a macrophage 
taken from http://www.deduveinstitute.be/trop/about/subject2.htm (b) Macrophage 
infected with Leishmania donovani taken from 
www.vet.uga.edu/VPP/clerk/joiner/fig4.jpg.  
 
2.1.1.3.4 Resolution of Leishmania spp. infection 
In the resistant murine model of leishmaniasis, neutrophils and macrophages engulf 
the invading promastigotes which stimulate the early stages of the immune response 
and release of high levels of MIP-1β (Figure 74) (Sallusto et al. 2000). Further to this 
in cutaneous leishmaniasis, mast cells have been identified as contributors to the 
activation of the innate response. Mast cell-deficient mice infected with L. major had 
predominately larger lesions with low levels of recruited dermal dendritic cells and 
secreted IL-12 compared to control naive mice (Maurer et al. 2006). These cells 
release TNF-α to promote the recruitment of neutrophils and in turn release 
chemokines MIP-1α/β. These act as potent chemoattractants of macrophages and 
dendritic cells to the site of infection (von Stebut et al. 2003). The release of TNF-α 
from both macrophages and neutrophils also activates parasite killing and clearance 
of the parasite (Ribeiro-Gomes et al. 2004;Wilhelm et al. 2005). Dendritic cells are 
recruited to actively phagocytose L. major, inducing IL-12 production and, in turn, the 
priming of both CD4+ and CD8+ Th1 cells (Konecny et al. 1999). Activated T cells 
secrete IFN-γ which stimulates a cascade of pathways including the production of 
nitric oxide in the infected macrophages via the upregulation of inducible nitric oxide 
synthase (Bogdan et al. 2000;Ribeiro-Gomes et al. 2004). This results in further 
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destruction of the parasite and downregulation of IL-10. The early production of both 
IL-12 and IFN-γ after infection promotes Th1 differentiation in resistant mice resulting 
in control of parasite growth and healing of lesions (Park et al. 2002;Sacks & Noben-
Trauth 2002;Stobie et al. 2000). IL-12 is essential in the Th1 development as 
C57BL/6 mice that are unable to express IL-12p40 failed to raise a Th1 response and 
control their infection. This is in part due to the essential requirement of an early IL-
12 production in redirecting IL-4 response toward a predominant Th1 response 
(Mattner et al. 1996) (Belkaid et al. 1998a) (Radwanska et al. 2007).   
There are critical steps within antigen presentation to naïve T cells. The interaction of 
CD40 and its ligand on activated T cells appears to be crucial for the generation of 
resistance as well as the role of both CD80 and CD86 and their ligand CD28. BALB/c 
mice deficient of CD28 demonstrated defective proliferation of Th1 but not Th2 T 
cells. Th1 differentiation is not inhibited when mice with a resistant background have 
a disrupted IFN-γ receptor gene, though these mice became highly susceptible to 
infection, illustrating the important role of IFN-γ production in parasite clearance 
(Swihart et al. 1995;Wang et al. 1994). Furthermore, upregulation of IFN-γ production 
in patients with active cutaneous leishmaniasis is associated with clinical cure 
(Castellano et al. 2009).   
2.1.1.3.5 CD8+T Cell response in leishmanial infections 
CD8+T cells are critical molecules in the defence against viruses such as Ebola and 
vaccinnia virus (Harty et al. 2000; Gupta et al. 2005; Synder et al. 2004). Although 
there has been extensive research into the role of CD4+T helper cells during a 
leishmanial infection, less is understood on the contribution of CD8+T cells. As 
described, antigen bound MHC class 1 molecules on APCs are recognised by naive 
CD8+T cells. This activates their differentiation into CD8+cytotoxic effector T cells and 
allows for the destruction of infected cells displaying this MHC class 1: antigen 
complex (Svensson and Wick 1999). However, to become fully activated CD8+T cells 
are dependent on the activation of dendritic cells and the differentiation of CD4+T 
cells. The activation of CD4+T cells involves the interaction of CD40 expressed on 
APC and CD40 ligand on CD4+T cells. This stimulates the production of cytokines 
that activates dendritic cells which in turn activates and stimulates the proliferation of 
CD8+T cells via the presentation of the leishmanial antigen via MHC class I 
(Bourgeois et al. 2003). This ‘CD4 help’ has been shown to be critical for the 
expansion and survival of CD8+T cells (Overstreet et al. 2011). Activated CD8 
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cytotoxic T cells have the ability to kill Leishmania-infected macrophages via 
apoptosis and stimulate the production of IFN-γ and activation of macrophages (Scott 
et al. 1998; Kima et al. 1999; Janeway 2008). CD8+T cells have been associated with 
both protection and cure of leishmaniasis in both humans and mice. This was 
highlighted by Belkaid and colleagues on the stimulation of a natural leishmanial 
infection in vivo. Intradermal administration of low doses of L. major promastigotes 
revealed that CD8+T cells are essential in shifting an early Th2 response to a 
protective Th1 response allowing control of infection. Induction of this Th1 response 
is associated with the activation of IFN-γ producing CD8+T cells. The Th2 response is 
sustained on removal of CD8+T cells (Belkaid et al. 2002;Uzonna et al. 2004). 
However, the extent of CD8+T cells to control primary infections appears to be 
dependent on the route of infection in mice. In contrast to Belkaid and colleagues, 
challenge with a high dose of L. major in CD8 deficient mice induced cure of CL 
lesions (Huber et al. 1998). IFN-γ producing CD8+T cells have been shown to 
contribute to the healing of secondary lesions that had developed after a primary 
challenge with L. major, indicating a role of CD8+ in protection in the mouse model of 
experimental cutaneous leishmaniasis (Muller et al. 1991; Muller et al. 1993). In 
human CL infections, acquired protection from L. major infections has been mediated 
through both antigen specific CD4+ Th1 cells and CD8+T cells producing IFN-γ (Da-
Cruz et al. 1994; Da-Cruz et al. 2001; Rostami et al. 2010). A large number of these 
Leishmania-specific CD8+T cells have been shown to locate in the inflammatory 
infiltrate of lesions in an active infection rather than the peripheral blood (Da-Cruz et 
al. 2005). Overall research suggests that CD8+T cells participate during infection and 
also contribute to protection and active investigations are ongoing in exploiting the 
benefits of CD8+ effector T cells for vaccination of Leishmaniasis (Gurunathan et 
al.2000; Iborra et al. 2004).   
2.1.1.4 The host immune response and clinical outcome of disease 
Control of a primary leishmanial infection results in the elimination of the majority of 
parasites with a small remaining number of parasites under tight control. Persisting 
parasites are beneficial to the host since they contribute to the development of 
memory and immunity to secondary infections. C57BL/6 mice that self-heal primary 
L. major infection develop long-lasting immunity to re-infection which has been 
shown to be related to the presence of a low number of viable parasites (102-104) in 
the site of the healed lesion and lymph nodes (Belkaid et al. 2002b). Even after 
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clinical healing has occurred post treatment, this sub-clinical asymptomatic infection 
can be life-long in the host.  However, Th1 responses are required but not sufficient 
for healing as evidenced by both mice and humans infected with particular strains of 
L. major that have generated a sustained Th1 response but failed to heal (Anderson 
et al. 2005). The non-healing infection in the presence of Th1 responses has been 
shown to involve the over-activation of IL-10 and regulatory T cells during infection 
leading to an imbalance in the homeostatic pathways that control inflammation and 
healing. In a chronic lesion, IL-10 production was found to originate from both innate 
cells, regulatory T cells and inducible T cells (Anderson et al. 2007). Production of IL-
10 from CD25-Foxp3-CD4+ T cells was found to strongly correlate to the severity of 
disease in mice infected with L. donovani and also in patients (Ghalib et al. 
1993;Stager et al. 2006). Regulatory T cells (CD4+CD25+) can control infection via 
soluble mediators such as IL-10 and TGF-β or suppression via cell to cell contact. 
CD4+CD25+ T cells are naturally occurring T reg cells that originate in the thymus and 
are governed by the activity of a transcription factor Foxp3 to maintain immunological 
self-tolerance (Holm et al. 2004). In healed lesions of resistant C57BL/6 mice, 
CD4+CD25+Foxp3+ T reg cells were found to act in an IL-10 dependent manner to 
maintain Leishmania major persistence and prevent sterile cure (Belkaid et al. 
2002a).  
Clinical outcome of a leishmanial infection in humans ranges from mild self-curing 
cutaneous lesions to a disseminated or severe life-threatening disease. This  is 
dependent on factors of the host, the vector and the parasite particularly the strain of 
Leishmania. Researchers found that in localised small CL lesions caused by L. 
braziliensis and L. major, Th1 cytokines IL-12 and IFN-γ appear to predominate. In 
more severe cutaneous infections IL-4 and IL-13 production have been detected 
(Bourreau et al. 2003). In peripheral blood mononuclear cells (PBMC’s) from patients 
cured from VL, both IL-12p40 and IFN-γ are upregulated in vitro upon stimulation 
with L. donovani. However, this is inhibited on addition of IL-10. PBMC’s from 
patients with active VL infections could not efficiently produce IL-12p40 or IFN-γ 
(Ghalib et al. 1995). Further to this, PBMC’s taken from patients with active 
cutaneous leishmaniasis lesions by L. major and those who had recovered 
demonstrated a Th1 cytokine profile after stimulation with Leishmania antigen (Ajdary 
et al. 2000). 
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The spectrum of disease is therefore determined, in part, by the immune response of 
the host in its development of a cell-mediated response and ability to mount a 
delayed type hypersensitivity reaction (Hogan et al. 2001;Weninger et al. 2001). This 
is utilised to test prior exposure to an antigen and, in this case, consists of a small 
quantity of crude Leishmania antigen injected intradermally (Vukmanovic-Stejic et al. 
2006) (Sassi et al. 1999). A positive response is indicated by an induration and 
swelling at the site of the injection within 24-72 hours which then dissipates (Tanaka 
et al. 2007). This reaction is dependent on the presence of memory CD4+ and CD8+ 
T cells and the secretion of IFN-γ (Pirmez et al. 1993) (Sun and Bevan 2003) 
(Lechner et al. 2007). Kemp et al performed a study in a village that was once 
endemic for cutaneous leishmaniasis in Sudan. They found that patients with a 
positive DTH included those that had been previously exposed to L. major infections 
and demonstrated a Th1 like response (Kemp et al. 1994) (Ben-áSalah et al. 2005).  
      A         B 
 
 
 
 
 
 
  
Figure 75: Clinical symptoms after a leishmanial infection are dependent on the 
host immune responses 
Photographs taken after two patients had both been bitten by an infected sand fly. 
Patient A developed a cutaneous lesion whereas Patient B presented with a healed 
lesion.  
 
To demonstrate how the immune response of the host can determine the nature of 
disease, Figure 75 illustrates photographs provided by Prof Sunil Shaunak. Two 
patients that had travelled together to the Mediterranean had both been bitten by an 
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infected sand fly. The two photographs illustrate cutaneous lesions taken at the same 
time before treatment commenced. On histological analysis of the tissue, Patient A 
had developed a dominant Th2 immune response with a lesion that was not healing. 
However, lesions from Patient B had healed rapidly without treatment and tissue 
sections revealed a predominating Th1 response. It must be noted that taking 
biopsies form healing lesions is controversial as there is growing evidence indicating 
that inflicting further injury to the site of infection could result in re-activation of the 
disease (Morgado et al. 2010).   
2.1.1.5 Immunotherapy 
Although current treatment of leishmaniasis is chemotherapy there is increasing 
research into alternative therapy involving modulating or enhancing the immune 
response. Utilisation of chemotherapy to effectively reduce parasite burden with an 
immunomodulator that can aid the generation of an appropriate immune response 
that can ensure eradication and sterile cure would be an attractive alternative to 
conventional therapy. However it should be noted that once differentiation of naïve T 
cells into either Th1 or Th2 phenotypes has been generated there is only a small 
window of opportunity to intervene. After this, the immune system appears locked 
into this response regardless of whether it is harmful for the host. Hence 
immunotherapies that attempt to induce Th1 differentiation are most effective during 
the initial phase of infection (>7 days) before an adaptive immune response has been 
irreversibly established (~10-21 days post infection) (Janeway et al. 2008).  
A topical immunomodulatory agent Imiquimod (R837) was approved by the United 
States Food and Drug Administration (FDA) in 1997 for the treatment of human 
papillomavirus (HPV) and in 2004 for treating actinic keratosis and appears to be well 
tolerated (Berman et al. 2009;Terlou et al. 2010;Winters et al. 2008). On investigation 
into its effects on cutaneous leishmaniasis, it has been shown to induce the 
activation of TLR 7 and TLR8 to stimulate IFN-γ, IL-12 and TNF-α production (Jurk et 
al. 2002;Zhang and Matlashewski 2008). It also appears to directly activate NOS2 
production to mediate killing of Leishmania parasites in the absence of primed T cells 
(Buates and Matlashewski 2001). Treatment alone with this formulation results in 
minor improvements of lesion with a high incidence of relapse. However, in 
combination with antimonial therapy has been shown to be effective and in one small 
study in Peru to accelerate healing and improve the quality of the resulting scar 
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(Arevalo et al. 2007;Miranda-Verastegui et al. 2009). Further larger clinical studies 
are needed.   
As described, IFN-γ is a necessary cytokine for clearance of the parasite and has 
been shown to be beneficial when administered with antimonial treatment (Badaro et 
al. 1990)  (Sundar et al. 1997). 93% of patients suffering from VL illustrated 
accelerated parasite clearance after 20 days of antimonial-IFN-γ treatment. This was 
compared to only 40 % cure with antimonial treatment alone (Sundar and Murray 
1995). This reduction in the duration of treatment was also observed in patients with 
Mediterranean VL. A small study of 8 patients in which low-dose IFN-γ was given 
with pentavalent antimonials for 19 days (instead of 31 days) resulted in 
parasitological cure with no major side-effects (van et al. 1993). Further to this, 
clinical healing was observed in patients with CL and MCL that were unresponsive to 
antimony treatment alone, when co-administered with IFN-γ and antimonials (Falcoff 
et al. 1994). Li and colleagues found that in susceptible BALB/c mice treatment of 
either sodium stibogluconate or IFN-γ over the same time period failed to induce 
cure. However upon co-administration, the infection had resolved indicating that IFN-
γ treatment alone is not enough to induce healing (Li et al. 1997). 
2.1.1.5.1 Vaccine 
Vaccination is an effective strategy in controlling and potentially eliminating an 
infectious disease. It is also cost-effective to health systems and accessible to the 
majority of people including those in rural-poverty stricken areas (WHO 2009) As 
previously described leishmaniasis is a neglected tropical disease and therefore 
would indisputably benefit from a vaccine that would generate life-long immunity. 
Moreover, it is clear that different Leishmania species differ with regard to their 
susceptibility to drugs and as symptoms can vary markedly between individuals due 
to the host defence system, it is becoming increasingly apparent that generating a 
vaccine may be a crucial development in combating the increasing incidence of 
disease. As yet there is still no effective human vaccine for cutaneous or visceral 
leishmaniasis(de Oliveira et al. 2009). 
The first attempts of vaccination evolved from the observation that patients with 
benign localised lesions of cutaneous leishmaniasis could heal spontaneously with 
life-long protection against re-infection and led to the development of 
leishmanisation. This consisted of subcutaneously injecting live Leishmania parasites 
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into an unseen area of the skin to produce a controlled lesion and has been believed 
to have been employed for hundreds of years in the middle-east and Russia. Over 2 
million people during the Iran-Iraq war were believed to be immunised. The immunity 
raised is essentially T-cell mediated and induces significant protection from re-
infection (Sassi et al. 1999). Although highly effective, safety issues in terms of cases 
developing chronic infections, lack of quality control, parasite persistence and ethical 
reasons has caused this type of vaccine to be abandoned by many countries whilst 
further, more standardised methods of leishmanisation are still being tested 
(Khamesipour et al. 2005;Tabbara et al. 2005). However, this first-generation vaccine 
based on killed autoclaved whole Leishmania spp., has shown poor efficacy in 
clinical trials and failed to induce protection against CL in Columbia (Noazin et al. 
2008;Velez et al. 2005). Recent investigations are more focused on developing 
second generation vaccines such as genetically modified parasites, using defined 
subunits or recombinant bacteria and viruses that express leishmanial antigens 
(Kedzierski et al. 2009). To this end, modifications did confer protection when 
autoclaved Leishmania spp. was administered with R848 or with a topical application 
of imiquimod on the skin. This protective immunity was limited to subcutaneous 
injection and was not observed on intramuscular vaccination (Zhang & Matlashewski 
2008). This variable efficacy was also noted by Bhowmick and colleagues whereby 
intraperitoneal and intravenous administration of L. donovani promastigote 
membrane antigens conferred protection against challenge, but not on subcutaneous 
or intramuscular injections (Bhowmick et al. 2009).    
As there are many Leishmania strains that are infective to humans, it would be ideal 
to identify surface antigens that are conserved in multiple strains and present in both 
promastigote and amastigote stages and also generate protective responses in the 
host. An antigen recently discovered that meets this criterion is the LACK antigen. It 
is a highly conserved 36-kD protein (p 36) that has been shown to be involved in 
stimulating T cells to produce Th2 cytokines in response to antigen presentation 
(Julia et al. 1996;Launois et al. 2007). Susceptible mice administered with LACK 
DNA vaccine demonstrated complete protection against non-healing infections of L. 
major. However, DNA vaccination is associated with mixed evidence in efficacy as a 
result of the route at which it is administered. Subcutaneous injection, in this case, 
was found to be effective, however on administration using a gene gun, a Th2 
response was raised and therefore failure of protection against re-infection. This 
observation may be dose-dependent (Gurunathan et al. 1997). However, a more 
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recent study determined that vaccination with LACK DNA gave rise to a strong Th1 
response both in vitro and in vivo, but failed to confer protection against secondary 
challenge (Melby et al. 2001). Further to this, work on evaluating the protective ability 
of a variety of different DNA vaccines including heat-killed L. major promastigotes 
(ALM), LACK and thiol-specific-antioxidant (TSA). It was found that the most effective 
in inducing protective immunity was that containing TSA (Mendez et al. 2001). This is 
a L. major protein that has homology to eukaryotic-thiol-specific-antioxidant proteins 
and was previously identified as enabling the host to generate protective responses 
(Campos-Neto et al. 2002;Webb et al. 1998). 
Bacillus Calmette-Guerin (BCG) has been researched as an adjuvant for vaccination 
of leishmaniasis resulting in some degree of protection. The benefits of using BCG 
are that it is safe to use with little severe side-effects. It therefore would appear to be 
a strong candidate in increasing the immunogenicity of a vaccine. However results 
into its benefit as an adjuvant are contradictory. Sharifi et al, demonstrated that a 
single dose of autoclaved L. major (ALM) and BCG was more immunogenic than 
BCG alone and induced protection against CL in children (Sharifi et al. 1998). 
Although Stefani and colleagues illustrated that high doses of either BCG or ALM 
gave rise to significantly less parasite burden upon secondary challenge and 
therefore no additional benefit was seen with administration of BCG (Stefani et al. 
1993). A more recent study illustrated inefficient immunity conferred using the 
vaccine consisting of ALM protein and BCG. Patients who were given the vaccine 
produced an insufficient Th1 response compared to those that had previous sub-
clinical infection and therefore were immunized from challenge (Mahmoodi et al. 
2003). However, a modified version of the vaccine involving the adsorption of 
aluminium hydroxide to L. major protein (alum-ALM) has given more promising 
results. Aluminium compounds are currently the only adjuvants used in human 
vaccines. Adjuvants aid in creating a more pronounced and prolonged immune 
response than that of the antigen alone. A small in vivo study involving 8 monkeys 
indicated efficacy of this modified vaccine against L. donovani infection and this was 
further validated by a larger in vivo study in Iran demonstrating 69.3 % efficacy in 
generating immunisation against canine leishmaniasis of a 447 cohort (Misra et al. 
2001;Mohebali et al. 2004). Furthermore, a phase II trial was conducted in 544 
healthy children with this alum-adsorbed ALM+BCG vaccine which conferred greater 
protection than that of ALM+BCG alone (Khalil et al. 2006).  
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2.1.1.6 Aims 
Optimisation of AmB-PMA synthesis had been achieved resulting in a water-soluble, 
non-toxic AmB-PMA formulation that could be reproducibly synthesised and was 
stable as a lyophilised powder over 9 months. This enabled the second aim of this 
thesis to be explored. This was to test the potential of AmB-PMA in vivo by using a 
murine mouse model and to determine the immunomodulatory effects, if any, that the 
drug induced. In vitro data described in Chapter 1 demonstrates that PMA-Na does 
not upregulate any immune response; however monocytes were stimulated to 
produce high levels of IFN-γ in the presence of AmB-PMA. This was of particular 
interest as the production of IFN-γ is imperative for the resolution of cutaneous 
leishmaniasis in both mice and humans. Investigations therefore consisted of 
determining and optimising the efficacy of AmB-PMA in vivo, and also evaluating the 
immunological profile of the infected treated mice compared to the infected untreated 
mice to identify whether the efficiency described in vitro can also been shown in vivo.    
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2.2 Materials and Methods  
2.2.1 In vivo studies 
2.2.1.1 Mice 
BALB/c mice were purchased from Charles River, UK and 6-8 week old females 
were used in all experiments. The animal colonies were screened regularly for 
mouse pathogens, and consistently tested negative.  Animal experiments were 
carried out with Dr I Mϋller in collaboration with Dr Matthew Rogers at the St Mary’s 
campus, Imperial College under Home Office Project Licence PPL70/6712. 
2.2.1.2 Isolation and maintenance of Leishmania parasites 
L. major LV39 (MRHO/SU/59/P-strain) parasites were maintained in a virulent state 
by monthly passage in mice. One infected BALB/c mouse was killed 2-4 weeks after 
infection by cervical dislocation and the infected footpad was removed under sterile 
conditions and placed in an eppendorf tube.  Single cell suspensions were prepared 
by gentle homogenisation of the footpad with a Tenbroeck tissue grinder (Fisher 
Scientific) in Dulbecco’s Modified Eagle’s Medium (DMEM. Gibco, Paisley UK) 
supplemented with 50 IU/ml penicillin and 50 µg/ml streptomycin. The cell 
suspension was transferred into a flask containing rabbit blood agar and cultured at 
26oC in a humid atmosphere containing 5% CO2 to allow transformation of 
intracellular amastigotes into motile promastigotes. After 3-5 days, the suspension 
was washed by centrifugation (5 min at 500 rpm) to pellet the debris.  The 
promastigotes in the supernatant were then washed (3500 rpm for 10 min) in DMEM. 
The pellet was resuspended in 5 ml DMEM and transferred into a new blood agar 
flask or they were maintained in liquid cultures supplemented with 10 % FCS.  Once 
isolated from an infected mouse, the parasites were maintained in vitro for a 
maximum of 4 weeks. 
2.2.1.3 Infection of mice 
L. major LV39 promastigotes were harvested from the stationary growth phase on 
the day of infection, washed three times and resuspended in PBS. They were then 
counted and 2 x 106 stationary phase promastigotes were injected subcutaneously 
(sc) into the left hind footpad in a final volume of 50 µl (day 0).  Each experimental 
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group contained 6 female BALB/c mice (Charles Rivers, 6-8 weeks old, approx. 20 
g).   
2.2.1.3.1 Blood agar 
Solid blood agar was prepared by autoclaving 3.0g nutrient agar (Difco) and 0.6g 
NaCl (Sigma) in 100ml nano-pure water for 20 min.  The mixture was cooled to 45oC 
in a pre-warmed water bath and 10 ml of rabbit or horse blood with 10 % sodium 
citrate (Merck) and 5 ml of a 30 % glucose solution (Sigma) was added.  Aliquots of 5 
ml of the agar mixture were distributed on the flat side of 25 cm2 polystyrene tissue 
culture flasks (Costar).  Once the agar mixture was solidified and cooled to room 
temperature, the flasks were tightly closed and kept at 4oC in a humid box (Neal 
1984). 
2.2.1.4 Preparation of AmB-PMA 
AmB-PMA was reconstituted immediately before injection at the required 
concentration in water then filter sterilised with a 0.2 µM filter and administered either 
via the peritoneum in 200 µl or subcutaneously in 50 µl into the infected footpad of 
the treated groups.  
2.2.1.5 Treatment Regimes  
Drug treatment was carried out via the peritoneum or subcutaneously into the 
infected left footpad of the mice with the indicated concentrations. The drug was 
administered at two different time-points:   
a) Early treatment of infections started on day 7 post infection.  At this time, the T cell 
response starts to polarise.  The treatment was terminated when the lesions of the 
untreated infected control group reached the severity limit of the project licence 
(maximal footpad lesion size of 7 mm). This limit was approximately 5 weeks after 
infection. A range of doses was tested with a total dose between 150 µg up to 500 µg 
AmB.  
b) Treatment of established lesions started when a clear swelling was visible at the 
site of parasite inoculation. This was usually between days 18-21 after infection and 
was followed by 3-4 injections of a total dose of either 400 or 500 µg AmB over a 
period of 7-10 days.  
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2.2.1.6 Determination of a delayed-type hypersensitivity reaction (DTH) 
Mice with an established lesion on their footpads and that were treated with AmB-
PMA as described, were monitored for a further 10-14 days after their lesions had 
healed to ensure that the resolution of the swelling was stable.  Approximately on day 
60 post infection, the contra-lateral footpad was infected subcutaneously with 2 x 106 
L. major promastigotes. Both footpads were monitored and the size of footpads 
recorded as described (section 2.2.1.7.1) for a total of 7 days at 24 h intervals. The 
presence of a DTH response was determined relative to the size of the footpads at 
the time of challenge.  At 24 h intervals, a mouse was sacrificed. 
2.2.1.7 Measurements during course of experiment 
2.2.1.7.1 Lesion development 
The size of the footpad lesions was measured, depending on the dosing schedule 
and at least once a week, before each injection using a vernier caliper. 
Measurements were taken from the top to bottom of the footpad and the lesion size 
was obtained by subtracting the value of the contralateral uninfected footpad from 
that of the infected footpad. On analysis, graphs were created using the mean ± SEM 
per group.   
2.2.1.7.2 Weight 
During optimisation of in vivo studies, the weight of the mice was recorded weekly. 
Loss of weight is indicative of adverse reactions and/or AmB-related toxicity and 
none of the drug doses tested resulted in weight loss.   
2.2.1.8 Analysis of in vivo studies 
2.2.1.8.1 Parasite Load  
Mice were culled by cervical dislocation and the area sprayed with 70 % ethanol 
before removal of the infected footpad under sterile conditions and placed in an 
eppendorf tube.  After the skin was removed the footpad was cut into smaller pieces 
before homogenisation using a metal sieve and single cell suspensions were 
prepared using a pestle in 2 ml of PBS. A 1/10 dilution in PBS was made before 
adding 10 µl to a haemocytometer and L. major parasites were counted. The total 
number of parasites/ ml was determined using the following calculation: 
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No. in count (9 squares) = 1(x104/ml x 2 ml = 2x104 parasites/ ml) 
2.2.1.8.2 Spleen 
Confirmation that the infection that took place in the mice was local and not systemic 
was required. On average, one spleen from each group of mice was harvested. The 
spleen was carefully removed and homogenised in 1 ml of Trisol using a motorised 
pellet pestle (Sigma Aldrich) and disposable sterile pestles (1.5 ml, VWR).  
2.2.1.8.3 Popliteal lymph nodes 
The lymph node draining the L. major infected footpad was removed by making an 
incision mid-way from behind the infected leg. Lymph nodes varied in size specifically 
between the untreated and treated groups, the latter noticeably smaller and therefore 
proved more difficult to extract. Lymph nodes were directly placed into Trisol (0.5 ml). 
Homogenisation of the lymph node was carried out using a motorised pellet pestle 
(Sigma Aldrich) and disposable sterile pestles (1.5 ml, VWR). 
2.2.1.8.4 Footpad lesions 
Footpad lesions were principally harvested for determination of parasite load. 
However, the remaining homogenate was centrifuged and re-suspended in Trisol. 
Optimisation of this technique involved pooling all 6 remaining lesion homogenates 
before centrifugation instead of keeping the remaining lesion homogenate separate 
and extracting the RNA individually. It was found that by pooling the homogenates, a 
higher yield of RNA could be extracted.  
Samples were stored at -20°C for at least 24 h before extraction of RNA. 
 
2.2.1.9 Measurement of cytokine and chemokine mRNAs from harvested 
mouse tissues 
2.2.1.9.1 Plasmid standards  
As previously described (Chapter 1, Materials and Methods), target nucleic acids can 
be quantified either by relative quantification or absolute. The former is most common 
to use and gives rise to a ratio between the quantities of target relative to the house 
keeping gene HPRT.  
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2.2.1.9.2 The generation of nominal copy numbers of mRNA 
Dr I Teo had created a multi-gene plasmid containing 2 housekeeping genes, β-actin 
and HPRT. A house keeping gene codes for proteins whose activities are essential 
for maintaining a functioning cell. This plasmid was used to create a standard curve 
so that quantification of the cDNA of the genes of interest was determined by 
interpolation of this curve which was performed using GraphPad Prism vs 5. In each 
PCR run a set of 8 HPRT standards was used to calculate the relative difference 
compared to the chemokines and cytokines of interest shown in Table 16. This 
generated nominal mRNA copy numbers of the specific primers used relative to 
HPRT. Mann-Whitney U tests were also performed on the normalised results to 
determine the significance of the data collected. The chemokines and cytokines 
tested and the primer sequences and conditions used are listed in Table 16. 
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Table 16: Mouse primer sequences 
Forward and reverses primer sequences of mouse chemokine and cytokines studied using quantitative rt- PCR. Primers created by    
myself, Debbie Harris and Ian Teo
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2.2.1.9.3 Generation of a plasmid to generate real mRNA copy numbers 
relative to HPRT for mouse in vivo samples 
During this thesis it became apparent that there was variability between PCR runs of 
the same samples using the same specific primers. It was essential to reduce this 
variability and in doing so Dr I Teo and Gabrielle Mroziewicz (MSc student) created a 
plasmid incorporating the target sequences of the chemokines and cytokines listed in 
Table 16. The method in generating this plasmid is summarised below.  
To construct a plasmid, PCR is used to amplify the desired target sequences which 
are then purified via gel electrophoresis on 2.5 % agarose gel. The bands can then 
be cut and cloned into a suitable vector e.g. pGAM TA or a TOPO vector. In this 
instance a multi-plasmid was created that contained 5 target sequences so to avoid 
the need to maintain and propagate 5 different plasmids. This would typically involve 
cutting individual plasmids to remove the target sequences and joining the 
sequences together by religating and re-cloning (Figure 76). This is a stepwise 
technique that is time consuming and can result in loss of material. Therefore an 
alternative strategy was employed. This is depicted in the diagram below. PCR 
products were repeatedly ligated and amplified before purification and ligation of the 
product into a vector. 
 
Figure 76: Schematic detailing two techniques of creating a plasmid 
The classical stepwise technique (shown in blue) and the alternative technique 
(shown in green) utilised to construct the mouse plasmid for rt-RT-PCR analysis. 
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The individual genes CCL-21, IFN-γ, IL-4, IL-10 and IL-12p40 were amplified via RT-
PCR and the amplified products were purified through S300 spin columns followed 
by separate kinase ligations to subsequently ligate together the genes in the 
following manner.  
1) CCL-21- IFN-γ, IL-4-IL-10 and IL10-IL12p40 
2) CCL-21-IFN-γ -IL-4-IL-10. 
Purification through S300 spin columns involved centrifugation through a Sephadex 
resin to desalt and hence purify the samples. The generation of the full length 
product involved carrying out an overlap PCR to ligate CCL-21- IFN-γ IL4-IL10 and 
IL-10-IL-12p40 using Gene AmP PCR system 9600, Perkin Elmer. Ten cycles of 
denaturation, hybridisation and extension took place before dilution and amplification 
by PCR. Agarose gel electrophoresis (2.5 % gel; 0.8 h; 80 volts) was used to check 
the success of the overlap reaction. This was then cloned into the plasmid vector 
pCR®4-TOPO® using a TOPO TA Cloning® Kit and competent E. coli DH5α cells 
(Invitrogen). On collection of positive colonies, the plasmid DNA was isolated from E. 
coli cells using a PureLink™ Quick Plasmid Miniprep Kit following the manufacturer’s 
instructions. Verification that the plasmid contained the sequences of the genes 
required was performed on an agarose gel (2.5 % gel; 0.8 h; 80 volts) before the 
positive colonies were sent for dideoxy sequencing (MRC DNA core facility). The 
sequence profile was read using a Chromas programme to generate the forward and 
reverse sequences for the plasmid. To align the individual clone sequences MultAlin 
(http://bioinfo.genotoul.fr/multalin/multalin.html) software was used. A BLAST search 
was used to align the plasmid sequences against mouse DNA 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).   
The generation of this plasmid enabled a standard curve to be generated specific to 
the primers used and then quantitative real copy numbers of mRNA relative to the 
housekeeping gene HPRT could be determined. This was carried out using Corbett 
RotorGene Software based on the exponential phase of the PCR reaction relative to 
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the standard curve generated using the plasmid containing primer sequence of the 
specific target. 
2.2.1.10 Histopathology 
Processing the paraffin blocks and staining were performed in collaboration with 
members of the histopathology lab; Pritesh Trivedi and Donna Horncastle at Imperial 
College Healthcare NHS trust, Hammersmith Hospital.  
2.2.1.10.1 Preparation of paraffin blocks 
2.2.1.10.1.1 Fixation of Tissue  
Footpads were extracted and cut into half (half used for parasite load) or remained 
whole. The skin was removed and the footpad cut into sections lengthways 
depending on its size. The sections were fixed in 10 % neutral buffered formalin (200 
x vol) for at least 20-24 h before processing.  
2.2.1.10.1.2 Decalcification treatment 
Before embedding into paraffin, the footpads were treated to de-calcify the bone by 
inserting into Gooding and Stewart’s Decalcification solution (10 % Formic Acid in 5 
% formalin). This treatment was over one or two days and the completed treatment 
was verified through end-point testing. This involved the removal of 5 ml of the decal 
solution onto litmus paper and the slow addition of ammonia until the litmus turned 
blue. 1 ml of saturated ammonium oxalate was then added and left for 30 min. At this 
point if there is a white precipitate that has formed then the tissue needs further 
decalcification as this indicates that ions are still present in the solution. Once no 
precipitate was formed, the tissue was removed and placed in formalin for paraffin 
processing. It was important not to carry out excessive de-calcification as this would 
cause damage to the cellular components of the tissue, affecting the subsequent 
quality of staining. 
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2.2.1.10.1.3 Embedding into Paraffin Block 
Paraffin wax is the medium of choice for embedding tissue as it is relatively cheap, 
safe to use and is easily used when cutting a wide range of tissue types. Embedding 
tissue permanently preserves samples that can be used later. A significant amount of 
water is still present within the sample on fixation with Formalin, which is immiscible 
with wax. Therefore a Vacuum Impregnation Processor series 5 (VIP, Tissue-Tek 
VIP, model 5E-F2) was used that employs gentle heat and pressure to remove water 
from tissue and replace with alcohol (industrial methylated spirit). This was then 
replaced by Xylene and then wax. This process is detailed in Table 17.   Once this 
had been completed, the paraffin wax processed tissue was embedded into paraffin 
wax blocks using the Tissue-Tek-Sakura embedding centre. Attention was required 
in choosing the appropriate sized mould for the tissue as this could affect the quality 
and ease of cutting the sections. There should be at least 1 mm space around the 
tissue in the mould. Consideration into the orientation of the sample should also be 
given as this will also impact on the sections cut. The selected mould was placed on 
a hot embedding plate and then approximately filled with molten wax. The tissue was 
then inserted into the mould and placed on a cold plate; where the tissue was gently 
pressed down to maintain its position as the wax hardened. It was then carefully 
topped up with wax without introduction of air bubbles. It was then left on the cold 
plate to harden for 20 min. 
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Solution Concentration 
(%) 
Time 
(Hours) 
Temp 
(oC) 
Pressure/Vacuum 
(P/V) 
Mix 
Formalin 10 1.3 37 On Slow 
Formalin 10 1.3 37 On Slow 
Alcohol 70 0.45 40 On Slow 
Alcohol 90 0.45 40 On Slow 
Alcohol 100 0.45 40 On Slow 
Alcohol 100 0.45 40 On Slow 
Alcohol 100 0.45 40 On Slow 
Xylene 100 0.45 40 On Slow 
Xylene 100 1.45 40 On Slow 
Xylene 100 1.3 40 On Slow 
Wax N/A 0.45 60 On Slow 
Wax N/A 0.45 60 On Slow 
Wax N/A 0.45 60 On Slow 
Wax N/A 0.45 60 On Slow 
Table 17: Process of preparing paraffin wax  
Preparation of paraffin wax for embedding processed tissue into a paraffin block. 
Table was extracted and modified from standard operating protocol (SOP) employed 
by Histopathology lab at Hammersmith Hospital. 
 
2.2.1.10.2 Cutting Sections 
Sections from the paraffin block were cut at 1 micron using a rotary microtome 
Olympus America inc. cut 4060, and were picked up on polysine microscope slides 
(VWR). These were then oven-dried before storing at room temperature. 
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2.2.1.10.3 Staining 
2.2.1.10.3.1 Pre-treatment 
Removal of paraffin wax was necessary to expose the tissue for staining. All sections 
that required staining were pre-treated via sequential treatment of 100 % Xylene, 100 
% ethanol, 70 % ethanol. Slides were introduced into each solvent for 1 min with 
agitation. Finally the slides were washed with tap water to remove residual solvent 
before addition of specific stains. Scott’s tap water was used as a substitute to tap 
water to prevent fluctuations in the pH during processing which would result in 
variations into the staining quality.  
2.2.1.10.3.2 Haematoxylin and Eosin Stain (H&E) 
Haematoxylin is a naturally occurring molecule extracted from the bark of a tropical 
log wood. It is an anionic molecule and therefore has no affinity for nucleic acids of 
cells and requires oxidation to haematin to become a nuclear stain. Hence, it is 
necessary to associate it with a metallic salt which will create a net positive charge 
due to the metal cation present. This results in a cationic metal-dye complex that is 
able to bind to anionic nuclear chromatin. Eosin is a xanthene dye and differentiation 
occurs initially on washing the slide with water and further still on washing through 
alcohol stages.  
A section that had been pre-treated was immersed in Harris’s haematoxylin for 10 
min before washing with tap water, followed by differentiation in 1 % acid alcohol for 
10 seconds. The section was then washed again with tap water before addition of 1 
% eosin stain for 5 min. Further washing with tap water (2 sec) is required before 
dehydrating, and mounting. Table 18 describes the colour of the cellular components 
that the dye stained.  
2.2.1.10.3.3 Periodic Acid-Schiff’s Stain (PAS) 
PAS stain contains Periodic acid which causes the oxidative cleavage of carbon-
carbon bonds in 1, 2-glycols to form dialdehydes. These are then able to react with 
fuchsin-sulphurous acid, which in turn combines with the alkaline pararosaniline to 
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form a magenta-coloured compound. Schiff’s reagent is an alkaline fuchsin solution 
that appears as a colourless solution due to the presence of sulphates. This reagent 
forms a similar compound to fuchsin in the presence of aldehyde groups, resulting in 
the production of purple (magenta). This colour is the end product of the PAS 
reaction.  
A section was washed with tap water before immersion in 1 % periodic acid for 5 min. 
This was followed by rinsing with distilled water and immersion in Schiff’s reagent for 
10 min. The section was then washed for 3 min under running tap water before the 
addition of Cole’s haematoxylin counterstain, dehydrating and mounting. Table 18 
describes the cellular components that are highlighted using this stain.   
2.2.1.10.3.4 Giemsa Stain 
This stain identifies eosinophils, basophils, neutrophils, chromatin cell granules in 
tissue sections. This dye consists of both acid (eosin a cationic protein that dyes 
pink) and an alkali (azure B (anionic DNA/RNA blue). The acid interacts with the 
alkali bound to certain cellular components to produce azure B-eosinate. To obtain 
the correct colour balance, the section is overstained with the Giemsa stain and then 
differentiated to achieve the metachromasia effect.  
The Giemsa stain was prepared by filtering the solution (Solmedia Laboratory 
supplies) using filter paper (Whatman, Grade 2). The section was immersed into the 
Giemsa solution for 2 h before blot drying the section using Postlip paper. It was then 
rapidly dehydrated and mounted as described. It is imperative that freshly diluted 
Giemsa solution is utilised as separation of the mixture of dyes occurs if left to stand.  
2.2.1.10.4 Dehydration of Stained Sections 
To prevent degradation of tissue the sections require dehydration. This is effectively 
the reversal of the pre-treatment process whereby the slide is rinsed in tap water and 
subsequently in 70 % alcohol, 100 % alcohol and twice with xlyene. This is to 
effectively remove water from the section to enable mounting of paraffin- embedded 
sections.  
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2.2.1.10.5 Mounting of Sections 
Addition of a drop of mounting medium is placed in the centre of the sections and a 
cover slip is added. Firm pressure was placed to remove air bubbles before the 
section was left to set. Once this had taken place the slide was stored at room 
temperature and could be permanently preserved. 
 
  H&E PAS Giemsa 
Nuclei Blue Blue   Blue  
Muscle Red -  - 
Collagen Pink  -  - 
Red blood cells Orange-Red - Red 
PAS +ve material - Magenta  - 
Leishmania - - Blue/Purple 
 
Table 18 : The cellular components highlighted by different stains 
Each stain used is tabulated to illustrate the cellular components that they highlight.  
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2.3 Results 
2.3.1 Part A: In vivo experiments 
Each in vivo study conducted was carried out using the techniques (parasite 
maintenance, infection, reconstitution and administration of the AmB-PMA) detailed 
in Materials and Methods. Different routes of administration and different times of 
drug administration were tested. Initially, the drug was administered via the 
peritoneum and intralesionally in the early phase of infection starting 2 days post 
inoculation and was used to assess the potential of AmB-PMA to control parasite 
growth in an infected host and to optimise the treatment regimen. Thereafter, the 
efficacy of the drug to resolve established disease and lesions was tested by the 
drug administration 21 days post infection. This was a more realistic assessment in 
terms of its potential for treatment of human leishmaniasis. 
2.3.1.1 Administration of AmB-PMA into mice 
In initial experiments in vivo, 5% dextrose was used to administer Fungizone 
intravenously as recommended by the manufacturer (Bristol-Myers Squibb). 
Consequently, batches of AmB-PMA were also administered in 5% dextrose. 
However, clinical grade 5% dextrose has a pH of 4.2.  This low pH could influence 
the state of aggregation of AmB within the AmB-PMA as seen in vitro (Chapter 1, 
Results part C). Therefore, there was the possibility that the carefully characterised 
batches were changing in the aggregation state of the AmB during their intravenous 
administration to animals. This could have contributed to reduced anti-leishmanial 
activity for L. donovani in vivo. Figure 77 shows that the AmB became more 
aggregated when it was present in 5% dextrose (increased OD at 325 nm). It was 
also found that solubilisation in 5 % dextrose gave rise to a higher RBC lysis ability 
as shown in Figure 78, which could be another contributing factor that was 
detrimental on administration intravenously. As a result, all further studies in the 
animal models were carried out by administering the AmB-PMA in water for injection. 
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Figure 77: Aggregation state of AmB in 5 % dextrose 
AmB-PMA was reconstituted at 1 mg/ml AmB in either water for injection or in 5 % 
dextrose. An aliquot with a final concentration of 10 µg/ml AmB was used to measure 
its UV spectra between 300-450 nm. AmB-PMA in water is shown in blue and AmB-
PMA in 5 % dextrose is shown in red.  
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 Figure 78: Haemolytic activity of AmB-PMA solubilised in 5 % dextrose or 
water  
AmB-PMA solubilised in either 5 % dextrose or water for injection were serially 
diluted and added to 2 % v/v solution of RBCs that had been taken from a healthy 
blood donor and separated via centrifugation.  After a one hour incubation, the 
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supernatant was removed to measure OD at 409 nm. The percentage of haemolysis 
of AmB-PMA was calculated using a 100 % positive reference of Triton X-100. AmB-
PMA solubilised in 5 % dextrose is shown in red, AmB-PMA solubilised in water for 
injection is shown in blue. Fungizone was also measured as a positive control and is 
shown in black (dashed line).  
 
2.3.1.1.1 Monitoring adverse side-effects 
As discussed, AmB is a toxic molecule known to produce a variety of side-effects on 
administration. Once introduced in vivo by the intravenous route, these side-effects 
are pronounced and typically result in seizures in the mice. Repetitive treatment with 
AmB results in renal failure and weight loss. The latter is a common indicator of 
adverse side effects presenting in the mouse. It was therefore pertinent to record the 
weight of the mice in all groups to assess whether the drug was producing adverse 
side-effects. As shown in Figure 79 the weight remained unchanged relative to the 
untreated infected mice over the duration of treatment.  
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Figure 79: Weight of mice during the course of treatment 
The average weight of L. major infected, untreated mice, shown in white and L. major 
infected, AmB-PMA treated mice, shown in black, over the course of treatment 
regimes.  
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2.3.1.2 Early treatment 
Preliminary experiments in the experimental mouse model of cutaneous 
leishmaniasis revealed the potential therapeutic effects of AmB-PMA in resolving 
lesions. The first in vivo experiment conducted for treating cutaneous leishmaniasis 
was found to have a 90 % inhibition of parasite growth and a reduction in lesion size 
of 94 % as compared to the infected untreated group. This experiment was 
conducted using a total of 6 injections of 50 µL administered subcutaneously into the 
footpad over a 3 week period using a batch with a loading of 40 % AmB.   The lesion 
development of L. major infected AmB-PMA-treated and untreated animals was 
monitored and organs were collected at day 35 post infection to evaluate the efficacy 
of the treatment. This preliminary data gave a starting point on which further 
experiments could be based to identify optimum parameters for the in vivo model. 
2.3.1.2.1 Optimisation 
2.3.1.2.1.1 Route of treatment 
Treatment of cutaneous leishmaniasis in an experimental mouse model is typically 
via the peritoneum or intra-lesionally. The route of choice is dependent on the half-life 
of the drug and its physico-chemical characteristics. Initially both routes were tested 
to evaluate which route of AmB-PMA administration was more effective. The dosing 
schedule that was established in preliminary experiments remained unchanged to 
limit variability. Lesions were measured weekly for a total of 37 days before 
harvesting the infected tissue. The untreated group were culled 30 days post 
infection due to the severity of the footpad lesions. Both routes of administration were 
found to be effective at reducing lesion development compared to the untreated mice 
(Figure 80 (a), p = 0.0043) with no significant difference in lesion reduction between 
the routes of administration on day of harvest. However, the group receiving the drug 
intra-peritoneally could be subdivided into two groups depending on their lesion size. 
Three mice had large lesions, suggesting that the drug had not had a lasting effect or 
had not reached the site of infection before its half-life. Three mice had no visible 
lesions indicating the treatment was successful. These findings correlated with the 
fact that 3 intralesional injections gave rise to a more significant reduction in parasite 
load in the infected footpad (Figure 80(b), 95.5 %, p= 0.0087) compared to 3 
injections into the peritoneum (Figure 80(b), 75.2 %, p=0.0260). All further in vivo 
experiments were conducted by intralesional administration.  
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The AmB-PMA was found to be not toxic on administration intraperitoneally and 
intralesionally, which confirmed previous findings of no toxicity during intravenous 
treatment.  What was also evident from this study was that both treatment groups 
appeared to have small lesions on the day of harvest (Figure 80a). This confirmed 
visual findings indicating that either more frequent dosing or a higher dose of AmB-
PMA was required to sustain healing. 
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Figure 80: Optimisation of route of treatment of AmB-PMA 
(a) Lesion development during the course of infection. Treatment of AmB-PMA via 
the intralesional route is shown in blue and intra-peritoneal route in purple (n= 6 mice 
per group).There was a significant reduction in lesion size of the infected footpads 
compared to the untreated footpads shown in black (triangles) (p = 0.0043). Each 
point represents the average lesion size of the 6 mice per group.  
(b) The parasite load within the footpad lesions of all three groups was determined on 
the day of sacrifice. In brief, 6 footpads from each group were individually harvested 
and homogenised through a metal sieve and viable amastigotes counted via 
microscopy. The reduction in parasite load was found to be more significant in the 
intralesionally treated group, shown in blue, compared to the intra-peritoneally 
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treated group shown in purple. Each bar represents the average parasite load for 
each group (n=6). The average parasite load of the untreated mice is shown in black. 
Mann Whitney U statistical analysis was used compared to the untreated control. ***= 
P < 0.002, **= P <0.01, *= P < 0.05, and ns = not significant. 
 
2.3.1.2.1.2 Use of Polymer 
As described in Chapter 2 Results Part A, both SB-GD-19 and HP-18 were found to 
have indistinguishable chemical and biological properties in vitro. It was concluded, 
after optimisation of the synthesis protocol, that tighter reproducibility could be 
maintained using HP-18 as a result of stringent manufacturing procedures that take 
place for the production of a commercial product. This was a significant change in the 
synthesis procedure which required thorough examination both in vitro (as described 
in Chapter 2, Part B and C) and in vivo.  This was to ensure that the change would 
not compromise treatment efficacy, as preliminary studies that were conducted in 
vivo were performed with a batch synthesised only with SB-GD-19 and indicated 
efficacy in treating cutaneous leishmaniasis intralesionally.  
An in vivo study was conducted whereby two days post infection, one group was 
treated intralesionally with AmB-PMA synthesised with HP-18 with a loading of 27 % 
AmB. Over four weeks 5 injections were administered intralesionally into the infected 
footpads providing a total dose of 500 µg AmB. The experiment terminated at day 35 
when the lesions of the infected but untreated controls had reached the severity limits 
of the project licence.  
The AmB-PMA treated group illustrated a lesion size reduction of 85.3 % compared 
to the infected, untreated controls where the lesions steadily increased over the 35 
days (Figure 81(a)). AmB-PMA was also efficacious in killing Leishmania parasites 
with a significant reduction in the parasite burden of the infected footpads (p= 0.0095, 
Figure 81(b)).  
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Figure 81 Effect of AmB-PMA synthesised with HP-18 on L. major infected mice 
(a) Lesion development during the course of the study. AmB-PMA synthesised with 
HP-18 polymer is shown in blue and the untreated group are shown in black (n=6 
mice per group). AmB-PMA treatment reduced lesion size by 85.3 % compared to 
the infected untreated controls. Each point is the average lesion size of 6 mice in the 
group. 
(b) Parasite load at the site of the lesion was determined by ex-vivo counting. In brief, 
6 footpads from each group were individually harvested and homogenised through a 
metal sieve and viable amastigotes counted via microscopy.The AmB-PMA 
synthesised with HP-18 treatment group is shown in blue and the infected untreated 
group shown in black. Each bar represents the average parasite load for each group 
(n=6).AmB-PMA treatment has significantly reduced the parasite burden within the 
footpads (p = 0.0095). Mann Whitney U statistical analyses were performed relative 
to the untreated control group shown in black. ***= P < 0.002, **= P <0.01, *= P < 
0.05, and ns = not significant. 
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2.3.1.2.1.3 Dosing Regimen 
2.3.1.2.1.3.1 Optimum Dose 
Both the route of administration and the type of AmB-PMA that was synthesised had 
been evaluated. This allowed focus on the optimal dosing schedule for AmB-PMA. 
On investigating a drug containing the toxic molecule AmB, it is ideal to have as little 
of AmB within the drug that will give rise to good efficacy and low toxicity in vivo. On 
evaluating findings of the treatment of visceral leishmaniasis in vivo, a total 
concentration of 300 µg AmB was used in the treatment of cutaneous leishmaniasis. 
As shown in Table 19, in vivo study 3 resulted in 94 % lesion reduction compared to 
the untreated animals. Studies 4 and 5 were conducted in an attempt to lower the 
total amount of AmB by altering the number of injections rather than the amount of 
AmB per injection which remained at 50 µg AmB. A total dose of 250 µg resulted in a 
reduction in lesion size of 97.7 % (Study 4a) however a total dose of 150 µg AmB 
(study 4b and 5) gave rise to a lesion reduction of 95.3 % and the other with a lesion 
reduction of only 74.3 %. This suggested that a threshold had been reached and to 
prevent this the dose was substantially increased to a total of 500 µg AmB (Study 6a, 
b and 7a, Table 19). This gave rise to efficacy previously seen (studies 3-5) of 
parasite inhibition in excess of 99 %. Study 7b was then conducted whereby 4 
injections totalling 400 µg AmB were administered. The result of which was 
indifferent to that of study 6 using a total of 500 µg AmB. Therefore focus was then 
applied to reducing number of injections by increasing the dose per injection. Dose 
per injection increased to 2.7 mg/ml AmB in study 8 so that only 3 injections were 
required to provide a total dose of 400 µg AmB.  
Through these studies described the number of injections was reduced by half whilst 
maintaining efficacy. The optimum total dose was found to be 400 µg AmB. 
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in vivo 
experiment 
Dose per 
injection 
(mg/ml) 
No. of 
Injection 
Volume per 
Injection 
(µL) 
Max Total 
Dose of 
AmB (µg) 
Total No. 
Treated 
Mice 
Average 
Parasite 
Inhibition 
(%)  
Average 
Lesion 
Reduction 
(%)  
3 1 6 50 300 6 99.81± 0.13 93.2± 1.5 
4 1 5 50 250 6 99.97± 0.02 97.1± 2.2 
  1 3 50 150 6 99.9± 0.09 94.7± 1.2 
5 
0.5             
1.25 
1               
2 
50 150 6 95.37± 4.0 75.5± 13.1 
6 2 5 50 500 6 99.81± 0.07 82.8± 4.7 
  2 5 50 500 6 99.95 ± 0.02  86.3± 2.4 
7 2 5 50 500 6 99.86± 0.07 84.3± 2.3 
  2 4 50 400 6 99.84± 0.11 87.3± 5.6 
8 2.7 3 50 400 24 99.73± 0.11 89.4± 4.0 
Table 19: Optimisation of the total dose of AmB for treatment using AmB-PMA 
A total of 6 in vivo studies were conducted to determine the optimum total dose of AmB within the AmB-PMA necessary for effective    
treatment of experimental CL. The number of injections was varied to adjust the final total dose of AmB administered. In turn, this also   
affected the dose per injection (mg/ml) that AmB-PMA is reconstituted at prior to administration. The average lesion reduction and parasite 
inhibition of the treated groups was calculated as a percentage compared to the untreated, infected control and is shown with the calculated 
standard deviation for each group (n=6 mice). 
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As a result of increasing the dose per individual injection, there was also the ability to further 
reduce the amount of injections required. On doubling the dose per injection, no adverse 
effects were observed, and with an increase to 133 µg AmB per injection, a total dose of 400 
µg AmB was administered providing a lesion reduction of 89.2 % and a 99.8 % inhibition of 
parasites (Study 8, Table 19). This was a biologically significant result. Figure 82 illustrates 
that within 6 in vivo studies, treatment of cutaneous leishmaniasis in the early phase of 
infection could result in healing by administering 400 µg AmB in only 3 injections weekly.    
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Figure 82: Overview of optimisation process in the aim of reducing number of 
injections of AmB-PMA and total dose of AmB administered in vivo 
Optimisation process to reduce the number of injections required for treatment. The first 
studies conducted were with frequent injections starting early on day 2 with a total dose of 
AmB between 150-300 µg AmB as shown by in vivo studies 3 and 4a. The study was 
conducted with only 3 injections starting later on day 7 (highlighted in blue). This gave rise to 
potent efficacy and was a more realistic strategy of treatment.   
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2.3.1.2.2 Commencement of Treatment 
Previous experiments had shown that AmB-PMA was effective when administered on day 2 
with the total number of injections ranging from 6 to 3 injections. An experiment was 
conducted to determine whether efficacy could be maintained if treatment started 7 days 
post infection. One group was treated 2 days post infection with a total of 5 injections and 
another group were treated starting 7 days post infection with a total dose of 4 injections 
over 4 weeks. The total dose of AmB in the latter group was reduced to 400 µg AmB due to 
the reduction of injections administered. Footpads were monitored and the lesions measured 
from day 14 weekly. On the day of sacrifice, one spleen from each group was collected and 
stored. The infected footpads and also their draining lymph nodes were harvested and 
processed to extract RNA. Before the harvest of material at day 35, both groups had shown 
a reduction in lesion size. Treatment that commenced on day 2 had a reduction of 84.1 % 
and on day 7 of 87.2 % compared to the infected untreated control group (Figure 83(a), p< 
0.05). There was no significant difference in reduction in lesion size between the treated 
groups. This finding reflected the calculated parasite burden load at day 35. A reduced 
parasite inhibition of 99.7 % (day 2) and 99.8 % (day 7) was found (Figure 83(b)). This 
showed that AmB-PMA was as effective (p=0.0009) when administered at 7 days post 
infection when the parasites had had 5 more days to multiply and establish an infection. The 
two separate batches of AmB-PMA synthesised with HP-18 effectively killed L. major 
parasites.   
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Figure 83: Comparison of the efficacy of AmB-PMA treatment started at different 
times after L. major infection 
(a) Lesion development during the course of the study. AmB-PMA treatment that started on 
day 2 is shown in purple (total dose of 500 µg AmB, n=6), and treatment that started on day 
7 is shown in blue (total dose of 400 µg AmB, n=6). Lesion reduction in both treatment 
groups were similar (84.1 %( day 2) and 82.7 % (day 7)) compared to the infected untreated 
group shown in black (n=6 mice). Each point is the average lesion size of 6 mice in the 
group. 
(b) Parasite load at the site of the lesion was determined by ex-vivo counting. AmB-PMA 
treatment on day 2 is shown in purple and treatment on day 7 is shown in blue. Both day 2 
and day 7 treatment groups had reduced parasite burden within the footpads compared to 
the untreated footpads shown in black (p=0.0044 and p=0.0009 respectively, n=6 
mice/group). Each bar represents the average parasite load for each group (n=6).Mann 
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Whitney U statistical analyses were performed relative to the untreated control group. ***= P 
< 0.002, **= P <0.01, *= P < 0.05, and ns = not significant. 
 
2.3.1.3 Course of Infection 
Once the dosing regimen was established a study was conducted to evaluate the parasite 
load and immunological features during the course of treatment as detailed in Figure 84. At 
each time-point (indicated by a red arrow, Figure 84) six mice were culled so that evaluation 
would be consistent with the previous in vivo studies. The lesions of the untreated mice 
increased as expected based on previous studies, and those of the AmB-PMA treated group 
ceased to develop (Figure 85 (a)). Figure 85(b) illustrates a 2 log reduction in parasite 
burden of the treated footpads after 2 doses of AmB-PMA (day 21). There is little change 
observed after the third treatment indicating yet further scope for healing to occur with fewer 
injections. It must be highlighted that on evaluating the course of disease the dosing regimen 
started on day 7, based on infection being present due to a one log increase in parasites. 
This point lead to the question of whether AmB-PMA could be administered after an 
established lesion is present. 
 
 
 
Figure 84: Schematic detailing the timeline of AmB-PMA early phase treatment 
The schematic illustrates the 3 treatment days; day 7, 14 and 21 shown in blue and the days 
that 6 mice were harvested indicated by a red arrow. Day 14, 6 mice that had been treated 
with one dose of AmB-PMA on day 7 were culled. Day 21, 6 mice that had been treated with 
two doses of AmB-PMA on days 7 and 14 were culled. Day 28, 6 mice that had been treated 
with three doses of AmB-PMA were culled. This was to evaluate the cumulative effects that 
each dose had on the lesion size, parasite load and also to generate an immunological 
profile through the course of disease. At each time point indicated by the red arrow, 6 
infected but untreated mice were culled so that a comparison could be made. 
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Figure 85: Effect of AmB-PMA during the course of an L. major infection 
(a) Lesion development during the course of the study. AmB-PMA treatment starting on day 
7 is shown in blue and the untreated group are shown in black. Treatment consisted of 3 
injections weekly for a total dose of 400 µg AmB. One week after each injection, the lesion 
size of the 6 mice in each group were measured. Each point is the average lesion size of 6 
mice.  
(b) Parasite load at the site of the lesion was determined by ex-vivo counting. AmB-PMA 
treatment starting on day 7 is shown in blue. After one treatment the parasite burden was 
reduced and this continued compared to the untreated footpads shown in black. One week 
after each injection, one group of six mice were culled and the footpads removed and 
homogenised in PBS to determine the parasite load via ex-vivo counting. Each bar 
represents the average parasite load for each group (n=6).  
 
Chapter 2 
Results Part A 
Karina D. Corware 
 
257 
 
2.3.1.4 Treatment of established cutaneous lesions  
The treatment of cutaneous leishmaniasis early after infection showed that AmB-PMA was 
efficient in restricting parasite growth and resolving the cutaneous lesions and it provided 
insight into its impact on the progression of disease over time. It was evident that by day 35, 
the lesions of the untreated mice were fully established, ulcerated and frequently had 
reached the lesion size limits imposed by the Home Office. There is a consistently noticeable 
difference in the lesion development and a pronounced reduction in parasite load of the 
treated mice in all 8 in vivo studies indicating the therapeutic potential of the AmB-PMA drug. 
These studies were necessary to prove that the drug could induce healing of cutaneous 
leishmaniasis in vivo.  
To determine whether AmB-PMA was also suitable for treatment of established cutaneous 
leishmaniasis, injections of the drug were started when an established lesion was present. 
After 21 days an untreated infected mouse has an inflamed nodule and swelling at the site of 
parasite inoculation which clearly shows the beginnings of a lesion emerging. A total of 3 
injections were administered over a week starting on days 21, 26 and 28 after infection 
(highlighted in blue, Figure 86 and the mice were monitored up until day 50 (indicated by red 
arrow, Figure 86).   
 
 
 
Figure 86: Schematic detailing the timeline of AmB-PMA treatment of established 
cutaneous leishmaniasis 
The schematic illustrates the 3 treatment days; day 21, 26 and 28 shown in blue and the 
days that mice were harvested indicated by a red arrow (n=16 treated and 6 untreated day 
51 and n= 6 treated at day 80).  
 
 
Chapter 2 
Results Part A 
Karina D. Corware 
 
258 
 
The parasite load present in the lesions of 4 infected mice was determined by ex-vivo 
counting on commencement of treatment on day 21. The remaining 3 groups were closely 
monitored and by day 32 there was a noticeable difference between the control and treated 
groups (average lesion size 1.55 mm and 0.85/0.7 mm respectively, Figure 87(a)). By day 
36, it was evident that the lesions of the treated groups were healing although, interestingly, 
during treatment (day 21-31), the lesion size continued to grow. It is at day 32 that the 
lesions again began to decrease. Importantly, lesions of the treated groups ceased to 
develop and at day 51, the lesions were, on average, below 0.5 mm, in stark contrast to the 
untreated groups that had lesions exceeding 3 mm in diameter (Figure 87(a)). This 
resolution of infection that had occurred was confirmed by more than a 3 log reduction of 
parasites counted in the treated footpads (Figure 87(b)).   
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Figure 87: Effect of AmB-PMA on an established lesion 
(a) Lesion development during the course of the study. AmB-PMA treatment started on day 
21 once an established infection had been determined through ex-vivo counting of four 
culled mice. A further two AmB-PMA injections on days 28 and 31 were administered to give 
a total dose of 400 µg AmB. Lesion size was monitored until day 51 when two of the three 
treatment groups were harvested (blue line). The untreated mice were also culled, shown in 
black. (n = 16 treated mice and 6 untreated mice.) Each point is the average lesion size of 6 
mice in the group.  
(b) Parasite load at the site of lesion determined by ex-vivo counting at day 51. AmB-PMA 
treatment is shown in blue and the untreated mice shown in black. Each bar represents the 
average parasite load for each group. Statistical analysis is based on 16 treated mice, and 6 
untreated controls. There was greater than a 3 log reduction in parasite load of the treated 
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mice (p<0.05). Mann Whitney U statistical analyses were performed relative to the untreated 
control group shown in black. ***= P < 0.002, **= P <0.01, *= P < 0.05, and ns = not 
significant. 
 
It should be noted that on day 51, there were 3 mice that appeared to have lesions re-
emerging. This was most noticeably in the parasite load in the lesion where only an average 
of one log reduction was calculated between the re-emerging lesions and the untreated mice 
(Figure 88). 
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Figure 88: Parasite load of re-emerging lesions after AmB-PMA treatment 
At day 50, 3 mice across three AmB-PMA treatment groups (n=6 mice/group, total dose 400 
µg AmB) presented with the appearance of a lesion at the original site of the infection. On 
homogenisation of the footpad and ex-vivo counting the parasite load was on average higher 
than that seen in the treated mice with healed lesions (one log instead of 3 log reduction), 
although it remained reduced compared to the control (p=0.0357). Each bar represents the 
average parasite load for the untreated group (n=6) and treated group (n=3). Mann Whitney 
U statistical analyses were performed relative to the untreated control group shown in black. 
***= P < 0.002, **= P <0.01, *= P < 0.05, and ns = not significant. 
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2.3.1.4.1 Prolonged healing 
To evaluate whether the treatment of established cutaneous lesions and disease was long-
lasting, 6 mice with healed lesions (Figure 87(a)) were maintained after day 51.  These were 
kept to evaluate whether relapse and re-emergence of the lesions would occur if no 
additional treatment was given. Lesion size was recorded weekly until day 80; over 51 days 
after the last injection of AmB-PMA (Figure 89) with no indication of a re-appearance of 
lesions and the footpad remained healed. Photographs were taken to visualise these 
findings. Figure 90 shows the contrast between a heavily infected untreated footpad taken at 
day 51 and treated, healed footpad at day 80.  
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Figure 89: AmB-PMA treatment of established lesion results in successful control of 
disease 
Lesion size of footpads treated with AmB-PMA (total dose of 400 µg AmB) after a lesion was 
established at day 21 post inoculation with L. major promastigotes (shown in blue). A further 
2 AmB-PMA injections over 5 days was administered and the lesion size was monitored until 
day 51 when two of the three treatment groups were harvested (blue line, n=12 mice). The 
final treated group of 6 mice were monitored until day 80 to determine whether AmB-PMA 
could promote long-term healing. Lesions in the treated mice did not re-emerge. Due to the 
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severity of the lesions on the untreated footpads, these were unable to be maintained up 
until day 80 (shown in black). Each point is the average lesion size of 6 mice in the group. 
 
 
 
Figure 90: Photographs of infected untreated footpad and an infected AmB-PMA 
treated footpad 
(a) Photograph of a heavily infected non-treated footpad. This footpad was harvested at day 
51 and is representative of 6 mice. It illustrates signs of inflammation as shown by red 
colouration and white areas indicative of pus forming beneath the skin. 
(b) Representative photograph of 6 footpads that had been infected with L. major 
promastigotes. The footpads were treated with AmB-PMA on day 21, 28 and 31 providing a 
total dose of (400 µg AmB). Treatment commenced on establishment of lesion as described 
(Figure 87(a)) and monitored until day 80.   
 
2.3.1.5 Delayed-type hypersensitivity response 
The in vivo experiments had shown that, after optimisation of total dose and frequency of 
injections, AmB-PMA could be administered intralesionally into the footpad and result in 
healing of both an early phase infection and that of an established lesion. For this to occur, 
speculation arose on whether the presence of AmB-PMA in the footpad had caused a shift in 
the immunological environment that aided the host to develop an appropriate immune 
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response. If so, would the host be then able to acquire immunity to future infections? To 
address these questions in vivo, we needed to determine whether mice that had healed their 
primary L. major infection in response to AmB-PMA treatment were able to mount a delayed-
type hypersensitivity response.  This involved the infection and treatment of mice (as per 
previous experiments) and monitoring of the healing process. After resolution of the 
cutaneous lesions, the contra-lateral footpad was infected with either antigen or L. major 
promastigotes and the local response at the site of challenge closely monitored. Usually a 
DTH is evident during the first 48 h post challenge by an induration and swelling at the site of 
infection that then disappears. This occurs only after activation and recruitment of memory T 
cells to the local site of antigenic challenge.    
A series of experiments were conducted involving treatment of mice with AmB-PMA on day 
21, 28 and 31 for a total AmB dose of 400 µg AmB. Mice were then monitored to determine 
prolonged healing. After which, on approximately day 61, the mice were challenged with 
2x106 L. major promastigotes into the contra-lateral (non-infected footpad) and the resulting 
DTH is shown in Figure 91(a). The contralateral footpads were measured and the data used 
as the baseline to determine the difference in inflammation. The footpads were monitored at 
24 h intervals to observe the kinetic of the response. After 24 h there was a marked rise in 
inflammation at the site of infection noted by a difference of 0.98 mm compared to the 
baseline measurements. Measurements returned to baseline after 72 h. This marked 
difference in lesion size illustrated in Figure 91 is indicative of a DTH response. The mice 
were monitored for a further five days to ensure no presence of a lesion. This DTH response 
was found in 12 mice that had resolved primary lesions.  
Another outcome was also generated during these studies.  In some infected mice treatment 
with AmB-PMA resulted in a decrease of the footpad lesions but not complete resolution of 
their lesions and healing. After treatment had finished, a group of eight mice with persisting 
lesions were monitored further and it was found the lesions re-emerged and did not resolve. 
Before challenge, the contralateral non-infected footpads were measured to determine the 
corresponding baseline. After challenge, all mice responded with an increase in footpad size 
illustrating the presence of an inflammatory response. However, mice with unresolved 
primary lesions were unable to resolve the swelling as illustrated by the persistent footpad 
swelling and visual presence of inflammation after 4 days (Figure 91(b)).  
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An overview of the DTH response in both instances is shown in Figure 92. The findings are 
noticeably different between the two responses when shown as the average size of the 
footpad. 
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Figure 91: DTH response in AmB-PMA treated mice 
(a) Individual data of a total of 12 mice from 2 separate experiments are shown in blue. Mice 
were treated with AmB-PMA once an established lesion had formed. This was confirmed by 
harvesting 4 untreated mice and determining the parasite load by ex-vivo counting. 
Treatment consisted of 3 injections over a maximum of 10 days with a total dose of 400 µg 
AmB administered intralesionally. The mice were then monitored until healing occurred. 
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Challenge with 2x106 L. major promastigotes into the contra-lateral footpad then took place 
and the lesion size recorded for a total of 8 days. Data shown is of mice that had a primary 
infection that resolved and developed a DTH upon challenge. Each point represents 
measurements of individual mice. 
(b) Individual data of a total of 8 mice from one experiment shown in black. Mice were 
treated with AmB-PMA once an established lesion had formed. This was confirmed by 
harvesting 4 untreated mice and determining the parasite load via ex-vivo counting. 
Treatment of 3 injections commenced over a maximum of 10 days with a total dose of 400 
µg AmB administered intralesionally. The mice were then monitored and although lesion size 
decreased, they then re-emerged once treatment ceased. Challenge with 2x106 L. major 
promastigotes into the contra-lateral footpad then took place and the lesion size recorded for 
a total of 4 days. Data shown is of mice that had a primary infection that did not resolve and 
did not develop a DTH upon challenge. Each point represents measurements of individual 
mice. 
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Figure 92: Responses of mice with resolved and persistent primary lesions to 
challenge with L. major promastigotes into the contra-lateral footpads  
Data shown is the average lesion size of mice that did and did not develop a DTH response. 
Mice that had an unresolved primary infection did not develop a DTH response upon 
challenge to their contra-lateral footpad (shown in black, n=8 mice). Mice that had resolved 
their primary infection did develop a DTH response upon challenge to their contra-lateral 
footpad (shown in blue, n=12 mice). Each point is the average lesion size in the group. 
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2.3.1.5.1 Re-emergence of lesions after AmB-PMA treatment 
As described when conducting the DTH response studies a relationship was established 
between resolution of infection after treatment with AmB-PMA and a positive DTH upon 
challenge. In this group of mice the lesion size was found to decrease during treatment with 
AmB-PMA (3 injections over a maximum of 10 days with a total of 400 µg AmB) although in 
all cases the lesions began to re-emerge as shown in Figure 93(a). It should be noted that 
treatment began on day 13 and took place over one week. Previous experiments had shown 
that commencement of AmB-PMA treatment of an established lesion occurred approximately 
at day 21. In this study, on visual findings, the lesions were more pronounced. This 
appeared to be an acceleration of the infection previously seen and this was reflected in the 
parasite load determined Figure 93(b). 
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Figure 93:  Accelerated infection and unresolved AmB-PMA treated lesions 
(a) Lesion size measured over the course of infection was measured in both untreated mice, 
shown in black, and treated shown in blue. This graph highlights the re-emergence of lesions 
by illustrating the data as a percentage of the untreated infected mice (n=8 treated mice and 
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n= 4 untreated). AmB-PMA was administered on presentation of an established lesion (day 
13). A total of 3 injections were administered with a total dose of 400 µg AmB. Each point is 
the average lesion size of 6 mice in the group. 
(b) The parasite load is shown and was determined by ex-vivo counting of parasites in the 
footpad homogenates. Previous experimental data is shown in black to illustrate the 
difference in infection progression (untreated mice shown as a dashed line with black 
triangle, and treated mice shown with a solid line and open square). A red dashed line 
represents 4 untreated mice with an accelerated lesion forming. The AmB-PMA treated mice 
with unresolved lesions is shown in blue (n=8). Each point is the average parasite load of 6 
mice in the group. 
 
2.3.1.6 Summary of the efficacy of AmB-PMA in vivo 
The in vivo studies demonstrate the potential of AmB-PMA to be a promising treatment for 
cutaneous leishmaniasis. In both tested treatment regimens, early after infection and at the 
time of established lesions, there was consistency in reducing lesion size and alleviating 
parasite burden in the infected footpad. There was no evidence of adverse toxicities due to 
the presence of the AmB, verifying in vitro data of successfully creating AmB-PMA using HP-
18.  
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2.3.2 Part B: Analysis of the impact of treatment of CL with AmB-PMA on the 
chemokine and cytokine profile in vivo 
2.3.2.1 RNA Extraction 
All RNA extractions were performed as described in Materials and Methods (Chapter 2). 
Both lymph node and spleen extraction resulted in consistently high yields of RNA for 
generation of complementary DNA. However, there were difficulties in extracting a high yield 
from the footpads harvested. The RNA extracted from the footpad homogenates collected 
from the studies conducted varied substantially from no retrieval of RNA to generation of 
high copies of mRNA. This was mainly due to the method of harvesting. As lymph nodes 
were not required for any other experiments, these were harvested straight into Trisol, 
maximising RNA retrieval. However, footpads were principally used for determination of 
parasite load and therefore were homogenised in PBS and were not introduced into Trisol 
for at least 3 hours post removal from the mouse. To maximise RNA retrieval, it is best to 
introduce the sample tissue into Trisol as soon as possible after removal from the mouse as 
this will instantly preserve the RNA. Loss of RNA also occurred during homogenisation due 
to shearing of the cells and therefore rupturing of cell content. This was inevitable in 
harvesting of all tissue material, however both lymph nodes and spleens were homogenised 
directly in Trisol considerably limiting RNA loss due to this technique. This would have 
impacted more on the yield of the footpads due to the fact that homogenisation had to take 
place in PBS to allow for ex-vivo counting of the parasites.  
2.3.2.2 Polymerase chain reaction (PCR) 
Polymerase chain reaction technique uses DNA polymerase to replicate millions of copies of 
small amounts of template DNA. This is performed using DNA polymerase with the most 
commonly used being Taq polymerase. This is an enzyme that was first extracted from the 
thermophilic bacteria Thermus aquaticus, and is now genetically engineered as it has a 
unique ability to maintain activation and is thermostable at high temperatures and therefore 
does not denature. The process of PCR involves firstly denaturation of the target DNA by 
heating to 95°C. This effectively breaks the hydrogen bonds and unwinds the DNA double 
helix into single stranded templates. The temperature is then lowered to approximately 55°C 
to allow for binding of primers to the complementary sequences of the single-stranded DNA 
templates. The temperature then rises to 60-75°C as DNA polymerase reads the nucleic 
acid sequence and produces a strand of DNA resulting in 2 newly generated double-
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stranded DNA molecules. This cycle of hot and cold temperatures allows for denaturation 
and re-annealing of DNA with DNA polymerase adding new complementary strands each 
time. A cycle is repeated every couple of minutes, each time doubling the DNA of interest 
per cycle, which in turn, increases the copies of DNA exponentially to create millions of 
copies of the original target DNA strand. If the process started with a single DNA molecule, 
after 30 cycles of the described process of PCR, more than 1 billion copies of double 
stranded DNA would be generated.  
2.3.2.2.1 Conventional PCR vs Real-Time PCR 
Typically a PCR reaction would be carried out in a thermo cycler whereby the multiple 
temperature changes could be controlled. The resulting amplified products would then be 
analysed using gel electrophoresis and detected using an ethidium bromide stain. A typical 
PCR run can be broken into 3 phases; Exponential phase whereby there is exact doubling of 
DNA amplified per cycle (assuming 100 % efficiency), Linear phase whereby the reaction 
reagents are beginning to be consumed resulting in a slower reaction and a plateau phase 
whereby the reaction has stopped as reagents have been used and the PCR products begin 
to degrade. Whereas the amplification of the product in the exponential phase occurs in a 
very precise manner, the latter 2 phases can occur at different rates for each replicate of the 
same sample due to the individual kinetics of each reaction. This is a limiting factor when 
using conventional PCR that can only detect the end-point of the PCR reaction when the 
reaction has plateaued. The amplified products yielded at the end-point of the reaction are 
then analysed using an agarose gel based on size discrimination that has a resolution of 
approximately 10 fold. Real-time PCR can detect as the reaction is occurring and therefore 
can measure the kinetics of the reaction in the early phase at the optimum exponential 
phase. This technique is also more sensitive as it is able to differentiate between subtle 2 
fold changes of amplified products between samples. Moreover, the output of an agarose gel 
does not yield real numbers and as ethidium bromide staining is not very effective for 
quantitation of products, it is difficult to produce conclusive findings without further 
techniques being applied. 
Real-time PCR is a novel technique utilising an optical sensing system whereby fluorescent 
probes are utilised to allow direct quantitation of the amplified products, eliminating the 
additional requirement of gel electrophoresis. The increasing amount of amplified DNA is 
recorded and can be viewed graphically as the increasing excitation of light over the number 
of cycles. In this thesis, Sybr green fluorescence was used that specifically binds to the 
minor groove of only double-stranded DNA. It can therefore bind to newly synthesised 
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copies of DNA and the fluorescence increases as the dye binds to the increasingly 
synthesised copies of DNA per cycle. To ensure that the correct DNA fragments of interest 
have been amplified to yield quantitation, a melting curve of the amplified products is also 
carried out at the end of each PCR run. The melting temperature is dependent on the base 
composition of the amplified product and should have the same melting temperature to the 
primer pair that was introduced at the start of the reaction. Sybr green does not distinguish 
between one strand of DNA and the other, so this is a useful check to verify that all samples 
have a similar melting temperature. At the melting point, the DNA double strands will 
separate and in turn the fluorescence will rapidly fall. This results in a graph of the rate of 
change of fluorescence with time with a peak at the melting point. Primer dimers occur 
occasionally due to the annealing of themselves creating small templates of DNA that can be 
amplified. The presence of primer dimers are clearly identifiable on a melting curve as it 
would give rise to a peak at a lower melting temperature due to the shorter strand of DNA. 
2.3.2.2.2 Reverse transcription PCR (RT-PCR) 
RNA extracted from tissue samples required the use of enzyme reverse transcriptase to 
generate complementary DNA (cDNA). This was carried out using the Reverse 
Transcriptase Qiagen kit as described in materials and methods. By using this technique, the 
mRNA that is expressed from a cell can be measured aiding evaluating the immune 
responses to specific stimuli.  
2.3.2.2.3 Use of Fluorescent probes 
Sybr Green jumpstart mix (Sigma Aldrich) was used as the standard for all real-time RT-
PCR reactions. However, it was noticeable that there was occasional batch-to-batch 
variability in the intensity of the sybr green fluorescence recorded. In these instances, Sybr 
Gold would also be added to the reaction mixture and quantitation using both fluorescent 
probes would be used so that the calculations were performed using optimum parameters. 
On exclusion of these instances, there was no difference between the quantitation of either 
fluorescent probe verifying that no additional variability was introduced by utilising Sybr gold.  
2.3.2.2.4 Reproducibility of real-time RT-PCR 
To maintain tight reproducibility, each sample was individually aliquoted into freshly made 
PCR mixture in triplicates. mRNA levels of chemokine and cytokine levels that were of 
interest were measured by calculating the nominal copies relative to copies of HPRT to 
correct for minor differences in input RNA quality and the efficiency of synthesising cDNA. 
On evaluation of the reproducibility between two runs of the same sample, it was found that 
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there were discrepancies. On closer examination of the raw copies generated from the real-
time RotorGene software, there were 100 fold differences, however the fold increases within 
each run remained consistent and the variation of numbers appeared to be due to a shift as 
a result of normalising against HPRT. The solution was to create a plasmid with the desired 
chemokines and cytokines of interest so to generate absolute copy numbers relative to 
HRPT. On re-performance of the RT-PCR using MIP-1β primers on a plasmid, there was 
greater consistency between runs as shown in Table 20.  On the creation of the plasmid, 
one of the variables associated with RT-PCR was avoided whilst enabling the generation of 
absolute (real) copies of mRNA of the chemokine or cytokine of interest relative to HPRT.  
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Table 20: Reproducibilty of real-time RT-PCR 
The differences recorded between runs on generation of nominal copies of MIP-1β relative 
to HPRT and absolute copies of MIP-1β expression. 
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2.3.2.2.4.1 Verification of amplified product  
The plasmid that was synthesised was sequenced and ran on an agarose gel to ensure that 
the overlap reaction of the primers had taken place. This was verified by the presence of 2 
bands representative of 2 differing dilutions at approximately 850 bp.  
100
200
300
400
500
600
800
1000
Lane 1: 100bp marker 
Lane 2: CCL21-IFNγ-IL-4-IL-10-IL-12 1/1000 dilution 
Lane 3: CCL21-IFNγ-IL-4-IL-10-IL-12 1/5000 dilution
1                2               3
(bp)
 
 
Figure 94: Verification of plasmid via gel electrophoresis 
Verification that the plasmid contained the primer sequences of the genes selected was 
performed on an agarose gel as described in Materials and Methods Chapter 2. In brief an 
agarose gel was created (2.5% gel; 0.8 h; 80 volts) before the positive colonies were sent for 
dideoxy sequencing (MRC DNA core facility). The sequence profile was read using a 
Chromas programme to generate the forward and reverse sequences for the plasmid 
(Appendix). 
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2.3.2.3 Early treatment of L. major infections 
Real-time RT-PCR was carried out to determine the immunological processes that were 
occurring in mice treated early after infection with virulent L. major promastigotes and in age-
matched infected but untreated control mice. The infected footpad was harvested as was the 
draining lymph node and also the spleen. The action of the AmB-PMA, if effective, would be 
clear at this time point. The harvested material was then processed (Materials and Methods) 
into cDNA so to evaluate the chemokine and cytokine levels present. During the optimisation 
process of the early treatment model, there was uncertainty into which chemokine and 
cytokines should be analysed.  As outlined in the introduction cytokines and chemokines that 
had been shown in the literature to be important in maintaining infection or aiding healing 
were studied. After the first analysis of in vivo data, focus was directed to those chemokines 
and cytokines that illustrated interesting effects and also the most relevant in the study of 
leishmanial infection. 
2.3.2.3.1 Optimisation 
2.3.2.3.1.1 Use of polymer HP-18  
In this experiment, spleens were processed separately to verify that the disease was not 
systemic in mice and the lymph nodes draining from the infected legs were harvested 
individually. Footpads were homogenised also individually to determine the parasite load 
and the remaining supernatant introduced into Trisol for mRNA analysis. On conducting RT-
PCR, the footpad samples did not yield any product which might have been the result of 
individual homogenisation. The overall analysis of mRNA data indicates a significant 
reduction in the chemokine and cytokine levels studies after treatment (Figure 95). As 
described, both the lesion size and the parasite load of the AmB-PMA treated group had 
dramatically decreased, indicating that the infection had resolved (Figure 72(a, b 
respectively). MIP-1β was significantly down regulated at day 35 in the treatment group (p= 
0.0005, Figure 95(a)). Both TNF-α and IL-4 production was not significantly different to that 
of the infected, untreated footpads (Figure 95(b, e respectively)). However both IL-10 
(p<0.0001, Figure 95(c)), IFN-γ (p<0.0001, Figure 95(d)) and to a lesser extent IL-12p40 
(p=0.0362, Figure 95(f)) were all significantly downregulated on treatment with AmB-PMA 
synthesised with HP-18.  
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The data of this study was re-analysed using the plasmid and is illustrated in Figure 96. MIP-
1β was significantly downregulated in the lymph nodes of the mice treated with AmB-PMA 
(Figure 96(a), p<0.0001) and this trend was echoed by IL-10 expression that also was 
significantly reduced (Figure 96(c), p=0.0236). IL-4 mRNA expression was close to the limit 
of detection of the PCR machine meaning that fewer data points were collected (Figure 
96(e)). This also was the case for IL-6, and in this instance, no statistical analysis was 
performed (Figure 96(f)). TNF-α interestingly was significantly reduced in the treatment 
group (p=0.0003, Figure 96(b)) however, IFN-γ mRNA expression exhibited no significant 
change compared to the untreated control group.  
In general both data sets illustrate similar trends; however it is noticeable that the normalised 
copies of mRNA have higher values than that of the copies generated via real quantitation 
using the plasmid. Due to the success of the treatment in both preparations there was a 
general trend of reduced levels of both chemokines and cytokines.   
2.3.2.3.1.2 Commencement of treatment 
The success of treatment using AmB-PMA promoted the idea of starting treatment later on 
day 7 instead of day 2 to evaluate the potential of the AmB-PMA as a drug treatment. In this 
study, the lymph nodes of the untreated group were large as expected. The draining lymph 
nodes from the group that received treatment starting 2 day after infection were smaller than 
those from the group of mice that received treatment starting 7 days after infection and were 
easier to find and hence extract. Lymph nodes from naïve BALB/c mice were also harvested 
during the course of this study to identify the levels of the chemokines and cytokines that 
were being looked at when neither an infection nor treatment was occurring in the mouse. 
The aim was to gain a greater insight into the fluctuations of mRNA levels found in the 
different treatment groups. 500 ng of RNA was used to generate cDNA and real-time PCR 
was conducted firstly by calculating nominal copies of mRNA relative to HPRT, before re-
analysis to generate real quantification as shown in Figure 97.   
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mRNA copies of TNF-α levels were significantly raised in the day 7 treatment group, 
whereas the day 2 showed no change relative to the untreated control (Figure 97(b), 
p<0.0001 and p=0.3758 respectively). However, both treatment groups showed reduced 
IFN-γ mRNA levels relative to the untreated group (Figure 97(d), day 2 p<0.0001 and day 7 
p = 0.0035). IL-12p40 was also detected and found that there was no upregulation in the day 
7 but a significant rise in the day 2 regime (Figure 97(f), p=0.4794 and p=0.0011 
respectively). No change occurred on analysis of mRNA of IL-4 (Figure 97(e), however there 
was decreased mRNA production of IL-10 in both treatment groups (Figure 97(c), day 2 
p=0.0004 and day 7 p=0.0036). 
2.3.2.4 Monitoring cytokine and chemokine expression in L. major infected mice 
during the drug treatment and progressive disease 
It appeared crucial to conduct a study whereby one could investigate into the immunological 
responses of infected and treated mice. This entailed sacrificing groups of mice at specific 
time-point during the 35 day experiment and harvesting tissue for mRNA analysis (Figure 
98). Both the footpad tissue and draining lymph nodes were processed and RNA was 
sufficiently extracted from all samples to yield RT-PCR product that was quantifiable. 
2.3.2.4.1 Cytokine and chemokine expression levels in the lymph node draining the 
local site of L. major infection 
Over the course of treatment MIP-1β expression is consistently and significantly upregulated 
in the L. major infected untreated group, (Figure 98(a), p<0.0001) which steadily increased 
over the three weeks. TNF-α expression of the untreated group failed to be upregulated 
compared to the AmB-PMA treated group (Figure 98(b)). More interestingly, TNF-α sharply 
increases between days 21 and 28 after 2 administered doses in the treated infected mice. 
This peak is mirrored by a slight increase in IFN-γ production that occurs only after day 21 
(Figure 98(d)), however this is present in both treated and untreated groups. IL-12p40 was 
measured but did not significantly change in both treated and untreated groups during the 
course of infection. IL-10 interestingly increased in both treated and untreated groups over 
the course of infection, however, in the treated group, IL-10 was significantly decreased at 
day 21 (Figure 98(c), p<0.0001). Noticeably this decrease is at the same time-point as a 
decrease in IFN-γ expression. 
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2.3.2.4.2 Cytokine and chemokine expression levels at the site of lesion 
Footpad homogenate was harvested and the data collected illustrated in Figure 99. 
Expression of MIP-1β in both untreated and treated groups was consistently low until day 28 
where greater than a fold increase is observed in the untreated footpads. Expression in the 
AmB-PMA treated footpads however remains low (Figure 99(a)). IL-10 illustrates a similar 
pattern, whereby the expression in both groups appears unchanged until day 28, when there 
is a rise in mRNA expression in the untreated footpads (Figure 99(c)). More activity in the 
treated group has occurred in the TNF-α and IFN-γ expression. TNF-α is detected at high 
levels compared to the untreated early on in treatment on days 14 and 21 which later falls by 
day 28 (Figure 99(b). A 6-fold increase of IFN-γ expression was detected on day 14 and 
maintained until day 21. However, it was below the limit of detection by day 28 (Figure 
99(d)). Statistical analysis was limited due to the low yield of mRNA expression in the 
untreated group.  
2.3.2.5 Summary of the data obtained in the model of early treatment of L. major 
infection 
Data that was generated through the optimisation process i.e. the use of HP-18 as the 
polymer for AmB-PMA synthesis and commencement of treatment on day 7 were pooled to 
obtain data representing mRNA expression at day 35. This was then added to the course of 
disease data to generate one graph that represents mRNA levels of each chemokine and 
cytokine analysed. As shown in Figure 100, this data demonstrated an overview of the 
trends of mRNA expression of time of both treated and untreated groups in the draining 
lymph nodes (bottom section of graphs) and at the site of lesion, the footpads (top section of 
graphs). As described, the RNA retrieval from the footpad homogenates varied and therefore 
did impact on the results obtained from the real-time RT-PCR reactions, most noticeably in 
the generation of low copies of amplified product.  
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Despite this limitation, the footpad data that was collected did result in significant differences 
between the infected treated and untreated footpads, most noticeably in the expression of 
IFN-γ in the treated footpads that was recorded at a greater level than the untreated and 
furthermore rose by day 35 (Figure 100(d), p<0.0001). MIP-1β appeared not to change in 
the treated footpads over 35 days in comparison to the untreated which steeply increased 
after day 21 to a peak of 1.5x106 mRNA copies/ 105 HPRT (Figure 100(a)). TNF-α 
expression slowly increased in the untreated group with only a 2 fold increase in mRNA 
expression levels over 14 days. TNF-α was measured at significantly higher levels in the 
treated group than in the untreated group after one dose of AmB-PMA (Figure 100(b)). 
These fall sharply a week after the 3rd injection. IL-10 was also measured at high levels in 
both the infected non-treated and treated footpad on day 14, the latter of which, most 
interestingly fell back to basal levels sharply by day 28, a week earlier than the untreated 
group. IL-10 expression in the treated footpads was unchanged at day 35 (Figure 100(c)).  
On review of this data it appeared pertinent to investigate whether iNOS and IL-2 mRNA 
expression alters over the course of infection. As IFN-γ can activate infected macrophages 
to kill parasites via iNOS enzyme, iNOS primer sequences were synthesised and data was 
compiled as nominal copies relative to HPRT. This data also revealed the most noticeable 
changes occurring at the site of infection in the lesion. Both untreated and treated groups 
were shown to express high mRNA levels of iNOS. However, in the infected untreated group 
this rapidly decreased as the disease progressed between days 21 and 35 (Figure 100(e)). 
iNOS expression in the treated group appeared to be sustained until day 28 before falling to 
levels equivalent to those of the untreated group. No significant changes took place in iNOS 
mRNA expression in the lymph node draining the infected foot, except an early rise in the 
treated group at day 28. IL-2 primer sequences were also generated however, even after 
optimisation, no PCR product was generated. 
On analysis of these graphs, it is clear that more subtle changes in mRNA expression 
occurred in the draining lymph nodes and the changes that occur at the local site of 
pathology and parasite growth in the footpads appears to be more substantial.  
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2.3.2.6 Treatment of an established cutaneous lesion 
On the success of early AmB-PMA treatment in resolution of lesions and reduction of 
parasite load, investigations began in assessing the ability to resolve infections that were 
more established. AmB-PMA treatment of an established lesion only commenced after 
harvesting four untreated infected mice and calculating the parasite load via ex-vivo 
counting. The experiment then commenced, typically around day 21, and terminated on day 
51, when 16 of the 19 mice were found to have healed lesions shown in Figure 101. The 
remaining 3 mice had lesions that appeared to be re-emerging indicated by both lesion size 
and parasite load (Figure 88). Therefore the lymph nodes of these mice were also analysed 
and data compiled to identify any variability in chemokine and cytokine levels. 
Mice that presented a healed footpad upon treatment with AmB-PMA had a noticeable 
increase in TNF-α mRNA levels compared to the untreated controls (Figure 101(b), 
p=0.0002). MIP-1β and IL-10 both had decreased significantly as well as IFN-γ compared to 
the untreated L. major infected controls (Figure 101(a, c and d respectively, p<0.0001). IL-
12p40 was below limit of detection and therefore not graphically represented.   
The mice that showed signs of re-emerging infection illustrated no significant differences 
compared to the treated healed lesion group in MIP-1β, TNF-α and IL-10 expression. 
However, IFN-γ was significantly decreased in the lesions that were re-emerging than those 
that had healed (Figure 101(d), p=0.0170).    
The footpads were also collected and individually homogenised through a metal sieve in 2 
mL of PBS before centrifugation and addition of Trisol. Values of RNA varied and in some 
instances were very low in the treated groups. The control infected untreated footpads 
showed high levels of MIP-1β and TNF-α compared to the treated footpad homogenates that 
had significantly lower mRNA expression (Figure 102(a, b, p<0.0001).  IFN-γ levels in the 
treated footpads at day 51 were significantly elevated (p<0.0001) as well as those of IL-10. 
However, it should be noted that IL-10 copy values were difficult to interpret. Data from the 
footpad homogenate of the mice with re-emerging lesions was at the limit of detection and 
therefore could not be graphically represented. 
 
Figure 101: Comparison of mRNA expression in the lymph nodes draining the L. 
major infected footpads that were extracted at day 51 subdivided into two groups 
depending on the presence of lesion
AmB-PMA treatment started on day 21 once an established L. major infection had been 
determined through ex-vivo counting of four sacrificed mice. A further two AmB-PMA injec-
tions on days 28 and 31 was administered to give a total dose of 400 µg AmB. Lesion size 
was monitored until day 51. The lymph nodes were extracted from the infected leg and in-
serted directly into Trisol before individual homogenisation and RNA extraction. Graph il-
lustrates mRNA expression from the draining lymph nodes of MIP-1β (a), TNF-α (b), IL-10 
(c) and IFN-γ (d). Untreated mice are shown in black (triangles), treated mice with healed 
lesions are shown in blue (squares) and mice with re-emerging lesions shown in purple 
(squares). Each point represents individual triplicates from PCR runs. Mann Whitney U 
statistical analyses were performed relative to the untreated control group shown in black. 
***= P < 0.002, **= P <0.01, *= P < 0.05, and ns = not significant. (n = 16 L. major infected, 
AmB-PMA treated healed mice, 3 AmB-PMA treated mice with re-emerging lesions and 6 
infected, untreated mice.) 
Figure 102: Comparison of mRNA expression at the site of the lesion in the foot-
pads of L. major untreated and AmB-PMA treated mice extracted at day 51
AmB-PMA treatment started on day 21 once an established infection had been deter-
mined through ex-vivo counting of four sacrificed mice. A further two AmB-PMA injections 
on days 28 and 31 was administered to give a total dose of 400 µg AmB. Lesion size was 
monitored until day 51 before the footpads were harvested and homogenised in PBS 
through a metal sieve and pooled into Trisol for RNA extraction. Data shown is of mRNA 
expression from the footpad homogenate of MIP-1β (a), TNF-α (b), IL-10 (c) and IFN-γ 
(d). Infected, untreated footpads are shown in black and AmB-PMA treated mice are 
shown in blue. Each point represents individual triplicates from PCR runs. Mann Whitney 
U statistical analyses were performed relative to the untreated control group shown in 
black. ***= P < 0.002, **= P <0.01, *= P < 0.05, and ns = not significant.  (n=16 L. major 
infected, AmB-PMA treated mice and 6 L. major infected, untreated mice.) 
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2.3.2.7 Local disease 
Throughout the in vivo studies, spleens were collected from L. major infected 
untreated and treated groups. To answer whether the disease developing in the 
BALB/c mice after infection with L. major promastigotes may disseminate into 
visceral organs and develop into a systemic disease, cytokine and chemokine 
expression levels in the spleen were analysed. Spleens were collected from each 
study conducted and representative data at day 51 are shown in Figure 103 and 
clearly illustrate that there were no significant differences between the untreated and 
treated groups in the spleens in respect to the levels of mRNA expression.  
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Figure 103: mRNA expression levels in the spleen of L. major infected 
untreated and AmB-PMA treated mice  
Spleens from both infected and treated groups of mice throughout the course of the 
optimisation experiments were harvested for mRNA analysis. Spleens were removed 
and individually homogenised in Trisol in preparation of RNA extraction and cDNA 
generation. The graph illustrates mRNA expression at day 51 of MIP-1β, TNF-α, IL-
10 and IFN-γ from spleen tissue in the L. major untreated mice shown in black, and 
the AmB-PMA treated mice shown in blue. Each bar represents the average of 
individual triplicates from PCR runs of each group of six mice. Mann Whitney U 
statistical analyses were performed relative to the untreated control group shown in 
black. ***= P < 0.002, **= P <0.01, *= P < 0.05, and ns = not significant. 
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2.3.3 Part C: Efficacy of AmB-PMA treatment on L. major-infected tissue 
determined via histology 
Staining of tissues was conducted as described in Materials and Methods (Chapter 
2). The tissue sections were then photographed at varying magnifications to visualise 
and confirm the efficacy of AmB-PMA treatment in reducing parasite load and healing 
L. major-infected tissue.  Through performing staining of the tissue it was evident that 
H&E stain was the most essential in identifying amastigotes and the presence of cell 
groups. Giemsa staining proved more challenging and, although it is a customary 
stain to identify Leishmania parasites, it was the least helpful in my studies. PAS 
staining was therefore performed on all tissue sections stained with Giemsa for 
further verification of the presence or absence of L. major amastigotes. Tissue 
samples were collected throughout the course of disease from day 14 to day 80 and 
the following is a description of the findings. 
2.3.3.1 Identification of Cellular components 
As described (Chapter 2 Introduction) an inflammatory response consisting of a 
variety of cells ensues after infection. In response to infection with Leishmania spp., 
neutrophils and macrophages are the key cells to identify within the site of infection 
(Voyich and DeLeo 2002). Further recruitment of cell types include monocytes, mast 
cells, lymphocytes and plasma cells and adipose tissue will also be present 
(Janeway et al. 2008;Mosser and Edwards 2008)  
2.3.3.1.1 Leukocytes  
Monocytes circulate in the peripheral blood and migrate to infected tissue in 
response to invading pathogens (Mosser & Edwards 2008). These cells are 
characterised by having a large eccentrically placed nucleus which can vary in shape 
but often have a slight indentation. On migration monocytes mature and differentiate 
into macrophages. As maturation occurs, the folding of the nucleus becomes more 
pronounced into a kidney-shape (van Furth et al. 1979). Macrophages have a highly 
variable appearance depending on their state of activity and location. An abundance 
of lysosomes can be visualised in resting inactive macrophages. Active phagocytic 
cells are recognised by their increased size due to the presence of engulfed material. 
Due to phagocytosis and amoeboid movement, the active macrophage has 
noticeable cytoplasmic projections, known as pseudopodia, giving rise to its irregular 
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shape (van Furth et al. 1970). Histiocytes are terminally differentiated cells which 
remain stationary within the body tissue of lymph nodes and supporting tissue such 
as the skin. They are often referred to as foamy macrophages or Langerhan cells 
(Cline 1994). Mast cells are also present in the skin, but due to their high water 
solubility are not readily identifiable by routine histology staining.   
B and T cells are the smallest leukocyte and can be identified by their accentrically 
positioned, round nucleus that spans the majority of the cell. Typically one can 
visualise a very small amount of cytoplasm described as a thin ‘halo’ within the cell. 
This cytoplasm becomes more visible as the lymphocyte increases in size upon 
activation (Young et al. 2006). When B lymphocytes become activated they 
differentiate into plasma cells within the tissue which are then responsible for the 
release of antibodies into the milieu. They can be recognised by their large 
eccentrically round, granular nuclei with an extensive cytoplasm containing a very 
active golgi apparatus for the release of antibodies (Okada and Cyster 
2006;Steinman and Cohn 1973).  
Neutrophils are the most abundant leukocyte in blood and due to their high motility, 
quickly migrate to a site of infection. They can be identified by their lobulated, 
granular nucleus containing azurophil granules (Faurschou and Borregaard 2003). 
Upon maturation up to 5 lobes can be visualised that may appear as separate nuclei. 
On maturation and activation of a neutrophil it is unable to continuously function and 
degenerates quickly (Kennedy and DeLeo 2009). A large infiltration of neutrophils at 
a site of a progressive infection can evolve into pus cells due to spontaneous 
apoptosis (Fox et al. 2010).  
Adipose tissue is typically located in the deeper layers of the skin. Adipocytes are 
non-membrane bound spherical structures that store fat and can fuse together to 
form large droplets. They are an important source of energy and act as thermal 
insulation (Poglio et al. 2010;Rajala and Scherer 2003). Processing of tissue for 
histology generally extracts the lipid from the tissues therefore these cells appear as 
unstained vacuoles.  
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2.3.3.2 Day 14 
Footpad tissue that was treated locally into the lesion with one dose of AmB-PMA 
(133 µg AmB) on day 7, was harvested one week later and compared with tissue that 
had been infected with L. major for 14 days. At x 4 magnification there is little 
difference in the morphology in the H&E stained tissue between the infected, 
untreated and infected AmB-PMA treated footpad (Figure 104A and B). On closer 
inspection, the infected untreated footpad tissue shows signs of a mixed 
inflammatory cell infiltrate  with the presence of neutrophils (Figure 104C, indicated 
by  a red arrow) and L. major amastigotes within the phagolysosome of, one can 
deduce to be, macrophages (Figure 104C and E highlighted in black). At x 40 
magnification, amastigote-filled macrophages are also present in the AmB-PMA 
treated tissue indicating that a single dose of AmB-PMA was not sufficient to 
eradicate the multiplying parasites (black arrows, Figure 104F). Neutrophils, some of 
which are indicated by red arrows, are also detectable (Figure 104D and 104F) and 
can be further seen with Giemsa (Figure 105F). At a high magnification (x 40) the 
Giemsa-stained tissue shows amastigote-filled macrophages in the infected, 
untreated tissue (Figure 105E highlighted by black arrows) which are not detected in 
the AmB-PMA treated tissue (Figure 105F). It should be noted that this difference 
may be due to the clarity of the stain. PAS stained tissue sections confirm the 
description of cell types present in the H&E sections and show with greater clarity 
findings from the Giemsa stained tissue. At a low magnification (x 4), there is an 
inflammatory infiltrate visible in both untreated and treated PAS stained tissue 
(indicated by a red arrow, Figure 106A and B). On closer inspection, infected 
macrophages can be seen in abundance in the untreated tissue sections (highlighted 
in black, Figure 106E). It is more challenging to identify the parasitized macrophages 
in the treated tissue; however a few neutrophils can be seen in both infected groups, 
some of which are highlighted by red arrows in Figure 106C, E and F).  
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2.3.3.3 Day 21  
Footpads were treated with two doses of AmB-PMA (total of 267 µg AmB) on days 7 and 14. 
The tissue was then harvested one week later, together with untreated tissue that had been 
infected with L. major for 21 days. In these photographs there is a more noticeable 
difference in the morphology of the footpad tissue between the two groups. The untreated 
H&E-stained tissue at low magnification demonstrates an active inflammatory response with 
an increased infiltrate of cells to the infected site (Figure 107A, indicated by a red arrow). 
Necrotic cells can be identified indicating the presence of an established L. major infection 
which is also shown by the PAS stained sections (Figure 109A, indicated by a red arrow). A 
greater magnification (x 40) illustrates a dense population of amastigotes replicating within 
the phagolysosomes of activated macrophages in both H&E and PAS stained tissue (Figure 
107C, E and Figure 109C, E respectively, highlighted in black). The Giemsa stained tissue 
highlights the presence of a few red blood cells trapped within the tissue suggesting the 
point of entry of treatment and/or inoculation that caused the skin to rupture in the AmB-PMA 
treated tissue (Figure 108D). On closer inspection, many neutrophils (indicated by red 
arrows, Figure 108E and F) and the presence of amastigotes can be identified in both 
infected groups, however noticeably more L. major amastigotes can be seen in the untreated 
tissue (indicated by black arrows, Figure 108E and F).  The treated group have received 2 
doses of AmB-PMA and at a low (x 4) magnification the H&E stained tissue appears intact 
and with a decreased cellular infiltrate (highlighted by a white arrow, Figure 107B). At a 
higher magnification, no L. major amastigotes can be visualised on both H&E and PAS 
stained tissue indicating that two doses of AmB-PMA were sufficient in reducing the parasite 
load (highlighted by a white arrow, Figure 107F and 109F respectively). Adipose tissue can 
be visualised as one would expect of skin tissue (H&E stained tissue, bottom right-hand 
corner, Figure 107B).  
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2.3.3.4 Day 28 
Footpads were treated with three doses of AmB-PMA (total of 400 µg AmB) on days 7, 14 
and 21. The tissue was then harvested one week later, together with untreated tissue that 
had been infected with L. major for 28 days. Disease progression is evident in the H&E 
stained infected untreated tissue with many foci of necrotic tissue (highlighted in red, Figure 
110A). A major infiltration of cells and the presence of amastigotes can be visualised at even 
low magnification which was not identifiable earlier during infection at day 14 (Figure 104A). 
This tissue destruction can be seen to a lesser extent in the Giemsa and PAS stained tissue 
(Figure 111A and 112A respectively).  H&E staining at x 20 magnification illustrates the 
extent of destruction (highlighted in red) of once healthy tissue and muscle in the untreated 
mice and the now stark difference (shown by a white arrow) to the treated tissue (Figure 
110C and 110D respectively). Greater magnification further illustrates the necrotic tissue 
containing apoptosed cells such as neutrophils in the untreated tissue (highlighted in black, 
Figure 110E). PAS staining further confirms these findings (highlighted in black, Figure 
112E). The AmB-PMA treated footpad tissue demonstrates healthy tissue with good 
morphology in terms of structure of the footpad tissue (highlighted by white arrows, Figure 
112B and 112D). Although the clarity of the stain compromises analysis, the Giemsa-stained 
tissue at a high magnification, also indicates no presence of L. major amastigotes 
(highlighted by white arrows, Figure 111F). At the same magnitude this finding is confirmed, 
with greater clarity, on the H&E and PAS stained AmB-PMA treated tissue and indicates 
healing of the lesion (highlighted by white arrows, Figure 110F and 1112F).   
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2.3.3.5 Day 51  
Visual findings of the infected, untreated footpads at day 51 post infection were of 
severely inflamed, red lesions. A L. major infection had progressed into an 
uncontrolled cutaneous leishmaniasis disease. On analysis of the tissue sections, 
focalised necrosis with a major cellular inflammatory infiltrate is clearly evident at low 
magnification in all 3 stains (highlighted by red arrows, Figure 113A, 114A and 
115A). At x 40 magnitude, PAS-stained tissue highlights clearly tissue with a dense 
population of L. major amastigotes multiplying within the phagolysosomes of the 
macrophages (Figure 115E, highlighted in black).  The overall quality of Giemsa 
stained tissue was noticeably improved and therefore at x 20 magnification the 
presence of necrotic tissue (highlighted by red arrows) can be seen surrounded by 
amastigote-laden phagocytic cells (highlighted in black, Figure 114C). At a higher 
magnitude one can identify a dense population of macrophages heavily loaded with 
L. major amastigotes in all three stained tissues, though most noticeably visible in the 
PAS stained tissue (Figure 115E).  
AmB-PMA treatment commenced once there was an established lesion and 
consisted of 3 injections on days 21, 26 and 28 with a total of 400 µg AmB. The 
pathology of the AmB-PMA treated footpads is similar to that of the footpad tissue 
treated during the early phase and harvested on day 28. The H&E stained tissue 
illustrates a marked difference in the morphology of tissue between the infected, 
untreated and the infected AmB-PMA treated groups at day 51, with a less defined 
inflammatory infiltrate present in the latter (highlighted by a white arrow in Figure 
113B compared to Figure 113A highlighted by a red arrow). This can also be clearly 
visualised in both Giemsa-stained and PAS-stained tissue (Figure 114B compared to 
114A and Figure 115B compared to 115A). This difference between the infected, 
untreated and infected AmB-PMA treated was less pronounced in the tissues 
harvested on day 28. At a higher magnification (x 40) there is no presence of 
amastigotes in any of the stained tissue harvested on day 51(Figure 113F, 114F and 
115F). The infiltrate of inflammatory cells has also dissipated (highlighted by white 
arrows). 



Chapter 2 
Results Part C 
Karina D. Corware 
 
308 
 
 
2.3.3.6 Monitoring of healed lesions 
As described (Results Part A), AmB-PMA treated mice with healed footpads were 
maintained up until day 80. These footpads were then harvested and the stained 
tissue sections can be visualised in Figure 116 and 117. At a low magnification, the 
H&E stained footpad tissue illustrates good pathology (highlighted by white arrows, 
Figure 116A). Furthermore no cellular inflammatory infiltrate can be visualised in 
either Giemsa or PAS stained tissue sections (Figure 117A and 117B respectively). 
At a higher magnification there is no presence of L. major amastigotes (Figure 117E 
and 117F). At a high magnitude H&E staining highlights the presence of histiocytes 
and also myofibroblasts present in the tissue indicative of healing occurring and 
tissue repair (indicated by white arrows Figure 116B) (Hinz et al. 2007). This 
confirmed visual findings of the footpad (Figure 116C). 
 
2.3.3.7 Does successful treatment prevent the dissemination of infection? 
To answer whether subcutaneous injections of L. major parasites in these studies 
resulted in dissemination to other tissue, and in particular, lymphoid organs, both 
lymph node and spleen were harvested from an untreated, heavily infected mouse at 
day 51. Both are highly organised lymphoid organs that are able to generate efficient 
immune responses by providing the structural framework whereby antigen presenting 
cells, T and B cells can interact (Janeway et al.2008). On examination of the 
histological sections, there was no indication of the presence of amastigotes over a 
range of magnitude in both secondary lymphoid organs (Figure 118).   
The popliteal draining lymph node is the main material used in this project to analyse 
the immune response to infection and to determine the cytokine and chemokine 
profile. The lymph node is an oval-shaped organ containing an outer cellular rich 
cortex with a central area called the medulla (Linderman et al. 2010). The photograph 
taken of the lymph node tissue illustrates the outer cortex where naive lymphocytes 
are densely packed into follicles (Figure 118A). These follicles can be sub-
characterised into primary or secondary follicles, both of which are devoid of 
macrophages, with the latter follicles containing a pale-stained germinal centre 
indicated by a white arrow in Figure 118A (Ryan et al. 2001).  
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On closer examination one can identify cells with large nuclei that span across the 
cytoplasm which one could deduce are lymphocytes (Figure 118C and 118E, 
indicated by a white arrow) (Okada & Cyster 2006). Dendritic cells are also known to 
be present within the follicles but are difficult to identify in routine H&E, with 
fluorescent imaging required (Stoll et al. 2002).  
The morphology of the spleen is slightly different containing nodules filled with T and 
B cells called white pulp surrounded by highly vascular tissue called red pulp (Hoek 
et al. 2010). A nodule can be identified in Figure 118B (highlighted by a white arrow) 
and upon closer examination there appears to be two distinguishable tissues which 
can be deduced are the different pulp (the highly vascular red pulp highlighted by 
white arrows in Figure 118D). Within these spherical nodules are densely packed 
cells that have large nuclei as seen in the lymph nodes and could be either T or B 
cells (Figure 118F). Importantly, there is no presence of L. major amastigotes or of 
an inflammatory infiltrate in these sections.   
 
2.3.3.8 Summary 
The aim of these histological studies was to demonstrate and visualise the effects of 
AmB-PMA on L. major infected tissue. It was also to verify findings recorded by ex-
vivo counting of the parasite load of the tissue and that the reduction in lesion size 
was associated with healing of the footpad tissue and a dissipated inflammatory 
infiltrate. Furthermore it was to ensure that the infection was locally confined and that 
no dissemination of infection occurred. Although previous reports have indicated that 
the L. major strain LV39 used does disseminate quickly to distant tissue, this, as 
demonstrated by Figure 118 was not found in these studies (da Silva and Sacks 
1987).  
Cellular subsets such as neutrophils, and lymphocytes could be identified in the 
tissue; however one would need to verify these findings through 
immunohistochemistry. As stated, Leishmania spp. reside and multiple within the 
macrophages of their host and the presence of amastigotes within the 
phagolysosome were identifiable in the infected tissue and also early on in AmB-
PMA treatment. However, after 2 doses, there was a marked difference in 
morphology of the treated tissue compared to the infected untreated tissue.  
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As H&E staining appeared to be the most useful in my studies in evaluating tissue sections, 
an overview of the sequence of events in both infected untreated tissue, and infected, AmB-
PMA treated tissue was compiled using oil emersion. This is illustrated in Figure 119. The 
untreated tissue shown was harvested over the course of the leishmanial infection and 
illustrates; an early infection stage at day 14 (Figure 119A), tissue during disease 
progression at day 28 (Figure 119B) and a heavily infected footpad tissue section at day 51 
(Figure 119C). All infected untreated mice were sacrificed no later than day 51 according to 
Home Office regulations. All untreated tissue illustrates the presence of macrophages 
infected with L. major amastigotes, with heavily loaded infected macrophages identifiable at 
later stages of the infection (Figure 119B (day 28) and 119C (day 51)).  In contrast, Figure 
119D illustrates tissue from an L. major-infected footpad that has been treated during the 
early phase of infection with AmB-PMA (400 µg AmB) over three weeks (days 7, 14 and 21) 
and harvested a week later on day 28. Many neutrophils can be visualised (shown by red 
arrows) illustrating a minor cellular infiltrate with no presence of L. major amastigotes. Figure 
119E also illustrates infected AmB-PMA treated footpad tissue, however this has been 
treated after a lesion was established. This tissue was treated on day 21, 26 and 28 and 
harvested on day 51. There is no indication of L. major amastigotes or of an inflammatory 
infiltrate. Further to this, Figure 119F illustrates tissue that has been AmB-PMA treated as 
described in Figure 119E and monitored until day 80. The presence of myofibroblasts and 
histiocytes can be seen in this tissue section, highlighting that the tissue is repairing and in 
the process of healing. Overall AmB-PMA treatment has been demonstrated via 
histologically stained tissue as effective in reducing parasite load and inflammation and 
causing long-term healing of the once infected footpad.  
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2.3 Discussion  
The second part of my thesis was to determine AmB-PMA efficacy in vivo. Resolution of 
both a natural and experimental leishmanial infection in humans and mice is dependent on 
the development of an adequate Th1 immune response (Diefenbach et al. 1998;Locksley et 
al. 1991;Park et al. 2002;Rogers et al. 2002) (Choi and Kropf 2009). As previously 
described, this involves the production of the signature cytokine IFN-γ which induces the 
activation of anti-parasiticidal pathways in infected macrophages (Bogdan et al. 
2000a;Sacks and Noben-Trauth 2002;Zaph and Scott 2003). BALB/c mice are genetically 
susceptible to leishmanial infection and cannot control parasite growth (Gumy et al. 
2004;Noben-Trauth et al. 2002) (Pearce and Reiner 1995;Wang et al. 1994). This is due to 
the presence of a dominant Th2 response that involves the upregulation of IL-10, and the 
inability to activate anti-parasiticidal pathways of infected macrophages to kill intracellular 
parasites (Anderson et al. 2007;Kropf et al. 2005;Modolell et al. 2009). The result is the 
development of a progressive, persistent non-healing disease. After completing the 
optimisation of AmB-PMA synthesis reaction and determining its in vitro efficacy, 
investigation began treating L. major infections in an experimental cutaneous leishmaniasis 
model using non-healing BALB/c mice.  
Treatment of an early infection was first devised to evaluate the potential of AmB-PMA to 
effectively reduce parasite load and resolve development of lesions. Optimisation of 
administration, treatment frequency and dosing were then performed before assessing the 
efficacy of AmB-PMA to treat an established lesion. The efficacy was assessed by the 
measurement of lesion development, determination of parasite load via ex-vivo counting and 
assessment of healing via histopathology sections of the footpad lesions. Real time RT-PCR 
was used to collect data on the immunological changes occurring during these studies to 
determine and identify differences in the immunological profile of the infected untreated and 
infected AmB-PMA treated BALB/c mice.  
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2.3.1 Optimisation of AmB-PMA treatment  
AmB is sensitive to pH in solution and, during investigations, observations that AmB within 
the AmB-PMA shifted to form aggregates were found on solubilisation in 5 % dextrose. 
Administration instructions from the manufacturer of Fungizone includes that the drug needs 
to be introduced into 5 % dextrose before delivery into man (Bristol-Myers Squibb). 
However, it was found that the pH of 5 % dextrose is 4.2.  My studies have shown that at a 
pH of 7.3 such as water for injection, AmB is stable within AmB-PMA (Figure 62). However, 
AmB is readily disrupted and precipitates on gentle centrifugation below a pH of 6.3. This 
resulted in only 30 % of AmB within AmB-PMA remaining. Introduction of AmB-PMA into an 
acidic solution such as 5 % dextrose gave rise to a spectrum containing predominately 
aggregated AmB (Figure 77). This in turn was found to give rise to a greater haemolytic 
potential (Figure 78). These observations are consistent with previous studies of other AmB 
preparations, administered intravenously, that showed that the pH of the formulation in 
solution needs to be carefully controlled in order to ensure that AmB is present in a stable 
micro-environment (Gagos et al. 2008;Romanini et al. 1999). This is because in an acidic 
pH, AmB has a preference to exist in its aggregated form. These aggregates have been 
shown in previous studies in animals to cause fever, rigors, shock and renal toxicity 
(Baginski and Czub 2009;Deray 2002). AmB-PMA was therefore administered in water for 
injection and throughout the in vivo studies there was no indication of toxicities. Weight loss 
was another important factor that could be easily monitored and was a good indicator of the 
health of the animal. No differences were observed over the course of treatment compared 
to the infected untreated mice (Figure 79).  
Current treatment of localised cutaneous lesions involves either intramuscular or 
intralesional administration of antimonials (Frezard et al. 2009;WHO 2009). More 
pronounced lesions and disseminated infections typically require intraperitoneal or 
intravenous administration of AmB formulations (Herwaldt 1999;Panagiotis et al. 2010). 
Therefore I assessed the efficacy of AmB-PMA to treat a cutaneous lesion using different 
delivery routes. Both intraperitoneal and intralesional routes of administration of AmB-PMA 
reduced lesion size compared to the infected untreated group over the course of 35 days. 
However, intralesional injections were significantly more effective at reducing parasite load 
(p= 0.0087, Figure 80(b)). This less efficient mode of action after intraperitoneal 
administration was also noted by researchers during treatment of patients infected with 
Candida spp. The study had shown that AmB dissipated quickly and was detected at very 
low levels after treatment (van der Voort et al. 2007). It is believed to have a half-life of 
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between 12-14 h (Hammersmith Pharmacy) and therefore it was unsurprising that this 
method of treatment was not as successful as intralesional injections. This was reassuring 
as it would be greatly limiting in the development of AmB-PMA for treatment of cutaneous 
lesions if efficacy was only found on peritoneal injections. Furthermore, the notion that local 
treatment is more efficient and desirable was also supported by the success of preliminary 
studies of incorporating AmB-PMA into gauze for local treatment (Figure 67(a, b)). Current 
treatments for CL lesions typically involve either intralesional or intramuscular injections of 
pentavalent antimonials and are associated with pain and require skill in administration 
(Berman 1997) (Firdous et al. 2009). Due to this, research into the incorporation of drugs 
into topical applications has been explored with resulting mixed efficacy in clinical trials. A 
topical ointment containing 15 % paromomycin and 12 % methylbenzethonium has been 
shown to be beneficial on applying twice a day, for 10 days in comparison to a placebo on 
treating L. major CL lesions (El-On et al. 1992). Armijos and colleagues also showed a 
benefit in comparison to antimonial (MA) treatment, however the topical application was 
associated with burning sensations and the lesions took longer to heal (Armijos et al. 2004). 
More recently Kim and colleagues found this topical treatment was only effective with select 
cases of L. major infections (Kim et al. 2009). Placebo-controlled studies investigating the 
use of 15 % paromomycin and 12 % urea ointment could not demonstrate any clinical 
benefit although there was evidence of reduced parasite load (Asilian et al. 1995) (Salah et 
al. 1995). On review of the research into topical treatments for CL, further investigations are 
urgently required. It was therefore extremely encouraging that in my preliminary experiments 
AmB-PMA was successfully incorporated into gauze. Further development of this type of 
application could result in a patient applying a self-adhesive patch containing the AmB-PMA 
gauze, similar to that of a nicotine patch (NICORETTE®). This self-administrable treatment 
could greatly minimise the cost of hospital treatment in endemic regions of the world. 
2.3.1.1 Dosing Schedule 
As previously discussed the ideal therapeutic drug for treating cutaneous leishmaniasis 
would require limited invasive techniques for administration and would have limited toxicity 
(Garnier T and Croft, 2002). Systematic optimisation of both frequency of intralesional 
injections and total dose of AmB was conducted (Table 19 and Figure 82). This involved 
methodically lowering the total amount of AmB by altering the number of injections rather 
than the amount of AmB per injection (which remained at 50 µg AmB). At a total dose of 250 
µg, efficacy was maintained with a decrease in parasite load of 99.9 %.  However, at 150 µg 
AmB total dose with 3 injections there were variable findings. Two studies were carried out 
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at this total dose with one resulting in a lesion reduction of 95.3 % and the other with a lesion 
reduction of only 74.3 %. This suggested that a threshold had been reached whereby 
administration of less than a total dose of 200 µg AmB would result in an insufficient quantity 
of AmB to kill the L. major parasites. Two studies were performed using a total dose of 500 
µg AmB (Study 6 and 7, Table 19). Previously, the dose per injection remained fixed at 50 
µg AmB and the total dose fluctuated by altering the number of injections that were 
administered. In this instance, the individual dose per injection was increased to 100 µg 
AmB, allowing the total dose to be administered in 5 injections. No side effects were found 
and efficacy of reducing lesion size rose back up to an average of 83.9 %, similar to that 
observed in the study conducted with a total dose of 300 µg AmB. As the optimisation 
process continued and the number of injections and commencement of treatment was 
evaluated, it was concluded that a total dose of 400 µg AmB was a reasonable amount of 
AmB that gave rise to good efficacy in vivo with no side effects. 
2.3.1.2 Commencement of Treatment 
Treatment during the early phase of infection entailed first administration starting 2 days post 
infection to assess the therapeutic properties of AmB-PMA for experimental cutaneous 
leishmaniasis. Verification of the use of HP-18 to synthesise AmB-PMA was first assessed 
and found to have a significant potential to reduce parasite load (p = 0.0238, Figure 81(b)), 
and lesion development compared to the infected untreated mice. The success of this 
preliminary study and also investigations into the route of administration promoted the 
evaluation of the treatment schedule. On administration of AmB-PMA treatment 2 days after 
L. major infection with a total of 5 injections resulted in successful healing and elimination of 
amastigotes. Titus and colleagues describe that at day 7 there is a log rise in parasite load 
justifying start of treatment (Titus et al. 1985).  Therefore studies were conducted to assess 
the limits of AmB-PMA therapy by firstly starting treatment on day 7 of infection. There was 
no difference found in the ability of AmB-PMA to reduce lesion size (84.1 % day 2 and 87.2 
% day 7, Figure 83(a)) and parasite load on day 7, with respect to the untreated infected 
footpads compared to treatment starting on day 2 (p= 0.0009 and p=0.0044 respectively, 
Figure 83(b)). On further analysis of AmB-PMA therapy, it was found that a significant 
reduction of parasite load (p= 0.0357) was achieved after only 2 doses (267 µg AmB of the 
total dose 400 µg AmB) of AmB-PMA ((Figure 85(b)). This achievement suggested the 
possibility of treating a developed lesion.  
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As previously described, lesions can develop over a period of months without any clinical 
indication of an infection in a patient (Cruz et al. 2009;Murray et al. 2005). Typically, medical 
care is only sought upon the development of an ulcerative lesion which results in an 
increased risk of dissemination. This is another obstacle in the success of treatment, as by 
the time a lesion has developed the host immune response has been compromised (Murray 
et al. 2005). In combination with other risk factors such as malnutrition that are typically seen 
in impoverished endemic area, the disease becomes increasingly difficult to treat (Machado-
Coelho et al. 2005). Due to this, both early diagnosis and also use of drug treatment that can 
act on an established infection are both vital. To this end, AmB-PMA treatment studies were 
conducted on the visual identification of an emerging lesion which was confirmed by ex-vivo 
counting of the parasite load. AmB-PMA treatment typically commenced no later than day 21 
of infection. By day 28, the lesions presented mixed morphology with often the appearance 
of pus indicative of necrotic tissue. Subcutaneous injections into pus-containing lesions 
would compromise the consistency of the results collected over the course of the studies. Its 
presence could alter the pharmaco-kinetics of AmB-PMA and its uptake into infected 
macrophages. In patients optimum treatment would require that the lesion is drained and 
cleaned before subcutaneous injections (Berman 1997). Investigations into the efficacy of 
treatment, depending on the type of lesion developed, would be incorporated into future 
work as a separate independent study with the knowledge of the efficacy and limitations of 
AmB-PMA.   
Treatment that commenced by day 21 on an established lesion with a total of 400 µg AmB 
administered over a week in genetically non-healing mice resulted in an 81.3 % (16/19 mice) 
success rate with a reduction in lesion size and visual findings illustrating healed footpads. 
Footpads from infected, AmB-PMA treated mice were harvested at day 51 when the 
untreated heavily infected mice needed to be sacrificed (Figure 87(a)). An impressive 3 log 
difference in parasite load was found in the footpads that had healed after treatment of an 
established infection compared to the untreated (Figure 87(b)). No re-emergence of infection 
was observed up to 80 days post infection indicating the ability of AmB-PMA to result in 
long-term cure of cutaneous leishmaniasis (Figure 89). It is important to stress that AmB-
PMA was able to resolve established lesions caused by L. major parasites in mice from a 
genetically susceptible strain after 3 injections over one week. This is a significant 
development in the treatment of L. major infections in comparison to the current intralesional 
treatment that is administered to patients. The standardised schedule of intralesional 
antimonials (SSG) consists of a total of 1-5 injections once to twice a week for at least a 
month before considering systemic treatment if cure has not occurred (Tallab et al. 1996) 
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(Blum et al. 2004). Healing of localised lesions has been shown with three injections on 
alternate days repeated for 2 months with doses increasing depending on the size of the 
lesions (Sharma et al. 2005). Further to this, the use of a combination of both intramuscular 
and intralesional SSG was required to increase the efficacy of the treatment of CL lesions 
(El-Sayed and Anwar 2010). As stated, 3 injections over one week of AmB-PMA gave rise to 
prolonged healing of a CL lesion. Considering the clinical studies described and the duration 
of treatment that is required at present for patients, my in vivo data suggests that AmB-PMA 
treatment via intralesional injections alone could be developed into a more effective 
treatment of CL.    
2.3.1.3 Route of inoculation 
To determine the efficacy of AmB-PMA treatment a high dose (2x106) of L. major 
promastigotes was inoculated via a needle subcutaneously into the mouse footpad on day 0. 
This typically gave rise to a lesion within 10-14 days and a chronic non-healing CL disease 
by day 28. Overall, the AmB-PMA treatment during the in vivo studies was successful in 
reducing both parasite load and also lesion size. However, on three occasions lesions re-
emerged on the infected footpad. Two of the three mice that had re-emerging lesions after 
AmB-PMA treatment of their established lesions were found to be in a different place to 
those that were normally observed. One lesion was occurring on the ankle of the footpad 
and the other at the side. Interestingly, the site of original infection remained healed; 
however there was only one log reduction in parasite load (Figure 88 and 93(b)). It appeared 
that the localised treatment of the mouse footpad infected with a high dose of L. major 
parasites had partially worked and that the re-appearing lesions may have been the result of 
setting an injury or trauma by the needle injection. In natural infections, transmitted by sand 
flies, between 5,000 and 10,000 metacyclic promastigotes are injected during a blood feed 
of the host (Kimblin et al. 2008). This is at the skin surface leading to the persistence of 
infection in the upper layers of the dermis resulting in the development of cutaneous lesions. 
Injection of a high dose of parasites (106 to 107) using a needle could result in the depositing 
of parasites deeper into the dermis and may have resulted in the development of lesion 
further from the original site of infection. Hence the local processes driven by the parasites 
and the probability of dissemination could present differently depending on the route and 
size of inoculation (Courret et al. 2003). Evaluation of the parasite load in these re-emerging 
infections illustrated significantly greater levels than that of those with healed lesions (Figure 
93(b)). It has become increasingly apparent that injection of high doses of Leishmania 
parasites to identify immunological profiles is a poor reflection compared to the more 
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recently used natural infection models whereby parasites are transmitted by infected sand 
flies into the mice to mimic natural transmission of infection (Belkaid et al. 1998;Rogers et al. 
2004).  
As a result of the in vivo studies the AmB-PMA has been shown to be efficacious in treating 
cutaneous lesions and therefore, further work would involve treating a naturally transmitted 
infection to see whether this efficacy is maintained and whether a different immunological 
profile would develop.  
 
2.3.2 Immunological profile  
The in vivo studies conducted in this thesis were to determine efficacy of both early and late 
treatment of cutaneous leishmaniasis with AmB-PMA. In addition to evaluating the effect of 
this treatment on the parasite load and pathology, the question of whether it modulated 
immune responses also needed addressing. Modulation was indicated in the in vitro data in 
Chapter 1 whereby monocytes stimulated with AmB-PMA induced the expression of 
proinflammatory cytokines IFN-γ and TNF-α. However this was not seen in the other cell 
types such as tissue and monocyte-derived macrophages. It was expected that this activity 
would be seen in both monocytes and particularly monocyte derived macrophages 
particularly considering that the origin of the cell types was indifferent. Optimisation of the 
method used to differentiate macrophages including the use of phorbol 12-myristate-13- 
acetate (PMA) may have generated more sensitive results. Furthermore experimentation 
using macrophages isolated from mice would have been beneficial in ascertaining the 
effects of AmB-PMA, particularly considering that drug efficacy was determined using an in 
vivo mouse model.     
On introduction of AmB-PMA into the infected footpad tissue, cells that are first encountered 
are resident tissue macrophages and Langerhans cells. Failure to activate these cells would 
demonstrate an overall reduced potential of the drug to act beneficially with the host immune 
system. As described, the recognition of Leishmania and activation of the innate immune 
response involves the use of the TLR signalling pathway. TLR’s present on macrophages, 
neutrophils, dendritic cells, T cells and NK cells recognise leishmanial surface molecules 
such as LPG which in turn stimulates the expression of proinflammatory cytokines and 
chemokines ((Antoniazi et al. 2004;Debus et al. 2003). Macrophages are the key molecule in 
a leishmanial infection as they are the host cell in which Leishmania replicate. They can 
activate the leishmanicidal activity of Th1 T cell and other effector cells which require the 
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presence of cytokines such as IFN-γ and TNF-α that are expressed by activated 
macrophages (Ribeiro-Gomes et al. 2004;Sacks & Noben-Trauth 2002;Wilhelm et al. 
2005;Zaph & Scott 2003). Monocytes are circulating in the periphery and are stimulated by 
inflammatory mediators to locate at the site of infection. Their purpose is to mature into 
tissue-resident macrophages APCs so that the innate and in turn the adaptive immune 
response can be initiated (Mosser and Edwards 2008). CD4+Th1 cells are essential for the 
clearance of  leishmanial infection in the host and are generated by the presentation of 
leishmanial antigen by APCs (Alexander and Bryson 2005). Monocytes are unable to fulfil 
this task and therefore stimulation of solely monocytes by AmB-PMA would be insufficient. 
As suggested further in vitro studies including the use of human and murine macrophages 
and also dendritic cells would be beneficial before a conclusion can be made on the 
proinflammatory effects of AmB-PMA in mice and humans. However, it has been shown, in 
vivo that there is a marked reduction in both lesion size and parasite burden in AmB-PMA 
treated mice. As Leishmania preferentially reside in macrophages, one can deduce that 
activity is associated with the ability to target these cells. Using real-time RT PCR one can 
measure the overall cytokine and chemokine responses in the harvested tissue. However, 
this method cannot specify the particular cell type that is releasing the cytokines and 
chemokines measured. Hence, the mode of action of AmB-PMA on specific host immune 
cells can be speculated but cannot be fully determined using solely this technique.  
To answer whether AmB-PMA treatment had an effect on immune responses, cytokine and 
chemokine levels in L. major infected untreated and AmB-PMA treated groups were 
compared. At the early treatment time-point, the L. major antigen induces the polarisation of 
a T cell response in vivo and between days 3 and days 8, there is increased cytokine 
responses generated by the proliferation of CD4+ T helper cells (Beil et al. 1992;Lang et al. 
2003;Theodos et al. 2004). At the time-point when the lesions are established, the T helper 
cell response and non-healing phenotype of BALB/c mice to leishmanial infection has been 
irreversibly established (Etges and Muller 1998;Lemos de Souza et al. 2000). One could 
argue that successful treatment of a leishmanial infection between days 2 to days 7 is more 
attainable, since the innate response is activated immediately and the early reduction in 
antigenic load is likely to result in an induction of T cell mediated immunity (Itano and 
Jenkins 2003;Janeway et al. 2008). In these in vivo studies it was essential to first determine 
the activity of AmB-PMA in killing Leishmania parasites. However, early treatment is not 
easily applicable in the field as patients typically seek medical assistance on presentation of 
a visible lesion which can take more than 6 months to develop. Therefore it was necessary 
to evaluate whether the efficacy of AmB-PMA during the early phase of treatment was 
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maintained on treating an established lesion. Furthermore, it was assessed whether effective 
late treatment of an established response would not only kill the intracellular parasites but 
also counteract the established Th2 response.  
During the course of treatment studies conducted, mRNA expression was recorded of 
cytokines and chemokines that have been described as important in the resolution of 
cutaneous leishmaniasis. As the development of a predominately Th1 or Th2 immune 
response plays a critical role in the persistence or healing of a cutaneous lesion, it was 
necessary to investigate cytokines that have been determined to be essential in either T 
helper cell subset differentiation. The cytokine IFN-γ drives and upregulates a Th1 immune 
response with the aid of IL-12 and TNF-α. During a parasitic infection such as L. major CL, 
increased mRNA levels of IFN-γ allow for the activation of macrophages to produce NO via 
iNOS resulting in rapid destruction of the internalized parasites (Liew et al. 1990) 
(Diefenbach et al. 1998). Increased IL-10 expression induces the activation of L-arginine and 
the production of polyamines which maintain parasite growth (Iniesta et al. 2001) (Padigel et 
al. 2003).  MIP-1β is a chemokine produced in high levels by antigen presenting cells such 
as dendritic cells (1 pg MIP-1β/hour/cell) early on in an inflammatory response to enhance 
and recruit circulating immature dendritic cells and other inflammatory cells to the site of 
inflammation (Sallusto et al. 2000). 
From each mouse the lymph nodes draining the site of the lesions, the footpads and the 
spleen were collected. This was so that an overall assessment of the immunological 
responses that were occurring in the mouse during an L. major infection could be 
established. As a secondary lymphoid organ, the spleen is the platform whereby T and B 
cells become activated and differentiate (Hoek et al. 2010). However, on evaluation of a 
locally induced L. major infection on day 51, the spleen illustrated no upregulation of the 
chemokine and cytokines studied, and furthermore no difference was observed in the locally 
AmB-PMA treated group compared to the untreated infected controls (Figure 103). This was 
further verified on analysis of the spleen tissue sections harvested (Figure 118). The spleen 
extracted from a heavily infected mouse 51 days post L. major inoculation appeared healthy 
at low magnification with the appropriate morphology (Figure 118B). On closer magnitude no 
evidence of L. major amastigotes or necrotic tissue could be seen (Figure 118F). This 
indicated that analysis of immunological changes by mRNA expression should include the 
draining lymph node and the site of the lesion in the footpads. Furthermore, the data verified 
that the immune response elicited in response to L. major infection that developed was 
localised and was most pronounced at the local site of the lesion. Previous findings had 
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suggested that L .major subcutaneous inoculation in susceptible BALB/c mice led to the 
infection disseminating into distant organs such as the spleen (Nicolas et al. 2000). 
However, the histological sections of spleens taken during the in vivo studies in this thesis 
did not demonstrate the presence of amastigotes. This is in accordance with Maioli and 
colleagues who found that complete removal of the spleen did not hinder the development of 
L. major infections in both resistant C57BL/6 and susceptible BALB/c mice (Maioli et al. 
2007).  
A more relevant lymphoid organ to investigate whilst assessing immunological responses 
during the development and persistence of a cutaneous leishmanial lesion was the lymph 
node draining the infected area. In this instance the popliteal lymph nodes draining the 
footpad lesions were collected.  During the studies it became apparent, that the infected but 
treated mice had smaller and more difficult to visualise lymph nodes than those that were 
draining a heavily infected footpad. The size of a lymph node draining the site of an infected 
but treated lesion of a mouse was of similar size to that of the draining lymph node of naïve 
BALB/c mice that were also collected. The lymph node draining the foot of an L. major-
infected mouse at day 51, when disease was progressed, was also harvested for histological 
analysis of the tissue to answer whether the infection remained local and had not spread to 
the lymphoid organ. The tissue sections illustrated no presence of amastigotes within the 
nodules of the tissue (Figure 118E) and the tissue appeared healthy and morphologically 
intact (Figure 118A).  
Initial real-time RT-PCR analysis of the immunological responses between AmB-PMA 
treated and untreated groups in preliminary in vivo studies was performed by relative 
quantitation of nominal mRNA copies to the house keeping gene HPRT. This analysis 
revealed an overall decrease in inflammatory cytokines such as IFN-γ and chemokines such 
as MIP-1β at 35 days post infection and AmB-PMA treatment. As MIP-1β is an early 
inflammatory chemokine, one could postulate that this would have been secreted before day 
35, and on resolution of infection in the AmB-PMA treated group, would not be required. 
Hence its upregulation would not be maintained which is what was found on analysis of the 
mRNA data. In contrast, the infected untreated group at day 35 illustrated increasing 
expression of MIP-1β. As there was a persistent infection one would expect a requirement 
for the continued recruitment of cells to the infected site and therefore secretions of MIP-1β 
to be maintained (Figure 95a).  Both levels of IL-10 and IFN-γ (Figure 95c, d respectively) 
also were significantly reduced in the lymph nodes of the infected AmB-PMA treated group 
which further added to the conclusion that the process of healing had already occurred and 
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that, after successful control of parasite growth, the antigenic load was strongly reduced and 
the stimulation of the immune response had ceased. It also highlighted that immunological 
assessment via mRNA expression would have to be assessed at earlier time points. 
Analysis of mRNA data generated on carrying out real time RT-PCR with a plasmid to 
generate absolute copies resulted in noticeably lower levels of mRNA expression levels and 
more subtle changes in the lymph nodes, that in some cases were at the limit of detection of 
the RT-PCR reaction. This limit of detection is introduced on analysis of PCR data sets to 
avoid miss-interpretation of the results. It is also known as the analytical sensitivity of an 
assay and is described as the minimum number of copies that can be accurately measured 
(Bustin et al. 2009). Low copy numbers generated are expected to have greater variability 
and are likely to be due to primer dimers rather than the amplification of the cytokine 
sequence that was being studied.  This was the case for both IL-4 and IL-6 mRNA 
expression where only a few data sets were collected above the limit (Figure 96e, f 
respectively). 
It was evident from preliminary work that investigating the immunological responses 
observed in the lymph nodes at one time-point (day 35) was not sufficient. Therefore in vivo 
studies involving the harvesting of both infected untreated and infected AmB-PMA treated 
groups weekly over the course of the 35 days was conducted. AmB-PMA treatment 
commenced in the early phase of infection when the infected mice were treated on day 7, 
day 14 and day 21 with a total average dose of 400 µg AmB (Figure 100). Collectively the 
changes in mRNA expression in the draining lymph nodes were significantly less 
pronounced compared to the mRNA analysis of the footpad homogenate at the site of 
infection. MIP-1β mRNA expression levels in the treated group did not appear to rise above 
levels found in naïve mice until day 28 (p<0.0001, Figure 100(a)). A greater increase in MIP-
1β production was found in the untreated lymph nodes which rose by day 35. MIP-1β 
expression in the treated lymph nodes also rose but more modestly resulting in a significant 
reduction compared to the untreated controls by day 35 (p=0.0148, Figure 100(a)). No 
upregulation in TNF-α mRNA expression was detected above the naïve levels in the 
untreated lymph nodes. This is in comparison to a gentle rise in TNF-α at day 28 which was 
then sustained by day 35 in the AmB-PMA treated lymph nodes (p<0.0001, Figure 100(b)). 
TNF-α levels were also raised significantly at day 35 in the day 7 treatment study (Figure 
97(b), p<0.0001). This may be due to the increased quantity of parasites that are within the 
tissue, resulting in a greater abundance of antigen stimulating an increase in the release of 
TNF-α to activate the leishmanicidal activity of macrophages. Wilhelm and colleagues have 
shown that TNF-α C57BL/6 knock-out mice infected with L. major develop an aggressive 
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visceral disease despite the development of a Th1 response and expression of iNOS, 
indicating how essential the cytokine is for healing and the development of protective 
immunity (Wilhelm et al. 2001;Wilhelm, Wiede, Meissner, Donhauser, Bogdan, & Korner 
2005).  
As described, extensive research has been conducted into the interplay of cytokines IL-10 
and IFN-γ in parasitic infections such as Leishmania (Alexander & Bryson 2005) (Anderson 
et al. 2008) (Castellano et al. 2009) (Caldas et al. 2005) In the in vivo studies of early 
treatment in this project both IL-10 and IFN-γ mRNA expression appeared to follow a similar 
pattern in the draining lymph nodes of the AmB-PMA treated footpads. IL-10 and IFN-γ 
mRNA expression in the treated lymph nodes rose above both naïve mRNA levels and 
infected untreated controls at day 28 and by day 35 post infection both IFN-γ (p<0.0001) and 
IL-10 (p=0.0236) mRNA expression in the draining lymph nodes of the AmB-PMA treated 
mice were significantly down-regulated compared to the untreated controls (Figure 100 c 
and d respectively). IL-10 has been described as a cytokine with pleiotropic properties but its 
most dominant role in respect to leishmaniasis is allowing the persistence of the parasites 
and the inhibition of Th1 cytokines, therefore a decrease in IL-10 is favourable in the treated 
lymph nodes (Buxbaum and Scott 2005;Murphy et al. 2001;Padigel et al. 2003). By day 35, 
the AmB-PMA treated mice presented healed footpads with no CL lesion therefore one could 
postulate that high levels of IFN-γ are not required in the draining lymph node.  
Overall during the course of an L. major infection the draining lymph nodes of the untreated 
mice showed increasing levels of MIP-1β and overall low levels of both IFN-γ and IL10. In 
contrast, the draining lymph nodes of the infected mice treated during the early phase of 
infection with AmB-PMA revealed a rise in TNF-α, IL-10 and IFN-γ by day 28 followed by a 
fall at day 35. One can conclude that a shift in the immunological profile of untreated and 
treated lymph nodes appeared on day 28 post infection when there was a rise in TNF-α in 
the AmB-PMA treated group (Figure 98(b)). The key cytokine IFN-γ is responsible for 
generating a Th1 based immune response and TNF-α also plays a role in activating infected 
macrophages to kill parasites via the upregulation of iNOS and NO production (Bogdan et al. 
2000;Ribeiro-Gomes et al. 2004).  
IL-12 has been shown to be fundamental in the generation of a Th1 response and the 
healing of a leishmanial infection. Mice deficient in IL-12 are unable to generate an IFN-γ-
driven Th1 response and L. major resistant C57BL/6 mice have been shown to require a 
sustained source of IL-12 to resolve a leishmanial infection (Magram et al. 1996) (Mattner et 
al. 1996) (Jones et al. 1998). Furthermore an intact heterodimer IL-12 receptor that is 
Chapter 2 
Discussion 
Karina D. Corware 
 
327 
 
composed of both IL-12Rβ1 and IL-12Rβ2 chains is essential for the action of the bioactive 
form of IL-12 (IL-12p70) (Presky et al. 1996). Therefore the presence of IL-12 in the draining 
lymph nodes of the infected untreated and AmB-PMA treated mice was determined. IL-
12(p70) consists of two differing chains, p40 and p35 which have both been shown to be 
required for continued resistance from L. major infections (Park et al. 2002;Toichi et al. 
2006). Further to this recent investigations by Pakpour and colleagues have suggested that 
this continued production of IL-12 is necessary for the promotion of CD4+ memory T cells 
that develop into a Th1 subset when challenged with a secondary infection and to maintain 
long-term immunity (Pakpour et al. 2008). Both IL-12p35 and IL-12p40 were investigated on 
the samples harvested from the in vivo studies. However, consistently the IL-12p35 mRNA 
expression fell below the limit of detection on analysis of the PCR data and hence could not 
be graphically represented. There was mixed yield when measuring the cytokine levels of IL-
12p40 and only those mRNA copies that had tight reproducibility were inserted into data sets 
to be analysed (Figure 95(f), Figure 97(f)). Absolute mRNA copies of IL-12p40 in one study 
were found to be significantly upregulated in the treated AmB-PMA group compared to the 
untreated (p<0.01, Figure 97(f)). The presence of IFN-γ was also upregulated in this treated 
group. As stated, both p35 and p40 subunits are required to be present for the bioactive form 
of IL-12 (IL-12p70) to be produced. However in my in vivo studies, IL-12p35 was not 
detected indicating that bioactive IL-12p70 was not produced at these time points. IL-12p40 
was not consistently detected, particularly in the AmB-PMA treated groups that 
demonstrated increased IFN-γ mRNA expression. The infected untreated BALB/c mice that 
had developed a progressive non-healing disease had low detectable mRNA expression of 
IL-12p40. This has also been found by Jones and colleagues that showed that disease 
progression in BALB/c mice correlated with low mRNA expression levels of both IL-12 
receptor chains in the lymph node and therefore low levels of bioactive IL-12 (Jones et al. 
1998). However, they also found that after the induction of a resistant phenotype by the 
addition of recombinant IL-12, the IL-12R was upregulated and in turn bioactive IL-12. As 
stated, on treatment with AmB-PMA there was an increased IFN-γ mRNA expression 
detected, indicating that this cytokine in concert with TNF-α (Figure 100 d, b respectively) 
was sufficient to stimulate parasitized macrophages for intracellular killing and thereby 
support the action of AmB.   
Further research into IL-12 has shown that the IL-12p40 subunit and the IL-12Rβ1 chain are 
shared with a recently described cytokine IL-23 (Oppmann et al. 2000) and IL-27 has been 
shown to be composed of the p35 subunit of IL-12 as well as Epstein-Barr virus-induced 
gene 3 (EBI3) (Kastelein et al. 2007). Taking this into consideration, future work would be 
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required to establish the role of IL-23 and IL-27 in infected and AmB-PMA treated mice in 
vivo. 
Although there is controversy regarding the presence of IL-4 and the importance in the 
development of a persistent infection using the experimental mouse models, the general 
consensus is that there are complex immune mechanisms involved that determine the 
progression of disease (Noben-Trauth et al. 1996). However more recently investigators 
have shown that a dominating Th2 response resulting in persistent parasite burdens can be 
generated independent of IL-4 using IL-4 knock-out mice and parasite burdens have been 
unaffected in IL-4 deficient BALB/c mice (Kropf et al. 2003) (Lehmann et al. 2000). Typically, 
in susceptible BALB/c mice, L. major disease progression involves an initial release of IL-4 
within one day of infection (Himmelrich et al. 1998). This leads to a down-regulation of IL-
12Rβ2 chain within the first 48 h which in turn suppresses the development of IFN-γ 
production by primed Th1 cells (Launois et al. 1997). IL-4 has also been shown to exhibit 
different roles depending on when it is expressed (Louis et al. 2003) (Himmelrich et al. 
2000). Biedermann and colleagues found that early expression of IL-4 was required for the 
differentiation of Th1 cells, although during T cell priming IL-4 is crucial for Th2 development 
and inhibits further Th1 differentiation (Biedermann et al. 2001).  
The data collected from the in vivo studies in this thesis demonstrated that mRNA IL-4 
expression was measured with a resulting mixed yield and was frequently below the limits of 
detection. However, absolute copies of IL-4 mRNA in the draining lymph nodes that were 
generated revealed no significant difference between the infected untreated group and AmB-
PMA treated groups when analysing the use of HP-18 on day 35 (Figure 96E). A second 
study showed a slight upregulation in mRNA expression in the draining lymph nodes of mice 
treated with AmB-PMA commencing on day 7 (Figure 97E). However, it is important to note 
that IL-4 is not indispensible for the development of non-healing cutaneous leishmaniasis 
and for Th2 responses (Noben-Trauth et al. 1996). Although, it has previously been shown 
that IL-4 is detected at high and sustained levels in L. major infected BALB/c mice, which in 
my in vivo studies, particularly in the diseased untreated mice was limited (Launois et al. 
1997). The lack of IL-4 detected in the AmB-PMA treated mice however may be due to the 
efficient reduction of parasite load and reduced antigenic stimulation as a result of the AmB-
PMA treatment. During treatment of L. major infected footpads, there was an increased 
expression of both IFN-γ and TNF-α observed which could down-regulate IL-4 production 
and further inhibit the expression of Th2 cytokines (Schindler et al. 2001).  
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Footpads were primarily harvested to calculate the parasite burden within diseased mice and 
those that were treated. As described in Materials and Methods, for ex-vivo counting to be 
conducted, homogenisation of the footpad was required in PBS. The combination of 
shearing of the tissue to release its contents in PBS limited the total RNA that could be 
extracted using Trisol from the homogenate. However, as discussed, the analysis of mRNA 
expression in the footpad was essential to gain a complete perspective on the disease, and 
alternative methods, such as pooling the homogenate of 6 mice before extracting the mRNA 
were used to ensure that the data could be generated. This gave rise to an overall analysis 
of the mRNA expression and illustrated that the most notable changes in the immunological 
profile between the infected AmB-PMA treated and infected, untreated mice was in the 
lesion of the footpad (Figure 100). During early treatment, TNF-α and IFN-γ were both 
elevated in the treated lesions with respect to the untreated lesions. TNF-α then fell rapidly 
to low levels over a week (between day 21 and day 28, Figure 99 and 100 (b)), but IFN-γ 
remained elevated until the cutaneous lesions had healed (p<0.001, Figure 100(d)). This is 
in agreement with research highlighting that resolution of CL lesions requires the presence 
of IFN-γ to drive the killing of L. major parasites via the activation of NO production (Bogdan 
et al. 2000;Rogers et al. 2002).  
IL-10 in both the untreated and treated footpad lesions was found to be similar in mRNA 
expression during the early phase of treatment (day 14 and 21, Figure 100 (c)). This was 
then followed however by a sharp and early decrease detected in the treated footpads 
compared to the untreated (also shown Figure 99(c)). As previously mentioned a reduction 
in IL-10 is important during treatment as it inhibits the upregulation of TNF-α and it 
synergizes with IL-4 to induce alternative activation of macrophages and hence allows the 
persistence of infection (Vouldoukis et al. 1997;Kropf et al. 2005). This reduced IL-10 
illustrated in the AmB-PMA treated footpads is in agreement with recent research that 
indicated that increasing levels of IL-10 in patients correlates with disease severity (Verma et 
al. 2010). Furthermore, this decrease in IL-10 was coupled with the sustained and increasing 
mRNA expression of IFN-γ in the treated footpads. This high level of IFN-γ was also 
maintained in the treated footpads at day 51 (p<0.002, Figure 102(d)). These observations 
have been reported in the serum levels of patients healing from a leishmanial infection in 
combination with low IL-10 levels (Mondal et al. 2010). In an active leishmanial infection, this 
was found to be the reverse whereby there were high levels of IL-10 expression with low 
IFN-γ levels (Saha et al. 2007). At day 51 however this sustained IFN-γ expression was 
found to be coupled with an increase of IL-10 in the treated footpads compared to the 
untreated footpads harvested at this time point. Both IFN-γ and IL-10 expression at the site 
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of the lesion in the footpad were exhibiting similar trends at day 51 that were also found on 
analysis of the immunological responses in the draining lymph nodes. One could deduce 
that the high and sustained expression of IFN-γ mRNA in the footpad up to day 51 induced 
the activation of a regulatory mechanism whereby IL-10 expression was upregulated. At this 
point in the footpads and at day 35 in the draining lymph nodes, both cytokines appear to be 
co-expressed which has been recently identified by Anderson and colleagues as antigen-
specific CD4(+)CD25(-)Foxp3(-) T cells. This highlights the complexity of both cytokines in 
the pathology of disease as it has been shown that the presence of IL-10 expressed from 
these T reg cells plays a key role in disease chronicity (Antonelli et al. 2004). This has been 
demonstrated by L. major infected resistant C57BL/6 mice whereby the presence of these T 
regs suppress the ability of L. major specific CD4+CD25+ cells to induce sterile cure (Belkaid 
et al. 2002). This co-expression of both IFN-γ and IL-10 has also been observed in patients 
with active leishmanial infections (Cillari et al. 1995)(Caldas et al. 2005). 
MIP-1β was maintained at low levels of expression in the AmB-PMA treated footpad lesions 
compared to the infected untreated footpads where there was a steady increase between 
days 21 and 35. The MIP-1β mRNA levels were also detected at significantly higher levels in 
the infected untreated footpads at day 51 compared to the AmB-PMA treated footpads 
(p<0.002, Figure 102(a)). This difference in mRNA expression of MIP-1β in the untreated 
and AmB-PMA treated footpads was also found in the draining lymph nodes, whereby low 
levels were found in the AmB-PMA treated group. As described MIP-1β is an early 
inflammatory chemokine released to attract an inflammatory infiltrate to the site of infection. 
Therefore one would expect that on AmB-PMA treatment and healing, the continued 
recruitment of an inflammatory infiltrate would cease. Indeed the mRNA expression of MIP-
1β in the treated footpads was reduced (Figure 100(a)). In contrast, the mRNA analysis of 
the infected untreated footpads illustrated an increase of MIP-1β which was also found in the 
draining lymph nodes. This increase in expression is in accordance with von Stebut and 
colleagues whereby macrophage recruitment is dependent on the secretion of MIP-1α and 
MIP-1β from activated neutrophils (von Stebut et al. 2003).  
Documenting the course of disease and AmB-PMA treatment using histology was a useful 
method to further illustrate the effects of the drug on pathology and parasite load. This 
method is continually used to clearly identify differences in tissue morphology in both man 
and experimental mouse models during an infection with Leishmania spp. (El-On et al. 1989) 
(Silveira et al. 2004) (Kurey et al. 2009). The resulting visual data can further confirm results 
generated by other analytical techniques such as real-time RT-PCR. Histological analysis of 
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the infected untreated footpad tissue sections over the course of the disease all presented 
with necrotic lesions with numerous macrophages containing L. major amastigotes (Figure 
119) as confirmed by ex-vivo counting of the parasites (Figure 85b). Overall H&E stained 
tissue sections provided the most clarity in visualising the differences in the tissue of the 
untreated and AmB-PMA treated footpad lesions. The treated footpad sections showed the 
rapid disappearance of amastigotes from the macrophage vacuoles after two doses (total of 
226 µg AmB, Figure 107F), and by day 80 the organisation of fibroblasts and decreasing 
presence of macrophages (Figure 119F). No amastigotes were identified within these 
myofibroblasts which is in contrast to previous research that have shown that fibroblasts 
harbour low numbers of leishmanial parasites and  have been linked to re-activation of 
infection (Bogdan et al. 2000b)  
This histological data supports the efficacy of the AmB-PMA drug in the control of cutaneous 
leishmaniasis. It clearly illustrates a significant reduction in parasite load and cellular infiltrate 
and inflammation in the tissues that have been treated with AmB-PMA. This, in combination 
with the monitoring of the lesion and counting of the parasite load, further verifies that 
healing has been induced in these highly susceptible BALB/c mice. 
2.3.2.1 Activation of memory 
A primary infection with Leishmania results in the priming of antigen-specific T cells. 
Immunity to re-infection is based on T cell mediated rather than humoral responses. During 
a primary infection, parasite specific T cells will be activated by recognition of antigenic 
peptide and MHC molecules and differentiate into effector cells. Exposure to a previously 
encountered antigen during challenge causes re-stimulation and recruitment of these 
parasite-specific T cells and the appearance of a delayed swelling, the delayed type 
hypersensitivity reaction (DTH). DTH responses are the only T cell mediated hypersensitivity 
responses; they occur upon recruitment of antigen-specific T cells to the site of challenge 
and the recognition and response to the recall antigen. DTH responses are excellent in vivo 
read-out systems to demonstrate the presence of antigen-specific T cells and immunological 
memory (Kraneveld et al. 1995;Vukmanovic-Stejic et al. 2006). Memory T cells differ in their 
distribution compared to naïve T cells as they can leave the lymph system and enter into 
non-lymphoid tissue. This allows for the induction of a rapid and effective immune response 
when presented with antigen in all types of tissue (Hogan et al. 2001;Sallusto et al. 
1999;Weninger et al. 2001). A DTH response is driven by IFN-γ producing memory CD4+ T 
cells that in turn stimulate the expansion of memory CD8+ T cells (Muller et al. 1994;Sun and 
Bevan 2003) (Bertholet et al. 2005). Visual findings are of an induration or swelling between 
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24-48 h after exposure which then dissipates (Nichols et al. 2002;Tanaka et al. 2007). This 
method is routinely used to determine immunity of TB, referred to as a Mantoux test (Reece 
et al. 2005; Vukmanovic-Stejic et al. 2006). To determine immunity to leishmaniasis the 
Montenegro skin test is used (Velez et al. 2005) (Nogueira et al. 2008). 
After treatment of established lesions with AmB-PMA, healing occurred (Figure 89). After 
complete resolution of the primary lesions (day 61), re-infection of the contralateral footpad 
with a high dose (2x106) of live L. major parasites resulted in a rise in footpad size 24 h post 
infection (Figure 92). This was followed by a decrease back to baseline after 72 h; indicating 
that a DTH response had occurred (Muller et al. 1994; Nichols et al. 2002; Okwor et al. 
2009; Rhee et al, 2002). In all in vivo experiments conducted a rise in lesion size post 
infection was not observed until after day 7 when there was a steady rise in lesion size of the 
untreated animals (Figure 80(a), 81(a), 83(a)). On this basis one can exclude that the rise 
and fall of these already treated and healed mice is due to a second infection being 
established. It has also been shown that IFN-γ is required for the recruitment of antigen-
specific T cells to the site of re-infection (Muller et al. 1994). Furthermore Colmenares and 
colleagues found that on investigating effective vaccination methods applied in IFN-γ 
deficient mice failed to induce protection (Colmenares et al. 2003). The in vivo studies in this 
project have shown that upon healing of the AmB-PMA treated footpads at day 51, there 
was a significant increase in mRNA IFN-γ expression at the site of the lesion. The ability to 
mount a DTH response after successful treatment with AmB-PMA indicates that the immune 
response of these highly susceptible BALB/c mice had been altered. The main cell types 
mediating DTH responses are CD4+ Th1 and CD8+ T cells.  A DTH response is typically 
found in resistant CBA and C57BL/6 mice that have healed their primary Leishmania 
infection. Challenge of healed resistant mice induces a strong DTH response mediated by 
both CD4+ and CD8+ T cells (Muller 1992).  However there is debate on whether a direct 
correlation between a positive DTH and protective immunity can be deduced. Researchers 
have found previously that although long term protection from Leishmania species via 
vaccination in BALB/c mice was successfully induced, no DTH was observed (Howard et al. 
1982). Furthermore my data has demonstrated that challenge to the contralateral footpad of 
mice, that did not resolve their primary lesion, did not give rise to a DTH response. The 
contralateral footpad increased in size over 48 h which was then sustained (Figure 91(b)). 
This is in agreement with previous work that showed that heavily diseased BALB/c mice do 
not mount a DTH response (Nasseri and Modabber 1979). Moreover, Dhaliwal and 
colleagues identified two stages of a DTH which resulted in different responses. The 
observation of an early DTH response, between 15-18 h post challenge lead to exacerbation 
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of a secondary infection (Dhaliwal and Liew 1987), whereas a DTH response that initiated 
within 48 h induced protection (De Rossell et al. 1987). Conflicting reports have also been 
shown in patients. Observations of a strong DTH were observed in both patients with an 
active MCL infection and those with a self-healing localised CL lesion (Nogueira et al. 2008). 
However, Silveira and colleagues found that during dissemination of cutaneous 
leishmaniasis, no DTH reaction was mounted in response to Leishmania antigen (Silveira et 
al. 2004). Furthermore, Pirmez and colleagues detected an equal amount of IFN-γ mRNA in 
both patient types (Pirmez et al. 1990). On evaluation of the literature, one can conclude that 
a direct correlation between a DTH response and protection still requires further clarification.   
As stated, BALB/c mice are genetically susceptible to L. major infection resulting in a 
progressive non-healing disease. However, AmB-PMA treatment has been shown to be 
effective in resolving an established lesion induced by infection with L. major. Furthermore, 
this treatment has created an environment whereby challenge to the uninfected contralateral 
footpad gave rise to a positive DTH response. It remains to be determined whether the DTH 
response was accompanied by acquired immunity to re-infection. From the results obtained 
one can deduce that after treatment with AmB-PMA, effector Th1 cells have been primed in 
the infected and treated BALB/c mice. On challenge with leishmanial antigen, these T cells 
that recognise the antigen from previous exposure become activated and migrate to the local 
site of challenge. Due to the presence of activated antigen-specific T cells there is a rapid 
inflammatory response that visually presents as a swelling or induration defined as a positive 
DTH. As described by Janeway and colleagues this local T cell mediated inflammatory 
response can only be induced by primed CD4+ Th1 and CD8+ T cells (Janeway 2008). 
Further experimentation would be required to determine whether these primed T cell subsets 
in AmB-PMA treated mice are sufficient to generate protection from re-infection.   
One can conclude that the BALB/c mice that demonstrate progressive cutaneous 
leishmaniasis due to a Th2 driven immune response, have healed on treatment with AmB-
PMA. This healing has been associated with a high and sustained expression of IFN-γ which 
suggests that the AmB-PMA treatment has provided a platform whereby a shift in the cell-
mediated response has occurred. In combination with effective killing of the parasites by the 
release of AmB, the treatment has equipped the host with the ability to generate primed T 
cells that on challenge with leishmanial antigen can migrate to the local site and induce a 
positive DTH. This indicates the possibility of an immunomodulatory role of AMB-PMA. 
Further investigations involving C57BL/6 mice that can heal from a primary infection and are 
resistant to re-infection would be necessary. However to date, these investigations could 
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potentially lead to the creation of a treatment that promotes the host to generate an 
appropriate immune response for the rapid healing of CL lesion. 
2.3.2.2 Limitations to the in vivo experimental design 
Although this thesis has presented results indicating efficacy in reducing both parasite load 
and lesion size, there are key factors that additionally need to be addressed before 
concluding that further in vivo studies and clinical trials should be performed. As described in 
Section 1.4, in vitro evidence indicates that addition of PMA to primary human and mouse 
cells does not activate an immunological response. There is also no toxicity on stimulation 
with PMA alone in vitro. However an additional study measuring the proinflammatory 
responses of PMA alone in L. major infected mice would be essential to provide conclusive 
evidence that PMA is inactive and non-toxic in vivo. Furthermore it would raise any 
unforeseen issues that may result from using a non-FDA approved material. This would be 
of great value when assessing the suitability of administrating AmB-PMA to humans in a 
clinical trial.  
Overall the mRNA results from the in vivo studies have shown a different immunological 
profile in mice that had been infected and AmB-PMA treated than mice that were infected 
and left untreated. Importantly, an early TNF-α response was found coupled with a 
progressive and sustained IFN-γ response over the course of AmB-PMA treatment. 
However, on evaluation of the studies one cannot conclusively state that the difference 
between the AmB-PMA treated and infected untreated groups was solely due to the addition 
of AmB-PMA. The differing proinflammatory responses over time could have correlated with 
the amount of leishmanial antigen present. To ascertain that AmB-PMA alone stimulated the 
cytokines such as TNF-α and IFN-γ in generating healing in the infected mice further in vivo 
studies are required. Utilising naïve uninfected BALB/c mice, the proinflammatory responses 
on stimulation with AmB-PMA could be evaluated to demonstrate the immunological effects 
of AmB-PMA alone with no infection.  
A factor that also requires further consideration in evaluating the immunological profiles 
generated from the in vivo studies is the impact of needle injury. Puncture of the skin alone 
can impact significantly through the microenvironment and stimulate the release of 
inflammatory mediators and infiltration of activated leukocytes, neutrophils and mast cells 
(Rossi and Zlotnik 2000).  Indeed, it has been shown that the wound response to the tissue 
injury caused by the sand fly bite during natural transmission of the parasites has a major 
impact on the onset of infection (Peters et al. 2008). 
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Another issue that has been raised on analysis of the data sets collected is the need for a 
positive standard drug control. The optimisation process and validation of the efficacy of 
AmB-PMA in vitro was carried out with the use of a positive control such as Fungizone or 
AmBisome. On evaluating the potential of AmB-PMA as anti-leishmanial drug in vivo, factors 
such as the individual and total dose, the route of administration and the length of treatment 
were explored. The volume of dose administered was kept constant at 50 µL per dose. 
During this optimisation process an optimum dose (400 µg AmB) and administration 
schedule (7 day period) was deduced. However, on assessing the efficacy in vivo, the only 
control used was that of L. major infected and untreated mice.  It is critical that further work 
involves validating the efficacy of AmB-PMA against a positive control of both Fungizone and 
AmBisome. This would validate its potential as an anti-leishmanial drug and also 
demonstrate the inefficacy of commercial brands in treating a localised cutaneous infection 
in mice. To consider AmB-PMA as a potential alternative therapeutic to commercially 
available AmB-derived drugs in the treatment of cutaneous leishmaniasis, the above 
described issues need to be addressed and carried out in further studies.  
The investigations described in this section, in combination with the data presented in this 
thesis, would provide clear evidence regarding the potential of AmB-PMA in acting as both 
an effective antileishmanial drug and a platform on which an appropriate Th1 driven 
response can be generated by the host.  
2.3.2.3 Proposed mechanism of action 
The in vitro and in vivo experiments collectively indicate that the interactions of HP-18 with 
AmB allows for effective killing of parasites within infected tissue. Leishmania parasites 
mainly survive and grow in the host within the phagolysosomes of macrophages therefore, 
one could postulate that HP-18 allows for the selective accumulation of the AmB-PMA in the 
phagocytic, acidic vacuoles of the L. major-infected macrophages (Burchmore and Barrett 
2001). Polymers have the potential to be readily taken up by macrophages in a process 
called lysosomotropic delivery via endocytosis (Alving 1983) (Nicoletti et al. 2009) (Duncan 
2007). Upon endocytosis, AmB-PMA is trafficked through acidic endosomes to the 
phagolysosomes where L. major amastigotes reside. It is within this acidic microenvironment 
that AmB is released from the polymer HP-18, as shown by the in vitro pH studies described 
in this thesis (Figure 61, 62). This release of AmB allows it to bind to membranes rich in 
ergosterol such as the replicating amastigotes within the endosomes of the macrophage 
(Kasai et al. 2008). Disruption of the integrity of the parasitic membranes ensues, causing an 
influx of protons into the cytoplasm of the parasite causing cell death (Baginski & Czub 
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2009). This rapid and pharmacologically mediated killing of amastigotes is combined with the 
induction of IFN-γ as described above giving rise to rapid healing through the development 
of an appropriate immune response raised by the host. This proposed mechanism of AmB-
PMA activity is illustrated in Figure 120. To further test this proposed mechanism of AmB-
PMA, incubation with cathepsin B has been reported to be useful in assessing drug release 
from polymer-drug conjugates (Erez et al. 2009) (Duncan et al. 2001).  
 
 
Figure 120: Proposed mechanism of AmB-PMA on L. major-infected macrophages 
The presence of PMA HP-18 within AmB-PMA allows for the lysosomotropic delivery of AmB 
into L. major infected macrophages via endocytosis. AmB-PMA is trafficked through acidic 
endosomes to the phagolysosomes where the amastigotes reside. Due to the acidic micro-
environment of the phagolysosome, the AmB is released from the AmB-PMA allowing it to 
target the ergosterol-rich membranes of the L. major amastigotes. This results in disruption 
of the amastigote membranes and cell death.   
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CHAPTER 3 
3.1 Conclusion 
These results show that an 18.5 kDa PMA-Na polymer based AmB (AmB-PMA) drug 
could be reproducibly synthesised and, in comparison to current marketed 
formulations such as Fungizone, have reduced toxicity in vitro. Induction of healing 
by AmB-PMA treatment during the early phase of a L. major infection and on 
established lesions was observed on administration of 3 injections of AmB-PMA. The 
6 mg/kg dosage of AmB in AmB-PMA that was administered was significantly less 
than 10 mg AmB/kg required to cure VL (Sundar et al. 2010). The AmB-PMA induced 
healing was associated with an early increase in TNF-α and IFN-γ in the footpads, 
followed by a fall in both TNF-α and IL-10, while IFN-γ was sustained. This, in 
conjunction with the in vitro data indicates that the interactions between AmB and 
PMA gives rise to a drug that is able to reach the site of infection within macrophages 
and to cause the killing of parasites whilst stimulating IFN-γ to counteract the 
persistent infection governed by an IL-10 driven Th2 response. The aim of this study 
was to create a cost-effective formulation of AmB that could be competitively priced 
in order to treat poverty-stricken people that are plagued by cutaneous leishmaniasis. 
Although original efforts of creating AmB-PMA with a polymer that was synthesised in 
the lab would have been much more attractive in cost, the consistency in efficacy in 
vitro and in vivo in combination with no toxic side effects observed in the latter, 
greatly justified the purchase of a GPC standard polymer that is stringently quality 
validated. The cost per 250 mg/vial of HP-18 amounts to £50. The source of AmB 
costs £3.59 per vial containing 50 mg of the active ingredient AmB. Each synthesis 
requires 5.15 mg/ml AmB and 5 mg/ml of HP-18 to create a yield of 75.6 mg (total 
weight of AmB-PMA). This synthesis reaction consistently produced AmB-PMA with 
an AmB loading of 26-30 %. Therefore, a batch of AmB-PMA with a loading of 28 % 
and a yield of 76 mg would give rise to 21.3 mg of AmB that can be administered. 
Our optimum dose was a total of only 400 µg of AmB based on 6 mg/kg and 
therefore per vial, 50 treatments could be given to treat experimental cutaneous 
leishmaniasis per vial. The preliminary studies indicating the potential of 
incorporation of AmB-PMA into a topical application also increases its therapeutic 
value. Investigators have attempted to incorporate AmB within an ointment for over 
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many years with limited success in translation of their findings into applications 
administered to man (Frankenburg et al. 1998;Vardy et al. 2001;Zvulunov et al. 
2003). On administration of topical treatment preference is for paromomycin or 
imiquimod ointments rather than AmB-incorporated ointments (Arana et al. 
2001;Faghihi and Tavakoli-kia 2003). This may be due to the structural re-
arrangement that AmB would have to demonstrate when incorporated into an 
ointment causing significant changes in the dynamics of the formulation and may 
lead to unforeseen toxicities. As AmB is very susceptible to many elements including 
pH, my successful preliminary studies of incorporating AmB-PMA into gauze with no 
additional elements required, increases its attractiveness as a potential therapeutic in 
man offering several advantages including ease of administration (Figure 67).  
The aim of this thesis was to develop a novel cost-effective treatment for cutaneous 
leishmaniasis. The data collected illustrates that AmB-PMA can be reproducibly 
synthesised at a low cost with low toxicity both in vitro and in vivo. Furthermore in 
vivo, the efficacy of the AmB-PMA has been assessed on treating an early phase 
infection and an established lesion. The outcome of reduced parasite load, lesion 
size reduction and pathological healing indicates that this treatment is a viable 
candidate for treating CL in man. Preliminary work into incorporation of this AmB-
PMA drug into a topical application indicates its potential for further development. 
Moreover, the immunological differences between the infected and untreated and 
infected, AmB-PMA treated groups indicate that the drug can manipulate the host 
immunity to stimulate rapid healing of experimental cutaneous leishmaniasis. Overall 
this thesis has illustrated results suggesting that it is possible to create an AmB-PMA 
exploiting the potency of AmB to kill L. major in vivo infections, with immune-
therapeutic manipulation of the host immunity, to produce healing of CL in highly 
susceptible BALB/c mice.     
 
3.1.1 Future Work 
 
Section 2.4.2.2 describes the limitations of the in vivo studies and specifically 
highlights the requirement of additional controls to validate the efficacy of AmB-PMA. 
Further studies would therefore include assessing the immunomodulatory effects of 
AmB-PMA in vitro of human and murine dendritic cells and tissue macrophages. 
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Moreover, to confirm that PMA does not contribute in stimulating a proinflammatory 
response and is non-toxic, an in vivo study using the optimum method deduced in 
this thesis for the treatment of AmB-PMA would be used. Furthermore an in vivo 
experiment should be performed stimulating naïve BALB/c mice with AmB-PMA. This 
would illustrate the ability of AmB-PMA to stimulate the production of cytokines TNF-
α and IFN-γ. A further in vivo study should also be conducted to compare the efficacy 
of AmB-PMA with commercially available AmB-derived products such as Fungizone 
and AmBisome.  
To assess the impact of repetitive needle injury due to drug administration on the 
immunological profile generated in the studies in this thesis, an in vivo experiment 
whereby one group is administered saline or water injections should be conducted. 
The frequency and total number of injections should be indifferent to the optimum 
treatment schedule of AmB-PMA. The cytokine and chemokine responses would 
then be compared to a control group of mice that were not administered needle 
injections.  
In this thesis, quantification of the parasite load was directly assessed using ex-vivo 
counting of the homogenate of the infected footpads and disease progression was 
determined indirectly by measuring the thickness of the lesions. However, more 
recent developments in fluorescence imaging have made available the ability to 
closely follow disease progression (Thalhofer et al. 2010). This can involve either 
using bioluminescent Leishmania expressing luciferase or GFP-transfected 
Leishmania to monitor in vivo the infection occurring in real-time without the need to 
sacrifice the mice (Ha et al. 1996;Lang et al. 2005;Lang et al. 2009;Mehta et al. 
2008). This technology could also be applied to testing of anti-leishmanial drugs 
(Singh et al. 2009). Furthermore recent investigations in the development of 
fluorescently-labelled PMA have yielded fruitful and indicate the possibility of 
generating a labelled-PMA-AmB (Lehmann et al. 2010). One would then be able to 
visualise disease progression, track the intracellular trafficking of the AmB-PMA into 
parasitized macrophages and verify the proposed mode of action by which AmB-
PMA locates within the phagolysosome of the L. major-infected macrophages before 
it dissociates, allowing AmB to exhibit its anti-leishmanial effects. 
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Appendix 1 
During this thesis, the immunological profile of mice infected with L. major and those infected 
and treated with AmB-PMA was assessed. Using real-time RT-PCR in a RotorGene 3000 
thermal cycler (Corbett Research), absolute mRNA copy numbers of key cytokines and 
chemokines were generated following their transcription to cDNA from tissue samples 
collected such as the draining lymph nodes and homogenised footpads. Analysis of the PCR 
data was carried out using the RotorGene software. The following illustrates the quantitation 
and melting curves produced by the RotorGene software including details of the PCR 
reaction. Each sample was run in triplicate with a total of two PCR runs. Typically the 
following profile including a standard curve over the range of 20 to 2x107 copies was 
generated. The melting curve generated at the end of each PCR run demonstrated that the 
PCR product had a single Tm in each reaction and that no primer dimers were formed during 
the PCR.  
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Raw Data For Cycling A.HPRT 
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Melt data for HPRT 
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Raw Data for Cycling A MIP-1β 
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Melt data for Melt A.Sybr Gold 
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Raw Data For Cycling A.Sybr Gold 
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Melt data for Melt A.Sybr Gold 
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Raw Data For Cycling A.Sybr Gold 
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Melt data for IFN-γ Sybr Gold 
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Raw Data For Cycling A.Sybr Gold 
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Standard Curve 
 
Appendix 1 
Karina D. Corware 
 
403 
 
 
Melt data for IL-10 Sybr Gold 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2 
Karina D. Corware 
 
404 
 
 
Appendix 2 
The following article was published in the Transactions of the Royal Society of Tropical 
Medicine and Hygiene. This was as a result of winning 1st prize award at the Annual 
Research in Progress meeting at the Royal Society of Tropical Medicine and Hygiene for 
presenting research detailed in this thesis entitled ‘Modifying amphotericin B for the 
treatment of cutaneous leishmaniasis’.   
Work from this thesis was also presented at the British Infection Society Annual Meeting 
2010 entitled ‘A cost effective cure for cutaneous leishmaniasis’.  
TS
A
m
K
a
b
a
A
R
R
A
A
K
L
C
P
I
A
P
1
p
t
e
T
t
i
a
t
p
z
(
m
C
H
p
0
dARTICLE IN PRESSG ModelRSTMH-1408; No.of Pages2
Transactions of the Royal Society of Tropical Medicine and Hygiene xxx (2010) xxx–xxx
Contents lists available at ScienceDirect
Transactions of the Royal Society of
Tropical Medicine and Hygiene
journa l homepage: ht tp : / /www.e lsev ier .com/ locate / t rs tmh
ociety Meeting Paper
n amphotericin B-based drug for treating experimental Leishmania
ajor infection
arina D. Corwarea, Matthew Rogersb, Ian Teoa, Ingrid Müllerb, Sunil Shaunaka,∗
Department of Infectious Diseases & Immunity, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
Department of Medicine, Section of Immunology, Imperial College London, St Mary’s Campus, Norfolk Place, London W2 1PG, UK
r t i c l e i n f o
rticle history:
eceived 15 April 2010
eceived in revised form 10 August 2010
ccepted 11 August 2010
vailable online xxx
a b s t r a c t
There is an urgent need for a non-toxic and low-cost treatment for cutaneous leishma-
niasis. We synthesised and tested in vivo an amphotericin B-poly(methacrylic acid) drug
(AmB-PMA) that had previously shown in-vitro activity against Leishmania major and L.
donovani parasites. Efﬁcacy was determined using L. major footpad infection in 30 non-
healing BALB/c mice. Three subcutaneous injections of AmB-PMA at days 7, 14 and 21eywords:
eishmania major
utaneous leishmaniasis
harmacological therapy
mmunomodulatory therapy
post-infection resulted in a reduction of ∼80% in lesion size by day 35 post-infection in 18
treated mice compared with six untreated controls, and complete healing of lesions by day
50 with no lesion relapse seen at day 80 post-infection in six treated mice. Healing was
associated with decreased IL-10 (P=0.002) and increased IFN- (P=0.005) in the footpad.
© 2010 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All
mphotericin B
oly(methacrylic acid)
. Introduction
Cutaneous leishmaniasis (CL) is caused by protozoan
arasites of the species Leishmania. Transmitted through
hebite of female phlebotomine sandﬂies, Leishmaniapref-
rentially infect, multiply and persist in host macrophages.
his neglected parasitic disease is endemic in over 70
ropical countries and presents as disﬁguring and deform-
ng skin lesions. To date, there is no effective vaccine,
nd drug therapy is limited by toxicity, increasing resis-
ance, and long treatment regimens that increase costs to
atients. Although deoxycholate-amphotericin B (Fungi-Please cite this article in press as: Corware KD, et al. An amphot
major infection. Trans R Soc Trop Med Hyg (2010), doi:10.1016/j
one, Bristol-Myers Squibb) and liposomal amphotericin B
AmBisome, Gilead) are effective at treating visceral leish-
aniasis (VL), they are ineffective against L. major-induced
L.1,2
 Based on a presentation to the Royal Society of Tropical Medicine and
ygiene Research in Progress Meeting on 16 December 2009. This oral
resentation was awarded ﬁrst prize at the meeting.
∗ Corresponding author. Tel.: +44 208 383 2301; fax: +44 208 383 3394.
E-mail address: s.shaunak@imperial.ac.uk (S. Shaunak).
035-9203/$ – see front matter © 2010 Royal Society of Tropical Medicine and H
oi:10.1016/j.trstmh.2010.08.010rights reserved.
Resolutionof a leishmanial infection isdependentupon:
(i) the development of an adequate Th1 immune response;
and (ii) production of IFN- to activate antiparasitici-
dal pathways in infected macrophages. BALB/c mice are
genetically susceptible to leishmanial infection and can-
not control parasite growth. This is due to a dominant Th2
response that involves upregulation of IL-10, and an inabil-
ity to activate infected macrophages to kill intracellular
parasites. The result is persistent and progressive non-
healing disease.3
We synthesised and tested a new amphotericin B-
poly(methacrylic acid) drug (AmB-PMA) and determined
its efﬁcacy against L. major footpad infection in BALB/c
mice. In this animal model, polarisation and establishment
of parasite-speciﬁc T-helper cell responses leads to a non-
healing disease phenotype.ericin B-based drug for treating experimental Leishmania
.trstmh.2010.08.010
2. Methods
Thirty BALB/c mice were infected in the footpad with
2×106 L. major LV39 (MRHO/SU/59/P-strain) stationary
phase promastigotes on day 0. Twenty-four mice were
ygiene. Published by Elsevier Ltd. All rights reserved.
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2 K.D. Corware et al. / Transactions of the Royal Society of TrFigure 1. Quantitative real-time mRNA RT-PCR for IL-10 and IFN- in
the Leishmania major-infected footpads of six untreated and eighteen
amphotericin B-poly(methacrylic acid) drug-treated mice at day 35 post-
infection. Data are presented as mean± SEM.
injected subcutaneously with AmB-PMA (reconstituted in
water) on days 7, 14 and 21 post-infection. A total of
400g AmB (6mg AmB/kg) was administered to the site
of infection. Six control mice received water injections.
Lesion size was monitored twice weekly using a vernier
calliper. Eighteen treated and six control mice were culled
at day 35 and the lesion’s parasite load determined by
ex-vivo counting; footpads were homogenised through a
metal sieve in PBS and parasites counted using a haemo-
cytometer. Another six mice continued to be monitored
twice weekly until day 80 and were then culled. Cytokine
mRNA levels were determined by quantitative real-time
PCR. RNA was extracted from homogenised footpads with
Tri Reagent (Sigma, Dorset, UK) and reverse transcribed
withaQiagenRTkit (Qiagen,Crawley,UK).QuantitativeRT-
PCRwasperformed in triplicateusingSybrGreen Jumpstart
PCR mix (Sigma) on a Corbett thermocycler. A multigene
plasmid containing cloned gene sequences of IL-10, IFN-
and HPRT (housekeeping gene) was used to determine the
absolute mRNA copy number, and the results normalised
for HPRT. The primer sequences were: IL-10 (forward)
GGTTGCCAAGCCTTATCGGAand (reverse)ACCTGCTCCACT-
GCCTTGCT; IFN- (forward) TCAAGTTCAAGTGGCATAGAT-
GTGG and (reverse) TGGCTCTGCAGGTTTTCATG; HPRT
(forward) GTAATGATCCAGTCAACGGGGGAC and (reverse)
GCAAGCTTGCAACCTTAACCA.
Results are given as the mean± SEM. P-values were
determinedusingaMann-WhitneyU test (GraphPadPrism,
San Diego, CA, US).
3. Results
The three injections of AmB-PMA on days 7, 14 and 21
led to an 82±2% reduction in CL lesion size by day 35
post-infection in 18 treated mice compared with the six
untreated mice. This was accompanied by a 99.85±0.03%Please cite this article in press as: Corware KD, et al. An amphot
major infection. Trans R Soc Trop Med Hyg (2010), doi:10.1016/j
reduction in the number of viable parasites. In another six
treated mice, there was complete lesion healing by day 50
with no lesion relapse seen at day 80 post-infection.
Quantitative mRNA PCR-based analysis of the infected
footpads at day 35 post-infection showed a 30-fold PRESS
opical Medicine and Hygiene xxx (2010) xxx–xxx
decrease in IL-10 (P=0.002) and a 6-fold increase in IFN-
 (P=0.005) in treated compared with untreated footpads
(Figure 1).
4. Discussion
Our results show that AmB-PMA administered sub-
cutaneously induced complete healing in genetically
susceptible BALB/c mice. There was a substantial reduc-
tion in lesion size and parasite elimination in this mouse
footpad model of L. major infection. Cure was associated
with reduced IL-10 and increased IFN- levels in treated,
infected footpads compared with untreated, infected foot-
pads.
A Th1 response enhances the healing of cutaneous
lesions because it promotes macrophage activation via
production of TNF- and IFN-. It also increases iNOS
production. Collectively, this leads to parasite killing.3,4,5
Cytokine analysis of the lesion site showed reduced IL-10
and increased IFN-.
Our results show that the pharmacologically medi-
ated killing of amastigotes by AmB-PMA was associated
with additional host-mediated immune responses that
facilitated cure of L. major-induced CL lesions.4,5 This cost-
effective AmB-PMAdrug has the potential to be suitable for
treating CL in low-income countries and further studies are
needed.
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